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To my wife and son, Daniela and Martin Emilio, who have taught me that 




Colombia is one of the most biodiverse countries in the world and 
consequently has sought to employ genetic resources to further both its 
economic development and technological and scientific advancement. 
Colombia’s implementation of the international regime on access to genetic 
resources and benefit sharing responds to the interests of the country in 
employing genetic resources for health research and also for the health 
industry. However, the relevant Colombian law leaves aside practices and 
knowledge that emanate from local, indigenous, and Afro-Colombian 
communities in adding value to biodiversity. Through an interdisciplinary 
analysis, this thesis adds a novel country case study to existing international 
socio-legal literature on the International Regime on Access to Genetic 
Resources and Benefit Sharing, showing its deficiencies when considered at 
national and local levels. Further, drawing on a Capability Approach, the thesis 
aims to suggest an alternative approach for Colombia, making the normative 
claim that such an approach would create a more inclusive model of innovation 
in the use of biodiversity. 
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Chapter One: Introduction 
 
For each hour you spend reading this thesis, Colombia – one of the most 
megadiverse countries in the world – loses 25 hectares of tropical forest. This 
adds up to approximately 219.973 hectares per year.1 It is the equivalent of the 
size of major cities such as Mexico City or Bangkok. Additionally, more than 
1,200 species in Colombia are threatened by extinction, of which 798 are 
plants and 313 are mammals and birds.2 Along with these genetic resources, 
Colombia’s biodiversity3 includes natural non-renewable resources, such as oil 
and minerals. The causes of Colombia’s biodiversity loss are a combination of 
various activities representing the complexities of Colombian socio-economic 
reality. For instance, conflict in Colombia is fuelled by the growth of coca leaf 
for illegal drug production and by illegal mining of minerals, such as gold. 
These activities devour water and land in the most biodiverse areas of the 
country.4 However, it is not only illegal activities that affect Colombia’s 
ecosystems. Activities that are key for the economic development of the 
country, such as oil extraction, animal husbandry, agriculture, and 
construction of infrastructure (e.g. roads, dams, housing projects, and so on), 
are also primary causes of biodiversity loss.5  
 
The loss of biodiversity through such a variety of legal and illegal economic 
activities also reflects other challenges facing countries such as Colombia. The 
places in which oil extraction and mining (either legal or illegal) take place are 
in general the poorest in Colombia, where local elites are also the most 
 
1 Ministerio de Ambiente, ‘Avances Estrategia Integral de Control de La Deforestación y 
Gestión de Bosques: Bosques Territorio de Vida’ <www.minambiente.gov.co> accessed July 8 
2018. 
2 Instituto Humboldt, ‘Biodiversidad Colombiana: Números Para Tener En Cuenta’ (Instituto 
Humboldt , 2017) <http://www.humboldt.org.co/es/boletines-y-comunicados/item/1087-
biodiversidad-colombiana-numero-tener-en-cuenta> accessed July 8 2018. 
3 Article 2 of the United Nations Convention on Biological Diversity defined biological 
diversity or biodiversity as “the variability among living organisms from all sources including, 
inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes of 
which they are part; this includes diversity within species, between species and of ecosystems.” 
4 Ministerio de Ambiente (n 1)., p 5  
5 ibid. 
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corrupt.6 Violence, fuelled by illegal activities that consume biodiversity, has 
caused almost eight million people to be internally displaced during 
Colombia’s long history of conflict.7 In turn, the displacement of people 
triggers further poverty and violence in urban areas, where victims of conflict 
have struggled to fit into the different dynamics of cities. Among those most 
affected are local, indigenous, and Afro-Colombian communities who have 
particular spiritual, social, and economic relationships with the country’s 
environment. 
 
While historians discuss why such a rich country in biodiversity has such 
recurrent patterns of violence as it negotiates a path towards economic 
growth,8 Colombia’s national authorities have struggled to channel such an 
abundance of biodiversity towards peaceful and sustainable development. 
There are many tales of what has gone wrong in terms of employing non-
renewable natural resources, such as oil and gold, for economic development, 
as well as the degradation of Colombian biodiversity to meet demands for the 
ever-persistent problem of drug consumption in the developed world;9 but this 
thesis focuses on a different tale, one in which the country aspires to employ 
its biodiversity, especially genetic resources, to pursue an ambitious 
technological and scientific agenda to advance its economic development and 
make sustainable use of such diversity. 
  
 
6 JP Soler, Locomotora Minero-Energética: Mitos y Conflictos Socio Ambientales (CENSAT 
Agua Viva Amigos de la Tierra Colombia 2012). 
7 More recently, apart from internal displacement, the figures of refugees have also peaked 
due to the exodus of Venezuelan cause by the economic collapse of the neighbouring country; 
UN Refugee Agency, 
‘UNHCR Population Statistics - Data - Overview’ (UNHCR, 2018) 
<http://popstats.unhcr.org/en/ 
overview#_ga=2.243524421.1747780701.1531058317-1147107829.1531058317> accessed 8 
July 2018.  
8 See for instance Frank Safford and Marco Palacios, Colombia: Fragmented Land, Divided 
Society (Latin American Histories) (Oxford Univ Press, Oxford 2001). 
9 See for instance: Aldo Civico, ‘“We Are Illegal, but Not Illegitimate.” Modes of Policing in 
Medellin, Colombia’ (2012) 35 PoLAR: Political and Legal Anthropology Review 77; Francisco 
E Thoumi, Illegal Drugs, Economy, and Society in the Andes (Woodrow Wilson Center Press 
2003); Steven Dudley, Walking Ghosts: Murder and Guerrilla Politics in Colombia 
(Routledge 2004). 
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Colombia’s place in the world and its implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing 
 
Although Colombia faces difficult challenges, the country enjoys a growing and 
vital economy. Indeed, it is expected that the economy will keep a gradual pace 
of development in the coming years (2019-2020), as there is currently a 
relatively low unemployment rate alongside steady and controlled inflation.10 
Colombia’s economic profile has led it to be placed alongside larger economies 
in terms of development. Recently, for instance, Colombia joined the 
Organisation for Economic Co-operation and Development (OECD), through 
which the most economically developed countries in the world share data and 
experiences, disseminate good practice, and establish market-oriented 
policies.  
 
The aspiration of becoming a key player at the international level has led to 
Colombia having a great interest in employing its biodiversity as a tool in its 
economic development. The Colombian National Development Plan or Plan 
Nacional de Desarrollo points explicitly to the importance of biodiversity and 
its components, including genetic resources, for both the economic 
development and technological innovation of the country and its economy. 11 
As a result, Colombia has great expectations of making the utilisation of 
biodiversity a key aspect of the activities of sectors such as health research and 
the health industry. 
 
Towards this goal, Colombia demands that those who employ the country’s 
biodiversity and its components, particularly genetic resources, require prior 
informed consent from national authorities, and must reach an agreement 
with the country to share the benefits arising from the utilisation of genetic 
resources. The sharing of benefits can take the form of monetary benefits (e.g. 
 
10 OECD, ‘Developments in Individual OECD and Selected Non-Member Economies: 
Colombia’, OECD Econmic Outlook (OCDE 2018) 
<http://www.oecd.org/eco/outlook/economic-forecast-summary-colombia-oecd-economic-
outlook.pdf> accessed 12 March 2019. 
11 Departamento Nacional de Planeación, Plan Nacional de Desarrollo 2014-2018 2015 Tomo 
I. 
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royalties, intellectual property rights, joint ownership) or non-monetary 
benefits, such as transfer of technology and training.12  
 
Although the access to genetic resources and benefit sharing might sound like 
a straightforward transaction, in reality, the use of biodiversity for research 
and industry is far more complex. In fact, despite the expectations of 
employing genetic resources as a key aspect in the economic and technological 
development of the country, there is not a single story of commercial success 
from the use of Colombian biodiversity. Yet, Colombia keeps those 
expectations high, as it has developed an important national scientific and 
technological infrastructure.  
 
As a result, Colombia has facilitated the rules on access to genetic resources 
for specific users, such as publicly funded projects in universities and research 
centres (i.e. local researchers), which are part of Colombia’s scientific and 
technological network. In that way, Colombian law and policy aims to 
encourage local researchers to carry out bioprospecting activities within the 
extensive biodiversity the country enjoys. Bioprospecting initiatives involve 
the activities of scanning and scoping biodiversity for the collection of new 
biochemical compounds for specific industries, particularly the 
pharmaceutical industry, as well as finding “leads” in the practices and 
knowledge of communities associated with genetic resources. Furthermore, 
Colombia encourages local researchers to assert property rights over the 
products and processes derived from genetic resources. Local researchers are 
encouraged to do so through patents, a form of protection of intellectual 
property that grants exclusive rights over inventions, including those based 
upon genetic resources. In that way, holders of patents retain a right to either 
exploit their own invention (manufacture, distribute, and so on) or license 
other stakeholders to do so.  
 
 
12 The classification is taken from the Bonn Guidelines on Access to Genetic Resources and Fair and 
Equitable Sharing of the Benefits Arising out of their Utilization (2002), which is part of the 
International Regime on Access to Genetic Resources  
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In addition, there are other sectors that, despite the fact that they benefit from 
the use of Colombian biodiversity, are exempted de facto from the 
International Regime on Access to Genetic Resources and Benefit Sharing. 
This is the case for the Colombian herbal industry, a growing national business 
which produces and manufactures phytomedicines, i.e. bioactive natural 
products that have pharmacological action and are derived from native and 
introduced plants. Rather than carrying out bioprospecting to define 
pharmaceutical effects of naturally occurring substances, this industry relies 
on knowledge and practices from local, indigenous communities. Reliance on 
this knowledge and practice supports both the production of herbal products 
and, crucially, the demonstration of their safety and effectiveness.  
 
Colombian implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing is in line with Colombia’s aspiration to become 
a key player in the international arena. The country claims that the use of 
biodiversity for health research and the health industry has a strategic value 
for economic development.13 Yet, as this thesis will uncover, there are 
complexities behind the use of biodiversity which reveal that such aspirations 
could have the effect of relegating, or at least rendering vulnerable, rights of 
people from local and indigenous communities, who through their knowledge 
and practices add value to the understanding of biodiversity for research and 
industry. Since knowledge and practices from those communities are not 
recognised as key aspects that add value to the industrial application of and 
research into Colombia’s biodiversity, the country has not established effective 
mechanisms of protection. This is despite the fact that Colombia has acquired 
international compromises in the International Regime on Access to Genetic 
Resources and Benefit Sharing to involve those communities in the decision-
making process.  
 
But the question of what would be an effective policy for Colombia to promote 
sustainable innovation in its health industry and in health research is not only 
about acknowledging and protecting communities’ knowledge and practices. 
 
13 See Paragraphs 4 and 8 of the Preface of the Decision 391 on the Common Regime on Access 
to Genetic Resources of 1996.    
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Ultimately, it is a question about justice. As already noted in the first lines of 
this thesis, the exploitation of natural resources to meet international demand 
for commodities, and the illegal trade of drugs, are the main causes of harm to 
those who share an historical, spatial, and spiritual connection with 
Colombia’s biodiversity. Of course, the use of biodiversity for scientific and 
technological advancement cannot be systematically compared with the 
extraction of natural resources and illegal drug trafficking, but since it is 
presented as a way to achieve sustainable use of biodiversity,14 Colombia 
should also consider those communities’ practices and knowledge when it 
adopts policies that aim to secure such a sustainable use of biodiversity.  
 
The Key Research Question 
 
Against this background, the thesis aims to answer the following research 
question: How should Colombia, a developing country rich in biodiversity, 
implement the International Regime on Access to Genetic Resources and 
Benefit Sharing in order to recognise the contribution from local, indigenous, 
and Afro-Colombian communities’ practices and knowledge in adding value to 
the use of genetic resources for the health industry and health research? 
 
The Approach and Method of the Thesis 
 
To that end, this thesis centres on an in-depth analysis of the various ways in 
which the contributions of local, indigenous, and Afro-Colombian 
communities to knowledge and understanding of the properties of Colombia’s 
biodiversity has been ignored in health research and the health industry in the 
country. This is so, even though that industry and its research draws upon 
genetic resources. According to the aims of the International Regime on Access 
to Genetic Resources and Benefit Sharing, as we will see in more detail in the 
 
14 See for instance the Colombian policy on the use of biotechnology for the use of sustainable 
development: Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 
Política Para El Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La 
Biodiversidad’ (2011) 
<https://colaboracion.dnp.gov.co/CDT/Conpes/Económicos/3697.pdf> accessed 5 June 
2018. 
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next chapter, it should therefore be part of Colombia’s implementation of that 
international regime.  
 
The primary focus of the research is on the Colombian regulatory framework 
that implements the International Regime on Access to Genetic Resources and 
Benefit Sharing. The analysis goes beyond an assessment of the legal texts 
according to the ‘standard’ methods of legal scholarship (sometimes known as 
the doctrinal or black letter approach). It also brings to bear scholarship from 
anthropological, ethnobotanic, and economic perspectives, and thus 
investigates the law from an interdisciplinary point of view. It adds data from 
a small dataset of original semi-structured interviews with representative 
actors in Colombia, as well as observations and photographs of the places in 
which the interviews took place. The thesis cross-references data available 
from published anthropological and ethnobotanical research with legal 
databases, such as for marketing approvals or patent applications. The aim is 
to provide a “deep” or “thick” analysis of the law and policy on the ground, in 
a single state, so as to strengthen our understanding of how the International 
Regime on Access to Genetic Resources and Benefit Sharing plays out in 
practice within a particular context. 
 
Colombia makes a pertinent case study because its biodiversity is an aspect 
that the country as a whole considers part of its very own foundations, its 
national identity. It is an aspect that involves a long-time aspiration of making 
Colombia’s biodiversity a key element in its economic and technological 
development. But such an aspirational objective in the use of Colombia 
biodiversity is rather a crossroad of different actors (e.g. local researchers, 
communities, government, national courts, etc.) and issues (sustainable use of 
biodiversity, economic development and so on) which is a pertinent example 
to illustrate the difficulties of regulating aspects related to a country’s 
biodiversity.  
 
Additionally, Colombia was chosen as the country for analysis for other 
specific reasons, a fundamental one being that Colombia is one of the most 
biodiversity-rich countries in the world because of its location in one of the 
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most megadiverse regions in the world; Colombia is in the north-west area of 
South America, where different “hot spots” converge; the Choco/Darren coast 
in the west coast, the tropical Andes, which begins in the centre and ends in 
the north coast of the country, and the Amazon rainforest in the south.15 As a 
result, Colombia has the largest diversity of amphibians and birds in the world, 
the second largest in plants, third in reptiles, and fifth in mammals.16 Also, to 
such indigenous diversity, Colombia has been the recipient of introduced 
species, including plants, which have had a profound impact in the country’s 
economy and cultural traditions.17 Colombia’s biodiversity also has a 
prominent interaction with the country’s diverse population that includes local 
(mestizo and peasants populations), indigenous, and Afro-Colombian 
communities;18 these communities, through their ancient knowledge and local 
practices, have revealed potential uses of introduced and native plants for key 
sectors such as the health industry. In addition, as Colombia enjoys a relatively 
stable economic development, the country seeks to make the use of 
biodiversity a key aspect in health industry and health research. Because of the 
convergence of those factors, it is the type of nation for which the International 
Regime on Access to Genetic Resources and Benefit Sharing seeks to secure 
fair access to genetic resources and the sharing of benefits in the context of the 
UN Convention on Biological Diversity. It is, in a sense, a ‘perfect’ test-case of 
the effectiveness of those international instruments in context. 
 
The research ‘puzzle’ that the thesis tackles is to explore why, despite the aim 
of the International Regime on Access to Genetic Resources and Benefit 
 
15 The most biodiversity-rich areas in the world are also the most threatened; as a result 
scientists have gathered together different areas in the world that account for most of the 
biodiversity, calling them 
‘hot spots’ further information regarding biodiversity hot spots is at 
https://www.conservation.org/How/ 
Pages/Hotspots.aspx  
16 Norman Myers and others, ‘Biodiversity Hotspots for Conservation Priorities’ (2000) 403 
Nature 853; Norman Myers, ‘Threatened Biotas: “Hotspots” in Tropical Forests’ (1988) 8 The 
Environmentalist 187. 
17 Colombia cannot request users of genetic resources to comply with ABS Rules to introduced 
plants, but only native plants. Some of the key Colombian agriculture products are introduced 
plants such as coffee (Coffea arabica), sugar cane (Saccharum offfinnarum), coconut (Cocos 
nucifera) and banana (Musa paradisiacai)  
18 Milton Romero, Edersson Cabrera and Néstor Ortiz, ‘Informe Sobre El Estado de La 
Biodiversidad En Colombia 2006-2007’ [2008] Instituto de Investigación de Recursos 
Biológicos Alexander von Humboldt. Bogotá DC, Colombia. 
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Sharing to establish a compensation mechanism in which developing 
countries rich in biodiversity and communities within those countries are 
supposed to obtain benefit sharing, its implementation in Colombia has led its 
users, especially local researches, to approach genetic resources as “raw 
materials” and indigenous communities’ contributions as mere “leads” in 
finding industrial applications in plants, rather than a benefit to be shared. To 
explore the Colombian case, the thesis employs an anthropological and 
ethnobotanical analysis of bioprospecting activities in other developing 
countries rich in biodiversity.  
 
This literature points out the ways in which the International Regime on 
Access to Genetic Resources and Benefit Sharing treats all conditions and 
actors behind the use of biodiversity in a way that is too one dimensional and 
too simplistic. Thus, under the regime, benefit sharing is to be agreed for 
downstream stages of research and development (R&D). But this leaves “the 
rest of the research process largely intact”. 19 Particularly, drawing on the work 
from authors such as Hayden, Osseo-Asare,20 and Cloatre,21 this thesis 
explores how innovation and the implementation of the International Regime 
on Access to Genetic Resources and Benefit Sharing in developing countries 
rich in biodiversity is underpinned by a market-oriented approach which is 
biased towards holders of technology and the way they produce and 
commercialise knowledge and information.  
 
The Colombian case is a specific example of this general observation, and the 
thesis also demonstrates how Colombia’s law and policy choices have created 
a sub-optimal situation for reaching the sustainable innovation that is claimed 
as Colombia’s hope for harnessing its biodiversity to economic ends, and for 
the health of its population. The examination of Colombia’s law and policy 
choices in the implementation of the International Regime on  Access to 
 
19 Cori Hayden, When Nature Goes Public: The Making and Unmaking of Bioprospecting in 
Mexico (Princeton University Press 2003). 
20 Abena Dove Osseo-Asare, Bitter Roots: The Search for Healing Plants in Africa (University 
of Chicago Press 2014). 
21 Emilie Cloatre, ‘Biodiversity, Knowledge and the Making of Rights: Reviewing the Debates 
on Bioprospecting and Ownership’ in M Bowman, P Davies and E Boodwin (eds), Research 
Handbook in Biodiversity and Law (Edward Elgar 2016). 
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Genetic resources is not limited exclusively to a documentary and 
interdisciplinary analysis. Throughout the final stages of this project, such an 
analysis led to a specific actors and networks which provided a better 
understanding of the way that stakeholders understand and approach to 
Colombia’s law and policy on innovation and the use of biodiversity for health 
research and health industry. Consequently, the research adopted a qualitive 
research that demonstrates how those actors engage with Colombia’ law and 
policy. It is also expected that the use of this methodology contributes to 
overcome the current limitation on legal scholarship that engage with 
fieldwork in Colombia in different areas of law, including intellectual property 
and environmental law.   
 
The fieldwork involves conducting semi-structured interviews with seven 
people, who fall into two groups of representative stakeholders. These are: a 
research group in the field, based in Bogotá (Colombia) which has carried out 
extensive investigation in two medicinal plants, Dividivi (Caesalpinia 
spinosa) and Anamú (Petiveria alliacea), for industrial applications; and, 
providers of those medicinal plants, who are sellers of plants or Yerbateros in 
a well-known urban market in Bogotá (La Plaza Samper Mendoza). In 
addition, the author’s observations in the urban market, captured in 
photographs, forms part of the data on which the analysis draws. Legal texts 
and policy documents are considered alongside data from the semi-structured 
interviews, and observations, to elicit more nuanced information about 
interactions and complexities on the ground in Colombia. The interviews and 
observations were carried out between September and October of 2019.  
 
The interviews were recorded, and in the case of the interviews with the 
research group were transcribed; these interviews took place at the 
immunology labs in the Javeriana University and the home of its lead 
researcher. The transcripts of the recorded data from the interviews with the 
plant sellers (which are of variable quality because of background noise in the 
location) are supplemented by notes and photographs taken by the author of 
the surroundings of Plaza Samper Mendoza. Interview quotes, translated by 
the author, were employed extensively to provide an appropriate account of 
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the participants’ discourse and to reveal the complexities behind the use of 
medicinal plants in practice.  
 
The limitations of interview data of this type are well-established. The 
possibility of mistakes or misunderstandings arising through transcription 
and translation was mitigated in the case of this research by the author’s 
mother tongue being the language in which the interviews were conducted, 
and the author being responsible for the transcription and translation. The 
author does not seek to over-claim or over-generalise from a small dataset 
taken from interviews with a specific research group, in a specific locality, at a 
specific time. However, the significance of this particular research group for 
the study lies in its claimed scientific and technical accomplishments in the 
use of medicinal plants in Colombia, as well as the professional and personal 
experiences of members of the group with the Colombian regulatory 
framework regarding access to genetic resources. Furthermore, the choice of 
location for interviews with market traders was justified by the necessity to 
corroborate the documentary analysis of the thesis, which point out how the 
law and policy behind the use of biodiversity do not capture the ways, 
traditions and costumes of those who work in the acquisition, transformation 
and trade of medicinal plants and knowledge related to them in the Colombian 
largest and most important market of plants. 
 
As noted above, alongside the interview data, observational notes taken by the 
author during the interviewing process were also used to draw a better picture 
of the participants’ life experience, interaction with other actors and places. 
One obvious limitation of this type of data is the dangers associated with 
cultural misunderstandings and misreadings: the fact that the author is a 
native of Colombia provides some mitigation of this limitation. 
 
Other resources such as maps are also employed in this thesis to locate the 
reader in the different locations across the country in which the interactions 
among stakeholders and life experience of the participants can be 
contextualized geographically.   
 
 12 
The final part of the thesis adds to that deep and “thick” analysis of the 
Colombian law and policy in context, by making a normative claim to justify a 
more inclusive regulation of innovation, in which practices and knowledge 
from indigenous communities are recognised and effectively protected. The 
implication of the aims of the International Regime on Access to Genetic 
Resources and Benefit Sharing is that this is what is required of countries that 
have agreed to its international norms. The normative part of the thesis draws 
from Sen’s Capability Approach.22 The Capability Approach seeks to make 
economic development inclusive, through an analysis of people’s wellbeing 
beyond economic terms, such as average income. The Capability Approach 
focuses on people’s conditions, i.e. what people are capable of doing and being, 
so they can live a life according to those doings and beings, (or so called 
functionings), making life worth living. In that way, the approach is able to 
incorporate, within an economic analysis, aspects of life which go beyond 
maximisation of wealth to entitle people and communities to pursue what they 
consider a good life. Although Sen’s main claim is to tackle poverty and 
improve people’s quality of life, his approach can also be an inspiration in 
interdisciplinary work such as this thesis because it allows to set up normative 
claims in the form of capabilities, which contains a list of conditions (i.e. 
functionings, what people are able to do or be); consequently, those conditions 
can be evaluated in order to define whether the proposed capability can be 
achieved.23  
 
For the particular case of the thesis, the argument is that there should be a 
capability for sustainable innovation in the health industry and in health 
research in Colombia. This claim departs from the standard view of Colombia’s 
policy on innovation, which has informed the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
the country. In the Andean nations, innovation has been constructed with a 
market-oriented perspective which measures and defines its scientific and 
 
22 As originally proposed in Amartya Sen, ‘Equality of What?’ [1979] The Tanner Lecture on 
Human Values- Stanford University. 
23 Ingrid Robeyns, ‘The Capability Approach’ in Edward Zalta (ed), The Standford 
Encyclopedia of Philosphy (Winter Edi, 2016) 
<https://plato.stanford.edu/entries/capability-approach/>. 
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technological infrastructure. This means that R&D in Colombia responds to a 
market logic, in which technology and science serves the purpose of bringing 
new products, process and services into the market. Translating this analysis 
into the thesis, local researchers, who are part of such an infrastructure, are 
evaluated and measured in terms of being able to produce new products, 
processes, and services derived from biodiversity, and bring them to the 
market. This means practices and knowledge from local, indigenous, and Afro-
Colombian communities that add value to the use of biodiversity for health 
research and the health industry, but which do not follow a market-oriented 
perspective, are not considered innovative.  
 
As those practices and knowledge are not seen as innovative in Colombia, this 
thesis argues that they are not properly acknowledged in R&D and industrial 
applications, nor effectively protected as Colombia implements the 
International Regime on Access to Genetic Resources and Benefit Sharing. As 
a result, knowledge and practices have been placed into the public domain, 
leading local researchers to appropriate them through, for instance, patents. 
Furthermore, the national herbal industry not only employs them as a source 
in the production of phytomedicines, but also uses them to prove safety and 
effectiveness of those products in order to obtain marketing authorisation 
from local authorities.  
 
That is why this thesis argues that Colombia’s implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
should instead aim to achieve a capability for sustainable innovation in health 
research and the health industry, so as to include practices and knowledge of 
indigenous communities that add value to the use of biodiversity. 
 
  
To explain what would achieve such a capability, this thesis puts forward an 
account of “functionings”: What local, indigenous, and Afro-Colombian 
communities are capable of doing and being in R&D contexts. Attention to 
those functionings in Colombia’s regulatory design when implementing the 
International Regime on Access to Genetic Resources and Benefit Sharing, the 
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thesis argues, would secure a more inclusive innovative health industry and 
health research sector in Colombia.  
 
As it can be observed, this thesis makes Colombia’s market perspective for 
health industry and health research on the use of biodiversity accountable for 
affecting communities’ rights. Yet, this research does not distance itself 
completely from the view that biodiversity could lead Colombia to enhance its 
technical and scientific capability, as well as encouraging economic 
development, while protecting communities. This means that the protection 
of communities’ practices and knowledge should be adequately integrated into 
the logic of the relevant markets in the use of biodiversity, i.e. the desire to 
bring new products and process into the market in order to impact positively 
countries’ economic agendas. This can be observed in the wording of the UN 
Convention on Biological Diversity (CBD), the core treaty of the International 
Regime on Access to Genetic Resources, which provides a definition of 
sustainable use of biodiversity, as this treaty states that countries should 
exploit their biodiversity, including genetic resources, in a way and at a rate 
that secures the needs of present and future generations (Article 2 and 10 of 
the CBD). In other words, according to the CBD, sustainable use does not mean 
countries should desist from using biodiversity for research and industrial 
proposes, but should exploit it only in a form and manner that ensures that it 
would last.  
 
Therefore, sustainable use demands countries to create adequate measures to 
preserve world’s biodiversity, while they aim to achieve their economic 
interests. The same can be extended to communities’ practices and knowledge 
associated with genetic resources. The implementation of the International 
Regime on Access to Genetic Resources cannot be contrary to countries’ 
economic agendas, yet, it requires that the role of communities in the use of 
biodiversity is fully acknowledged. Although there is extensive critique on 
creating a balance between markets and economic development with 
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environmental and societal issues (i.e. “green capitalism” or neodesarrollo),24 
it is not only possible but also desirable. In fact, there are scholars such as 
Greene who brings into the discussion the ideas of market-oriented policies in 
the use of traditional knowledge without forgetting historically inequalities 
that affects indigenous communities.25 This requires not only establishing 
mechanisms to protect and recognise the role of communities in the use of 
biodiversity for health industry and health research, but also actively involving 
those communities so as to empower them to make their own decisions.  
 
Consequently, concepts such as sustainability and innovation in the use of 
biodiversity should be open to discussion to address communities’ concerns. 
It is precisely forums such as the UN Convention on Biological Diversity, and 
even the World Trade Organization, that have served as a platform to discuss 
economic and social aspects that affect the most vulnerable, including ethnic 
minorities and peasants.26 This is even more relevant in places such as 
Colombia where divisive and polarised perspectives of the market economy 
have also fuelled Colombia’s long internal conflict. In fact, Colombia witnessed 
the rise of left guerrillas who opposed any form of capitalism, and State-backed 
forces, including paramilitary armies, which defended the status quo, leading 
to a ferocious civil war that lasted more than 50 years.  In response, to be more 
precise, and to focus on the legal and constitutional settlement that followed, 
the Colombian Constitution of 1991 and the Constitutional Court of Colombia, 
the highest constitutional tribunal in the country, seek to create a balance 
between economic interests and societal concerns to secure an adequate path 
to peace and prosperity.  
 
As a consequence, sustainable use of biodiversity and innovation cannot be 
proposed exclusively as an unidimensional perspective in which the only thing 
 
24 For further information on this discussion in the context of Latin-American countries see: Fabio De 
Castro, Barbara Hogenboom and Michiel Baud, Environmental Governance in Latin America 
(Springer 2016). 
25 Shane Greene, ‘Indigenous People Incorporated? Culture as Politics, Culture as Property in 
Pharmaceutical Bioprospecting’ (2004) 45 Current anthropology 211. 
26 See for instance: Terry Mitchell, Ken Coates and Carin Holroyd, The Internationalization of 
Indigenous Rights: UNDRIP in the Canadian Context (Centre for International Governance 
Innovation 2014). 
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that matters is to bring products and process for profit in order to protect 
biodiversity. In addition, it is also important to include communities in the 
discussion about how to create a fairer and inclusive model of innovation in 
the use of biodiversity in Colombia. That is why this thesis also choose the 
Capability Approach for its normative frame, since it is a theoretical 
framework that aims to conciliate economic development with the needs of 
vulnerable populations in order to entitle them to pursue the life they want.  
 
Who Will Be Interested in the Research? 
 
This analysis of Colombia’s implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing, innovation and the 
contribution from local, indigenous, and Afro-Colombian communities in 
adding value to the use of biodiversity for the health industry and health 
research is significant to a broader audience in Colombia and those who are 
interested in understanding Colombia’s implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing. First, the thesis 
has obvious implications for the constitutionality of Colombian law and 
practice. The 1991 Colombian Constitution brings an extensive catalogue of 
liberties and rights. It includes the recognition and protection of community 
rights, and seeks to ensure that economic development does not violate those 
rights. Thus, in order to be constitutionally compliant, policy makers in 
Colombia should implement the International Regime on Access to Genetic 
Resources and Benefit Sharing so as to recognise and protect the role of 
indigenous communities’ practices and knowledge in the use of biodiversity. 
This thesis provides an assessment of whether the current legislation in 
Colombia requires amendment(s) to meet that constitutional aim. 
 
Second, the thesis is important for the various users of genetic resources and 
the wide range of stakeholders within health research in Colombia and its 
health industry. The thesis focuses on health research and the health industry 
since biodiversity is an important source for treatment of human diseases. 
Relevant stakeholders thus include not only users – such as laboratories, 
research centres, universities and even pharmaceutical companies which, for 
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instance, synthesise genetic resources for drug production – but also other 
stakeholders who employ those resources to produce and distribute medicinal 
plants to treat human diseases (e.g. the herbal industry). Since they invest time 
and economic resources in bringing products and processes with human 
therapeutic activity into the market, it is only natural that they are concerned 
about the scope and the potential impact of the International Regime on 
Access to Genetic Resources and Benefit Sharing on their R&D and industrial 
activities into genetic resources. Wider still, stakeholders include everyone 
who falls within the Colombian health system. 
 
As a single-country case study, the main contribution to existing knowledge 
that the thesis makes is its in-depth analysis of the Colombian implementation 
of the International Regime on Access to Genetic Resources and Benefit 
Sharing, its national health industry and health research sector, the rights of 
local, indigenous, and Afro-Colombian communities, in the light of the use of 
biodiversity, and its innovation policy. However, without wanting to over-
generalise, the thesis may also provide guidance to other developing countries 
rich in biodiversity, especially members of the Andean Community of Nations 
(of which Colombia is a member), to adopt policies and legal mechanisms that 
will lead them to take advantage of their genetic resources. The Andean 
Community of Nations is a regional organisation comprised of four 
neighbouring developing countries rich in biodiversity (Bolivia, Colombia, 
Ecuador, and Peru). Among its trade instruments, the Andean Community of 
Nations sets up general guidelines and a common policy on access to genetic 
resources which each member should implement at the national level, 
according to their country’s legal system.  
 
Further, the thesis adds to the literature mentioned above a case study from a 
different context. In particular, the Colombian case demonstrates the tensions 
between imaginaries of innovation in healthcare, the workings of research and 
industry at several levels (drug development and phytotherapy), and the 
position of local knowledge-holders. It contributes to a field of study that has 
demonstrated why international law has failed to seize the complexity of social 
relations surrounding plant and medicinal knowledge in biodiversity-rich 
 18 
countries, while expanding its reach to a new local context. Finally, it 
contributes to existing literature by interrogating the little-explored 
constitutional ramifications of a debate, in which international and national 
jurisdictional tensions are apparent. 
 
The Scope of the Thesis 
 
This research centres on the use of biodiversity by the health industry and in 
health research. Other important industries that are based on genetic 
resources, such as the agricultural industry, are beyond the scope of this thesis. 
This is because the regulation on plant genetic resources for agriculture and 
food involves different legal mechanisms and international organisations. 
Indeed, the discussion on plant genetic resources and intellectual property 
rights is quite different from that of genetic resources for human health, as the 
former have shown a different evolution. The core regulatory framework for 
plant genetic resources is the plant variety rights system, which is governed by 
the International Union for the Protection of New Varieties of Plants. 
Originally, this kind of protection was not intended to be introduced as an 
intellectual property rights system, but as a legal mechanism to encourage the 
sector of plant breeders.27 Developing countries have also campaigned in the 
Food and Agriculture Organization (FAO) to create an alternative legal 
framework that benefits them, and especially their farmers (i.e. the 
International Treaty on Plant Genetic Resources for Food and Agriculture).28  
 
The International Regime on Access to Genetic Resources and Benefit Sharing 
focuses on genetic resources found in microorganisms, animals, and plants as 
defined by Article 2 of the UN Convention on Biological Diversity. Although 
such a definition is broad enough to include human genetic resources, the 
 
27 For further information see: Margaret Llewelyn and Mike Adcock, European Plant 
Intellectual Property (Bloomsbury Publishing 2006); Margaret Llewelyn, ‘Which Rules in 
World Trade Law–Patents or Plant Variety Protection’ [2003] Intellectual Property: Trade, 
Competition and Sustainable Development 303.; for further information on the conflict 
between plant breeders protection and patents in Europe see A. Andreas Hübel, Ulrich Storz 
and Aloys Hüttermann, Limits of Patentability: Plant Sciences, Stem Cells and Nucleic Acids 
(Springer Science & Business Media 2012). 
28 The International Treaty on Plant Genetic Resources for Food and Agriculture adopted by 
the Food and Agriculture Organisation Conference through Resolution 3/2001  
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Conference of Parties of the UN Convention on Biological Diversity (the 
governing body of the UN Convention on Biological Diversity) has already 
excluded human genetic resources from the scope of Article 2.29 This indicates 
that the International Regime on Access to Genetic Resources and Benefit 
Sharing does not regulate access to human genetic resources.30 Therefore, the 
scope of the thesis includes genetic resources involving genetic material from 
plants, microorganisms, and animals and the information encoded in the DNA 
or RNA. It does not include human genetic resources.  
 
Equally, the analysis in this thesis focuses on the practice, cultural expression, 
and knowledge that indigenous and local communities hold on genetic 
resources. This means that the personal scope of the analysis covers not only 
ethnic communities (i.e. indigenous communities), but also groups of people 
whose cosmo-vision, social, and economic practices are interrelated with 
biodiversity (local communities). In the particular case of Colombia, the 
concept of communities also includes Afro-descendants. Despite the fact they 
are not natives of Colombia, they have nonetheless constructed its socio-
economic and spiritual heritage around Colombia’s biodiversity.  
 
In terms of its legal analysis, the thesis focuses on one particular set of 
international instruments: The International Regime on Access to Genetic 
Resources and Benefit Sharing. It includes three international agreements: 
The UN Convention on Biological Diversity,31 and the subsequent instruments 
that clarify the scope of access and benefit sharing of the UN Convention on 
Biological Diversity, notably the Bonn Guidelines32, and the Nagoya 
Protocol.33 However, to understand those legal instruments in the context of 
 
29 Conference of Parties of the UN Convention on Biodiversity, n 44 
30 For further information on human genetic resources and the International Regime on 
Access to Genetic Resources and Benefit Sharing see Doris Schroeder and Carolina Lasén-
Díaz, ‘Sharing the Benefits of Genetic Resources: From Biodiversity to Human Genetics’ 
(2006) 6 Developing World Bioethics 135; Doris Schroeder and others, ‘Sharing the Benefits 
of Genetic Research’. 
31 UN Convention on Biological Diversity, Rio de Janeiro, as adopted in June 1992 
32 Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the 
Benefits Arising out of their Utilisation, adopted by the Conference of the Parties of the UN 
Convention on Biological Diversity at its sixth meeting, in The Hague in April 2002 
33 Nagoya Protocol on Access to Genetic Resources and Fair and Equitable Sharing of the 
Benefits Arising from their Utilisation, adopted by the Conference of Parties of the UN 
Convention on Biological Diversity at its tenth meeting, in Nagoya, Japan in October 2010 
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broader international law, the thesis also contemplates other instruments, 
such as the Agreement on Trade-Related Aspects of Intellectual Property 
Rights 1994 (TRIPs),34 which aims to standardise patent protection among 
members of the World Trade Organization (WTO), including Colombia. 
Patents are relevant in the analysis of this thesis, since the products and 
processes which are considered to be innovative are protected through this 
intellectual property rights mechanism.  
 
Patents protect the generation of information and knowledge that flow in the 
market. Although patents protect all fields of technology, patent law and 
practice normally does not affect forms of production which do not necessarily 
involve invention. More specifically, and for the interest of this thesis, those 
forms of production include practices and knowledge from local and 
indigenous communities. Patents work on the basis of documented disclosure 
of inventions to the relevant authorities. Where indigenous and local 
communities pass on their knowledge verbally, rather than in written forms of 
patents or in scientific journals, holders of technology have documented, 
collected, and synthesised inventions deriving from that indigenous 
knowledge and those practices in order to place products and processes onto 
the market. This has led to what advocates of community rights groups and 
governments call “biopiracy”. In general terms, the term biopiracy is deployed 
to relate to any practice that involves the unlawful (and unethical) 
appropriation (generally via patents) by holders of technology of a country’s 
biodiversity or indigenous people and local communities’ traditional 
knowledge and practices. As the discussion of biopiracy has been taken to 
different forums, including the World Intellectual Property Organization 
(WIPO) and the International Regime on Access to Genetic Resources and 
Benefit Sharing, there have been attempts to narrow down the concept of 
biopiracy to two private international law definitions: Misappropriation and 
misuse. 35 While the former refers to non-contractual disputes in which prior 
 
34 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs), Annex 1C of 
the Marrakech Agreement Establishing the World Trade Organization, signed in Marrakech, 
Morocco April 15 1994   
35 For further information see Claudio Chiarolla, ‘Biopiracy and the Role of Private 
International Law under the Nagoya Protocol’ (2012) 02/12; The Conference of Parties of the 
UN Convention on Biological Diversity, ‘Report of the Eighth Meeting of the Ad Hoc Open-
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informed consent and mutually agreed terms were not obtained, the latter 
refers to situations in which prior informed consent and mutually agreed 
terms were obtained, but there was a breach of contractual obligations. 
Although those concepts have not been included in the final text of any of the 
binding instruments of the International Regime on Access to Genetic 
Resources and Benefit Sharing, this thesis adopts a narrowed down term of 
biopiracy to refer to both misuse and misappropriation.  
 
Since the herbal industry is within the scope of this thesis, the Colombian 
regulation on market approvals for pharmaceutical products, in which 
phytomedicines are included, is also evaluated. Market approvals for 
medicines consists of a risk-benefit assessment, which is carried out by a 
health authority, which in the case of Colombia is the Instituto Nacional de 
Vigilancia de Medicamentos (INVIMA)). In this evaluation, the 
pharmaceutical product has to meet certain scientific criteria on quality, safety 
and efficacy, which are normally corroborated by clinical trials. However, 
“traditional phytomedicines” are not required to carry out clinical trials, 
instead safety and efficacy can be corroborated through the documentation of 
communities’ traditional knowledge and practices. Consequently, any 
proposed legal solution on how to include communities’ understanding of 
biodiversity in the health industry demands inclusion of this regulation.  
 
The core focus of the thesis is policies and legal mechanisms on benefit 
sharing. Although the research mentions different types of benefit sharing 
agreements (i.e. licensing and joint ownership of intellectual property rights, 
milestone payments, etc.), an analysis of specific provisions in mutually agreed 
terms (such as different types of licensing agreements related to genetic 
resources and intellectual property rights; or alternative mechanisms of 
licensing technology in the context of biodiversity and genetic resources, such 
 
Ended Working Group on Access and Benefit Sharing’, UNEP/CBD/COP/10/5/Add.2 (2009) 
<https://www.cbd.int/doc/meetings/cop/cop-10/official/cop-10-05-add2-en.pdf> accessed 
August 22 2017; IGC, ‘Glosarry of Key Terms Related to Intellectual Property and Genetic 




accessed August 22 2017. 
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as patent pools, open sources, or clearing houses) is beyond its scope. Instead, 
the thesis brings a modest interdisciplinary perspective to the doctrinal 
analysis of the International Regime on Access to Genetic Resources and 
Benefit Sharing. 
 
The Thesis Road Map 
 
Chapter Two introduces the International Regime on Access to Genetic 
Resources and Benefit Sharing. It identifies the main provisions of this 
international framework, particularly the rules on access, benefit sharing, and 
communities’ rights over their traditional knowledge associated with genetic 
resources. This chapter’s analysis points out that, despite efforts to include 
communities’ rights within the scope of the regulation, the implementation of 
this treaty at the national level demonstrates the difficulty of capturing the 
complexity or “messiness” of the different actors (users of genetic resources, 
the industry, communities, government agencies, etc.) behind the use of 
communities’ practices and knowledge over genetic resources for health 
industry and health research. In fact, the implementation of this treaty in 
developing countries rich in biodiversity indicates that there are difficulties in 
recognising and protecting communities’ contributions in adding value to 
biodiversity for health research and the health industry, since it conflicts with 
the model of innovation that is primarily focused on specific sectors such as 
the pharmaceutical industry, and countries’ interests in exploiting their 
biodiversity for economic development.  
 
Chapter Three focuses on the particularities of Colombian law related to the 
thesis’ subject matter. There are two key aspects: The Andean Community 
legislation on access to genetic resources and benefit sharing, in which 
Colombia is a member; and the constitutional provision that aims to reconcile 
communities’ rights with economic development. This chapter also studies in 
particular how regulation from different governmental agencies in Colombia 
has eased the rules on access and benefit sharing for local researchers, which 
apparently contradicts the Andean Community’s provisions and constitutional 
mandates. Also, throughout the study of the implementation of the 
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International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia, it is also noted that the government, through different 
administrative decisions, has carefully exempted the herbal industry from the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia, meaning it is not required to comply with this legislation. In other 
words, the current legislation on the implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing benefits local 
researchers and the herbal industry, and is in apparent contradiction with the 
Andean Community’s legislation and constitutional provisions.  
 
Having explained the particularities of the Colombian legal system, Chapter 
Four analyses how Colombian law worked out in practice for health research 
in genetic resources as the country implements the International Regime on 
Access to Genetic Resources and Benefit Sharing. Drawing on data from semi-
structured interviews, the chapter analyses in particular how local research 
has benefited from legislation that leaves aside practices and knowledge 
emanating from local, indigenous, and Afro-Colombian communities in 
adding value to biodiversity. In particular, it analyses how in health research, 
the current implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing has placed into the public domain those 
practices and knowledge since local researchers of genetic resources (e.g. 
universities) have access to them without reaching prior informed consent and 
signing mutually agreed terms with those communities. The chapter does so 
through the examples of two native plants Dividivi (Caesalpinia spinosa) and 
Anamú (Petiveria alliacea), in which publicly funded research realises the 
therapeutic value of the plant thanks to practices from local communities, yet 
those communities have not been acknowledged for their contribution in the 
research.  
 
The evidence collected from local researchers in a Colombian university and 
from market traders in two locations where medicinal plants are traded also 
demonstrates that, in practice, there is a fragmented implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia. This involves, on one hand, the different provisions of the Andean 
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Community legislation and Colombian constitutional mandates that secure 
extensive prerogatives to communities, and, on the other hand, different 
Colombian authorities (ministries, state agencies, etc.) and administrative 
decisions that have benefited and encouraged local researchers to access those 
communities’ knowledge without even consulting them.  
 
Regarding the health industry, Chapter Five raises a fundamental question: To 
what extent should the herbal industry comply with the International Regime 
on Access to Genetic Resources and Benefit Sharing in the same way other 
industries so, such as the pharmaceutical industry, since it benefits from 
communities’ practice and knowledge associated with genetic resources? As a 
result, this chapter explores the herbal industry in Colombia and how it has 
also benefited from Colombia’s implementation of the International Regime 
on Access to Genetic Resources and Benefit Sharing. The chapter illustrates 
that this industry employed communities’ practices and knowledge in the 
production of phytomedicines, as well as in proving safeness and effectiveness 
of these products, without being required to comply with the International 
Regime on Access to Genetic Resources and Benefit Sharing and without 
consulting communities. 
 
Chapter Five also argues that this has occurred because Colombia has 
implemented the Access to Genetic Resources and Benefit Sharing Regime to 
include the use of technologies on genetic resources (e.g. chemical synthesis 
or biotechnology) and the use of legal mechanisms to protect inventions that 
derive from those resources such as patents. Those technologies and legal 
mechanisms of protection are common in sectors such as the pharmaceutical 
industry, but not in the herbal industry. As a result, again drawing on data 
from semi-structured interviews and observations in an important urban 
market in Bogotá, this chapter studies how the herbal industry operates in 
practice in Colombia. It explores how this industry benefits from Colombian 
access to genetic resources and benefit sharing regulation that does not include 
it within its scope.  
 
 25 
Additionally, Chapter Five explores how the industry benefits from the efforts 
of scholars and authorities in documenting communities’ practices and 
knowledge over the use of medicinal plants. Since those efforts have placed 
into the public domain those practices and knowledge, the herbal industry has 
accessed them to understand the medicinal use of plants, and to prove safeness 
and effectiveness of phytomedicines so as to obtain marketing approvals of 
those products.  
 
As the thesis notes that Colombia has tried to reconcile economic development 
with other interests, particularly those who have historically suffered most 
from Colombia’s complex history of violence, including communities, Chapter 
Six points out that this has not been the case with the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing. 
Because Colombia has pursued an ambitious economic agenda and 
international trade in the use of genetic resources for health research and the 
health industry, the government has supported local researchers and the 
herbal industry to the detriment of communities’ rights.  
 
That is why Chapter Six points out that, despite the fact that health research 
and the health industry is constructed in a market-oriented perspective, it 
would be possible to involve other aspects, such as social concerns. Chapter 
Six suggests that this could be achieved by including social concerns such as 
communities’ rights in Colombian innovation policy. As a result, this chapter 
includes communities in Colombian innovation policy by making a normative 
claim through Sen’s Capability Approach.  
 
In particular, Chapter Six correlates Sen’s economic analysis of countries’ 
development with the problems highlighted in the thesis. This thesis points 
out that Colombia has failed to include the valuable contribution of 
communities in the use of biodiversity for the health industry and health 
research in its market-oriented innovation policy. As a result, Chapter Six 
makes a normative claim, arguing for sustainable innovation in health 
research and the health industry, and its articulation through a list of 
functionings: what local communities are capable of being and doing in the 
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context of health research. Sen’s approach allows an analysis of the steps it 
takes to achieve a particular capability. Therefore, thinking about sustainable 
innovation in terms of capabilities aims to recognise practices and knowledge 
over biodiversity as a fundamental aspect for health research and the health 
industry in Colombia.  
 
Finally, Chapter Seven discusses and accommodates the normative claim of 
capability for sustainable innovation and its list of functionings so as to 
propose amendments to Colombia’s implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing. Thus, Chapter 
Seven aims to provide both a normatively grounded and a practical solution to 
the thesis’ main research question: How should Colombia, a developing 
country rich in biodiversity, implement the International Regime on Access to 
Genetic Resources and Benefit Sharing to recognise the contribution from 
local, indigenous, and Afro-Colombian communities’ practices and knowledge 
in adding value to the use of genetic resources for the health industry and 
health research? It does so by proposing legal amendments grounded in a 
normative claim supporting a Capability Approach to sustainable innovation 
in health research and the health industry. This capability is, in turn, formed 
by a list of three functionings, and thus the legal amendments suggested are 





Chapter Two: A Review of the International Regime on 
Access to Genetic Resources and Benefit Sharing 
Introduction 
 
The drafting and wording of the International Regime on Access to Genetic 
Resources and Benefit Sharing, and its implementation in developing 
countries rich in biodiversity as well as its amendments, reveal how 
international law that was supposed to be about conservation and sustainable 
use of biodiversity became a more complex tale.  
 
This is a tale that is still evolving as interdisciplinary scholarship uncovers 
further aspects that add to our understandings of a continually transformative 
international legal regime. As matter of fact, the UN Convention on Biological 
Diversity, which is the core treaty of the International Regime on Access to 
Genetic Resources and Benefit Sharing, was designed at a time in which the 
loss of biodiversity was already a major preoccupation for environmental non-
governmental organizations (NGOs).36 Their campaigning for the UN 
Convention on Biological Diversity focused on that preoccupation, but as the 
negotiations advanced in the drafting of the UN Convention on Biological 
Diversity, different issues emerged which revealed that the protection of the 
world’s biodiversity was a rather more complex matter.  
 
Since a great deal of the world’s biodiversity is mainly located in the developing 
world, at the time the UN Convention on Biological Diversity was negotiated 
there was a sense that those who would have the stewardship of the world’s 
environment would be its poorest countries. Far from protecting their 
resources in the somewhat simplistic model advanced by some NGOs, these 
countries were relying on natural non-renewable resources such as oil and gold 
 
36 For a full account of all actors that work in the drafting of the UN Convention on Biological 
Diversity see David Eugene Bell, ‘The 1992 Convention on Biological Diversity: The 
Continuing Significance of US Objections at the Earth Summit’ (1992) 26 Geo. Wash. J. Int’l 
L. & Econ. 479.  
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for their economic growth.37 For the global north to ask the global south to 
eschew economic development to preserve global biodiversity was an 
unethical extension of the forces of colonialism that created the economic 
disparities in the first place. 
  
Furthermore, the question of economic disparities within developing 
countries was also an important factor. The UN Convention on Biological 
Diversity negotiation was also a space to advocate for groups which had been 
long neglected by governments in developing countries, especially indigenous 
and local communities which have a deeply spiritual, social, and economic 
“dependence” on biodiversity.38 The authors of the UN Convention on 
Biological Diversity tried to construct a cooperative treaty in which countries 
would embrace the conservation and sustainable use of biodiversity as a 
“common concern”39 of mankind, as well as addressing local and indigenous 
communities’ concerns in environmental issues. Both conservation and 
sustainable use of biodiversity became two of the three objectives of the UN 
Convention on Biological Diversity. 
 
However, in practice the UN Convention on Biological Diversity, and 
particularly its implementation, turned into something rather different than 
was originally planned. Developing countries sought to secure that they would 
not be dictated to on what measures on conservation and sustainability they 
should adopt, as that could slow their path to economic prosperity. As a result, 
the UN Convention on Biological Diversity also centred on securing 
sovereignty, ownership, and control of biodiversity by developing countries 
 
37 This is also known as a stewardship obligation of conservation and sustainability over the 
exploitation of biodiversity, which means that developing countries rich in biodiversity should 
consider conservation and sustainability in the exploitation of their biodiversity. This 
stewardship obligation is reflected in the UN Convention on Biological Diversity as this treaty 
requires States to adopt and develop a series of measures that involve, for instance, developing 
plans and strategies for the conservation and sustainable use of biodiversity (Article 6 of the 
UN Convention on Biological Diversity) as well as identifying and monitoring components of 
biological diversity (Article 7 of the UN Convention on Biological Diversity).  For further 
discussion see:  William NR Lucy and Catherine Mitchell, ‘Replacing Private Property: The 
Case for Stewardship’ (1996) 55 The Cambridge Law Journal 566. and Christopher Rodgers, 
‘Property Rights, Land Use and the Rural Environment: A Case for Reform’ (2009) 26 Land 
Use Policy S134. 
38 See Paragraph 13th of the UN Convention on Biological Diversity. 
39 Paragraph 4th of the UN Convention on Biological Diversity. 
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rich in biodiversity.40 Further, as new technologies (e.g. biotechnology), that 
make use of biological material to create new products and processes, 
consolidated and other stakeholders such as the pharmaceutical industry 
raised interest in those resources as an important source for drug 
development, developing countries rich in biodiversity seized the sovereignty 
issue as an opportunity to claim also sovereign control over genetic resources; 
hence, they were entitled not only to be asked beforehand to grant access to 
genetic resources, but also to secure benefit sharing from the use of those 
resources. The result was the establishment of a third objective in the UN 
Convention on Biological Diversity: access to genetic resources and sharing of 
benefits that arise from their utilization.  
 
Since its inception, the provisions on access and benefit sharing of the UN 
Convention on Biological Diversity have been at the centre of discussion in the 
Conference of Parties, the executive body of the UN Convention on Biological 
Diversity. Although access and benefit sharing obligations are to be 
implemented by country members in the context of the Convention’s other two 
objectives (conservation and sustainable use of biodiversity), those provisions 
have been amplified and clarified by the Bonn Guidelines and, consequently, 
the Nagoya Protocol. These three international instruments make up the 
International Regime on Access to Genetic Resources and Benefit Sharing. As 
is discussed in detail in this chapter, these provisions have also evolved over 
 
40 This is reflected in the negotiation process of the UN Convention on Biological Diversity as 
it can be observed how sovereignty gained relevance over other principles. The first draft 
established 18 principles including principles related to sustainability and conservation of 
biodiversity. The principle of sovereignty was presented through the final version. It was in 
the seventh negotiating session that the Chairman of the Intergovernmental Negotiating 
Committee circulated a reduced version of Article 3 based on the fifth revised draft (which 
only included sovereignty as a principle) with the aim of assisting the parts of the committee 
to reach an agreement; see Article 3 of the following drafts and European Patent Office on the 
negotiation process of the UN Convention on Biological Diversity: Intergovernmental 
Negotiating Committee for a Convention on Biological Diversity, ‘Second Informal Note by the 
Chairman of the INC and the Executive Director of UNEP Regarding Possible Compromise 
Formulations for the Fifth Revised Draft Convention on Biological Diversity’, Fourth Session, 
UN Environment Programme, UNEP/Bio.Div/N5-INC. 3.4, (1991); Intergovernmental 
Negotiating Committee for a Convention on Biological Diversity, ‘Third Revised Draft 
Convention on Biological Diversity’, Fifth Session, UN Environment Programme, 
UNEP/Bio.Div/N5-INC. 3-2 (1991); Intergovernmental Negotiating Committee for a 
Convention on Biological Diversity, ‘Fourth Revised Draft Convention on Biological Diversity’, 
Sixth Session, UN Environment Programme, UNEP/Bio.Div/N5-INC. 4-2, (1991). 
 32 
the years so as to embrace further economic, technical, social and political 
complexities.  
 
In brief, the International Regime on Access to Genetic Resources and Benefit 
Sharing seeks to provide general provisions to countries on how to establish 
rules on access to genetic resources and traditional knowledge associated with 
genetic resources, how users should share benefits from the utilisation of 
genetic resources, and what mechanism of compliance countries shall take 
into account. This has led to discussions on how to implement those provisions 
and the consequences for research and industry, as well as indigenous 
communities. Equally, the International Regime on Access to Genetic 
Resources and Benefit Sharing has prompted a significant body of scholarly 
work on different issues, ranging from the balance of power among countries 
and economic development41 to matters of justice, ethics42, and the tensions 
arising from the protection of technologies that employ genetic resources with 
intellectual property rights, including patents, and how it is claimed that 
patent protection on products and processes derived from biodiversity 
promotes biopiracy.43  
 
41 On the balance of power and dynamics between the global South and global North in the 
making of the International Regime on Access to Genetic Resources and Benefit Sharing see: 
Sabrina Safrin, ‘Hyperownership in a Time of Biotechnological Promise: The International 
Conflict to Control the Building Blocks of Life’ (2004) 98 The American Journal of 
International Law 641; Kal Raustiala and David G Victor, ‘The Regime Complex for Plant 
Genetic Resources’ (2004) 58 International Organization; Laurence Helfer, ‘Regime Shifting: 
The TRIPs Agreement and New Dynamics of International Intellectual Property Lawmaking’ 
(2004) 29 Yale Journal of International Law; Sam F Halabi, Intellectual Property and the 
New International Economic Order : Oligopoly, Regulation, and Wealth Redistribution in 
the Global Knowledge Economy. 
42 On the different perspectives on what sort of ethical principles the International Regime on 
Access to Genetic Resources and Benefit Sharing is constructed upon see: Doris Schroeder and 
Balakrishna Pisupati, Ethics, Justice and the Convention on Biological Diversity (United 
Nations Environment Program 2010); Doris Schroeder and Julie Cook Lucas, Benefit 
Sharing: From Biodiversity to Human Genetics (Springer Science & Business Media 2013).  
43 Chapter One introduced this discussion by analysing the difficulties to conciliate, on one 
hand, a market-oriented perspective of protecting inventions derived from genetic resources 
through patents, and, on the other hand, the interest of developing countries rich in 
biodiversity in maintaining access control on genetic resources, and including other forms of 
knowledge production over genetic resources, particularly traditionally knowledge and 
practices from local and indigenous communities. Further information on the conflict between 
intellectual Property Rights and the International Regime on Access to Genetic Resources and 
Benefit Sharing see: Graham Dutfield, ‘Sharing the Benefits of Biodiversity: Is There a Role 
for the Patent System?’ (2002) 5 The journal of world intellectual property 899; Graham 
Dutfield, ‘Traditional Knowledge, Intellectual Property and Pharmaceutical Innovation: 
What’s Left to Discuss?’ [2015] Sage Handbook of Intellectual Property. London: Sage 649; 
Michael Blakeney, ‘Proposals for the Disclosure of Origin of Genetic Resources in Patent 
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Since the International Regime on Access to Genetic Resources and Benefit 
Sharing encompasses different issues, this chapter aims to locate the scope of 
the thesis within the analysis of the main features of the International Regime 
on Access to Genetic Resources and Benefit Sharing, its implementation, and 
the academic critique. As observed in the introduction to the thesis, this thesis 
argues that – at least in Colombia – the contributions from local and 
indigenous communities in adding value to the use of biodiversity have not 
been properly acknowledged and effectively protected throughout the whole 
R&D process, and the commercialisation of products and services based upon 
biodiversity. The implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing is unbalanced towards both a model of 
innovation, i.e. it only recognises and protects a market oriented-R&D, and to 
promoting new economic sectors, such as the herbal industry.  
 
Overall, Chapter Two provides both a legal analysis of international texts and 
a literature review of academic debates on the implementation of the 
provisions of International Regime on Access to Genetic Resources and 
Benefit Sharing, particularly, those which reveal the difficulties in regulating 
the different complexities behind the use of genetic resources, including the 
contribution of communities’ practices and traditional knowledge associated 
with genetic resources for the health industry and health research.  
 
This chapter underlines that the International Regime on Access to Genetic 
Resources and Benefit Sharing and its implementation is centralising the 
recognition of the role of communities in adding value to the use of biodiversity 
and establishing mechanisms of compliance towards downstream stages of 
research and development (R&D). It also discusses how the wording of the 
International Regime on Access to Genetic Resources and Benefit Sharing has 
been constructed to include specific industries such as the pharmaceutical and 
biotechnological industries, leaving outside its scope other sectors such as the 
herbal industry, which also employ not only genetic resources to elaborate and 
 
Applications’ [2005] Study for the World Intellectual Property Organization.; Efferth T and 
others, ‘Biopiracy versus One-World Medicine–From Colonial Relicts to Global Collaborative 
Concepts’ [2018] Phytomedicine 
 
 34 
commercialise medicinal plants and phytomedicines, but also the knowledge 
and practices of communities. This chapter also points out that since the 
International Regime on Access to Genetic Resources and Benefit Sharing has 
raised so many different issues, it is difficult for a body of international law to 
regulate all complexities surrounding biodiversity. The chapter concludes that, 
as a result, despite the fact that the International Regime on Access to Genetic 
Resources and Benefit Sharing aims to tackle all those issues, in practice it has 
favoured a market-perspective in the use of biodiversity for health research 
and the health industry, limiting the recognition and protection of 
communities’ practices and knowledge. 
 
Chapter Two proceeds as follows. It first reviews the wording of the 
International Regime on Access to Genetic Resources and Benefit Sharing, 
pointing out the main features of this international framework. It particularly 
clarifies, distinguishes and contextualises the three objectives of the UN 
Convention on Biological Diversity: conservation, sustainable use of 
biodiversity, access to genetic resources and benefit sharing. Second, the 
chapter provides an overview of the implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing in developed and 
developing countries. This has led to a range of discussions among policy 
makers and academics, including how to acknowledge and protect 
contributions of indigenous communities in adding value to biodiversity which 
is subsequently deployed in health research and by the health industry. The 
third part of the Chapter discusses in detail how the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing has 
focused on downstream users, leaving intact upstream users, revealing that 
communities’ contributions in the use of genetic resources for health research 
and the health industry are not properly acknowledged. This part also 
identifies that the implementation of this international law has focused on 
specific users of genetic resources, leaving other sectors, such as the herbal 




The Wording of the International Regime on Access to Genetic Resources and 
Benefit Sharing: From the UN Convention on Biological Diversity to the Nagoya 
Protocol 
 
As noted above, the UN Convention on Biological Diversity establishes three 
main objectives: (i) conservation, (ii) sustainable use of biodiversity, and (iii) 
access to genetic resources and benefit sharing. These objectives create 
obligations for developing countries rich in biodiversity and also for developed 
countries.  First, developing countries rich in biodiversity, as stewards of 
biodiversity and providers of genetic resources, should create policies that aim 
to protect biodiversity (i.e. conservation and sustainable use of biodiversity) 
and to facilitate access to genetic resources. Second, developed countries have 
an obligation to facilitate financial and technical cooperation, transfer of 
technology to developing countries rich in biodiversity, and to comply with 
access to genetic resources and benefit sharing legislation in developing 
countries rich in biodiversity. This section analyses, establishes differences 
between, and contextualises the three objectives of the UN Convention on 
Biological Diversity, and the obligations that emanate from those objectives 
for developing countries rich in biodiversity and for developed countries.   
 
Conservation, Sustainable use, Sovereignty, Developing Countries Rich in Biodiversity’s 
Stewardship Role and Developed Countries’ Obligations in the UN Convention on Biological 
Diversity  
 
Article 1 of the UN Convention on Biological Diversity sets out its objectives: 
‘the conservation of biological diversity’ (objective 1), ‘the sustainable use of its 
components’ (objective 2); and ‘the fair and equitable sharing of the benefits 
arising out of the utilization of genetic resources, including by appropriate 
access to genetic resources, and by appropriate transfer of relevant 
technologies, taking into account all rights over those resources and to 
technologies, and by appropriate funding’ (objective 3). 
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The first two objectives of the UN Convention on Biological Diversity are based 
on a compromise of the interests of all relevant parties. Although this means 
that most developing countries rich in biodiversity have a stewardship 
obligation of conservation of biodiversity and sustainable use of its 
components, the UN Convention on Biological Diversity calls on other parties, 
especially developed countries, to cooperate with those efforts. But these 
aspects of the Convention are not designed in a way that creates legally binding 
measures. Conversely, the third objective of the UN Convention on Biological 
Diversity aims to create an actual obligation on those who access genetic 
resources (users), to share the benefits of the utilisation of those resources. 
This subsection of the Chapter explains the obligations of both developing 
countries rich in biodiversity and of developed countries that emanate from 
the first two objectives of the Convention (conservation and sustainable use). 
The next subsection explains the third objective: access to genetic resources 
and benefit sharing.  
 
First, the obligations that derive from Article 1 for developing countries rich in 
biodiversity depart from the express recognition that developing countries rich 
in biodiversity have unfettered sovereignty over their own biodiversity and its 
components, including genetic resources. Indeed, the UN Convention on 
Biological Diversity recognises in Article 3 that the only principle of the UN 
Convention on Biological Diversity is the sovereign right that states have over 
their biodiversity (Article 3) and genetic resources (Articles 3 and 15.1) to 
decide their own policies of conservation of biodiversity and sustainable use of 
its components, and access to genetic resources and benefit sharing.  
 
The UN Convention on Biological Diversity imposes a stewardship obligation 
on developing countries rich in biodiversity. Despite the UN Convention on 
Biological Diversity’s recognition of sovereign rights over biodiversity, this 
treaty also creates obligations to protect biodiversity. Indeed, under the 
mandate of Article 6 of the UN Convention on Biological Diversity, developing 
countries rich in biodiversity should develop a national biodiversity strategy 
which includes programmes and policies to comply with the measures set up 
in the UN Convention on Biological Diversity, such as identification and 
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monitoring of biodiversity and its components (Article 7), conservation of in 
situ areas (e.g. rain forest) (Article 8) and ex situ collections (e.g. botanical 
gardens, genetic banks) (Article 9), and allowing access to genetic resources 
for environmentally sound uses (Article 15). For instance, the Andean 
Community has developed a regional strategy on the conservation and 
sustainable use of their biodiversity and natural resources which creates a 
general policy framework for the Andean region (Bolivia, Colombia, Ecuador 
and Peru) on the implementation of the UN Convention on Biological 
Diversity.44  
 
Article 26 of the UN Convention on Biological Diversity requires the parties to 
the Convention to provide further information via national reports on what 
measures and mechanisms they have taken to implement the Convention, and 
how they have advanced national or regional strategies for conservation and 
sustainability. These national reports are submitted before the Secretary of the 
UN Convention on Biological Diversity, the executive body of the UN 
Convention on Biological Diversity. The reports also feed to the Clearing-
House Mechanism,45 which provides a platform for the exchange of 
information on aspects related to the implementation of the UN Convention 
on Biological Diversity. 
 
Second, with the exception of Australia and the United States, developed 
countries do not possess most of the world’s biodiversity. Through their 
history of activities such as deforestation, agriculture, and industrialization, 
 
44 Decision 523 Regional Biodiversity Strategy for the Tropical Andean Countries as signed in 
Lima, Peru on July 17 2002 
45 The core of the Clearing House Mechanism is the use of the World Wide Web (www) in order 
to classify, organise and find information related to conservation of biodiversity and 
sustainable use of its components. This web-based mechanism acts as a channel of 
communication between the national and regional levels, and the Secretariat of the UN 
Convention on Biological Diversity. The information collected may include all national 
biodiversity-related information necessary to give support to stakeholders (companies, 
governments, NGOs, etc.); hence they could accomplish the obligations imposed by the UN 
Convention on Biological Diversity; for further information see The Conference of Parties of 
the UN Convention on Biological Diversity, ‘X/15 Scientific and Technical Cooperation and 
the Clearing-House Mechanism’, UNEP/CBD/COP/DEC/X/15 (2010) 
<https://www.cbd.int/doc/decisions/cop-10/cop-10-dec-15-en.pdf> accessed July 30 2017. 
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they have nonetheless contributed to the deterioration of global biodiversity.46 
Because developed countries have contributed to the deterioration of the 
world’s biodiversity, the UN Convention on Biological Diversity contemplates 
that those countries should also contribute to the global effort of protecting 
biodiversity via international cooperation.    
 
The UN Convention on Biological Diversity provides different measures of 
cooperation and financial assistance to support developing countries rich in 
biodiversity in the implementation of the UN Convention on Biological 
Diversity. For example, Article 5 of the UN Convention on Biological Diversity 
requires parties to the Convention to cooperate through international 
organisations in the implementation of measures of the Convention, such as 
those described in Articles 7 to 10 of the Convention. For instance, since 1910 
the British-based organisation CABI has led taxonomy initiatives in different 
countries, particularly former British colonies47, which help us to understand 
the potential of world biodiversity in different areas such as drug discovery, 
tourism, and agriculture. The UN Convention on Biological Diversity is also 
leading the Global Taxonomy Initiative which has the support of organisations 
such as national museums and botanical gardens in developed countries and 
developing countries rich in biodiversity.48  
 
 
46 Biodiversity Information System for Europe (BISE), ‘Species’ <http://biodiversity. 
europa.eu/topics/species> accessed August 4 2017; Timothy Swanson, ‘Why Is There a 
Biodiversity Convention? The International Interest in Centralized Development Planning’ 
(1999) 75 International Affairs 307. 
47 Originally known as Commonwealth Agriculture Bureaux (CAB), in 1986 CAB transformed 
into CAB International (CABI) for further information see http://www.cabi.org/about-cabi/; 
for further information on the role of these international organisations in the making of the 
UN Convention on Biological Diversity see: Brian Groombridge, Global Biodiversity: Status 
of the Earth’s Living Resources (Chapman & Hall 1992). Harriet Bulkeley and others, 
Transnational Climate Change Governance (Cambridge University Press 2014).  
48 Taxonomy initiatives are important for developing countries rich in biodiversity as they 
could help those countries to understand the potential of their own biodiversity in different 
areas such as drug discovery, tourism and agriculture. 48 The UN Convention on Biological 
Diversity is also leading the Global Taxonomy Initiative which has the support of developed 
countries and developing countries rich in biodiversity organisations such as national 
museums and botanical gardens The Global Taxonomy Initiative included organisations such 
as the Food and Agriculture Organization, the UN Environment Programme, the International 
Union for Conservation, the European Strategy Forum for Research Infrastructure; for more 
information on the Global Taxonomy Initiative see http://www.cbd.int/gti/    
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The UN Convention on Biological Diversity calls on developed countries to 
support the implementation of the Convention in developing countries rich in 
biodiversity by providing financial assistance (Articles 20 and 21) and 
technical and scientific cooperation (Article 18) such as the creation and 
implementation of the Clearing House Mechanism. Additionally, the UN 
Convention on Biological Diversity creates a broad mandate in technological 
and financial cooperation between developed countries and developing 
countries rich in biodiversity (e.g. Articles 5 and 18 of the UN Convention on 
Biological Diversity). 
 
The Third Objective of the UN Convention on Biological Diversity: The Cornerstone of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
 
Technical cooperation has not been the only mechanism through which 
developing countries rich in biodiversity aim to comply with the obligations of 
conservation of biodiversity and sustainable use of its components. The third 
objective of the UN Convention on Biological Diversity, i.e. the sharing of the 
benefits that arise from the utilisation of genetic resources, gives to developing 
countries rich in biodiversity an entire legal framework to obtain benefits, 
including access to relevant technologies such as biotechnology.  
 
Such a legal framework is mainly designed in Articles 2, 3, 8 (j) and 15 of the 
UN Convention on Biological Diversity, and, subsequently, amplified and 
clarified by the Bonn Guidelines and the Nagoya Protocol. These two legal 
instruments do not derogate from or amend the UN Convention on Biological 
Diversity; instead both clarify the Convention’s wording. The Bonn Guidelines, 
however, are not a legally binding instrument, rather they are an international 
instrument that assists states and users of genetic resources to implement and 
comply with the UN Convention on Biological Diversity. However, the Nagoya 
Protocol is a legally binding instrument that creates obligations for states in 
the way that the UN Convention on Biological Diversity should be 
implemented at the national and regional level.  
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As countries implement those provisions, the ways in which they understand 
the terms contained therein, and the legal and administrative mechanisms 
used, form a key part of the legal and policy context surrounding the 
International Regime on Access to Genetic Resources and Benefit Sharing. 
Consequently, it is important to provide an explanation of those terms and 
their scope in order to facilitate, in the next section, the analysis of how 
countries have implemented them into their national legislation.  The next 
subsection of the chapter considers those matters and is divided as follows: (i) 
the definition of the nature of genetic resources; and (ii) the legal and 
administrative mechanisms for access to genetic resources and benefit sharing 
(prior informed consent and mutually agreed terms).  
The Definition of Genetic Resources  
 
The analysis of the definition of genetic resources in the International Regime 
on Access to Genetic Resources and Benefit Sharing allows us to understand 
the difficulty in regulating the complexities behind the use of biodiversity for 
research and industry. For instance, depending on how the term genetic 
resources is implemented by Members of the UN Convention on Biological 
Diversity, it defines whether or not specific uses given to genetic resources 
(chemical synthesis, sequencing of DNA, etc.) constitutes an access activity 
that is required to comply with the access and benefit sharing rules. Also, the 
arrival of new technologies such as gene editing and synthetic biology that 
relies more in the intangible aspects of genetic resources rather than the actual 
resource present technical and scientific challenges that could disrupt the 
definitions of the UN Convention on Biological Diversity. For those reasons, it 
is important to analyse in detail Article 2 of the UN Convention which defines 
genetic resources, and how the Bonn Guidelines and Nagoya Protocol have 
aimed to clarify and update the term. 
 
Genetic Resources in the Wording of the Article 2 of the CBD 
 
As discussed in the previous section, Article 1 of the UN Convention on 
Biological Diversity establishes three principles, of which two are related to 
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conservation and sustainable use of biological resources, and the third is 
related to access to genetic resources and sharing of the benefits that arise 
from the utilization of those resources. A key aspect to differentiate the 
objectives of Article 1 is precisely to differentiate the variety of terms that the 
International Regime on Access to Genetic Resources and Benefit Sharing 
creates regarding those objectives. For instance, there is the distinction 
between biological resources and genetic resources which emanates from 
Article 2 of the UN Convention on Biological Diversity. The former entails an 
obligation of conservation and sustainable use of biological resources. The 
latter is related to appropriate access to genetic materials.  
 
Article 2 of the UN Convention on Biological Diversity defines genetic 
resources as ‘genetic material of actual or potential value’, while genetic 
material means ‘any material from plant and animal, microbial, or other origin 
containing functional units of heredity’. In the context of Article 2, functional 
units of heredity refer to genetic elements that contain DNA and RNA such as 
seeds, cuttings, individual organisms, DNA extracted from plants, animals, or 
microorganisms. A biochemical extract, for instance, that does not contain any 
functional units of heredity is not considered to be genetic material.49 
‘Potential or actual value’ is the element of the definition of genetic resources 
that helps to distinguish genetic resources from genetic material. Value here 
refers to ‘a use that can be ascribed or is likely’.50  
 
Article 2 also defines biological resources as including ‘genetic resources, 
organisms or parts thereof, populations, or any other biotic component of 
ecosystems with actual or potential use or value for humanity’. In other words, 
biological resources refer to ‘real entities’ that range from animals to genes and 
ecosystems and that have a value for humanity.51 However, as discussed above, 
biological resources mainly involve an obligation to conservation and 
sustainable use,52 which means that activities related to conservation and 
 
49 Lyle Glowka and others, A Guide to the Convention on Biological Diversity (IUCN, Bonn 
(Alemania) Environmental Law Centre IUCN, Gland (Suiza) Biodiversity Programme 1994). 
50 ibid., pp 21-21 
51 ibid., p 16 
52 For instance see Preamble, Articles 6, 7, 8, 10, 12(c) of the UN Convention on Biological 
Diversity.  
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sustainability are not required to comply with the access and benefit sharing 
rules.  
Genetic Resources in the Bonn Guidelines and the Nagoya Protocol  
 
The Bonn Guidelines and the Nagoya Protocol have helped to clarify the 
content of Article 2 by employing the term ‘derivative’ and a standard of utility. 
The use of these terms aims to include not only functional units of heredity, 
but also the products that are derived from genetic resources, such as chemical 
compounds that are modified, created, or synthesised from genetic resources 
and the different uses given to them. The Bonn Guidelines do not extend the 
scope of the definition of genetic resources in Article 2 of the UN Convention 
on Biological Diversity, but suggest that derivatives and products that arise 
from the utilisation of genetic resources should be part of the negotiation of 
mutually agreed terms under the Convention.53 Furthermore, the Bonn 
Guidelines also focus on the term ‘utilisation of genetic resources’ from 
Articles 1 and 15 of the UN Convention on Biological Diversity in order to focus 
on a standard of utility. As it focuses on a standard of utility, it is possible to 
extend the definition of genetic resources to any use given to those resources 
within particular users such as the biotechnological and pharmaceutical 
industries.54  
 
The Nagoya Protocol establishes two terms: ‘Utilisation of genetic resources’ 
and ‘derivative’ in Article 2 (c) and (e) respectively. The former focuses on the 
different uses or utilisation given to genetic resources, for instance, in R&D for 
drug development processes. The Nagaya Protocol’s definition of ‘utilisation 
of genetic resources’ aims to clarify the definition of genetic resources so as to 
include not only the actual or potential value of genetic material (with 
functional units of heredity), but also the uses given to genetic resources. There 
is no list of uses or technologies, which would have helped to exemplify the 
 
53 Morten Walløe Tvedt and Olivier Rukundo, ‘Functionality of an ABS Protocol’ (2010) 9 
Journal of World Intellectual Property 189.  
54 See for instance Guidelines 8, 16 (b)(vi), 24, 41, 44 (1); n subsection 1.3 Chapter Four; for 
further analysis on the term ‘utilisation of genetic resources’ see Morten Walløe Tvedt and 
Tomme Young, Beyond Access: Exploring Implementation of the Fair and Equitable Sharing 
Commitment in the CBD (IUCN 2007).) 
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scope of the term utilisation, because it was agreed within the negotiations that 
led to the Nagoya Protocol that an open-ended term would cover new uses and 
technologies that were not discussed there.55 For instance, synthetic biology, a 
field which aims to apply engineering principles (e.g. standardization, 
decoupling, etc) to generate predictable outputs for different industries, is to 
believe to be included within the scope of the access and benefit sharing 
obligations. Bagley and Rai suggest that researchers who are in the field of 
synthetic biology are advised to inquire into the origin of the genetic material 
that they employ, so as to comply with access and benefit sharing obligations. 
Both authors also pointed out that, regarding the information of the genetic 
material, developing countries rich in biodiversity could assert that such 
information falls within the scope of the term in Article 2 of the UN Convention 
and the Nagoya Protocol. 56 This means that, by focusing on the utility criteria 
of access to genetic resources in a binding instrument, the Nagoya Protocol 
covers the different technologies (e.g. genetic modification and DNA synthesis 
or biochemical techniques) employed within particular sectors, including the 
pharmaceutical and biotechnology industries.57  
 
On derivatives,58 the Nagoya Protocol states that derivatives are ‘naturally 
occurring biochemical compound(s) resulting from the genetic expression or 
metabolism of biological or genetic resources’ even if they do not have 
functional units of heredity (Article 2 (e) of the Nagaya Protocol). The 
definition of derivative is extended, therefore, to biochemical compounds such 
 
55 Kabir Bavikatte and Brendan Tobin, ‘Cutting the Gordian Knot: Resolving Conflicts over the 
Term “Utilisation.”’ (2010) 4 Biores. For further information on negotiations regarding the 
term derivatives and utilisation see IISSD Reporting Service, ‘Summary of the Ninth Meeting 
of the Working Group on Access and Benefit Sharing of the Convention on Biological Diversity’ 
(2010) 9 Earth Negotiation Bulletin <http://enb.iisd.org/download/pdf/enb09503e.pdf>.  
56 Margo A Bagley and Arti K Rai, ‘The Nagoya Protocol and Synthetic Biology Research: A 
Look at the Potential Impacts’ (2014) 5 Virginia Public Law and Legal Theory Research 
Paper ; Carlos Augusto Conde Gutiérrez, ‘Governing Synthetic Biology in the Light of the 
Access and Benefit Sharing Regulation (ABS)*’ (2014) 41 Law and the Human Genome 
Review 63. 
57 Thomas Grieber and others, An Explanatory Guide to the Nagoya Protocol on Access and 
Benefit-Sharing (IUCN 2012). 
58 For further information of how the negotiations on the protocol were carried out see UNEB 
CBD, ‘Report of the Fourteenth Meeting of the Subsidiary Body on Scientific, Technical and 
Technological Advice’, UN Doc UNEP/CBD/COP/10/3, Nagoya, Japan (2010); UNEB CBD, 
‘Report of the Second Part of the Ninth Meeting of the Ad Hoc Open-Ended Working Group 
On Access and Benefit Sharing’, UN Doc. UNEP/CBD/COP/10/5/ad. Nagoya, Japan (2010). 
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as aromas, resins and biochemicals in cells employed in, for instance, 
pharmaceutical products.59  
 
As observed, the Nagoya Protocol has actually extended the scope of genetic 
resources of Article 2 of the UN Convention on Biological Diversity, so as to 
include uses and technologies that are employed upon genetic resources to 
develop products and process within well- established industries such as the 
pharmaceutical industry. This means that the International Regime on Access 
to Genetic Resources and Benefit Sharing has been discussed and written to 
include users which heavily rely on specific technologies (i.e. chemical 
synthesis or biotechnology). The Nagoya Protocol does so with the aim of 
securing transfer of technology from those industries to developing countries 
rich in biodiversity.60  
 
However, those definitions do not necessarily reflect all aspects and 
complexities that emerge in the development of products and processes for 
industries such as pharmaceuticals, and recent technological developments. In 
fact, Tvedt et al. point out the difficulties in governing the different 
circumstances in the development of products that derive from genetic 
resources, particularly in the relationship between those resources and final 
products.61 Tvedt et al. make a comparison in the drug development process 
between products “harvested from one genetic resource” and other 
pharmaceutical products that require a more complex R&D process.62 Tvedt 
takes two examples to make this comparison: (i) the Cyclosporine A3, 
employed in organ transplant, which is simply harvested from the fungal 
culture of the Tolypocladium inflactum (a species native to Norway) and (ii) 
complex R&D initiatives on enzymes, which might require optimising well 
known enzymes, looking for enzymes in libraries or searching for new enzymes 
 
59 Elisa Morgera, Elsa Tsioumani and Matthias Buck, Unraveling the Nagoya Protocol : A 
Commentary on the Nagoya Protocol on Access and Benefit-Sharing to the Convention on 
Biological Diversity (Brill 2014). pp 59-71 
60 ibid. pp 59-71 
61Morten Walløe Tvedt and Peter Schei, ‘The Term Genetic Resources’ in Sebastian Oberthür 
and G Kristin Rosendal (eds), Global Governance of Genetic Resources: Access and Benefit 
Sharing after the Nagoya Protocol (Routledge, Taylor and Francis 2014). 
62 Morten Walløe Tvedt, ‘The Missing Link in ABS The Relationship between Resource and 
Product.’ (2016) 46 Environmental Policy & Law 227. p 228 
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in bioprospecting projects to find a potential compound that could eventually 
become a pharmaceutical product. Obviously, this R&D initiative also requires 
laboratory-based genetic modification of one or different enzymes to obtain a 
final product.63  
 
In the context of Cyclosporine A3, the relationship between genetic resources 
and the final product is easy to determine since it is only one genetic resource 
which immediately leads to one pharmaceutical product. In the example of the 
enzymes, however, the different possible combinations to reach one or 
different potential candidates create a difficulty to define from an early stage 
in the drug development process whether it is a singular genetic resource (or 
the combination of different ones) or solely the technology employed on those 
enzymes which leads to the final product. For Tvedt et al., the definitions of 
the UN Convention on Biological Diversity and, especially, the Nagoya 
Protocol on the concepts of derivative and utilization of genetic resources do 
not reflect how in a complex R&D initiative the shared benefits of the outcome 
of the research will take place.64  
 
Examples, such as that of the enzymes, of how difficult is to fit a combination 
of different techniques and genetic resources to reach a specific product into 
the definitions of the Nagoya Protocol can prove even more difficult with the 
coming of new techniques of gene editing, such as CRISPR-Cas9.65 This is 
because those techniques could lead researchers to transfer digitally specific 
sequences of DNA, entire microorganisms or even genomes, and synthetize 
them into living organisms without access to the actual genetic material in a 
 
63 ibid., p 229 
64 ibid., p 232 
65 The way that this technique operates can be summarise as follows: a specific segment of DNA 
which can be removed or replaced, always using the same tools: a segment-guide that is a RNA with 
the copy of the DNA, which has to be identified (RNA guide), and a pair of scissors that is the protein 
Caspase 9 (Cas9) that cuts the specific segment of DNA, and separating the double helix from DNA 
to open its strands so that it can be edited. Further information see Natalia Lamprea and Oscar 
Lizarazo-Cortés, ‘Tecnología CRISPR/CAS9 Presente y Futuro En Biotecnología, y Controversias de 
Sus Patentes’ (Boletin Departamento Propiedad Intelectual, 2015) 
<http://propintel.uexternado.edu.co/tecnologia-crisprcas9-presente-y-futuro-en-biotecnologia-y-
controversias-de-sus-patentes/> accessed 2 September 2015. 
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specific territory.66 As a result, researchers will be able to digitally access 
genetic resources, combine and incorporate them into products or processes; 
meaning that they could circumvent any access to genetic resources and 
benefit sharing obligation, since they will not interact with any physical aspect 
of the actual country that, tracing back to the beginning of the process, 
provides those resources.  
 
Further, if there is indigenous and local communities’ traditional community 
knowledge or practices associated with genetic resources, it would become 
increasingly difficult to accommodate them in a complex R&D situation. This 
is even more problematic in the light of the International Regime on Access to 
Genetic Resources and Benefit Sharing, since none of the instruments that are 
part of it define traditional knowledge, or indigenous and local communities. 
Regarding the definition of traditional knowledge, Morgera et al. argue that 
since there is not an explicit definition of traditional knowledge, it is necessary 
to combine different elements of the International Regime on Access to 
Genetic Resources and Benefit Sharing.67 According to that line of reasoning, 
traditional knowledge can be understood within the definition of “utilization 
of genetic resources”. Therefore, traditional knowledge within the definition 
of Article 2 of the Nagoya Protocol would serve as “lead information for the 
utilization of genetic resources”,68 meaning that any uses given in different 
industries (e.g. biotechnology or pharmaceutical) to that lead information 
would fall within the definition of genetic resources. Yet, it remains open to 
interpretation what traditional knowledge is, especially as countries 
implement the Nagoya Protocol.  
 
On the definition of what are indigenous and local communities, since none of 
the instruments of the International Regime on Access to Genetic Resources 
and Benefit Sharing gives a definition, it is necessary to bring to bear other 
international instruments to provide guidance. In the case of indigenous 
 
66 International Civil Society Working Group On Synthetic Biology, ‘Synthetic Biology and the UN 
Convention on Biological Diversity’ [2016] ICSWGSB <https://www.boell.de/sites/default/files/2016-
11-icswgsb_synbio_brief_cop13_.pdf>. 
67Morgera, Tsioumani and Buck (n 59)., p 74 
68 ibid. 
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communities there is the Indigenous and Tribal People Convention of the 
International Labour Organization (1989), which provides subjective and 
objective criteria. The subjective aspect is a self-assessment, meaning people 
who consider themselves to be indigenous or tribal people. In the case of 
indigenous communities, the objective aspect applies to those who are 
descended from people who inhabited an specific region at a time of conquest 
or colonization.  In the case of tribal communities, the objective aspect of the 
definition refers to those who have social, cultural and economic conditions, 
as well as costumes, laws or traditions that make them different from the large 
majority of the country, for example, Afro-descent communities. However, 
when it comes to local communities, the term is rather more difficult to define 
objectively since local communities are group of people that do not share a set 
of costumes or traditions that make them different from the majority. At the 
same time, however, they have one or more specific characteristics that 
distinguish them (e.g. ancestral relation, geographical location, socio-
economic activities, etc.).69 Since it is difficult to provide a general definition, 
it would depend on countries to define in a case-by-case approach whether we 
are confronting a local community, as mentioned by the International Regime 
on Access to Genetic Resources and Benefit Sharing.  
 
Although, on the one hand, this lack of definitional clarity might make it even 
more difficult in practice to define what is a community, what role traditional 
knowledge and practices play in R&D activities, how communities should 
participate in them, and the use of techniques such as gene editing, on the 
other hand, the definitional flexibilities in the international regime give the 
opportunity to countries to define with more clarity the scope of the definition 
of genetic resources and the roles and entitlements of those who participate in 
the development of a product or process.  The significance of this national 
flexibility, and of the distinction between ‘ethnic’ (indigenous and Afro-




69 ibid. pp 38-41 
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To summarise, there is little clarity on the definitions of the International 
Regime on Access to Genetic Resources and Benefit Sharing, since they have 
focused on including specific technologies and industries within the scope of 
genetic resources. The International Regime on Access to Genetic Resources 
and Benefit Sharing aims to secure that users which hold technologies to 
transform genetic resources into processes and products are obliged to share 
the benefits that arise from the utilization of those genetic resources. However, 
as analysed, it is difficult to encompass within the regime all possible and 
complex scenarios that emerge from R&D activities in genetic resources. This 
is even more problematic in situations in which traditional knowledge and 
practices might be involved, since the International Regime on Access to 
Genetic Resources and Benefit Sharing does not even define traditional 
knowledge and practices, nor the communities which deploy them. Yet, as 
countries implement those international obligations, they can potentially 
narrow down those concepts, either by establishing more precise definitions, 
or by reaching consensus with the different actors that participate in the use 
of genetic resources, including industries, researchers, and communities.  
The Legal and Administrative Mechanisms for Access to Genetic Resources and Benefit 
Sharing  
 
Articles 3 and 15(1) of the UN Convention on Biological Diversity give 
countries the sovereign right to determine who can access their genetic 
resources and under what conditions. However, Article 15 also sets up the 
minimum requirements that Members of the UN Convention on Biological 
Diversity should consider when they implement the Convention into their 
national or regional legislation. These are (1) prior informed consent, 
including from indigenous and local communities; and (2) how to reach an 
agreement with developing countries rich in biodiversity. These agreements 
are called ‘mutually agreed terms’. They include among other things the type 
of benefit sharing that will take place. However, Article 15 also allows countries 
not to adopt any of these requirements. For instance, developed countries such 
as Germany and the UK have decided not to implement these requirements at 
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the national level.70 By contrast, the Nagoya Protocol extended the ownership, 
access, and control of developing countries rich in biodiversity beyond their 
borders. Articles 15 and 16 of the Nagoya Protocol calls on countries to adopt 
mechanisms of compliance to ensure that genetic resources and traditional 
knowledge and practices utilised within their territory have been lawfully 
accessed according to the International Regime on Access to Genetic 
Resources and Benefit Sharing in developing countries rich in biodiversity. 71 
Prior Informed Consent  
 
Article 15.5 of the UN Convention on Biological Diversity establishes that 
access to genetic resources should be subject to prior informed consent from 
the country that provides the genetic resources, unless members of the 
Convention provide otherwise. In order to respect state sovereignty, the 
Convention requires users of genetic resources to secure consent from 
countries before they can actually have access to those resources. This 
necessarily means that the UN Convention on Biological Diversity leaves 
countries to determine the legal procedures and requirements for consent to 
access genetic resources located in their own territory, as well as establishing 
a national authority that oversees the procedure.  
Indigenous and Local Communities’ Prior Informed Consent  
 
Additionally, prior informed consent not only refers to countries, but 
potentially to indigenous and local communities, particularly on the issue of 
 
70 For more information on the implementation measures of UN Convention on Biological 
Diversity at the national and regional level see 
https://www.cbd.int/information/parties.shtml  
71 Article 6.1 of the Nagoya Protocol limits the geographical scope of ABS to genetic resources 
that are from countries that regulate access. This means that genetic resources that are in ex 
situ collections should not require prior informed consent, for example. On the temporal 
scope, the Nagoya Protocol do not make any clarification of whether access to genetic 
resources before the entry into force of the protocol would be into the scope of the ABS 
Regulation, despite the fact that developing countries rich in biodiversity want to extend the 
scope of the protocol at least to those resources that were accessed after the UN Convention 
on Biological Diversity came into force. For further discussion on whether the temporal scope 
of the Nagoya Protocol and possible interpretation to include genetic resources accessed 
before the Nagoya Protocol see: Carlos Maria Correa, ‘Implications for BioTrade of the Nagoya 
Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits 
Arising from Their Utilization’ (2011) <http://www.unctad.org/biotrade> accessed February 
11 2019.   
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traditional knowledge associated with genetic resources. Local or indigenous 
communities employ genetic resources for different aspects of their lives and 
practices, such as healing or treating diseases. The ancient knowledge that 
those communities have over genetic resources increases the likelihood of 
others using that knowledge to find therapeutic properties of plants or 
animals, which facilitate the discovery of new biochemical compounds for drug 
development. However, the UN Convention on Biological Diversity only refers 
to indigenous and local communities in Article 8 (j) which calls on countries 
to respect, preserve and maintain traditional knowledge relevant for 
conservation and sustainability, and to involve indigenous and local 
communities in benefit sharing.  
 
The Bonn Guidelines, as a non-binding instrument, recommend that countries 
should require users of genetic resources to disclose all the necessary 
information regarding those resources, including the source of genetic 
resources and whether the research is commercial or not.72 It also calls on 
users to require prior informed consent from communities.  
 
The Nagoya Protocol demands that holders of traditional knowledge and 
practices, especially those associated with genetic resources, are to be 
considered as countries which grant access to users of genetic resources. In 
fact, while Article 8 (j) of the UN Convention on Biological Diversity only 
requires countries to respect, preserve, and protect traditional knowledge, as 
well as to involve their holders in benefit sharing, the UN Convention on 
Biological Diversity and Bonn Guidelines did not require countries to regulate 
any particular aspects of prior informed consent from local or indigenous 
communities. Article 7 of the Nagoya Protocol goes a step further by calling on 
countries to take measures to ensure that prior informed consent of 
indigenous and local communities is obtained when there is access to 
traditional knowledge associated with genetic resources.  
 
 
72 Guidelines 11 (j) and 16 (c) (ii) 
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As the Nagoya Protocol goes into detail on what countries should “take into 
consideration” regarding traditional knowledge associated with genetic 
resources, it can be observed that the protocol aims to give further guidance 
on relevant aspects that parties to the protocol shall observe as they implement 
these measures such as local communities’ customary laws, community 
protocols and procedures (Article 12).  Also, Article 22.3 of the Nagoya 
Protocol calls on countries to assess capacity to develop their own endogenous 
research, which demands countries must recognise communities’ contribution 
towards innovation.73  
 
The protocol does not, however, go as far as imposing on countries specific 
obligations of how prior informed consent from those communities should 
take place,74 leaving countries enough legal room to freely implement Article 
7 and 12 of the protocol appropriately in their national contexts.  
Mutually Agreed Terms and Benefit Sharing  
 
Mutually agreed terms are agreements (or contracts) that need to be reached 
by users of genetic resources and the designated national authority (Article 
15.4 of the UN Convention on Biological Diversity). Mutually agreed terms set 
up the terms and conditions for the use of genetic resources and the way that 
users should share the benefits derived from the utilisation of those resources. 
This is also proof that there is prior informed consent from a national 
authority. Reaching mutually agreed terms means that the users of the genetic 
resources have successfully obtained prior informed consent and benefit 
sharing. However, mutually agreed terms might differ from each other as there 
might be, for example, different benefit sharing agreements – i.e. economic 
benefits such as royalties and upfront payments, or non-economic benefits 
such as the transfer of technology. This makes mutually agreed terms a 
 
73 Harry Jonas, Kabir Bavikatte and Holly Shrumm, ‘Community Protocols and Access and 
Benefit Sharing’ (2010) 12 Research and Information System for Developing Countries. 
74 Elisa Morgera, Elsa Tsioumani and Matthias Buck, Unraveling the Nagoya Protocol : A 
Commentary on the Nagoya Protocol on Access and Benefit-Sharing to the Convention on 
Biological Diversity <http://www.brill.com/2010-nagoya-protocol-access-and-benefit-
sharing-perspective> accessed July 28 2017., pp 217-218 
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particularly flexible mechanism in the negotiations for benefit sharing, as they 
follow the contractual rules and legislation of each country. 75  
 
Finally, Articles 15 and 16 of the Nagoya Protocol call on countries, particularly 
developed ones, to adopt mechanisms of compliance to ensure genetic 
resources and traditional knowledge utilised within their territory have been 
lawfully accessed according to the International Regime on Access to Genetic 
Resources and Benefit Sharing in developing countries rich in biodiversity. 
Therefore, Article 17 of the Nagoya Protocol decides what those mechanisms 
are in order to monitor the compliance of users of genetic resources. These 
include (1) checkpoints and (2) an international certificate of compliance. 
First, Article 17.1 states that members should designate one or more 
checkpoints which collect and receive information relating to the access and 
utilisation of genetic resources and traditional knowledge, prior informed 
consent, and mutually agreed terms, to address the situation of non-
compliance by users of genetic resources in both developed countries and 
developing countries rich in biodiversity. The designation of checkpoints and 
the procedure to collect and receive information should be regulated at the 
national level. Second, Article 17 of the Nagoya Protocol also adopted the 
Internationally Recognized Certificate of Compliance which can also be 
employed by the designated checkpoint. This is a mechanism to track and 
monitor the flow of genetic resources. Such a certificate is issued at the 
moment that access has been granted and mutually agreed terms issued 
(Articles 6.3 (e) and 17.2 of the Nagoya Protocol). The issuance of an 
Internationally Recognized Certificate of Compliance should be notified to the 
Clearing-House Mechanism of the UN Convention on Biological Diversity via 
national focal points.  
 
So far, the chapter has analysed the wording and scope of the International 
Regime on Access to Genetic Resources and Benefit Sharing, which includes 
the UN Convention on Biological Diversity, the Bonn Guidelines, and the 
 
75 For further information on different mutually agreed terms rules and agreements in 
different national jurisdiction see Shakeel Bhatti and others, Contracting for ABS: The Legal 
and Scientific Implications of Bioprospecting Contracts, vol 4 (IUCN 2009). 
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Nagoya Protocol. It has shown how the UN Convention on Biological 
Diversity’s requirements and compliance mechanisms have evolved through 
the Bonn Guidelines and the Nagoya Protocol. The following section of the 
chapter takes a step further away from the literal wording of the UN 
Convention on Biological Diversity. It sets out the main discussions in 
academic literature on the International Regime on Access to Genetic 
Resources and Benefit Sharing, and its implementation in both developed 
countries and developing countries rich in biodiversity. In particular, the next 
section focuses on how practices and knowledge from indigenous and local 
communities have been considered as the International Regime on Access to 
Genetic Resources and Benefit Sharing has been implemented. 
 
The Implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing 
 
The International Regime on Access to Genetic Resources and Benefit Sharing, 
and more specifically the UN Convention on Biological Diversity, was 
originally intended to be only a treaty about conservation and sustainability, 
as it was the result of the efforts, during the 1980s, of environmentalist 
campaigners and national parks to create an international instrument to 
reduce the extinction of species and deforestation.76 Whereas conservation 
involves the mandate to protect ecosystems and natural habits of biological 
diversity and components of biological diversity which are collected in, for 
instance, botanical gardens, zoos, and universities, sustainable use of 
biodiversity is part of a broader commitment which is to achieve sustainable 
development regarding not only biological diversity, but also natural resources 
such as oil and coal.77 Both commitments involve a stewardship obligation, 
which demands economic limitations on the use of biodiversity for developing 
countries rich in biodiversity.  
 
76 Swanson (n 46). pp 326-327 
77 Under this mandate, the Conference of Parties, the executive body of the UN Convention on 
Biological Diversity, and the Secretary of the UN Convention on Biological Diversity have 
worked on how to identify and achieve sustainability in the context of biological diversity 
through workshops, meetings and decisions, in order to implement principles and operational 
guidelines, (e.g. the Addis Ababa Principles and Guidelines of 2007) which establishes a set of 
14 practical principles to accomplish sustainable use; yet the these instruments are not binding 
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As an alternative, bioprospecting was presented as a model of doing business 
which did not run counter to environmental commitments. In particular, 
scientists such as Eisner pointed out that the importance of conservation and 
sustainability was not only about environmental protection and prevention of 
the loss of biodiversity, but also about the fact that biodiversity could permit 
different industries (e.g. chemical and pharmaceutical) to collect and identify 
new chemical and biological compounds for drug production based on genetic 
resources (i.e. bioprospecting).78 In exchange, developing countries rich in 
biodiversity would claim a share of the benefits that arise from the 
commercialisation of inventions based upon genetic resources located in their 
territory as a mechanism of compensation.  
 
Consequently, developing countries rich in biodiversity enthusiastically 
endorsed the promises of a compensatory approach, linking conservation and 
sustainability with access to genetic resources and benefit sharing. An earlier 
example of this approach was the first deal between Costa Rica’s National 
Biodiversity Institute (INBio – Spanish acronym) and the US pharmaceutical 
company Merck. This agreement included that this biodiversity-rich country 
allowed access to their genetic resources to Merck in exchange for training, 
scientific infrastructure, and payment of royalties by Merck.79 The 
compensatory mechanism of benefit sharing also provided reassurance to 
developing countries rich in biodiversity as they could effectively assert 
property rights over genetic resources located within their territory by 
granting or denying access to those resources.  
 
 
78 For further information on bioprospecting see Thomas Eisner and Elizabeth A Beiring, 
‘Biotic Exploration Fund: Protecting Biodiversity Through Chemical Prospecting’ (1994) 44 
BioScience 95; Thomas Eisner and Jerrold Meinwald, ‘The Göteborg Resolution’ (1990) 1 
CHEMOECOLOGY 38; Thomas A Kursar and others, ‘Securing Economic Benefits and 
Promoting Conservation through Bioprospecting’ (2006) 56 BioScience 1005. 
79 Carmen Richerzhagen and Karin Holm-Mueller, ‘The Effectiveness of Access and Benefit 
Sharing in Costa Rica: Implications for National and International Regimes’ (2005) 53 
Ecological Economics 445.(providing an effectiveness analysis of bioprospecting initiatives in 
Costa Rica and arguing that the public value of biodiversity is not assessable, although private 
investment is) 
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This approach aimed to end the discussion over the legal status of genetic 
resources as developed countries had campaigned to adopt “common heritage” 
as the legal status for genetic resources.80 If common heritage had been 
adopted by the UN Convention on Biological Diversity, then genetic resources 
would have been freely accessible. The position of developing countries rich in 
biodiversity on the legal status of genetic resources was the polar opposite of 
common heritage: They claimed sovereignty over genetic resources. This 
position reflected the economic and political stand that most developing 
countries rich in biodiversity had already taken over the sovereignty of their 
natural resources such as oil, gold, etc. after the second half of the twentieth 
century.81  
 
Yet, this view of compensating developing countries rich in biodiversity for the 
use of genetic resources for industrial application was constantly challenged 
for two main reasons. First, bioprospecting projects and activities, including 
Costa Rica’s INBio, did not deliver the promises of benefit sharing, as there 
had not been any significant commercial breakthrough.82 Second, biodiversity 
is not the only source for the development of new products and processes. In 
fact, the pharmaceutical industry has relied on synthetic products or 
compounds collected and deposited in their own libraries a long time ago. For 
instance, Telavancin (marketed under the name of Vibativ to treat infections) 
 
80 Common heritage has been employed in international law when has been difficult or 
inconvenient to allocate ownership, particularly the seabed. The use of this term was 
important for developed countries after the middle of the twentieth century as their economies 
relied on natural resources allocated outside of their jurisdiction; but, biodiversity-rich 
countries have watered down this term as they consider that the use of Common Heritage 
could dismiss ownership of natural resources (such as oil and gold) that could belong to these 
countries; for further information see: Christopher C Joyner, ‘Legal Implications of the 
Concept of the Common Heritage of Mankind’ [1986] International and Comparative Law 
Quarterly 190; Bradley Larschan and Bonnie C Brennan, ‘Common Heritage of Mankind 
Principle in International Law’ (1982) 21 Colum. J. Transnat’l L. 305. 
81 Biodiversity-rich countries have been campaigning to include sovereignty before the UN 
Convention on Biological Diversity was enacted, but in natural resources such as oil and 
minerals rather than genetic resources. Indeed, the UN in 1962 decided through a General 
Assembly resolution that control and access to natural resources should be understood under 
the principle of sovereignty; individual States decided under which conditions it would be 
possible to have access to natural resources. Sovereignty aimed to satisfy the interests of 
biodiversity-rich countries (most of which had just declared independence from colonial 
empires at the time the resolution was issued) in the control of natural resources; See 
Paragraphs 4 and 5 of Preamble to the UN–General Assembly Resolution 1803 (XVII) 14 Dec 
1962 Permanent Sovereignty over natural resources 
82 Rex Dalton, ‘Natural Resources: Bioprospects Less than Golden’ (2004) 429 Nature 598. 
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is a derivative of Vancomycin and was launched on the US market in 2009,83 
yet Vancomycin was isolated for the first time in 1953. 84 Both aspects illustrate 
that the promises of benefit sharing throughout bioprospecting remain 
distant, since the use of biodiversity is not as indispensable for industries such 
as the pharmaceutical industry as Eisner imagined, before the UN Convention 
on Biological Diversity was agreed.   
 
However, supporters of bioprospecting still campaign to make biodiversity an 
important source for the industry, as the development of new tools and 
technologies in recent years could unleash the hidden commercial potential of 
biodiversity. For instance, Cragg et al. point out that there have been 1,073 
small molecules that have led to new biochemical entities related to genetic 
resources in the period from 1980-2010.85 Although Cragg et al. also identify 
that 66% of those small molecules are ‘formally synthetic’, they highlight that 
they were either derived from or inspired by natural products.86 Indeed, 16% 
of those formally synthetic molecules contain ‘pharmaphores87 derived 
directly from natural products’, while 14% of the molecules were models of ‘a 
natural product inhibitor of the molecular target of interest’ or they mimic ‘the 
endogenous substrate of the active site’.88 This means that only 36% of the 
1,073 molecules were purely synthetic or free from any natural inspiration. 
Oldham et al.’s paper on patent activity on biodiversity also estimates that the 
research activity on genetic resources and traditional knowledge associated 
with genetic resources is very low as it represents only 4% of taxonomically 
described species on the planet.89 Nevertheless, as molecular biology tools 
have become faster and cheaper, research centres such as the National 
 
83 USA Food and Drug Administration, ‘FDA Approves Vibativ for Hospitalized Patients with 
Bacterial Pneumonia’ (FDA website, 2013) 
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 
ucm358209.htm> accessed November 23 2014  
84 Donald P Levine, ‘Vancomycin: A History’ (2006) 42 Clinical Infectious Diseases S5.  
85 Gordon M Cragg and others, ‘The Impact of the United Nations Convention on Biological 
Diversity on Natural Products Research’ (2012) 29 Natural product reports 1407; David J 
Newman and Gordon M Cragg, ‘Natural Products as Sources of New Drugs from 1981 to 2014’ 
(2016) 79 Journal of Natural Products 629. 
86 Cragg and others (n 85)., p 1408 
87 Pharmacophore refers to a part of a molecular structure that is responsible for a particular 
biological or pharmacological interaction that it undergoes 
88 Cragg and others (n 85)., p 1408 
89 Paul Oldham, Stephen Hall and Oscar Forero, ‘Biological Diversity in the Patent System’ 
(2013) 8 PLOS ONE 1. 
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Institute of Cancer in the US have maintained interests in carrying out 
bioprospecting projects in areas rich in biodiversity such as Panama (e.g. the 
Panama International Cooperative Biodiversity Group).90 De Luca et al. also 
highlight that, despite the fact that pharmaceutical companies have lost 
interest in genetic resources because of the costly chemical synthesis of small 
molecules, the low cost of gene sequencing is increasing the possibility of 
research on new pathways and enzymes of genetic resources, as well as 
different technologies (e.g. virus induced gene (VIG) silencing, RNA 
interference (RNAi), and improvements in RNA isolation) that help to identify 
gene functions.91 These developments could lead to the creation of new 
medicines or improvement of existing ones based upon developing countries’ 
biodiversity.92 However, the promises of materialising the Convention on 
BioDiversity’s benefit-sharing through bioprospecting remain elusive, as there 
have been no products or processes derived from genetic resources with any 
market yet. 
 
Balance of Power among Countries and Intellectual Property in the International Regime on 
Access to Genetic Resources and Benefit Sharing  
 
Biodiversity has not only been subscribed to the expectation of obtaining 
benefit sharing and market success, but has also been employed to balance the 
power relations between developed and developing countries in different 
forums. Authors such as Helfer,93 Safrin,94 Raustalia, and Victor,95 have 
pointed out that the International Regime on Access to Genetic Resources and 
Benefit Sharing sought to offset the imbalances that have occurred in forums 
such as TRIPs in the WTO, in which developing countries accepted higher 
standards of intellectual property rights protection, including patents in 
inventions related to biological resources, so they could have access to 
developed countries’ markets.  
 
90Kursar and others (n 78)., pp 1007-1010 
91 Vincenzo De Luca and others, ‘Mining the Biodiversity of Plants: A Revolution in the 
Making’ (2012) 336 Science 1658 LP. 
92 ibid., p 1661 
93 Helfer (n 41).  
94 Safrin (n 41). 
95 Raustiala and Victor (n 41). 
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Also, the International Regime on Access to Genetic Resources and Benefit 
Sharing was employed as a form of recalibrating the relationship between 
developing and developed countries in the World Intellectual Property 
Organization (WIPO).96 In fact, developing countries have managed to discuss 
access and benefit sharing-related provisions since Colombia, supported by 
the Andean Community of Nations and other developing countries, presented 
in 1999 a submission before the Standing Committee on Patents 97 which 
proposed that patent procedure for members of WIPO should guarantee 
protection of countries’ biological and genetic resources by requiring that if a 
patent application was related to genetic resources, the applicant should 
demonstrate that those resources were acquired legally.98 Albeit, the 
Colombian submission was not specific and clear on how to protect biological 
and genetic resources through patents, it raised for the first time in WIPO the 
issue of the relationship between the regulation of genetic resources and 
patents.99 Colombia removed the submission on the condition that WIPO 
would create an international committee to discuss this issue, and the 
Intergovernmental Committee on Intellectual Property and Genetic 
Resources, Traditional Knowledge and Folklore was duly established.100 In 
2001, the committee began negotiations for the creation of an international 
instrument related to intellectual property rights and access to genetic 
resources.101 The negotiations ended in 2013 with a draft of a ‘consolidated 
document’.102 Despite the fact that some progress was made in the 
consolidated document, parties have not reached any compromise in key and 
basic aspects, such as definition of genetic resources, biopiracy, and 
 
96 The fact that WIPO is not an international organization related to free trade and access to 
markets (TRIPs actually is related to trade) has facilitated the inclusion of this issue in the 
WIPO agenda; 3 
97 This is the WIPO’s Committee that held the discussion that led to the PLT; for further 
information see http://www.wipo.int/meetings/en/topic.jsp?group_id=61  
98 Proposal by the Delegation of Colombia, Protection of Biological and Genetic Resources 
(WIPO, SCP/3/10, 1999) 
99 David Vivas-Eugui, ‘Bridging the Gap on Intellectual Property and Genetic Resources in 
WIPO’s Intergovernmental Committee (IGC)’ [2012] ICTSD’s Programme on Innovation, 
Technology and Intellectual Property (34). Geneva, Switzerland: International Centre for 
Trade and Sustainable Development. quno. org. 
100 Standing Committee of Patents, Report of the Third Session (WIPO SCP/3/11, 1999) 
101 IGC, Report of First Season (WIPO/GRTKF/IC/1/13, 2001) 
102 IGC, Consolidated Document Relating to Intellectual Property Rights and Genetic 
Resources (Facilitators’ draft, WIPO, Rev 2, 2013) 
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misappropriation. Furthermore, the General Assembly of WIPO, the executive 
body of this organization, has made no substantial decision to advance in the 
implementation of an international treaty that counterbalances those relations 
of power.103 Similarly, the World Trade Organisation (WTO) has reported no 
significant advance in the discussions related to the use of biodiversity by 
different industries.104  
The Problematic Aspect of Finding a Solution to the Issues of Biopiracy and Compliance of 
the International Regime on Access to Genetic Resources and Benefit Sharing   
 
Although there is an apparent failure to offset the historical imbalance created 
by trade and intellectual property rights in other forums, the International 
Regime on Access to Genetic Resources and Benefit Sharing has also served as 
a platform to mobilise different actors which have been neglected or ignored. 
From farmers to non-governmental organizations and campaigners for open 
access, since the 1990s forums such as the International Regime on Access to 
Genetic Resources and Benefit Sharing have served as a platform to raise 
issues of injustice towards populations whose customs, tradition, or protocols 
do not adjust readily to the logics of markets and the balancing of international 
power among countries. In particular, a significant number of scholars have 
denounced in specific cases how the developed world has abusively 
appropriated knowledge and practices from local and indigenous communities 
because it does not fit within the model of production and appropriation of 
information supported by intellectual property rights. For instance, the 
University of Mississippi obtained a patent in 1995 for ‘Use of Turmeric in 
Wound Healing’, despite the fact that turmeric powder had been traditionally 
used for healing purposes by different generations of local communities in 
India.105 Equally, neem or Azadirachta indica is a plant that has been 
 
103 WIPO, Adoption of the General Report and of the Individual Report of each Governing 
Body (A/54/13, 2015) 
104 WTO, ‘Reviews, Article 27.3b, Traditional Knowledge, Biodiversity - Background’ (WTO, 
2019) <https://www.wto.org/English/tratop_e/trips_e/art27_3b_background_e.htm> 
accessed March 6 2019 
105 This is an emblematic case not only because a US research institute aimed to obtain patent 
exclusivity over a well-known therapeutic activity of a plant, but also because the case led to 
mobilise social activists, Indian authorities and communities to file oppositions in developed 
countries’ patent offices in order to have the patent dismissed. Such efforts led to the US Patent 
and Trademark Office to revoke the patent. For further information see R. Gupta and L 
Balasubrahmanyam, ‘The Turmeric Effect’ (1998) 20 World Patent Information 185. Also, this 
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employed for more than 200 years by Indian local communities for different 
uses (pesticides, fungicides, etc.).106 Yet its antimycotic agent has been 
patented in both the US and the Europe for the treatment of fungal 
infections.107 
 
These cases of biopiracy brought international condemnation and raised the 
question of how other forms of knowledge associated with the use of 
biodiversity were significantly diminished by the market-oriented perspective 
of intellectual property rights. For instance, authors such Shiva and Stenton 
put the blame for those cases upon the international standardization of 
intellectual property rights in the WTO-TRIPs, since it represents a new form 
of colonialism and biopiracy that threatens the rights of indigenous 
communities.108 There has also been a significant amount of scholarly work on 
the bioethical implications of traditional knowledge for R&D in genetic 
resources.109 As a result, there have been different proposals to avoid 
situations in which practices and knowledge of indigenous and local 
communities can be unlawfully or unethically appropriated.  
 
More significantly, there are proposals seeking to solve the problem of 
compliance with intellectual property rights, in which disclosure of origin has 
 
case added to the discussion on whether the patent system and traditional knowledge could 
coexist see:   Claudia Finetti, ‘Traditional Knowledge and the Patent System: Two Worlds 
Apart?’ (2011) 33 World Patent Information 58; Shubha Ghosh, The Implementation of 
Exhaustion Policies Lessons from National Experiences (ICTSD Progamme on Innovation, 
Technology and Intellectual Property 2013); Michael A Gollin, ‘Biopiracy: The Legal 
Perspective’ (2007) 2007 Policy Brief Series 1. 
106 Further information on the neem case see: Graham Dutfield, ‘Biopiracy’, Intellectual 
Property, Biogenetic Resources and Traditional Knowledge (Routledge 2010); Cormac 
Sheridan, ‘EPO Neem Patent Revocation Revives Biopiracy Debate’; Kari Moyer-Henry, 
‘Patenting Neem and Hoodia: Conflicting Decisions Issued by the Opposition Board of the 
European Patent Office’ (2008) 27 Biotechnology Law Report 1. 
107 EPO Patent Application, EP1945237 Use of Extracts of Myrtle and Other Mediterranean 
Agent Towards Yeast and Yeast-Like Microorganism; USPTO Patent, US20110091555A1, Use 
of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a 
disintegrate in the manufacture of a medicament for treating female genital disorders 
108 Vandana Shiva, Biopiracy: The Plunder of Nature and Knowledge (South End Press 1997); 
Gavin Stenton, ‘Biopiracy within the Pharmaceutical Industry: A Stark Illustration of How 
Abusive, Manipulative and Perverse the Patenting Prices Can Be Towards Countries of the 
South’ (2004) 26 European Intellectual Property Review 17. 
109 See for instance: Schroeder and Lucas (n 42); Schroeder and Pisupati (n 42); Michiel 
Korthals and Bram De Jonge, ‘Two Different Ethical Notions of Benefit Sharing of Genetic 
Resources and Their Implications for Global Development’ (2009) 28 New Genetics and 
Society 87; Bram De Jonge and Michiel Korthals, ‘Vicissitudes of Benefit Sharing of Crop 
Genetic Resources: Downstream and Upstream’ (2006) 6 Developing World Bioethics. 
 61 
been prominently analysed.110 During the process of granting a patent, it is 
usually required that the applicant describes his invention, so an ordinarily 
skilled person can replicate it. In order to do so, the patent holder has to 
disclose information relevant to the invention. Developing countries rich in 
biodiversity have added an extra requirement within the disclosure. 
Legislation in countries such as members of the Andean Community demands 
that whoever uses genetic resources should disclose all information related to 
the origin of the genetic resources and demonstrate that such information was 
extracted following the rules of the International Regime on Access to Genetic 
Resources and Benefit Sharing. In this way, a link between patent 
requirements and the regulation of access to genetic resources and benefit 
sharing of the International Regime on Access to Genetic Resources and 
Benefit Sharing could serve as a mechanism of compliance.  
 
However, there is no international unified position on disclosure of origin, 
making it difficult to create a practical and effective mechanism of compliance. 
In fact, despite the fact some developed countries have similar dispositions, 
failing to meet these requirements does not affect the grant of a patent on 
genetic resources. For example, Recital 27 of the European Biotech Directive111 
states that ‘the patent application should, where appropriate, include 
information on the geographical origin of such material, if known’, but this 
requirement should not be contrary to ‘the processing of patent applications 
or the validity of rights arising from granted patents’. As a result, disclosure of 
 
110 Disclosure of origin was originally proposed by Hendrickx, Gadgil and Devasia, but it was 
India that introduced this issue in the Conference of Parties of the UN Convention on 
Biological Diversity in 1995; see The Conference of Parties of the UN Convention on Biological 
Diversity, ‘REuropean Patent Officert of the Second Meeting of the Conference of the Parties 
to the Convention on Biological Diversity’, UNEP/CBD/COP/2/19, 1995 (COP 1995). For 
discussions carried out by the Conference of Parties of the UN Convention on Biological 
Diversity in this issue see: The Conference of Parties of the UN Convention on Biological 
Diversity, ‘The Convention on Biological Diversity and the Agreement Related Intellectual 
property rights (TRIPs): Relationships and Synergies’, (UNEP/CBD/COP/3/23, 1996) (COP 
1996).; see also  Frédéric Hendrickx, Veit Koester and Christian Prip, ‘Access to Genetic 
Resources: A Legal Analysis’ in Vicente Sánchez and Calestous Juma (eds), Biodiplomacy: 
Genetic Resources and International Relations (ACTS Press 1994); Madhav Gadgil and 
Preston Devasia, ‘Intellectual property rights and Biological Resources: Specifying 
Geographical Origins and Prior Knowledge of Uses’ (1995) 69 Current Science 637.; for a 
different analysis of different disclosure of origin proposals Blakeney (n 43); Dutfield, ‘Sharing 
the Benefits of Biodiversity: Is There a Role for the Patent System?’ (n 43).  
111 Directive 98/44/EC of the European Parliament and of the Council of July 6 1998 on the 
legal protection of biotechnological inventions 
 62 
origin has triggered disagreements on how to implement the directive and 
whether it is effective in protecting developing countries rich in biodiversity 
and communities within those countries against misappropriation.112 For 
instance, the issue has been the subject of conflict in the WTO’s TRIPs and 
WIPO, particularly because developed countries have been emphatically 
opposed to any inclusion of extra requirements in patent protection that could 
weaken patent holders’ rights, specifically intellectual property rights of the 
pharmaceutical and biotechnological industries.113  
 
Authors such as Straus have given opinions on how to unlock the stalemate on 
this issue based on a national approach in which it is up to each country to 
adopt the disclosure of origin according to their capacity.114 There are also 
other voices such as those of Correa and De Carvalho that argue that disclosure 
of origin is indeed a mechanism not only to create a bridge between TRIPs and 
the International Regime on Access to Genetic Resources and Benefit Sharing, 
but also a way to improve credibility and trust between developing countries 
rich in biodiversity and patent holders.115  
 
112 The controversy lies in whether Recital 27 of the Biotech Directive indicate an obligation to 
EU Members to adopt disclosure of origin in patents. As the European Court of Justice rules 
that patentability of genetic resources does not affect the interests of developing countries rich 
in biodiversity in monitoring and tracking their own genetic resources, Members of the EU 
should not take those interests into account in the implementation of the Biotech Directive in 
their national patent legislation. Netherlands v Parliament and Council Case-377/98 (1998) 
1 7149. 
113 For a summary of the discussions in the Council for TRIPs see: the Secretary of WTO, ‘The 
Relationship Between the TRIPs Agreement and the Convention on Biological Diversity’, the 
Council For Trade-Related Aspects of Intellectual Property Rights, IP/C/W/368/Rev.1, 
(WTO 1996).; Regarding the discussion on disclosure of origin in the WIPO, it was Switzerland 
that proposed to include disclosure of origin in the Patent Cooperation Treaty (PCT), (1970, 
Washington, as in force from April 1, 2000) which is a WIPO treaty. In the PCT, a patent 
applicant can fill one international patent application, and simultaneously seek patent 
protection in one of the 152 members of the PCT. Switzerland proposes that countries could 
require the patent applicant to disclose the origin of an invention related to genetic resources 
and traditional knowledge, when or after the applicant seeks patent protection in one of the 
members of the PCT; in the event that a patent applicant does not comply with the 
requirement, members of the PCT would not process the patent application until the 
requirement has been fulfilled. However, this proposal did not materialise. See: Working 
Group on Reform of the PCT, ‘Proposal Submitted by Switzerland. Declaration of the Source 
of Genetic Resources and Traditional Knowledge in Patent Applications’ (2007). 
114 Joseph Straus, ‘How to Break the Deadlock Preventing a Fair and Rational Use of 
Biodiversity’ (2008) 11 The Journal of World Intellectual Property 229. 
115 Carlos Maria Correa, ‘Establishing a Disclosure of Origin Obligation in the TRIPS 
Agreement’ (2003) 12 Occasional paper; Nuno Pires De Carvalho, ‘Requiring Disclosure of the 
Origin of Genetic Resources and Prior Informed Consent in Patent Applications without 
Infringing the TRIPS Agreement: The Problem and the Solution’ (2000) 2 Wash. UJL & Pol’y 
371; Jon Santamauro, ‘Reducing the Rhetoric: Reconsidering the Relationship of the TRIPs 
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As a result, the disclosure of origin centred much of the discussion on biopiracy 
on the holders of the technology that could transform genetic resources and 
traditional knowledge into products and process. However, disclosure of 
origin is a mechanism which patent offices have not effectively used since they 
normally carry out patent examination with scientific and technical 
information, but do not cross-check patent applications against practices and 
knowledge from local and indigenous communities. This is because of the 
difficulty of documenting traditional knowledge, since indigenous and local 
communities have passed on this knowledge orally rather than through 
written forms of patents or scientific journals. The latter are the information 
that patent offices normally employ to examine patent requirements.  
 
The deficiency of disclosure of origin as a compliance mechanism has led to 
other proposals which aim to overcome some of the difficulties in cross 
checking communities’ practices and knowledge within patent examination 
processes. Such proposals aim to provide defensive measures against 
misappropriation within the patent system rather than imposing new 
requirements such as disclosure of origin. For instance, there is the Indian 
Traditional Knowledge Digital Library that seeks to document through 
internet databases traditional knowledge with the aim that patent offices and 
courts decline patent protection to inventions on the basis that the invention 
does not fulfil the patent requirement of novelty and non-obviousness.116 A 
relatively rare example of success of such approaches, the Indian Traditional 
Knowledge Digital Library’s efforts led the patent application on neem to be 
withdrawn in 2012 after evidence of prior art was disclosed before the 
European Patent Office. But the US patent remains standing.117  
 
Agreement, UN Convention on Biological Diversity  and Proposed New Patent Disclosure 
Requirements Relating to Genetic Resources and Traditional Knowledge’ (2007) 29 European 
Intellectual Property Review 91. 
116 See website: http://www.tkdl.res.in/; for further discussion see: Jean-Paul Gaudillière, ‘An 
Indian Path to Biocapital? The Traditional Knowledge Digital Library, Drug Patents, and the 
Reformulation Regime of Contemporary Ayurveda’ (2014) 8 East Asian Science, Technology 
and Society 391. 
117 Stefano De Luigi Brushchi and Federico Mailland, ‘Use of a Hydrophilic Matrix Comprising 
a Polyacrylic Acid Derivative, a Cellulose Ether and a Disintegrant in the Manufacture of a 
Medicament for Treating Female Genital Disorders.’ 
<https://patents.google.com/patent/US20110091555/en> accessed July 11 2018. 
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A clear problem with such an approach is that would automatically place 
knowledge and practices from indigenous communities into the public 
domain, limiting the practical ability of communities to prevent their 
knowledge from being appropriated. Yet, there are systems which seek to 
address those concerns by entitling communities to have a more profound role 
in deciding the fate of their knowledge. For instance, the Peruvian Collective 
Knowledge Protection Regime creates a national database for traditional 
knowledge associated with genetic resources, in which local and indigenous 
communities decide whether to include their knowledge in the database, how 
much they want to share, and with who they want to share it.118 The Peruvian 
approach secures that communities decides whether their practices and 
knowledge would go into the public domain so as to be employed, for instance, 
as a defensive mechanism in patent prosecution, or shared with users to 
develop new products and process. Furthermore, this protection regime also 
establishes “licenses” for users who want to access those resources. 
 
However, the implementation of databases such as the Peruvian Collective 
Knowledge Protection Regime to protect communities’ practices and 
knowledge could clash with the interests of populations in need. For instance, 
at least hypothetically, if a community does not want to share a potentially life-
saving medicinal plant, it would deny patients, for instance, in developing 
countries to access those medicines. Although such an eventuality has not 
emerged yet, the Nagoya Protocol, Article 8 calls on parties to pay due 
consideration to situations such as lack of access to medicines as they enforce 
access and benefit sharing rules. This obligation could include easing the rules 
of secrecy in databases. Nonetheless, it would depend on each country to 
decide the way that they will pay due consideration to those situations.   
 
In a similar line of enquiry, Dutfield has also indicated that courts and patent 
offices in developed countries have already taken into account traditional 
 
118 Ley que Establece el Régimen de Protección de los Conocimientos Colectivos de los Pueblos 
Indigenas vinculados a los Recursos Biológicos (Ley 27811 de 2012) 
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knowledge to deny or revoke patent protection on genetic resources.119 For 
instance, Dutfield points out that Lord Hoffman, from the then120 British 
House of Lords, highlighted that, despite the fact that an Amazonian Indian 
was not able to describe in chemical terms the therapeutic value of quinine in 
treating fevers, he knew that ‘the bark has a quality which makes it good for 
fever and that is one description of quinine’.121 Another important example 
that Dutfield describes is the rejection of a claim on a ‘method of treating 
erectile dysfunction’ based upon four references to the use of a traditional 
medicine Ying Yang Hou (horny goat weed) that anticipate the claim, despite 
the fact that those four references did not describe the claim in chemical 
terms.122 Both examples indicate that there are patent examiners and courts in 
developed countries that consider relevant traditional knowledge associated 
with genetic resources in order to dismiss the novelty or non-obviousness of a 
patent, regardless of such information not having been presented in scientific 
or technical terms.  
 
But those defensive mechanisms rather seek to fit traditional knowledge 
within the patent system, which, as mentioned above, is intrinsically a form of 
protection that follows a market-oriented perspective. Drahos and Frankel 
also find that difficulties in accommodating this knowledge in patent systems 
are not exclusively connected with the difficulty of documenting the relevant 
practices and knowledge, but that there are substantial aspects of the 
innovation process in communities that are different from what patents 
protect.123 The authors find that innovations in those communities are 
intrinsically interconnected with the land that those communities inhabit, 
their cosmology, and the diffusion of such information does not depend on the 
expiration of a patent term. This can be reflected in cases such as the San 
 
119 Graham Dutfield, ‘A Critical Analysis of the Debate on Traditional Knowledge, Drug 
Discovery and Patent-Based Biopiracy’ (2011) 33 EIPR.   
120 Now the Supreme Court of the UK. 
121 Merrell Dow Pharmaceuticals Inc v. HN Norton & Co Ltd [1996] R.P.C. 76 (HL)  
122 Dutfield, ‘A Critical Analysis of the Debate on Traditional Knowledge , Drug Discovery and 
Patent-Based Biopiracy’ (n 119). see also Board of Patent Appeals and Interferences of 
USPTO, Ex Parte Pfizer, Inc. 
123 Peter Drahos and Susy Frankel, ‘Indigenous Peoples’ Innovation and Intellectual Property: 
The Issues’ in Peter Drahos and Susy Frankel (eds), Indigenous Peoples’ Innovation (ANU 
Press 2012). 
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people and Hoodia plant. This case involves the Council for Scientific and 
Industrial Research (CSIR), a South African research institute, which carried 
out research on hoodia, a medicinal plant employed by the San people in 
staving off hunger. The CSIR obtained a patent for the hoodia and eventually 
reached an agreement with Pfizer for the possible commercialisation of the 
patented product. At first, the CSIR did not recognise any benefit sharing over 
the patented product to South Africa and the San people, but pressure from 
the South African authorities and other organisations led the CSIR to 
renegotiate over the possible commercialization of the product with Pfizer and 
share benefits with the San people.124 After intensive pressure and 
negotiations, the CSIR agreed to recompense the San people with monetary 
benefits. Although the deal was deemed an important breakthrough, as it was 
the first of its kind, authors such as Wynberg consider that the final agreement 
did not provide appropriate benefits to the San people because the CSIR 
exclusively owned the patent and the indigenous communities would receive 
only a percentage of the royalties.125  
The Complexities and “Messiness” behind the Use of Biodiversity  
 
Another important concern in the implementation of the International Regime 
on Access to Genetic Resources and Benefit Sharing is the sociological impact 
of using western values to pay off local communities for the use of their genetic 
resources, as they might have a more communal and non-economic interest in 
the use of those genetic resources.  
 
 
124 Pfizer withdrew clinical trials in 2003; however, the biotechnological company Unilever 
stepped in, but the latter also abandoned the project as Unilever’s clinical studies revealed that 
products that employ hoodia did not meet its standards of safety and efficacy; according to 
Kamau, solely in the US there is more than 5 patent applications on hoodia; see Unilever, 
'Sustainable Development 2008: An Overview' (2008) 
<http://www.unilevernigeria.com/Images/Unilever_Sustainable_Development_Overview2
008_v3_tcm199-163522.pdf> accessed July 17 2014. See also: Evanson Chege Kamau, 
‘Common Pools of Traditional Knowledge and Related Genetic Resources: A Case Study of 
San-Hoodia’ in Evanson Chege Kamau and Gerd Winter (eds), Common Pools of Genetic 
Resources: Equity and Innovation in International Biodiversity Law. (Taylor and Francis 
2013).  
125 Rachel Wynberg, ‘Rhetoric, Realism and Benefit-sharing’ (2004) 7 The Journal of World 
Intellectual Property 851. 
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Since there are so many different concerns regarding communities’ practices 
and knowledge associated with genetic resources, there has also been 
interdisciplinary scholarship that aims to identify what is missing in the 
International Regime on Access to Genetic Resources and Benefit Sharing. 
This is extensively reflected in the work of Hayden, who finds that there is a 
prominent market-oriented perspective in the way that the International 
Regime on Access to Genetic Resources and Benefit Sharing has been 
underpinned by bioprospecting. As Hayden takes as a case study the 
partnership between the International Cooperative Biodiversity Project 
(ICGB), an US-based initiative, and the Universidad Nacional Autonoma de 
Mexico (UNAM), a local user of Mexican genetic resources, she discloses that 
the role of local researchers in R&D is to establish the plausible “leads” of 
pharmaceutical activity in medicinal plants. In turn, those users secure 
mutually agreed terms with holders of knowledge associated with the use of 
those medicinal plants. As soon as those leads are established, and mutually 
agreed terms are signed up, the UNAM send what they have collected to US 
partners of the ICGB to carry out R&D in labs upon those “leads” with the aim 
to transform them into products and processes for the pharmaceutical 
industry. Through this R&D process, as genetic resource went towards 
upstream stages, what holders of knowledge contributed to R&D is blurred 
through different aspects in the drug development process which include 
issues such as use of different techniques on those genetic resources, 
confidentiality in the information collected, filing of patents, and potentiality 
to transform those genetic resources into products and processes.  
 
As a result, Hayden concludes that benefit sharing in bioprospecting leaves 
intact the upstream stages of R&D, because it singularises the role of holders 
of knowledge by making local researchers such as the UNAM establish “leads” 
and negotiating mutually agreed terms in order to separate the contribution of 
holders of knowledge as medicinal plants make their way through 
bioprospecting partnerships. That is why Hayden considers that the role of 
local researchers is that of brokers between upstream users of genetic 
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resources and local and indigenous communities.126 Furthermore, the author 
employs an ethnographic approach to claim that local and indigenous 
communities’ knowledge and practices on medicinal plants is not the only 
aspect that should be considered in bioprospecting. 
 
Through her ethnographic methodology, which includes interviews, history, 
and socio-economic analysis, Hayden provides an inclusive and critical 
scrutiny that identifies who else is behind those “leads”, i.e. a complex network 
of actors that goes from indigenous communities, road travellers, mine 
workers, wholesalers of plants, peasants or campesinos, urban markets which 
create, acquire, develop, sell, and share the knowledge on medicinal plants.127 
Such analysis led Hayden to criticise how the International Regime on Access 
to Genetic Resources and Benefit Sharing and its implementation in 
developing countries rich in biodiversity do not explain all those complexities 
behind bioprospecting. In fact, Hayden’s analysis permits us to point out that 
those who are in downstream stages are centralising the compliance of the 
International Regime on Access to Genetic Resources and Benefit Sharing so 
as to benefit upstream stakeholders such as ICGB. With a similar perspective, 
Osseo-Asare highlights how six African medicinal plants reveal intricate 
stories of power-relations, colonisation, patent protection, and fairness, in 
which R&D activities such as bioprospecting in genetic resources just tell a part 
of the story.128  
 
From a socio-legal scholarship perspective, Cloatre also asserts a similar 
discourse as she considers that the International Regime on Access to Genetic 
Resources and Benefit Sharing reflects a simplistic view of bioprospecting, in 
which it is only important to identify a single compound from biodiversity to 
obtain patent protection and, eventually, negotiate and place them towards 
upstream industries, hence, benefit sharing can take place.129 For Cloatre, 
access and benefit sharing regulation and its implementation in developing 
countries rich in biodiversity are unable to comprehend and regulate the 
 
126 Hayden (n 19). p 105 
127 ibid. 
128 Osseo-Asare (n 20). 
129 Cloatre (n 21). 
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“messiness” of the different dynamics of communities’ knowledge and 
practices, leading to incomplete solutions, which at the end of the day exclude 
and affect the more vulnerable. Clearly the work of Hayden, Osseo-Asaren, and 
Cloatre testifies significant numbers of actors and conditions behind 
biodiversity, which have not fitted into the scope of the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing.  
Improving Compliance in the Implementation of the Nagoya Protocol: Lessons from the EU 
 
Although the use of biodiversity involves different complexities and 
“messiness”, which it is difficult to encapsulate within a body of law, it provides 
opportunities to improve the implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing. Since the Nagoya Protocol 
established guidelines on acknowledging the role of communities in the 
utilization of genetic resources and on how to create mechanisms of 
compliance, the Nagoya Protocol helps amplify the discussion on how to 
protect communities’ knowledge and practices. For instance, since the EU has 
not established disclosure of origin in patents as a mechanism of compliance 
for EU members,130 the EU has implemented the Nagoya Protocol in a way that 
not only holders of technology that employ genetic resources are obliged to 
comply with this international body of law, but also other users.  
 
Indeed, the EU has included within the scope of its regulation a variety of 
industries which range from cosmetics to herbal medicines. This can be 
reflected in the EU’s mechanisms of compliance established by the EU 
Regulation 511/2014.131 This Regulation has created two important elements 
to comply with the International Regime on Access to Genetic Resources and 
Benefit Sharing within EU territory. These are (1) users and due diligence; and 
(2) measures of monitoring users’ compliance. On the user and due diligence 
element, the Regulation requires users of genetic resources to exercise due 
diligence in order to comply with the requirements of the regime on access to 
 
130 Netherlands v. Parliament and Council Case-377/98 (n 112). 
131 Regulation (EU) No 511/2014 of the European Parliament and of the Council of 16 April 
2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic 
Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the 
Union 
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genetic resources and benefit sharing and traditional knowledge associated 
with genetic resources. Due diligence is a mechanism to demonstrate that 
users of genetic resources have made the necessary efforts to comply with the 
regulation of access to genetic resources and benefit sharing. Although Article 
4 of the EU Regulation states that users of genetic resources should exercise 
due diligence in accordance with the International Regime on Access to 
Genetic Resources and Benefit Sharing, users can prove that they have 
complied with the EU Regulation through best practices set up by users, such 
as the Guidelines for BIO Members Engaging in Bioprospecting132 (Article 8). 
But it is not only members of the biotechnology industry, such as BIO, who are 
discussing what are best practices in bioprospecting to comply with the EU 
Regulation. In addition, the Association of the European Self-Medication 
Industry (AESGP), the organisation that represents the interest of the herbal 
industry in Europe, has begun a dialogue with the EU Commission on how to 
establish specific guidelines to comply with the EU Regulation 511/2014 in the 
form of best practices.133 However, in 2019 the EU Commission reported that 
there has been no significant progress in establishing best practices with the 
different industries across the EU.134  
 
Article 5 of the EU Regulation also states that member states of the EU should 
consider the registration of collections, which includes institutions such as 
universities and botanical gardens that collect genetic resources, following the 
requirements of Article 5.3, e.g. standardised procedures for verification and 
collection of information on genetic resources. Collections should request EU 
member states to include a register of the collection in the EU (‘the register’), 
which is established and maintained by the EU Commission (Article 5.1). Yet, 
 
132 BIO, ‘Guidelines for BIO Members Engaging in Bioprospecting – BIO’ 
<https://www.bio.org/articles/guidelines-bio-members-engaging-bioprospecting> accessed 
July 31 2017. 
133 AESGP, ‘Comunication of the AESGP to the EU Commission on the EU ABS Regulation 
511/2014’ 
<http://ec.europa.eu/environment/nature/biodiversity/international/abs/pdf/AESGP.pdf> 
accessed  January 29 2019.  
134 Report From The Commission to the European Parliament and the Council Regulation 
(EU) No 511/2014 of the European Parliament and of the Council of April 16 2014 on 
compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and 
the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union 
COM/2019/13 final 
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to date there is only one registered collection in the register.135 The importance 
of registered collections is the role these will play in R&D. By acquiring genetic 
resources through a registered collection, users operating towards upstream 
research (e.g. applied research, clinical trials, or manufacturing) can prove 
their due diligence (Article 4.7). This entire approach indicates that the EU is 
centralising compliance with the International Regime on Access to Genetic 
Resources and Benefit Sharing on users that interact directly with developing 
countries rich in biodiversity and communities. Hence, users operating at the 
downstream stages (e.g. users that carry out bioprospection, collections, 
botanical gardens etc.) will be complying with prior informed consent and 
mutually agreed terms.  
 
Articles 6, 7 and 9 of the EU Regulation establish measures to monitor users’ 
compliance. Each member state of the EU should establish a competent 
authority to oversee that users of genetic resources comply with the Regulation 
and the Nagoya Protocol (Article 6.1.). Moreover, each member state should 
create a national focal point that provides information on prior informed 
consent and mutually agreed terms. In order to monitor user compliance, the 
EU Regulation suggests two mechanisms: (1) Article 7.1 requires member 
states and the European Commission to request publicly funded research to 
comply with due diligence as established by Article 4 of the EU Regulation; 
and (2) Article 7.2 demands users should declare to the competent authorities 
their compliance with due diligence ‘at the stage of final development’.  
 
On the definition of what is the stage of the final development, Article 7.6 
delegates to the EU Commission to ‘determine the stage of final development 
of a product to identify the final stage of utilisation in different sectors’ such as 
the pharmaceutical industry. The EU Commission in the Implementing 
Regulation 2015/1866 defines this concept with different events: When a 
product developed via utilisation of genetic resources needs market approval 
 
135 See: EU Commission, ‘Register of Collection-EU ABS Regulation’ 
<http://ec.europa.eu/environment/ 




or authorisation or when a notification is required before the product is placed 
in the market; or, if there is no need for notification or marketing 
authorisation, when it is placed in the EU market for the first time; or when 
the result of the utilisation is sold or transferred; or when the utilisation in the 
EU has ended and is then transferred outside of the EU. As observed, the EU 
has established a comprehensive catalogue of activities that fall within “the 
stage of final development”, which is not only directed to holders of 
technology, but also to other industries. In the case of the European herbal 
industry, the AESGP has pointed out that this Regulation will not only affect 
their market approved products (e.g. phytomedicines), but also other activities 
such as providing plant starting material to upstream users (e.g. the 
pharmaceutical industry).136 As a result, this industry, which did not have to 
follow access and benefit sharing rules, will now be obliged to comply with the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
the EU.137    
 
The EU Regulation also designs a procedure which enables the competent 
authority to carry out checks to verify if users comply with the Regulation 
(Article 9). These procedures can take place in two situations. First, the 
competent authority should carry out periodical checks following a risk-based 
approach in which states should take into account the best practices to reduce 
users’ risk of non-compliance. Second, the competent authority can also carry 
out checks when it is in position of having relevant information of non-
compliance, which might be provided by a third party, and if such information 
is provided by a provider’s country (developing countries rich in biodiversity) 
‘special consideration shall be given’ to that information (Article 9.3 (b)). 
Finally, despite the fact the EU Regulation indicates that states should accept 




136 AESGP (n 133). 
137 Yet, the herbal industry had already acquired compromises of conservation and 
sustainability in the growing and harvesting of plant material as required by the European 
Medicine Agency in the Guidelines of Good Agricultural and Collection Practice of EMA 
(EMA/HMPC/246816/2005) 
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Although the effects of the implementation of the EU Regulation remain to be 
seen,138 there are already authors that are at least sceptical about the effect of 
this Regulation in, for instance, R&D on genetic resources. Burton et al. and 
Kang et al. point out that this legal framework will place the responsibility of 
complying with the UN Convention on Biological Diversity and the Nagoya 
Protocol on users at the beginning of the R&D process.139 In fact, the creation 
of registered collections indicates that other potential users will comply with 
due diligence by accessing genetic resources through those collections. In 
other words, since this Regulation will centralise user measures in the EU, it 
indicates that it will be at downstream stages (i.e. basic and applied research) 
where compliance will have more impact. Also, the EU Regulation has 
included sectors such as the herbal industry to comply with access and benefit 
sharing regulation. These are businesses that were in a “blind spot” as they did 
not have to comply with any of the access and benefit sharing rules such as 
prior informed consent and mutual agreed terms despite the fact that they 
actually benefit from the commercialisation of medicinal plants.  
 
The EU’s implementation of the Nagoya Protocol in Europe has brought two 
important lessons. First, it indicates that developed countries are focusing on 
users that are in downstream stages of the research (e.g. universities and small 
and medium size companies) to comply with the International Regime on 
Access to Genetic Resources and Benefit Sharing’s requirements.140 Second, 
there are new actors who have been included within the scope of the 
International Regime on Access to Genetic Resources and Benefit Sharing, 
particularly the herbal industry.  
 
The approach of the EU to implementation of these aspects of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
gives important insights for the particular case of Colombia, the country on 
 
138 The EU Commission has already pointed out that the regulation is at its early days as EU 
Members have just began to make institutional changes to comply with it see: Report From 
The Commission to the European Parliament (COM/2019/13 final). 
139 Geoff Burton and Elizabeth A Evans-Illidge, ‘Emerging R and D Law: The Nagoya Protocol 
and Its Implications for Researchers’ (2014) 9 ACS Chemical Biology 588; Kyung-Nam Kang, 
Chan-Sik Jung and Tae-Kyu Ryu, ‘The Nagoya Protocol and the Biotechnology Industry’ 
(2015) 4 International Journal of Pharma Medicine and Biological Sciences 209. 
140 Burton and Evans-Illidge (n 139)., p 590 
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which this thesis focuses. As we will see in subsequent chapters, in the 
Colombian context, local researchers such as universities and research centres 
are also playing an intermediary role between the industry and communities, 
as they are the first to access genetic resources or obtain lead information on 
practices and knowledge from local communities on the industrial application 
of genetic resources. Also, the Colombian herbal industry is in a “blind spot” 
as it is not required to comply with the access and benefit sharing rules in the 
country, even though the industry benefits from communities’ practices and 
knowledge associated with genetic resources.  
 
All in all, the recognition, protection and establishing of mechanisms of 
compliance to protect the role of traditional knowledge associated with genetic 
resources has been placed in downstream stages, which means that countries’ 
implementation of the International Regime on Access to Genetic Resources 
is centralising compliance at the beginning of the R&D process, in which 
mainly universities, local researchers, and small and medium size companies 
are located, so as to benefit upstream stakeholders such as large industries. 
The consequence is that local and indigenous communities’ participation in 
R&D is limited and restricted so as to leave the rest of the innovation process 
intact. This means it is not only difficult to accommodate communities’ rights 
into patent regulation, but also in the International Regime on Access to 
Genetic Resources and Benefit Sharing. Indeed, the implementation of these 
instruments has resulted in placing the role of communities in adding value to 
biodiversity for industrial application almost exclusively in downstream stages 
of R&D. A critical problem with this approach, as observed in the following 
chapters, is that knowledge and practice which goes on in upstream stages 
(applied research, clinical trials, production, and distribution) tends to 
become less relevant because users and other stakeholders focus exclusively 
on the biochemical description of genetic resources, rather than what has led 
them to find the therapeutic activity of that resource. This situation has 
become even more complex in the context of new technologies such as 
synthetic biology and gene editing which aim to rely less on the actual genetic 
resource and communities’ practices and knowledge to develop products and 
process. As a result, communities are relegated to be mere “leads” in the 
 75 
discovery of therapeutic activity. Equally, other industries which are not 
considered innovative, such as the herbal industry, openly employ the 
knowledge and practices from indigenous communities in the production of 
phytomedicines, as well as in proving safety and effectiveness of those 
products, without even recognising the role of those communities in the 
industrial application of their practices and knowledge.  
 
This thesis shows how Colombia is a perfect illustration of this point, found in 
the broader literature. Regulation of R&D in genetic resources for the health 
industry and in health research aims to make technological innovation and 
market interest prevail over other forms of knowledge and information 
production, particularly those from local, indigenous, and Afro-Colombian 
communities. In the case of Colombia, this is evident not only in the way that 
Colombia has implemented the International Regime on Access to Genetic 
Resources and Benefit Sharing, but also in the forms in which the country’s 
laws, policies, and practices approach innovation and the commercialisation 





A legal analysis of the evolution of the International Regime on Access to 
Genetic Resources and Benefit Sharing, its implementation in developing 
countries rich in biodiversity, and its academic critique, reveals a range of 
discussions. These include questions pertaining to the geopolitical and 
economic balancing of power among countries with historically very different 
relations to biodiversity. They also concern questions about issues from 
different communities within countries, and the balancing of their various 
interests. In the particular case of the practices and knowledge of local and 
indigenous communities in adding value to biodiversity for industrial 
application and research, what can be observed is a narrative of a constant 
search for recognising and protecting them as the International Regime on 
Access to Genetic Resources and Benefit Sharing has evolved from the UN 
Convention on Biological Diversity to the Nagoya Protocol. However, that 
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progression has centred the discussion of recognition and protection (through 
mechanisms of compliance) in downstream stages of R&D, leaving untouched 
upstream stages, where that contribution can potentially fade away as users 
employ technology to isolate and synthetize genetic resources for industrial 
production, not considering the knowledge and practices from those 
communities. 
 
Therefore, the problem for countries such as Colombia is that the discussion 
of how to implement the International Regime on Access to Genetic Resources 
and Benefit Sharing in order to protect communities’ participation in R&D and 
industrial process needs to be addressed. An effective response would be to 
create a more inclusive approach to innovation and the commercialisation of 
medicinal plants, which considers the complexities and actors behind the use 
of biodiversity throughout the entire R&D process, and in the distribution and 
production of medicinal plants (e.g. phytomedicines). These aspects are 









The International Regime on Access to Genetic Resources and Benefit Sharing 
sets up an ambitious agenda aiming to secure benefit sharing arising from the 
use of biodiversity and the practice and knowledge related to genetic 
resources. It is up to each member of the UN Convention on Biodiversity to 
implement this legal framework, by adopting the access and benefit sharing 
provisions into their national legislation. However, such an implementation is 
not exclusively a question of creation of legal mechanisms or administrative 
provisions, for instance through creation of a national authority or procedures 
to obtain prior informed consent and mutually agreed terms. It is also a 
question of whether, and if so how, countries make those provisions 
enforceable, meaning how they implement the International Regime on Access 
to Genetic Resources and Benefit Sharing, so as to make users comply and 
obey this international treaty. In fact, the previous chapter points out that one 
of the key problems in the International Regime on Access to Genetic 
Resources and Benefit Sharing is that its implementation does not effectively 
impose an obligation on users of genetic resources to comply with its 
provisions. For example, as already noted, a publicly funded research centre 
in South Africa originally failed to include an indigenous community into a set 
of mutually agreed terms, even though this user aimed to commercialise that 
community’s knowledge in the medicinal use of a plant.141 This is despite the 
fact that South Africa had implemented the UN Convention on Biological 
Diversity, including provisions regarding respect for, and acknowledgment of, 
communities’ knowledge and practices. 
 
 
141 Eventually, the research centre included those communities in mutually agreed terms after 
the pressure from NGOs and academics. In Chapter One, Section 2.  Kamau (n 124).Wynberg 
(n 125). 
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This thesis focuses on the International Regime on Access to Genetic 
Resources and Benefit Sharing in Colombia. It discusses whether Colombia’s 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing recognises contributions from local, indigenous, and Afro-
Colombian communities’ practices and knowledge in adding value to the use 
of genetic resources for the health industry and health research. To that end, 
this chapter centres on the particularities of Colombia’s legal system and how 
it works. The next chapter assesses whether – in practice – Colombia’s 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing recognises communities’ contribution and practices, in 
compliance with Colombia’s international obligations.  
 
The analysis here of the Colombian legal system is not exhaustive.142 Its core 
focus is the particularities of Colombian law that are related to the subject 
matter of the thesis. There are two key facets of Colombian law: Its obligations 
as a member of the Andean Community of Nations, and its constitutional 
provisions that reconcile cultural rights with economic development. 
 
Since Colombia is a member of the Andean Community, and Andean 
Community membership entails obligations relevant to access to genetic 
resources and industrial property, it is necessary to analyse the relevant 
measures of Andean Community law. In particular, these are Decision 391 of 
1996 on the Common Regime on Access to Genetic Resources and Decision 
486 of 2000 on the Common Industrial Property Regime of the Andean 
Community. Andean decisions are of direct application, which means they 
automatically become part of Andean countries’ legislation without further 
requirements (e.g. passing through the congress). Those Andean decisions 
also demand that each member regulates them through legal and 
administrative dispositions, and these are analysed below.  
 
 
142 Colombia legal system is mainly influenced by the Civil or Continental Law tradition, in 
which principles and rules are in Statutes or Codex. For instance, the Civil Codex, which is 
inspired in the Napoleon Civil Codex, sets up all rules for equity, trust and contract law. There 
is also the Commerce Codex, influenced mainly by the Italian and Spanish Codex of 
Commerce. For a general introduction of Colombia law see: Arturo Valencia Zea and Álvaro 
Ortiz Monsalve, Derecho Civil. Tomo I: Parte General y Personas (18th edn, Temis 2016). 
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The Colombian Constitution 1991 is “the primary source” of the Colombian 
legal system. It includes a comprehensive catalogue of fundamental rights. In 
the event of an incompatibility between the constitution and any law or 
regulation, the former must prevail and be applied.143  
 
The constitution creates the Constitutional Court of Colombia, the highest 
constitutional tribunal in the country. The constitutional court has two judicial 
mechanisms that aim to secure the supremacy of the Colombian constitution 
and make enforceable fundamental rights such as freedom of speech. The 
constitutional court can carry out judicial review of specific situations via the 
writ of protection of fundamental rights (acción de tutela). In addition, the 
constitutional court is entitled to order the government and parliament to 
create effective mechanisms of protection or to either amend or reject any 
legislation that goes against the constitution (acción de inconstitucionalidad). 
The relevance of those aspects of the constitutional court’s jurisdiction to this 
thesis is that they have served to solve social, political and economic conflicts 
effectively. In other circumstances, such conflicts would either have taken 
years of endless judicial procedures, or would have unjustifiably benefited 
ruling elites against the interests of the most vulnerable, including local, 
indigenous, and Afro-Colombian communities.144  
 
One example of the conflicts that the constitutional court has helped to solve 
is the protection of local, indigenous, and Afro-Colombian communities’ 
rights. Indeed, those communities have been victims of the long cycle of 
exclusion and violence in Colombia, involving state agents, businesses, 
multinational companies, landlords, far-left and far-right armies, drug barons, 
and so on. The constitution establishes as a fundamental right the “recognition 
and protection of ethnic and cultural diversity”. The constitutional court has 
exercised its jurisdiction under acciones de tutela and acciones de 
inconstitucionalidad to interpret this constitutional provision. In doing so, it 
 
143 Article 4 of the 1991 Constitution 
144 Because of such a judicial activism, the court has been accused of stepping into the role of 
other high tribunals such as the Supreme Court and the Council of State, and even into the 
role of other branches of government; for further discussion see Manuel José Cepeda-
Espinosa, ‘Judicial Activism in a Violent Context: The Origin, Role, and Impact of the 
Colombian Constitutional Court’ (2004) 3 U. Global Stud. L. Rev.  
 82 
has recognised and developed a set of rights of local, indigenous and Afro-
Colombian communities. These constitutionally-protected rights include a 
right of subsistence (as an aspect of the right to life), a right of cultural 
integrity, right to be publicly consulted, and a right to communitarian land. 
 
The 1991 Colombian Constitution prevails over the entire Colombian legal 
system. The constitutional court gives practical effect to its provisions through 
the acción de tutela and acción de inconstitucionalidad. In so doing, the 
constitutional court gives effect to the purposes of the Colombian Constitution. 
The following section of this chapter therefore explores some of the reasons 
behind the particular rules in the 1991 Colombian Constitution. It argues that 
the 1991 Colombian Constitution was constructed with the idea of reconciling, 
on the one hand, economic development and international trade, and, on the 
other hand, other social and cultural concerns, including the rights of local, 
indigenous, and Afro-Colombian communities. The final part of the chapter 
turns to analyse the International Regime on Access to Genetic Resources and 
Benefit Sharing in the Andean Community, and how Colombia has integrated 
relevant Andean legislation within the Colombian system, including within the 
1991 Colombian Constitution.  
 
The focus of this chapter is a textual analysis of the relevant legal provisions. 
In the following chapters, the focus is on the law in practice. It is not enough 
to understand what the legal texts envisage. We also need to understand how 
the implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing has worked out in practice for the health 
industry and health research, and whether communities’ practices and 
knowledge have been recognised by local authorities and users according to 
the requirements of the Andean decisions and Colombia’s constitution. 
 
The Colombian Constitution 1991: Reconciliating Economic Development and 
International Trade with Communities’ Rights  
 
As discussed in the introduction to this thesis, to carry out any analysis of 
Colombian law, it is essential to understand the context of Colombia’s long 
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history of favouring the economic interests of ruling elites (businesses, 
landlords, politicians, etc.), over other sectors such as its rural population and 
minorities, including local, indigenous, and Afro-Colombian communities. For 
instance, it was very common in Colombia during the 19th century and a good 
part of the 20th century for policy decisions to be taken with regard to family 
and business links, rather than, for instance, rational economic interests. 
These practices led to the creation of strong and close elites that continue to 
enjoy considerable power even nowadays. Indeed, two of the three last 
presidents of Colombia (i.e. Juan Manuel Santos and Andres Pastrana) belong 
to families that for a long time have politically, economically, and culturally 
dominated the country.145 As those elites have benefited from Colombian 
development, their influence has led to cultural, economic and social tensions, 
which is one of the reasons for Colombia’s civil conflict. Among the different 
accounts of why Colombia has such a long history of violence since its 
independence in the 19th century, there is one explanation that relates the 
conflict to the economic prevalence of ruling elites. Colombia has a 
geographical situation that makes it difficult to access remote areas. Those 
remote areas are where local, indigenous, and Afro-Colombian communities 
live. This distance and difficulty of access make it hard to reconcile the 
economic interests of educated ruling elites in the capitals with those of rural 
elites. At the same time, rural elites have embraced power through violence. 
The conflict between those elites has ended up affecting minorities and 
communities.146  
 
However, since the 1990s, Colombia has aimed to reconcile economic 
development and international trade with those social circumstances, so as to 
 
145 Further information see Mario Aguilera Peña, Insurgencia Urbana En Bogotá: Motín, 
Conspiración y Guerra Civil (Instituto Colombiano de Cultura 1997); Sergio Paolo Solano and 
Roicer Alberto Flórez Bolívar, ‘Historia Social y Literatura En Colombia a Comienzos Del Siglo 
XX. Los Sectores Sociales Medios En La Novela Cosme de José Félix Fuenmayor’ (2011) 71 
Revista de Indias 601.   
146 For instance, the political parties dispute between Liberals and Conservatives during the 
second half of twenty century led to an unprecedent scale of violence in rural areas; further 
information see: Safford and Palacios (n 8)., p 159. For a review of different accounts of history 
of Colombia’s violence see John H Coatsworh, ‘Root of Violonce in Colombia’ (2003) 11 
ReVista -Harvard Review of Latin America. For an explanation of the different dynamics of 
Colombia diversity and violence see James D Henderson, When Colombia Bled: A History of 
the Violence in Tolima (University of Alabama Press 1985). 
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have a more inclusive state that safeguards and protects the most vulnerable. 
As a result, Colombia enacted a constitution in 1991 which sets up the 
principles for an open economy,147 but also brings a comprehensive set of 
fundamental rights to safeguard and protect all Colombians, regardless of 
status. The constitution thus includes civil and political rights such as freedom 
of speech, but also economic and social rights, such as union rights, gender 
rights, and the right to health.148 In an effort to make both types of rights 
enforceable, the constitutional court has pointed out that those rights are 
constitutional principles, meaning that three branches of government must 
give them material effect through legislation, administrative procedures, and 
rules, as well as judicial decisions.149 Hence, it is under those constitutional 
principles that the state is designed. In other words, the Colombian legal and 
administrative system is underpinned by the 1991 Constitution’s catalogue of 
fundamental rights. As a matter of legal principle, the enforceability of 
fundamental rights in Colombia cannot be deterred or defined by contingent 
circumstances, such as changes in government, judicial interpretation, 
contractual dispositions among citizens, or economic circumstances.150   
 
The 1991 Colombian Constitution and the Rights of indigenous, Afro-
Colombia, and local communities  
 
The rights of indigenous, Afro-Colombian, and local communities enjoy the 
status of prevalence of fundamental rights in Colombian constitutional law. 
Indeed, the constitution has established the “recognition and protection of 
ethnic and cultural diversity” (Article 7 of 1991 Constitution) as a fundamental 
 
147 This is known in Colombia as the Apertura. The Apertura was an economic plant by 
President Cesar Gaviria to open Colombia economy as to include Colombia in the economy to 
international trade (selling public companies and softening taxes on Foreign Direct 
Investment (FDI) further information see WTO, ‘Trade Policy Review-Colombia’, 
WT/TPR/S/18 (WTO 1996). For further information in the history of Colombia’s economy 
see: José Antonio Ocampo Gaviria, Historia Económica de Colombia. (FCE - Fondo de 
Cultura Económica 2017). 
148 For more information on Colombia’s constitutional reforms see Manuel Fernando Quinche 
Ramírez, Derecho Constitucional Colombiano de La Carta de 1991 y Sus Reformas: Tercera 
Edición (Editorial Universidad del Rosario 2009). 
149 T-  406  of  1992., Constitutional Court; see also T-881 of 2002, Constitutional Court and 
C-143 of 2015, Constitutional Court 
150 T-426 of 1992, Constitutional Court  
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principle. This legal status leads to the recognition of a set of rights that derive 
from this fundamental principle. Those rights include: (i) a right of 
subsistence, which involves protecting communities’ form of life (e.g. values, 
beliefs, knowledge, and so on),151 (ii) rights of self-determination and self-
governance, which derive from the right of integrity,152 and (iii) the right to 
possess their own communitarian land, where they can exercise their cultural, 
social and economic activities.153 In a series of landmark rulings, the 
constitutional court has prevented Colombian authorities from applying 
specific duties under the law in contexts where to do so would threaten the 
cosmo-vision and cultural practices of certain Colombian communities. For 
instance, military service is compulsory for all Colombian males when they 
reach their legal capacity (i.e. 18 years old). Notwithstanding, the 
constitutional court, in an acción de constitucionalidad, found that members 
of indigenous communities should not be obliged to serve in the military as 
such a situation could threaten the very existence of those communities.154 
Further, the constitutional court has stated that communities are entitled to 
create their own form of governments and justice, regardless of whether to do 
so contradicts Colombian law.155  
 
Furthermore, the constitutional court has not only focused on aspects of self-
government and self-determination, but also on how to strike a balance 
between economic development, and communities’ cultural, economic, and 
social relations with the environment. Through a number of rulings on 
acciones de tutela, the constitutional court has pointed out that, even though 
natural resources such as oil and gold are the property of the state, if their 
 
151 T-380 of 1993, Constitutional Court  
152 C-882 of 2011, Constitutional Court  
153 Frank Semper, ‘Los Derechos de Los Pueblos Indígenas de Colombia En La Jurisprudencia 
de La Corte Constitucional’ (2006) 2 Anuario de derecho constitucional latinoamericano 761. 
154 C-058 of 1994, Constitutional Court. Indigenous communities have been particularly 
victimized by all sides of Colombian conflict as their territories are unfortunately located in 
the most conflicted areas in the country; further information see William Villa and Juan 
Houghton, Violencia Política Contra Los Pueblos Indígenas En Colombia 1974-2004 (Grupo 
Internacional de Trabajo sobre Asuntos Indígenas 2005). 
155 The right to those communities to decide their own form of government and justice is 
expressly protected by the Constitution in Article 246 and 287, which is a materialisation of 
the principle of cultural and ethnic diversity protected in Article 7 of the Constitution.  
However, if the indigenous form of justice and government go against other constitutional 
principles such as human dignity, the latter should be prevailed and protected. See T-496 of 
1996, Constitutional Court 
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economic exploitation affects the rights of communities (such as the right of 
subsistence or cultural integrity), those communities have the right to decide 
whether such activity can take place, by means of a public consultation.156  
 
Indeed, the Colombian Constitutional Court has suspended exploitation of 
those resources until communities are involved or publicly consulted before 
the economic activity of extraction of those resources takes place. For instance, 
in 2015, the constitutional court ordered suspension of the activities of 
extraction of oil until the Awa community, a native population located in the 
south-west of the country, was consulted on how to protect their territories.157 
Similarly, in 2017, the constitutional court ordered the government to suspend 
the exploitation of gold by Gran Colombia Gold until the different indigenous, 
Afro-Colombian, and local communities located in Marmato (Caldas) were 
included in public consultations. Despite the fact the government had granted 
to the company the right (Titulo) to exploit gold, the court found in favour of 
those communities because they have environmental, cultural, and economic 
links with the region (including the practice of artisanal mining). As a result, 
the government was obliged to include those communities in the decision-
making process through public consultations. In particular, the court ordered 
the government to consult with the communities on how the exploitation of 
natural resources should respect communities’ environment and culture. The 
government was also ordered to include those communities in the exploitation 
of the non-renewable resource. In particular, the court requested the 
government to help them to technically improve and formalise their artisanal 
mining.158 The ruling in this case has led different communities across the 
country to demand public consultations whenever there are plans from the 
government to perform activities of oil and mining exploitation in those 
 
156 According to Article 332 of the 1991 Constitution, natural non-renewable resources such as 
gold are property of the State. Since those resources are owned by the State, it is the President 
through its Ministers and Agencies who decide how to exploit those resources. Such an 
exploitation is normally granted to private owned companies such as Gran Colombian Gold 
company. This also reflects what developing countries, more specifically former colonies, 
campaigned in the UN as to establish that natural non-renewable resources belong to States 
rather than being considered common heritage,  see Paragraphs 4 and 5 of Preamble to the 
UN–General Assembly Resolution 1803 (XVII) Dec 14 1962 Permanent Sovereignty over 
natural resources   
157 T-539 of 2015, Constitutional Court 
158 SU-133 of 2017, Constitutional Court  
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territories.159 As a result, communities have the fundamental right to be 
publicly consulted about the exploitation of resources in their land before the 
action of the state or any other agent takes place.160  
 
However, there is a legal distinction between ethnic communities, indigenous 
and Afro-Colombian communities, and non-ethnic communities or local 
communities. While any project that involves ethnic communities needs to 
obtain prior informed consent from those communities, projects in territories 
of local communities do not necessarily have to obtain prior informed consent. 
Rather, local communities should be included in the decision-making process 
if the activity affects their environment and socio-economic activities.  
 
Regarding ethnic communities, there are two separate pieces of legislation.161 
On one hand, there is the Decree 2164 of 1995, which regulates indigenous 
communities. This decree defines these communities as a group of people, who 
are of Amerindian descent, are aware of their identity, and share values, uses 
or customs, as well as having their own form of government and law. All of 
these aspects distinguish them from other communities. In order to have 
representation before Colombian authorities and have recognition over their 
territories, Decree 2164 creates Cabildos Indigenas (Indigenous Councils). 
This legal entity is created not to establish a form of government or rule in 
those communities, but to adjust whatever form of government, political 
organization, law and customs those communities possess, which entitles 
them to specific rights, including communal land rights (Resguardo 
Indigena), self-governance (e.g. how they make their own decisions regarding 
use of their soil or traditional knowledge). Since indigenous communities vary 
 
159 There are approximately 8 public consultation in course, 5 which have been suspended and 
there are nine acción tutela demanding to carry out a public consultation; further information 
see Juana Marina Hofman-Quintero, ‘El Falso Dilema de Las Consultas Populares’ (La Silla 
Vacía, 2018) <http://lasillavacia.com/silla-llena/red-verde/historia/el-falso-dilema-de-las-
consultas-populares-64228> accessed July 2 2018. 
160 The Constitutional Court has included as part of Colombia constitution the Indigenous and 
Tribal Peoples Convention, 1989, of the International Labour Organization, which calls 
countries to public consulted those communities when their rights and guarantees might be 
affected. As this treaty is part of Colombia constitution, its provision including public 
consultation should be guarantee and protected in the same way that any fundamental rights. 
See SU-510 of 1998, Constitutional Court 
161 Both regulations implement the Indigenous and Tribal People Convention of the International 
Labour Organization (1989), which is discussed in Chapter Two 
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in the way that they govern themselves, each community establishes how its 
decision-making process takes place and how they want to be represented 
before national authorities or other agents that, for instance, want to access to 
their ancestral land, knowledge and practices.  On the other hand, for Afro-
Colombians, there is the Decree 1745 of 1995. This regulation states that Afro-
descendent communities can create Consejos Comunitarios, which are the 
main administrative authorities within these communities’ land (Tierras de 
las Comunidades Negras). However, since they are not considered to have an 
ancestral origin as in the case of indigenous communities, the wording of 
Decree 1745 establishes basic guidelines on how those Consejos Comunitarios 
are organized and managed, as well as how they can make decisions that affect 
communities’ rights. For instance, the main body of Consejos is the General 
Assembly, whose decisions should have a majority of 50 plus 1. Both 
indigenous and Afro-Colombian communities have the right to be previously 
consulted in order to grant their consent if any activity is carried out in their 
lands.  
 
However, by contrast, local communities do not have a specific law that 
recognizes the right to be consulted beforehand. There is no even a legal 
definition of what a local community is. Yet, this does not mean that local 
communities are not constitutionally protected. As there is an absence of a 
legal definition, there has been a case-by-case approach from the 
Constitutional Court to protect local communities, for instance, of peasants 
that are affected by infrastructure and exploitation of non-renewable 
resources projects.162 For instance, the construction of the hydroelectric 
station Urrá I in the north of the country was delayed until local and national 
authorities assessed the potential socio-economic damages and consulted 
rural and fisherman communities (Pesqueros), whose main socio-economic 
activities were affected by the infrastructure project.  As a result, although 
there is not a legal text that grant rights to local communities such as 
communal land, the Constitutional Court has imposed an obligation on 
authorities and other agents interested in carrying out infrastructure projects 
 
162 T-194 of 1999, Constitutional Court 
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(e.g. bridges, dams, etc.) or mining and oil activities, which could have a 
potential impact in local communities’ socio-economic activities, to identify 
those communities and include them in decision making process. In 
particular, agents should assess any potential negative impact of carrying out 
their projects for local communities’ socio-economic activities, and should 
agree with local communities’ mechanisms to overcome those difficulties.163   
 
Additionally, even if there is a legal distinction between ethnic and non-ethnic 
communities regarding prior informed consent,  in practice, the Constitutional 
Court’s rulings illustrates that, since infrastructure or extractive projects affect 
considerable extension of territory, there is no single and specific community 
involved, but rather indigenous, Afro-Colombian and local communities are 
joined in one territory as occurred in the case of Marmato (Caldas). 
 
Furthermore, the fundamental principle of “recognition and protection of 
ethnic and cultural diversity” of indigenous and Afro-Colombian communities, 
as well as the constitutional protection of local communities’ socio-economic 
relationship with their environment has not only been relied upon to require 
authorities involved in the exploitation of non-renewable resources in 
Colombia to carry out public consultations. The Constitutional Court has also 
drawn on the principle to request the government and parliament to consider 
communities’ concerns on international intellectual property rights-trade 
related compromises. This is exemplified in the government’s efforts to give 
greater protection on plant variety for agriculture to plant breeders and 
multinational companies by implementing the 1991 International Convention 
for the Protection of New Varieties of Plants (UPOV 1991). Colombia acquired 
the obligation of implementing the Convention 1991 in two separate Free 
Trade Agreements: the US-Colombia Free Trade Agreement164 and the EU-
Colombia and Peru Free Trade Agreement.165  
 
 
163 T-348 of 2014, Constitutional Court, and T-135 of 2013, Constitutional Court  
164 See Article 16.1.3 (c) of the US-Colombia Free Trade Agreement  
165 See Article 232 of the Trade Agreement Between the European Union and its Member 
States, of the one part, and Colombia and Peru, of the other part (EU/CO/PE/en 1) 
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The Constitutional Court held that the legislative effort to implement the 
International Convention for the Protection of New Varieties of Plants in 
Colombia was unconstitutional. The main reasoning of the Court was to the 
effect that unconstitutionality arose because indigenous and local (peasants) 
communities did not participate in the implementation of the 1991 
Convention. That lack of participation in the implementation of the 
Convention rendered it constitutionally deficient. For the Constitutional 
Court, the government was ignoring both “the practices and traditional 
knowledge of ethnic people and peasants, communities” and “the rights that 
such communities may have over traditional or native varieties, particularly 
those that do not circulate within commercial and technological channels”. 166 
Furthermore, although there is an apparent legal distinction between ethnic 
and non-ethnic communities regarding prior informed consent for 
infrastructure projects and extractive activities (mining or oil), this 
constitutional ruling on the implementation of the UPOV 1991 shows that such 
a distinction does not even operate when local and indigenous communities’ 
practices and traditional knowledge associated with genetic resources for 
agriculture are at stake.167 In other words, prior informed consent is 
mandatory equally for all communities if their practices and traditional 
knowledge can be potentially affected by an industrial activity such as plant 
variety protection.  
 
To summarise, the Colombian legal system, through the acción de tutela and 
acción de inconstitucional, has elevated communities’ rights to the level of 
fundamental rights. It seeks to provide an effective mechanism of protection 
 
166 C-1051 of 2012, Constitutional Court; for further information in this case see: Jhonny 
Antonio Pabón Cadavid, ‘Indigenous and Traditional Communities Must Be Consulted before 
Approval of Intellectual Property Treaties’ (2015) 10 Journal of Intellectual Property Law & 
Practice 11.; the supremacy of the Constitutional Court rulings on communities’ rights 
regarding the implementation of international treaties has also been reflected in other 
governmental non-binding actions. This is the case of the Consultant Body of the Council of 
State, which is the techno-legal adviser of the government. It recently recommended the 
government to consult communities before it officially implements the Nagoya Protocol in the 
country. This recommendation was based completely upon the Constitutional Court rulings, 
see: Recommendation 2017-00057-00 of the Consultant Body of the Council of State  
167 This is also reflected in the Constitutional Court’ ruling on the constitutionality of a bilateral 
environmental agreement between Colombia and Canada, in which the terms indigenous and local 
communities were used indistinctively to demand prior informed consent from both local and 
indigenous communities in any State decision that affect them. See C-915 of 2010, Constitutional Court 
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to those communities. In the case of exploitation of non-renewable resources, 
the Constitutional Court highlights that, since the economic use of those 
resources affects the cultural and socio-economic link that exists between 
communities and their environment, the rights of subsistence and cultural 
integrity are at risk. As a result, those communities have the right to be publicly 
consulted. It is also important to notice that, despite the fact that the 
Colombian legislation makes a distinction between ethnic communities, and 
local communities, regarding the obligation to obtain prior informed consent, 
the Constitutional Court has extended that right to local communities too 
when their socio-economic activities are affected by State and different agents’ 
actions or inactions.   
 
Furthermore, the Court rulings are not only limited to an obligation on the 
government to reconcile economic development and communities’ rights, but 
also to reconcile those rights with international trade agreements. The 
constitution and the rulings of the Constitutional Court have been used as 
instruments to ensure that the action – or inaction – of different stakeholders 
does not transgress the fundamental rights of local, indigenous, and Afro-
Colombian communities. This means that the three branches of government 
must observe those communities’ rights if any policy, ruling, or legislation 
(including in economic development and international trade) affects their 
right of cultural integrity, right of communitarian land, etc.  
 
The next section analyses how the legislation that implements the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia, including the Andean Decisions, is articulated within those 
principles of the Colombian Constitution and constitutional court decisions.  
 
The Access and Benefit Sharing Regime in the Andean Community and 
Colombia 
 
Although Colombia has comprehensive legislation on the protection of its 
biodiversity, including the rights of communities, the legal and administrative 
implementation of the Access and Benefit Sharing Regime in Colombia has not 
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been carried out exclusively within the country’s legislative processes. 
Colombia has geographical, historical, cultural, and economic links with its 
neighbouring countries.168 The Andean countries have worked together in 
specific areas of common interest. As a result, Bolivia, Colombia, Ecuador, and 
Peru have addressed the interests of biodiversity protection, and communities’ 
rights, through the Andean Community.169 The Andean Community is a 
regional organisation which aims to form a common Latin-American market 
in order to compete with other countries (particularly developed countries) 
and to negotiate en bloc within international institutions such as the WTO. 
Therefore, the following section explains how the Andean Community of 
Nations legislation works and is implemented within its members, and how it 
fits within the Colombian constitutional regime. As an example of such an 
organizational relation with its members, it also explains how the 
International Regime on Access to Genetic Resources and Benefit Sharing has 
been implemented through the Decision 391 in the Andean sub-region and 
Colombia.  
 
The Andean Community of Nations, the Colombian Constitutional Regime and 
ABS Implementation  
 
The Andean Community is composed of the state members and the Andean 
System of Integration or SAI (Spanish acronym).170 The SAI is comprised of 
different Andean institutions that promote the integration of the Andean 
region as a whole or key industry or sectors (e.g. banking, agro industry, 
etc.).171 For the specific interest of this thesis, the institutions of the SAI that 
 
168 For instance, all the Andean countries have the same official language (Spanish), were 
Spanish colonies and were freed by Simon Bolivar (El Libertador), have the same main 
religion (Catholicism), follow the Civil law tradition, belong to the same international and 
regional organizations (e.g. Organization of American States (OAS)) and so on).     
169 Chile was a country founder member of the Andean Community of Nations but renounced 
its membership on 30 October 1976; whereas Venezuela was added to the Andean Subregional 
Integration Agreement (Cartagena Agreement) on October 30 1973, but renounced its 
membership on April 22 2006.   
170 Article 5-6 of the Cartagena Agreement 
171 There are three sets of institution in the Andean Community of Nations: (1) 
intergovernmental institutions such as the Presidential Council, the Andean Council of 
Ministers of International Affairs and the Commission; (2) communitarian organisations 
which are the Tribunal of Justice, the Andean Parliament, the Secretary of the Andean 
Community of Nations, the Latin American Development Bank, the Latin American Fund, the 
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define policies and legislation on access to genetic resources are: (i) the 
Andean Presidential Council (led by the presidents of each state member), the 
top decision making body of the Andean Community which sets up the policies 
of integration;172 (ii) the Andean Council of Ministers of International Affairs 
that coordinates the common international agenda on issues that affect the 
common market, such as the negotiation of international trade with the 
WTO;173 (iii) the commission, the executive body of the SAI, whose main role 
is to implement through decisions the policy of integration of the common 
market;174 and (iv) the Andean Tribunal of Justice (v) which interprets Andean 
legislation to ensure it is applied uniformly by member states. The Andean 
Tribunal of Justice does so via the following: Pre-judicial interpretation; 
actions for annulment against an Andean law that might be in opposition to 
the Andean legislation; actions against member states or SAI institutions for 
failure to act according to the Andean legislation and labour actions; as well as 
serving as an arbitral tribunal for SAI institutions and contractual disputes 
among parties that employ Andean legislation in private contracts.175 
 
The Andean Community’s legislation (acts and decisions) is legally and 
automatically binding on state members and does not require further local 
legal procedures to be enforceable. At the same time, Andean Community Acts 
and Decisions might need to be harmonized with national legal systems by 




Andean Organisation of Health and the Andean University Simon Bolivar; and (3) institutions 
that represent civil society, such as the Consultative Business Council, Consultative Labour 
Council, Consultative Indigenous People Council and the Andean League for the Defence of 
the Rights of Consumers; see Article 6 of the Cartagena Agreement, n 399 
172 Articles 11-14 of the Cartagena Agreement 
173 Articles 15-22 ibid.  
174 Articles 21-28 ibid. 
175 Articles 40-41 ibid. and Treaty which creates the Tribunal of Justice of the Andean 
Community of Nations as subscribed on May 28 1979 as modified by the Trujillo Protocol 
176 See Article 1-4 of the Treaty which creates the Tribunal of Justice of the Andean Community 
of Nations as subscribed on May 28 1979 as modified by the Trujillo Protocol of 1996; for 
further information on the Andean legal system see: Galo Pico Mantilla, ‘Temas Jurídicos de 
La Comunidad Andina’ [2009] Editorial Académica Española; Galo Pico Mantilla, Derecho 
Andino (1992); Luis Carlos Plata López and Donna Yepes Ceballos, ‘Naturaleza Jurídica de 
Las Normas Comunitarias Andinas’ [2009] Revista de Derecho 196. 
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Harmonising the Andean Legislation in Colombian Constitutional and Legal System  
 
As mentioned above, the acts and decisions of the Andean Community are 
binding for its members; yet, it also requires that Andean countries regulate in 
detail the obligations that emanate from the sub-regional organisation. For 
instance, Decision 391 is a law that is part of the Colombian legislation, despite 
the fact this regulation did not go through the normal law-making process. 
Normally, the implementation of any international treaty in Colombia involves 
the three branches of government. The Colombian Constitutional Court has 
stated that Andean legislation does not contradict the Colombian Constitution 
as Andean decisions are of direct application to all state members. According 
to the constitutional court, Andean legislation is “mandatory from the moment 
of its promulgation”, prevailing over local laws.177 In this regard, the 
constitutional court has pointed out that, since Andean law is constructed with 
the main purpose of securing Andean integration, its content is not limited to 
creating general compromises through treaties, protocols, or conventions. 
Rather, state members have delegated to the Andean Community’s institutions 
the attributed power of generating binding legal norms.178  
 
 
The Constitutionality of the Andean Community’s Legislation in Colombia  
 
To explain how the Andean Community’s structure and legislation fits within 
the Colombian Constitution and legal system, the Constitutional Court 
highlights that there are two types of Andean Community laws: Primary and 
secondary law. Primary law takes the form of international treaties in which 
the Andean Community acts as a representative of all state members. Primary 
Andean law is not directly binding.179 For instance, the Andean Community 
acted on behalf of state members in the negotiation of the Patent Cooperation 
Treaty of the World Intellectual Property Organisation (WIPO), yet it is up to 
each state member to adopt that treaty locally.180 Secondary law are acts of the 
 
177 C-231 of 1997, Constitutional Court  
178 Ibid., Paragraph 6 
179 Ibid, Paragraph 8 
180 Ecuador, Colombia and Peru have already joined the Patent Cooperation Treaty, while 
Bolivia has not done so yet, further information see WIPO, ‘The PCT Now Has 152 Contracting 
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Andean Community’s institutions which make possible the integration of the 
Andean Community in different areas. One such area is the International 
Regime on Access to Genetic Resources and Benefit Sharing. Secondary law, 
as mentioned above, is mandatory from the moment of its promulgation and 
prevails over local regulations.181 This means that the Andean Community 
structure and its legislation do not contradict the Colombian legal system, 
including its Constitution. Rather, it develops specific areas of common 
interest in the process of integration of the Andean countries.  
 
The implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing in the region is an example of how primary and 
secondary law operate in the Andean Community and Colombia. The Andean 
Community has negotiated on behalf of its state members the different 
international instruments that are part of the regime (i.e. the Convention on 
Biodiversity, the Bonn Guidelines and the Nagoya Protocol). Yet each Andean 
Community state member has separately ratified and included those 
instruments in their domestic legislation. For instance, Colombia adopted the 
Convention on Biodiversity through a piece of national legislation, Act 165 of 
1994. Act 165 merely replicates the exact content of the convention. It did not 
create any specific guidance or obligations for the country. To achieve this, and 
as part of a regional strategy in the use of biodiversity, Colombia delegated to 
the Andean Community the power or competence to implement the 
Convention on Biodiversity through Andean Community secondary law. This 
was done through the Andean Community’s Decision 391.182 This decision, as 
the constitutional court has ruled,183 is directly applicable in Colombia, as it 
regulates an area of common interest: The use of genetic resources and 
traditional knowledge in the Andean region.  
 
States’ (WIPO, 2018) <http://www.wipo.int/pct/en/pct_contracting_states.html> accessed 
September 8 2018. 
181 C-231 of 1997, Paragraph 8 
182 The latest regional strategy in conservation and the sustainable use of biodiversity was set 
up in the Decision 523 Regional Biodiversity Strategy for the Tropical Andean Countries as 
signed in Lima, Peru on 17th of July 2002; Achim Seiler and Graham Dutfield, ‘Regulating 
Access and Benefit Sharing Basic Issues, Legal Instruments, Policy Proposals’ (2001) 
<https://www.bfn.de/fileadmin/MDB/documents/ 
access.pdf> accessed September 19 2018. 
183 C-231 of 1997, Paragraph 8 
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Regulating Particular Aspects of Decision 391 in Colombia: Property Regime over Colombia’s 
Biodiversity, and the Scope of the Definitions of Biological Resources, Genetic Resources and 
Traditional Knowledge  
 
In addition to primary and secondary Andean Community law, each member 
of the Andean Community may accommodate its binding provisions into their 
legal system through administrative mechanisms and regulations. For 
instance, since Decision 391 is based on the concept of sovereignty over genetic 
resources (Article 5),184 the property regime over those genetic resources is 
determined by each state member. In fact, Article 6 of Decision 391 mentions 
that genetic resources are property that belongs to the Andean state members 
according to their own legislation. These resources are inalienable. In other 
words, the Andean Community law on access to genetic resources is subject to 
the sovereignty of states (Article 5). As a result, Article 6 of Decision 391 
establishes that genetic resources are subject to a property regime in which 
Andean state members could ensure that those resources are not transferable. 
Additionally, Decision 391 establishes that each county decides its own policies 
on biological resources.  
 
As analysed in Chapter Two, biological resources are all living and non-living 
entities that have any value for humanity. Biological resources include 
animals, ecosystems, genetic resources and so on. However, in law, the 
distinction between biological resources and genetic resources emanates from 
the Convention on Biodiversity. This legal distinction creates two different 
legal obligations, pertaining to biological resources and genetic resources 
respectively. The former entails an obligation of conservation and sustainable 
use of biological resources. The latter is related to appropriate access to genetic 
materials. As a result, a single biological component may fall under two 




184 It follows what Articles 3 and 15 of the UN Convention on Biological Diversity establishes 
(see Chapter Two) 
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On one hand, biological resources are regulated by the 1974 Colombian 
National Codex of Renewable Resources and Protection of the Environment. 
This is the national regulation that establishes rules for conservation and 
sustainable use of biodiversity.185 Although, in principle, renewable resources 
are also public property, the Colombian legislation allows private property 
over those resources, but imposes a stewardship obligation on those who own 
land where renewable resources are located.186 For instance, if an owner of a 
farm is located in an area certified as protected in which there are renewable 
resources such as water or forest, the owner cannot exploit their land in a way 
affecting the enjoyment of those resources. Furthermore, according to the 
administrative Decree 309 of 2000, which regulates research activities in 
biological resources and complements the National Codex of Renewable 
Resources, research activities on biological resources are not subject to the 
rules of Decision 391. The objective of administrative Decree 309 is to 
encourage the conservation and sustainability of biological resources. It does 
not seek to control access to genetic resources or benefit sharing.187 As Decree 
309 regulates the activities of conservation and sustainability, it is more 
flexible than the access and benefit sharing rules. For instance, publicly funded 
research institutions may carry out research activities (e.g. collection and 
classification of biological species) without governmental authorisation.188 
 
On the other hand, genetic resources as found in nature are considered public 
property. In fact, the Council of State, one of the highest tribunals in the 
country, held that genetic resources as found in nature are public property, 
inalienable, and not subject to prescription or seizure.189 In line with the public 
status of genetic resources as found in nature, Decision 391 regulates how to 
 
185 Decree 2811 of 1974, National Codex of Renewable Resources and Protection of the 
Environment; for further discussion on the regulation of biological resources in Colombia see 
L Villar and others, ‘Evaluación y Perspectivas Del Código Nacional de Recursos Naturales En 
Colombia En Sus 30 Años de Vigencia’ [2004] Bogotá: Universidad externado de Colombia.  
186 See Articles 42 and 43 of the National Codex of Renewable Resources and Protection of the 
Environment; the Constitutional Court, when deciding on the constitutionality of Articles 42 
and 43, found that the Colombian Constitution does not forbid private property but demands 
that if there is private property over renewable natural resources it should have an ‘ecological 
function’; this means that in these cases, private property should be employed with due regard 
to sustainability and conservation of the environment; C-126 of 1998, Constitutional Court   
187 Articles 1 and 2 of Decree 391  
188 Paragraphs 1 and 2 of Article 2 of Decision 391 
189 Sentence No 997 of 1997, Council of State  
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access them. According to Decision 391 and the Council of State, there cannot 
be private property in genetic resources as found in nature as they are public 
property, inalienable, and not subject to prescription or seizure. As a result, 
the state requires users who seek to access to those resources to obtain prior 
informed consent and reach mutually agreed terms. Furthermore, Decision 
391 establishes the primacy of regulation on access to genetic resources over 
regulation of biological resources. It does so by establishing that biological 
resources are subject to Decision 391 if there is any activity that involves access 
to genetic resources. This is the case regardless of the property regime 
applicable to the biological resources concerned.190 
 
Decision 391 is thus a critical element of the Colombian regulatory regime on 
access and benefit sharing, and its scope is therefore important. The decision 
defines genetic resources as including both genetic resources themselves, and 
also derivatives and by-products, which do not include functional units of 
heredity. Decision 391 embraces most of the wording of Article 2 of the 
Convention on Biodiversity on the definition of genetic resources. The 
Convention defines genetic resources as ‘genetic material of actual or potential 
value’, that contain functional units of heredity such as DNA and RNA from 
plants, animals, or microorganisms. However, Decision 391 goes further, by 
including elements that do not contain functional units of heredity, such as by-
products. According to Article 2 of Decision 391, by-products includes any 
molecule, a combination or mixture of natural molecules, including crude 
extracts of live or dead organisms of biological origin that come from the 
metabolism of living beings.  
 
However, Decision 391 does not include any definition regarding traditional 
knowledge associated with genetic resources. Nonetheless, Article 1 of the 
Decision 391 brings a broad definition of communities, which includes 
indigenous, Afro-American and local communities in one concept, as a group 
whose own socio-economic and cultural conditions makes different from the 
“national collectively” and which are governed by its own costumes, laws and 
 
190 See Articles 2 (c), 4 (b), 6, 14, 23 and 26 (b) of Decision 391 
 99 
traditions. This means that Decision 391, in an ample way, creates a definition 
that is not limited by ethnic considerations alone, but it rather focusses on 
communities’ conditions and own governance.191 This is a definition that is 
even adopted by the Constitutional Court in a decision related to the 
ratification of an environmental bilateral agreement between Canada and 
Colombia.192 This means that Decision 391 does not conflict with the 
Colombian legislation and constitutional rulings on ethnic communities 
(indigenous and Afro-Colombian) and local communities, which were 





The obligations imposed by Decision 391 also include important procedural 
obligations. Each Andean Community member must create a procedure under 
which users of genetic resources seeking to access those resources (which are 
broadly defined) must obtain prior informed consent, and secure mutually 
agreed terms. State members must appoint a local authority in charge of that 
procedure. In the case of Colombia, the local authority that is legally 
authorised to oversee this procedure and sign up to mutually agreed terms on 
behalf of the state is the Ministry of the Environment. 193 In particular, the 
Ministry of the Environment has created within its administrative structure a 
specific agency in charge of centralising, carrying out and negotiating mutually 
agreed terms. The agency is known as the Dirección de Bosques Biodiversidad 
y Servicios Ecosistémicos-Grupo de Recursos Genéticos. 
 
Colombia has also regulated the administrative procedure according to which 
a body seeking to use genetic resources may obtain prior informed consent and 
 
191 This definition is even broader than the one provided by the Indigenous and Tribal People 
Convention of the International Labour Organization (1989), which establishes conceptual difference 
between tribal and indigenous communities, and does not include local communities; See Chapter 
Two.  
192 C-915 of 2010, Constitutional Court 
193 Paragraph 2, Article 81 of the Colombia Constitution requires the State to oversee access to 
genetic resources; Article 5 (21) of Act 99 of 1993 (or Environmental Act) indicates that it is 
the Ministry of Environment which is the local authority in charge of the regulation on access 
to genetic resources 
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reach mutually agreed terms, as required by Decision 391, through the 
Ministry of Environment Resolution 620 of 1997.194 Articles 16 and 17 of 
Decision 391 establish three steps in this procedure: (1) admission and formal 
review of the user’s application; (2) publication and public registration of the 
user’s application; and (3) technical and legal evaluation, and negotiation of 
mutually agreed terms.195 The procedure is to operate as follows. 
 
First, the local authority should examine whether the applicant fulfils formal 
requirements. Formal requirements include a description of the access 
activities, a template of mutually agreed terms, identification of the user, and 
identification of the specific local area in which the access will take place.196 
Once the first step has been reviewed and formally approved, the application 
should be registered in a public registration office. The registration should also 
be published in a national newspaper of the Andean Community.197 These 
steps involve transparency. Consequently, the application is technically and 
legally evaluated by the local authority to define its viability. For instance, the 
local authority should analyse whether there is an activity that involves access 
to genetic resources or whether users have disclosed all relevant information 
to determine the origin of the resource. Once the evaluation has been carried 
out and there are no objections, the local authority will begin the process of 
negotiating the mutually agreed terms. Those negotiations include what 
benefit sharing mechanisms should take place. However, Decision 391 does 
not define what these mechanisms are.198  
 
Decision 391 imposes some temporal obligations on the process. Admission 
and formal review must be completed within a deadline of 15 days. The 
publication and public registration of the user’s application has a deadline of 
90 days, but this may be extended indefinitely by the agency in charge in the 
Ministry of the Environment. This means that the ministry can delay any 
 
194 Resolution 620 of 1997 by which is Implemented the Andean Community of Nations 
Decision 391 of 1996 
195 Articles 29-31 of Decision 391 and Articles 11-20 of Resolution 620 
196 See Articles 26 and 27 of Decision 391  
197 Article 28 of Decision 391 and Articles 9-12 of Resolution 620 
198 Articles 31-37 of Decision 391  
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evaluation and negotiation of mutually agreed terms for as long as it considers 
convenient. 
 
Mechanisms of Compliance: From Administrative and Criminal Sanctions to Disclosure of 
Origin in Patents 
 
Decision 391 also calls on parties to create mechanisms to enforce access 
requirements (Articles 46 and 47). As a result, Colombia has established 
within its environmental sanctioning legislation different sanctions for those 
who access genetic resources without complying with access and benefit 
sharing rules before any access activity takes place. Those sanctions include 
fines, confiscation of genetic resources, disciplinary sanctions for public 
servants who participate in illegal access activities, and criminal 
prosecution.199  
 
Furthermore, the Andean legislation on patents also establishes a mechanism 
to enforce Decision 391. In fact, Decision 391 is linked to the Andean 
legislation on patents. Since intellectual property, including patents, is a 
matter of common interest for all state members of the Andean Community, 
they have established a common regime in Decision 486. As analysed in 
Chapters 1 and 2, inventions are protected through patents, giving patent 
holders the opportunity to exclusively exploit those inventions. This is the case 
even though the inventions at issue are based upon natural resources, 
including genetic resources. Countries rich in biodiversity therefore aim to 
secure the position that users of genetic resources share benefits from the 
exploitation of the relevant intellectual property rights when genetic resources 
belonging to that country are involved in those inventions. To achieve this, the 
Andean Community has established a mechanism within its patent regulation 
that seeks to ensure that the filing and granting of patents should be carried 
out in accordance with Decision 391. The Andean Community’s Decision 486 
requires its state members’ patent office to observe and favour the Andean 
regulation on access to genetic resources (Decision 391), when they grant 
 
199 Act 1333 of 2009, Colombian Environmental Sanctioning Procedure  
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exclusivity rights on inventions.200 In the case of Colombia, the relevant 
national authority is the Superintendencia de Industria y Comercio (SIC)).  
 
The legal bridge between Decision 486 and Decision 391 is found in the 
obligation of origin disclosure. Disclosing origin plays a fundamental role in 
the regulation of genetic resources in Colombia, and access to and sharing of 
the benefits of those genetic resources. Disclosure obligations are very strict 
because those who do not comply with these obligations not only face 
Colombian environmental sanctioning legislation, but also legal consequences 
within patent law. Articles 22 and 25 of Decision 391 make it mandatory for 
users of genetic resources to disclose any information that involves genetic 
resources in patent application. A similar wording is found in Article 26 (h) of 
Decision 486 as it requires that any patent application that involves genetic 
resources must include mutually agreed terms. Otherwise the patent should 
not be granted (Articles 38 to 49) or if granted, the patent office should decree 
the absolute invalidity of a patent at any time after the patent was granted 
(Article 75 (g) of Decision 486).201 
 
On these aspects of the link between patents and regulation of access to genetic 
resources, it is also important to mention that Colombia’s Free Trade 
Agreements with the US and the EU include aspects related to disclosure of 
origin of Decision 391. In fact, although the US is not part of the Convention 
on Biodiversity, it reached an agreement with Colombia in a side letter to the 
main text of the US-Colombia Free Trade Agreement that both parties would 
“endeavour” to share information relating to genetic resources, including 
traditional knowledge, via public databases.202 Although scholars are still 
discussing whether the side letters of the US are binding,203 it proves how 
 
200 See paragraph 4 Article 3 of Decision 486 
201 As explained in Chapter One, the conditions for access to genetic resources and benefit 
sharing are included in mutually agreed terms (Article 15.7 of the UN Convention on Biological 
Diversity); this agreement is reached by users of genetic resources and a governmental 
authority  
202 US and Colombia Governments- “Understanding Regarding Biodiversity and Traditional 
Knowledge” (November 22, 2006) 
<http://www.ustr.gov/sites/default/files/uploads/agreements/fta/colombia/ 
asset_upload_file953_10182.pdf> accessed September 17 2018  
203 For further information on the nature of side letters in Free Trade Agreements with the US 
see Rodolfo Cruz Miramontes, ‘The North American Free Trade Agreement and the So-Called 
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important it is for Colombia to include at least some provisions into the Free 
Trade Agreement that link patent legislation with access and benefit sharing 
regulation. As for disclosure of origin in patents in the EU-Colombia and Peru 
Free Trade Agreement, this treaty does not require the adoption of the legal 
mechanism of disclosure of origin. The free trade agreement does acknowledge 
its ‘usefulness’ in creating a more transparent mechanism of protection of 
countries’ genetic resources. That said, there is nothing in the text of the treaty 
to suggest that the EU will create further patent requirements, such as 
disclosure of origin, in the Union.204  
 
Disclosure of origin is an important element of Colombian regulation on access 
to genetic resources, linking Colombian patent law (Decision 486) with access 
to genetic resources (Decision 391). However, in Colombia disclosure of origin 
operates only for patent applications. It does not extend to other 
administrative procedures, such as market approvals of medicines. Market 
approval/authorisation or market notification are mechanisms that require 
certain manufacturers, producers, or distributors to obtain permission from 
health and safety authorities to place certain products into a market, as those 
products could have potential risks for the general population. Market 
authorisation applies to products such as food, chemicals, and medicines. For 
instance, the EU’s Regulation on the International Regime on Access to 
Genetic Resources and Benefit Sharing requires that, when such mechanisms 
are required, users of genetic resources should disclose how they obtained 
those genetic resources (see Chapter Two). Even if those mechanisms are not 
required, users should disclose such information when a product is placed in 
the EU’s market for the first time, if that product is developed via utilisation of 
genetic resources, or the result of the utilisation is sold or transferred, or the 
utilisation in the EU has ended and then transferred outside of the EU (see 
Chapter Two). Although Colombia has a health agency, the Instituto Nacional 
 
“Parallel Letters”’ [2005] Anuario mexicano de Derecho Internacional; Pedro Roffe and 
Christoph Spennemann, ‘The Impact of FTAs on Public Health Policies and TRIPS 
Flexibilities’ (2006) 1 International Journal of Intellectual Property Management 75; Carsten 
Fink and Patrick Reichenmiller, ‘Tightening TRIPs: Intellectual Property Provisions of US 
Free Trade Agreements’ in Richard S Newfarmer (ed), Trade, Doha, and development: A 
window into the issues (World Bank 2006).  
204 Article 201, Trade Agreement between the EU and its Members, of the One Part, and 
Colombia and Peru, of the Other Part (EU/CO/PE/1 en).  
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de Vigilancia de Medicamentos y Alimentos (INVIMA), which grants market 
approvals (Registros Sanitarios) for the production and distribution of 
chemical, biological, and natural/herbal medicines, it does not require them 
to disclose any information related to genetic resources.205  
 
The Andean and Constitutional Protection of Communities’ Practices and Knowledge 
Associated with Genetic Resources  
 
Decision 391 stresses that genetic resources, as well as communities’ practices 
and knowledge related to those resources, have a “strategic value” in the 
international context of the region biodiversity, since they are “a primary 
source of products and processes for industry”.206 Decision 391 thus regulates 
the contribution that local, indigenous, and Afro-American communities give 
to the understanding of the Andean countries’ biodiversity. Consequently, the 
wording of Decision 391 seeks to protect the knowledge and practices that 
indigenous, Afro-American, and local communities possess over genetic 
resources. It does so by calling on Andean Community state members to 
recognise that they have the right to decide on the use of their knowledge and 
practices if someone is interested in accessing traditional knowledge 
associated with genetic resources (Article 7).207  
 
Article 7 of Decision 391 also found echoes in the Constitutional Court’s 
rulings. The Constitutional Court aims to strike a balance between the state’s 
economic interest in the use of biodiversity and the rights of its indigenous 
communities. In fact, with similar reasoning to that in Decision 391, the court 
emphasises that Colombia has the exclusive “faculty to use [genetic resources] 
and take advantage of them economically according to their own interests”,208 
while it should recognise and respect the rights of communities over their 
practices and knowledge. In other words, according to the Constitutional 
 
205 For further information on INVIMA see: Decree 677 of 1995  
206 See Paragraphs 4 and 8 of the Preface of the Decision 391 on the Common Regime on 
Access to Genetic Resources of 1996.    
207 Also, the Preamble of the Decision 391 “recognises the historic contribution made by the 
native, Afro-American, and local communities to the biological diversity, its conservation and 
development and the sustained use of its components, as well as to the benefits generated by 
that contribution”  
208 C-519 of 1994, Constitutional Court 
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Court, since genetic resources are valuable for economic development, they are 
property of the state. At the same time, Colombia should consider it of vital 
importance to include local, indigenous, and Afro-Colombian communities in 
any decision that involves the use of their practices and knowledge related to 
Colombia’s genetic resources.  
  
As a result of all of the legal provisions discussed above, Colombia has 
extended the mechanism of public consultation in the exploitation of non-
renewable resources to the use of ethnic communities’ (i.e. indigenous, and 
Afro-Colombian) practices and knowledge associated with genetic resources. 
This means if any user wants to access genetic resources associated with 
traditional knowledge, it is necessary for that user to publicly consult those 
ethnic communities beforehand. For instance, the Minister of Environment’s 
Decree 1375 points out that the collection of samples such as medicinal plants 
for research and non-commercial activities in ethnic communities’ lands (i.e. 
Resguardos Indigenas or Territorios de Comunidades Negras) requires 
obtaining prior informed consent according to the Ministry of State’s 
regulation. This procedure requires three steps. First, users of genetic 
resources must request from the Ministry of State a permit to contact ethnic 
communities. Once the Ministry of State grants the permission, users should 
carry out a public consultation with the community. The aim of the 
consultation is to obtain that particular community’s prior informed consent. 
Finally, in that public consultation, users should also negotiate what benefits 
will be shared with the community.  
 
In this way, Colombia seems to give effect to Decision 391’s disposition on 
traditional knowledge and practices associated with genetic resources. 
Colombian legislation grants property control over all its natural resources, 
including genetic resources, exclusively to the state. At the same time, the legal 
system aims to grant the right to be publicly consulted to communities when 
their knowledge and practices associated with genetic resources is at stake.209 
 
209 See Article 7 of Decision 391 and Decree 1320 of 1998 of the Ministry of State Colombia, 
further information see PNUD, ‘Política Pública Pluricultural Para La Protección de Los 
Sistemas de Conocimiento Tradicional | El PNUD En Colombia’ (PNUD, 2014) 
<http://www.co.undp.org/content/colombia/ 
 106 
However, the Ministry of State and Ministry of Environment regulations also 
indicate that it is only ethnic communities (Afro-Colombian and indigenous) 
which are entitled to be publicly consulted before the access activity takes place 
(prior informed consent), meaning that local communities, whose practices 
and knowledge are at stake, such as peasants, are not to be considered to have 
a right to be consulted. This is in clear contradiction with Decision 391 and the 
Constitutional Court’s jurisprudence on ethnic and local communities’ right to 
be consulted a priori when their traditional knowledge and practices can be 
affected by industrial applications and research.  
 
The Difficulties in Protecting Communities Rights in the Light of Colombian Government 
Administrative Decisions 
 
Although communities benefit from an important set of constitutional rights 
and the recognition of their role in the use of biodiversity by Decision 391, the 
administrative design of the public consultation was originally created for the 
activities of extraction of minerals and oil, as well as infrastructure projects, in 
territories in which those communities are located. This means that the legal 
structure of public consultation responds to the exploitation of natural non-
renewable resources, rather than genetic resources. For instance, the national 
authority that oversees the public consultation is the Ministry of State, a 
political orientated ministry, rather than the Ministry of the Environment, 
which actually has a specialized and technical dependency on genetic 
resources (i.e. Dirección de Bosques Biodiversidad y Servicios Ecosistémicos-
Grupo de Recursos Genéticos).  
 
Furthermore, recent administrative regulations on access to genetic resources 
do not seem to provide sufficient clarity on how the contribution from 
communities is adequately protected according to the mandates of Decision 
391 and the Constitutional Court, nor on a clear definition of what traditional 
knowledge and practices are. For instance, through Ministerial Decrees 1375 
and 1376 of 2013, Colombia does not demand local researchers such as public 
 
es/home/presscenter/articles/2014/12/16/pol-tica-p-blica-pluricultural-para-la-protecci-n-
de-los-sistemas-de-conocimiento-tradicional-.html> accessed April 7 2018. p 32 
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universities and research centres to obtain prior informed consent and reach 
mutually agreed terms with local (or non-ethnic) communities when they 
carry out non-commercial activities, specifically the collection and sampling of 
genetic resources. Also, the Ministry of Environment in 2014 enacted 
Resolution 1348, which establishes that only two activities require prior 
informed consent and mutually agreed terms. These are: (i) activities on native 
species in situ or ex situ, including virus and viroids, which involve either the 
isolation of functional and non-functional units of DNA and RNA, as found in 
nature; and (ii) the isolation of one or more molecules, including micro and 
macromolecules, produced by the metabolism of an organism. In other words, 
users of genetic resources’ activities that do not fit within these two activities 
do not need to require prior informed consent and reach mutually agreed 
terms. However, Resolution 1348 does not make any mention of what occurs 
if users of genetic resources access traditional knowledge and practices, but 
their activities do not fit within the content of this regulation. This means for 
instance that if local researchers carry out research activities on traditional 
knowledge associated with non-native species, users might not be required to 
obtain prior informed consent from holders of that knowledge such as local 
communities.  
 
Similarly, the effect of Resolution 1348 is also to exempt de facto the herbal 
industry in Colombia from obtaining communities’ prior informed consent. 
The herbal industry produces and distributes phytomedicines, pharmaceutical 
preparations which are based upon medicinal plants. Since phytomedicines 
are not products whose therapeutic activity is accredited to isolated and 
purified molecules, or combination thereof, as occurs with chemical 
synthetized products or biological medicines, they fall outside the scope of 
Resolution 1348. That means those products do not require prior informed 
consent and mutually agreed terms, even if that knowledge belongs to ethnic 
communities. There are two reasons why the herbal industry enjoys such a 
legal treatment: First, throughout the wording of Decision 391, the Andean 
Community and its members have focused primarily on industries which 
transformed genetic resources into products by means of specific technologies 
such as biotechnology and chemical synthesis (see Chapter Three). In fact, 
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Article 2 of Decision 391 defines terms such as biotechnology210 and 
synthesised products211 as to include the biotechnology and pharmaceutical 
industry within its legislation.212 Second, as the nature of phytomedicines do 
not fit within the definitions of genetic resources and by-products in the 
Colombian access and benefit sharing rules, there is a “blind spot” for 
phytomedicines, which clearly benefits this growing industry in the country.   
 
Additionally, herbal producers and distributers are only required to file for 
market approval before Instituto Nacional de Vigilancia de Medicamentos y 
Alimentos (INVIMA), according to the Ministry of Health’s Decree 2266 of 
2004. Furthermore, the regulation of INVIMA has created a subcategory 
within the regulation of phytotherapeutic medicines that allows the herbal 
industry to prove safety and efficacy of a phytotherapeutic product with 
traditional knowledge and practices. In brief, Decree 2266 regulates the 
marketing approval of phytomedicines in Colombia. Producers and 
distributers of phytotherapeutic products are required to prove therapeutic 
activity through clinical studies. However, Decree 2266 has created a 
subcategory called “traditional phytotherapeutic product”, which excepts the 
herbal industry from proving therapeutic activity through clinical trials, if two 
conditions are demonstrated: (i) the medicinal plant, either native or 
introduced, is locally produced; and (ii) there is either documentary proof that 
the plant has been employed for medical uses by three or more generations in 
Colombia,213 or, in the case there is no documentary proof, it can be proved by 
a “competent professional” or the knowledge from “indigenous or Afro 
 
210 Article 2 defines biotechnology as follows: any technological application that utilizes 
biological systems or live organisms, parts of them or their by-products, to create or modify 
products or processes for specific uses. 
211 Article 2 defines synthesised product as follows: a substance obtained through the artificial 
processing of genetic information or of information from other biological molecules. Includes 
semi-processed extracts and substances obtained by converting a by-product through an 
artificial process (hemisynthesis) 
212 Alejandro Grajal, ‘Biodiversity and the Nation State: Regulating Access to Genetic 
Resources Limits Biodiversity Research in Developing Countries’ (1999) 13 Conservation 
Biology 6. 
213 Decree 2266 requires that the documentary proof is included within the Vademécum 
colombiano de plantas medicinales, which is the Colombia pharmacopeia for medicinal 
plants. This document is elaborated by the Specialised Working Group of Natural Products of 
the Health Minister; for further information of the Vademécum see Sala Especializada de 
Productos Naturales, Vademécum Colombiano de Plantas Medicinales (Ministerio de Salud 
2007) <https://www.minsalud.gov.co/sites/ 
rid/1/Vademecum Colombiano de Plantas Medicinales.PDF> accessed June 6 2018.   
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Colombian groups”.214 Yet, even though it relies on traditional knowledge of 
genetic resources, this law does not impose any obligation on the herbal 
industry to carry out public consultation when it employs communities’ 
practices and knowledge in the granting process of marketing approvals.  
 
All in all, it is fundamental to notice that the wording of Andean Community 
laws, the Colombian Constitution and the rulings of the Constitutional Court 
suggest that Colombia seems to provide a balance between economic 
development, including international trade, and the interests of all 
communities in the exploitation of both natural non-renewable resources and 
genetic resources. In particular, Colombia aims to secure such a balance 
through the right of public consultation. However, the objective of finding a 
balance does not seem to be clear enough in the different administrative 
mechanisms and regulations that Colombia employs in the use of genetic 
resources and communities’ practices and knowledge associated with genetic 
resources.  
 
In fact, Colombia is not enforcing communities’ rights against local 
researchers of genetic resources and the herbal industry. Different 
administrative decrees have already exempted those actors from meeting 
Decision 391’s requirements, including the due recognition of indigenous, 
local, and Afro-Colombian contributions. This means that Colombia has 
benefited local researchers and the herbal industry despite the fact that there 
are constitutional rules and legislation which seek to make communities’ 
rights enforceable. In other words, those administrative mechanisms and 
regulatory exceptions clearly depart from the aims of Decision 391 and the 
Constitutional Court mandates regarding the rights of those communities.  
 
It is therefore important to analyse whether, in practice, local authorities are 
acting contrary to those Andean and constitutional principles. The next 
chapters consider that question in more depth. They do so through the analysis 
of two particular cases: (i) the Dividivi and the Anamú plant cases, which 
 
214 Articles, 2, 31 to 36 Decree 2266; Although traditional phytotherapeutic products can be 
produced in any conventional pharmaceutical form, except injectables and ophthalmic forms.    
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involve the commercial exploitation of a traditional medicinal plant employed 
by a local community of peasants, and (ii) how the herbal industry have been 
employing communities’ practices and knowledge to get marketing approval 
of traditional phytomedicines without obtaining those prior informed consent 
from those communities. This analysis of the law in practice will help us 
understand whether Colombia is effectively protecting indigenous, local, and 




The 1991 Colombian Constitution and the Constitutional Court have designed 
an extensive catalogue of fundamental rights that should serve as a platform 
for the construction of any law, policy decision, and administrative structure 
of the Colombian state. This means that each action or inaction of the three 
branches of government should observe and safeguard those fundamental 
rights. Among those rights, there is the fundamental principle of “recognition 
and protection of ethnic and cultural diversity” of Colombia, which has led the 
Constitutional Court to create a set of rights for communities that derive from 
this fundamental principle. Rights of communities in Colombian 
constitutional law include a right of subsistence, which flows from the right to 
life, a right of cultural integrity, and rights to communitarian land. 
 
Furthermore, the Constitutional Court has relied upon this principle to 
generate a balance between the exploitation of natural non-renewable 
resources and the rights of indigenous, local, and Afro-Colombian 
communities when their cultural, social, and economic environment is 
affected by such an economic activity. As a result, the Constitutional Court 
points out that although the state is the sole owner of non-renewable 
resources, it is required to publicly consult those communities before any 
activity takes place.    
 
Equally, the wording of the Decision 391 and the Constitutional Court’s 
jurisprudence on communities’ traditional knowledge and practices associated 
with genetic resources have pointed out the importance of striking a balance 
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between the strategic value of genetic resources, which are also the property of 
the state, and the recognition of the contribution of those communities in 
adding value in the use of biodiversity for the industry. In principle, such a 
balance is possible through public consultation, as occurred with exploitation 
of natural non-renewable resources. However, administrative decisions and 
regulations from different ministries (environment, state, and health) seem to 
favour the interests of local researchers and the herbal industry as some of 
their access activities are not required to comply with the requirements of 
Decision 391, including the obligations to recognise those communities’ 
contributions in health research and the health industry. Therefore, those 
administrative mechanisms and regulations appear to contradict Decision 391 
and the Constitutional Court’s mandate. To explore whether local authorities 
are contradicting those obligations, the next chapter will carry out an analysis 
of two specific cases in which indigenous, local, and Afro-Colombian practices 
and knowledge associated with genetic resources are in the balance. 
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Chapter Four: Making Genetic Resources and Traditional 




Chapter Three introduced the central elements of the Colombian legal system 
pertaining to genetic resources and to communities’ practices and knowledge 
related to those resources. The chapter highlighted the extensive catalogue of 
fundamental rights that are the foundation for any law, policy, and 
administrative mechanism in the country. In particular, the 1991 Constitution 
established as a fundamental right the “recognition and protection of ethnic 
and cultural diversity” of Colombia. Also, the Constitutional Court of Colombia 
has expanded the scope of this provision to establish a set of rights for 
communities, which includes a right of subsistence, which flows from the right 
to life; a right of cultural integrity; and rights to communitarian land. As a 
result, the Court has intervened in the country’s economic development policy 
and trade, with the aim of generating a balance between the exploitation of 
genetic resources, and the rights of indigenous, local, and Afro-Colombian 
communities. For the Court, the balance between the use of genetic resources 
and communities’ rights should be reached through public consultation.215 The 
Constitutional Court’s reasoning is also reflected in the Andean Community’s 
Decision 391 regarding communities’ traditional knowledge and practices 
associated with genetic resources.  
 
Yet, as Chapter Three also points out, the Ministry of the Environment’s recent 
administrative decisions and regulations have focused on protecting the 
interests of local researchers, rather than enforcing the fundamental rights to 
which those communities are entitled over their knowledge on Colombian 
biodiversity for health research and health industry. This means that 
 
215As explained in Chapter Two, Colombia has rather employed the same public consultation 
procedure for access to other natural resources such as oil and minerals.   
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Colombian government practice appears to depart from the aims of Decision 
391 and the Constitutional Court’s mandates.  
 
This chapter explores that claim more fully. It investigates why those recent 
administrative decisions and regulations have, in effect, placed communities’ 
practices and knowledge into the public domain, in a way they can be 
employed or appropriated by local researchers without the protections 
envisaged by Decision 391 and the Constitutional Court rulings. Such a 
position would be a violation of Decision 391 and the Constitutional Court 
rulings.  
 
To summarise the chapter’s conclusion: this is indeed the case. Through an 
analysis of litigation, administrative decisions, policy papers, and drawing on 
semi-structured interviews with seven relevant and representative actors, the 
chapter shows that the apparent protections of Decision 391 and the 
Constitutional Court rulings are a de facto sham.  Further, the chapter offers a 
possible explanation of why this is the case. It argues that the reason Colombia 
placed communities’ understanding of Colombia’s biodiversity into the public 
domain is because of the way Colombia has framed innovation in its aims to 
become a more competitive country. In brief, ‘innovation’ is seen as 
encompassed within research and development (R&D) activities for specific 
industries, such as biotechnology or information technology. In contrast, 
traditional knowledge and practices of local communities do not fit within the 
scope of ‘innovation’ as conceived in Colombian law and practice. As a result, 
communities’ understanding is considered to be mere ‘leads’ to scientific 
innovation for local researchers, not an asset or value in itself, to be protected 
through fundamental rights norms.  
 
This approach to ‘innovation’ is particularly reflected in the role of the 
Colombian Scientific and Research Department, known as Colciencias, the 
national science and technological authority. Colciencias is charged with 
addressing resources for universities and research centres, including local 
researchers. It is responsible for measuring what can be considered 
‘innovative’. In this regard, Colciencias does not act in a vacuum, or by 
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reference only to internal considerations. Rather, Colciencias follows 
international standards of innovations set up by the OECD’s Oslo Manual.216 
These standards echo research and development activities in different 
industries to define and measure innovation. The Oslo Manual standards 
involve industrial applications from sectors well placed in international 
markets, such as internet companies, biotechnology, or the pharmaceutical 
industry.  
 
Those standards do not reflect other forms of knowledge or information, such 
as those from local, indigenous, and Afro-Colombian communities. Since 
innovation is only defined and measured by reference to research and 
development activities from the biotechnology industry, the strategic value of 
genetic resources and traditional knowledge means that, in practice, genetic 
resources and traditional knowledge are placed in the public domain, so as to 
benefit the country’s economy in the international trade arena.   
 
Although such an approach has the potential of bringing benefits for 
Colombian capabilities in R&D, and Colombian global competitiveness in 
sectors such as health, the effect of the approach is in contradiction of the 
fundamental right of local communities to be recognised as actors that also 
contribute to innovation with their understanding and use of Colombia’s 
biodiversity. As such, Colombia’s innovation policy is biased towards holders 
of technology, as it is considered that only the use of those technologies in 
biodiversity contributes to the industrial application of biodiversity.  
 
There are at least three different governmental authorities which have 
different approaches on traditional knowledge and practices: the Ministry of 
the Environment; the Ministry of State; and Colciencias. The Ministry of the 
Environment oversees the International Regime on Access to Genetic 
Resources and Benefit Sharing, and has taken recent decisions to facilitate 
 
216 OECD and Eurostat, Oslo Manual-Guidelines for Collecting and Interpreting Innovation 
Data (4th edn, OECD Publishing 2018) <https://www.oecd-
ilibrary.org/docserver/9789264304604-
en.pdf?expires=1541951164&id=id&accname=guest&checksum=F1A8012F0687F122BA16F5
D31ABF15CF> accessed 8 November 2018. 
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access to genetic resources to local researchers without due consideration of 
holders of traditional knowledge and practices, particularly local 
communities. This has occurred since the Ministry of Environment only 
requires users of genetic resources, including local researchers, to obtain prior 
informed consent from indigenous and Afro-Colombian (i.e. ethnic) 
communities, without due consideration to local communities such as 
peasants. The latter, as explained in Chapter Three, have been recognised as a 
subject of constitutional protection when their socio-economic activities and 
their relationship with the environment are affected, including their practices 
and traditional knowledge. The Ministry of State should enforce communities’ 
rights, particularly public consultation, but it has not carried out any public 
consultation yet. Colciencias, the science bureau, defines what research 
activities, including those over genetic resources, are innovative, in order to 
allocate resources into those activities. However, this governmental authority 
does not deem communities’ practices and knowledge as innovative, placing 
these cultural assets into the public domain.  
 
This means that it is Colombian central authorities who do not comply with 
Decision 391 and constitutional mandates to conciliate communities’ rights 
with other economic interests. Although in theory, states such as Colombia 
should work as a unified entity, in practice, governance acts in different 
directions as it pursues different interests, which potentially run against each 
other. This is the particular case when economic interests clash with 
fundamental rights.217 This has occurred because, as observed throughout this 
chapter, Colombian authorities are pursuing an economic agenda to meet 
 
217 Different authors have argued that international trade has led to the fragmentation of 
States. For instance, rules of international organizations such as the International Monetary 
Fund and the World Bank, and economic interests of multinational companies have set 
countries’ economic agendas despite the fact that could go against other interests such as 
protection of human rights or the environment. For further information see Sol Picciotto, 
‘Networks in International Economic Integration: Fragmented States and the Dilemmas of 
Neo-Liberalism’ (1996) 17 Northwestern Journal of International Law & Business; Sol 
Picciotto, ‘Fragmented States and International Rules of Law’ (1997) 6 Social & Legal Studies 
259; Mahmood Monshipouri and others, Constructing Human Rights in the Age of 
Globalization (Routledge 2015). There is also in Colombia a study by Gomez-Lee who analyses 
the different interests (farmers, communities, agro and chemical industries, plant breeders, 
etc.) in the use of biodiversity in Colombia: Martha Isabel Gómez Lee, Biodiversidad y 
Políticas Públicas: Coaliciones de Causa En Las Políticas de Acceso a Los Recursos Genéticos 
En Colombia (Universidad Externado de Colombia 2017). 
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global markets’ interests regardless of international commitments and local 
constitutional obligations to enforce communities’ fundamental rights.  
 
Consequently, a problematic aspect of Colombia’s current implementation of 
International Regime on Access to Genetic Resources and Benefit Sharing is 
that the Colombian government, in practice, does not observe, and even 
ignores, communities’ rights. This means that Colombia is constructing a 
policy over the exploitation of genetic resources which considers that only 
technical and scientific contributions are worth encouraging and protecting. A 
more appropriate approach would be to strike a balance between Colombia’s 
interest in constructing and supporting its scientific and technical capacity, 
which encompasses local researchers, and in safeguarding communities’ 
rights. To adopt such an approach would mean that the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia and its innovation policy would be inclusive. The policy would reflect 
the fact that products that derive from biodiversity are not exclusively the 
result of research and development, defined in a techno-scientific way, but 
rather are also the outcome of dynamics that involve knowledge and practices 
from local, Afro Colombian and indigenous communities.  
 
Having introduced the main features of Colombian access and benefit sharing 
regulation in the previous chapter, this chapter first carries out an analysis of 
Colombia’s political and economic considerations in implementing the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
the 1990s, and how it has tried to overcome, since the 2010s, some of the 
difficulties of implementing this international regime, particularly responding 
to concerns among local researchers (e.g. public universities and publicly 
funded research groups). Second, this chapter analyses in some detail how 
Colombia’s innovation policy has also been a key aspect in benefiting and 
encouraging local researchers to access genetic resources, without recognising 
communities’ contribution. Finally, this chapter studies two practical cases in 
which it can be observed how the recent legal and administrative changes, and 
the innovation policy, have led to genetic resources and communities’ 
practices and knowledge being placed into the public domain to be freely 
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employed by local researchers. This part also provides insightful evidence from 
interviews with a local research group on how these users operate in practice 
within the complexities of carrying out research and development in medicinal 
plants, dealing with legal requirements and meeting the economic 
expectations of Colombian authorities. The chapter concludes by explaining 
why it is important to recognise and protect practices and knowledge that 
comes from local and indigenous communities in Colombia.   
 
The Implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing and Holders of Technology  
 
As explained in Chapter Three, the evolution of the access and benefit sharing 
regulation in Colombia indicates that the country moved from a very strict and 
comprehensive legislation in the 1990s towards a less restrictive regulatory 
approach in the first two decades of the twenty-first century. The less 
restrictive approach facilitates access to local researchers. However, despite 
such a change in the tone of the legislation, there has always been an implicit 
assumption in the implementation of the International Regime in Colombia; 
that assumption is that holders of technology are only those who are capable 
of employing genetic resources in contributing to the processes of innovation 
in the country. This has occurred because Colombia has approached genetic 
resources and communities’ practices and knowledge as a key aspect of its 
economic development, rather than focusing on recognising those 
communities’ contribution in the understanding of Colombia’s biodiversity for 
industrial applications. 
 
At first, in the 1990s as Colombia implemented the International Regime on 
Access to Genetic Resources and Benefit Sharing along with other members of 
the Andean Community, Colombia sought to counterbalance technological 
disparity in sectors such as the pharmaceutical industry through the trade-off 
of natural resources with technology. In fact, the Andean Tribunal of Justice, 
in a prejudicial interpretation, points out that these policy aspects were already 
considered by state members, such as Colombia, even before the Andean 
Community discussed and enacted Decision 391, as follows:  
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Lack of sufficient resources for an autonomous development of the 
chemical and pharmaceutical industry, since, among other things, 
[developing countries] should import raw materials that incorporate 
a high technological level, these [developing] countries cannot cope 
with an open competition in the world market with likely possibilities 
to succeed. This situation consolidates and increases this dependence, 
in general terms, to the detriment of the few available comparative 
advantages, such as cheap labour and unskilled production and, in 
general, other raw materials (mainly natural resources). (Translation 
by the author)218  
 
That reasoning became a key aspect leading Colombia and other Andean 
countries to create a comprehensive and strict access and benefit sharing 
legislation in Decision 391. The Decision was expected to create a framework 
in which holders of technology, particularly multinational companies, and 
activities in R&D would be regulated with the purpose of securing benefits 
from the utilization of the Andean Community’s biodiversity. This approach 
reflected the international environment at that time, in which developing 
countries rich in biodiversity expected that large multinational companies 
would turn to these countries’ biodiversity to extract and synthetize single 
chemical compounds which would become market valuable products.219 
 
However, the expectations of obtaining valuable products or transfer of 
technology from multinational companies through the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
were not delivered. Instead the actual application of the access and benefit 
sharing rules brought a different panorama, which the country’s legislative and 
institutional architecture did not anticipate. Particularly, these circumstances 
include: Colombian government expectations that overseas users (e.g. 
multinational companies) would be eager to access to genetic resources and 
 
218 Prejudicial Interpretation of Articles 5 (c) and 22 of Decision 85 of the Commission of the 
Andean Community of Nations (1989) 7-IP-89. 
219 For instance, the case of INBio in Costa Rica; see Richerzhagen and Holm-Mueller (n 79). 
For a critical perspective to this approach see: Dalton (n 82). 
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share benefits were not met; those who were actually interested in accessing 
genetic resources were local and publicly funded researchers, specifically 
universities and research centres; and those local researchers experienced 
difficulties in complying with access and benefit sharing rules.  
 
This meant that, even though Colombia’s’ expectation, lying behind its strict 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing, was that overseas users such as multinationals would 
access genetic resources, official records of the Ministry of the Environment 
point out that those who actually accessed genetic resources were local 
researchers, particularly universities and research centres, which were mainly 
publicly funded.220 Those local researchers had neither the experience nor the 
resources to carry out R&D in the way that large business operates.221 Since 
the access and benefit sharing rules in Colombia were comprehensive and 
strict, local researchers also lacked resources necessary to comply with the law. 
For instance, the National University of Colombia, the largest publicly funded 
university, was involved in tortuous administrative procedures that took 
around 12 years to obtain prior informed consent and mutually agreed terms. 
These aspects also demonstrate that the lack of understanding was not only 
the main reason why publicly funded institutions were in breach of the access 
and benefit sharing regulation, but also demonstrate a fragmented State in 
enforcing a particular regulation.222 In fact, on one hand, the Colombian 
government was trying to implement and enforce the International Regime on 
Access to Genetic Resources and Benefit Sharing with a precarious 
infrastructure as the Ministry of the Environment was handling all mutually 
 
220 Dirección de Bosques Servicios Ecosistémicos y Biodiversidad-Ministerio de Medio 
Ambiente, ‘Seguimientos a Los Contratos de Acceso a Recurso Genéticos Marzo 2018’ (2018) 
<http://www.minambiente.gov.co/images/BosquesBiodiversidadyServiciosEcosistemicos/p
df/Recursos_Genéticos_/seguimiento_EXp_CARG_Mar_2018.pdf> accessed April 7 2018. 
221 In fact, research and development transforms constantly to meet different stakeholders’ 
interests. For instance, in recent time, the drug development has gone from in-house research, 
in which large companies cover the whole de drug development process, to a more diversified 
model that includes different players. In the new models, large pharmaceutical companies rely 
more in acquisitions, merges or licensing, rather than investing from the very beginning of the 
drug development process; for further information see WHO, WIPO and WTO, Promoting 
Access to Medical Tecnologies and Innovation: Intersections Between Public Health, 
Intellectual Property and Trade (WTO 2013)., pp 102-114  
222 Gabriel Ricardo Nemogá Soto and Dali Alexandra Rojas Díaz, ‘Desencuentros 
Institucionales Sobre La Investigación En Diversidad Genética’ (2010) 12 Revista Colombiana 
de Biotecnología 4. 
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agreed terms obligations through only two public servants, 223 and, on the 
other hand, other actors who officially belong to the state (e.g. publicly funded 
universities) were in breach of the law.224  
 
Further, this was not the only case in which public institutions clashed over 
the enforceability of the access and benefit sharing rules. For instance, the 
Technological University of Pereira filed a patent application on the 
development of primers from the genome of the Boroja Patinoi Cuarecasas 
(Borojo) employed to identify the sex of plant species at an early stage of 
development, particularly in the Borojo plant.225 Although the plant species is 
native to the Choco/Darrien region, the university did not disclose all 
information related to the genetic resources employed in the invention. In fact, 
the Colombian patent office requested the university to comply with Decision 
486 of 2000 (the Andean Patent legislation), as it requires inventions from 
genetic resources to disclose any information of their origin. Therefore, the 
university should have ensured that it obtained prior informed consent and 
reached mutually agreed terms with the Ministry of the Environment.226 The 
university responded that it had been carrying out the process of obtaining 
mutually agreed terms for more than three years with the Ministry of the 
Environment, but nothing had been decided.227 As a result of the non-
compliance with Decision 486, the patent was not granted.228  
 
Along with this difficulty of compliance and a fragmented structure of the 
state, local researchers such as research centres accessed genetic resources 
without requesting prior informed consent or negotiating mutually agreed 
 
223 Ministerio de Ambiente, ‘Política Nacional Para La Gestión Integral de La Biodiversidad y 
Sus Servicios Ecosistémicos’ (2012) 
<http://www.humboldt.org.co/images/pdf/PNGIBSE_español_web.pdf> accessed May 4 
2018. 
224 Although Colombia granted to public and private universities the right of self-governance, 
public universities are public institutions which are subject to fiscal and disciplinary rules as 
any other public institution. Public university staff are also selected and evaluated by the rules 
of the civil servant service. Further, the directive boards of all public universities are formed 
by members of either central and regional governments, see Act 115 of 1994     
225 Superintendencia de Industria y Comercio (SIC), Resolution Number 3654 of June 2012 
which upholds SIC, Resolution 60646 of October 2011 
226 Ibid., p 1 
227 Ibid., pp 2-3 
228 Ibid., p 6 
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terms. In fact, there were only 45 sets of mutually agreed terms from 1996 (the 
year in which Colombia implemented the International Regime on Access to 
Genetic Resources and Benefit Sharing) to 2012, despite the fact that during 
this time there was significant research activity involving those resources from 
local researchers.229 For instance, Chaparro et al.’s study into the research 
activities involving biological resources of 957 research groups registered in 
Colciencias in 2010 found that almost half of them involved access to genetic 
resources. These investigations did not comply with Colombia’s access and 
benefit sharing rules.230  
 
The lack of understanding of access and benefit sharing rules, and the 
dysfunctionality in applying those rules among public institutions, led local 
researchers to mobilise the demand that the government amend the law in 
order to facilitate access.231 In response, from 2011, the government set up a 
different policy in White Papers such as the Plan Nacional de Desarrollo232 
and the 2011 Política Nacional para la Gestión Integral de la Biodiversidad y 
sus Servicios Ecosistémicos.233 These papers aimed to conciliate the interests 
of local researchers, including public institutions, and the government interest 
in employing genetic resources as a strategic value for economic development. 
As observed in Chapter Three, these reforms involved excluding local 
researchers from prior informed consent and mutually agreed terms 
 
229Dirección de Censos y Demografía, ‘Colombia Una Nación Multicultural’ (2007) 
<https://www.dane.gov.co/files/censo2005/etnia/sys/colombia_nacion.pdf> accessed April 
4 2018. 
230 Gabriel Ricardo Nemogá Soto and Alejandro Chaparro, ‘Regímenes de Propiedad Sobre 
Recursos Biológicos, Genéticos y Conocimiento Tradicional’ (2005) 1 Series Plebio; Florelia 
Vallejo Trujillo, Gabriel Ricardo Nemogá Soto and Dalí Aleixandra Rojas Díaz, Guía Práctica 
Para El Acceso a Los Recursos Biológicos, Los Recursos Genéticos y/o Sus Productos 
Derivados, y El Componente Intangible (Grupo PLEBIO-U Nacional 2009); Villar and others 
(n 185). 
231 See Gómez Lee (n 217)., pp  
232 Plan Nacional de Desarrollo is the political and economic guidelines of the President in 
Colombia; in content it is similar to Party Manifestos in the UK, but due to Colombian civil 
law and constitutional tradition it is treated as a binding law. See Title XII, Chapter Two of the 
1991 Colombian Constitution and the 1994 Colombian Act of the National Development Plan 
(Ley 152 de 1994 or Ley Organica del Plan de Desarrollo); see also, Departamento Nacional de 
Planeación Plan Nacional de Desarrollo 2014-2018 (n 11). and Consejo Nacional de Política 
Económica y Social, ‘Documento Conpes 3527 Política Nacional de Productividad y 
Competitividad’ (2008) 
<http://www.mincit.gov.co/publicaciones/14894/politica_nacional_de_productividad_y_c
ompetitividad> accessed October 10 2017. 
233 Ministerio de Ambiente (n 223). 
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obligations when such local researchers were carrying out non-commercial 
activities on genetic resources. Additionally, the Ministry of the Environment 
adjusted its administrative structure, so as to create a specific agency within 
the ministry charged with centralising, negotiating, and implementing 
mutually agreed terms in order to overcome the lack of adequate infrastructure 
to enforce access and benefit sharing rules. This agency is the Dirección de 
Bosques Biodiversidad y Servicios Ecosistémicos-Grupo de Recursos 
Genéticos. The new agency was also in charge of diffusing and providing 
training in access and benefit sharing rules across the country, to encourage 
universities and research centres to comply with the law, and build their 
capacity to do so.234 Also, the Ministry of the Environment set a goal of 
increasing capacity in the process of granting mutually agreed terms, through 
measures such as reducing evaluation and negotiation periods.235  
 
Those governmental administrative measures resulted in the ministry 
subscribing to 37 sets of mutually agreed terms in 2013 and 20 in 2014. This 
indicates that the number of mutually agreed terms negotiations increased 
dramatically compared with the period 1996-2011, which involved only 45 sets 
of mutually agreed terms. Furthermore, in 2013, the ministry, in a 
performance and accountability report, highlighted that the average time to 
reach mutually agreed terms with users of genetic resources was seven 
months.236  
 
Furthermore, the National Government and the Ministry of the Environment 
enacted Decrees 1375 and 1376 of 2013,237 and Resolution 1348 of 2014238 to 
clarify that non-commercial research such as collecting and sampling of 
genetic resources, which were the main activities carried out by local 
 
234 Dirección de Bosques Servicios Ecosistémicos y Biodiversidad-Ministerio de Medio 




May 5 2018. 
235ibid. 
236 Ministerio de Ambiente (n 223). 
237 Further information on the content of both Decrees see Chapter Two 
238Further information on the content of this regulation see Chapter Two 
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researchers, require neither permission to access, nor mutually agreed terms. 
This regulation also states that prior informed consent is only required when 
both commercial and non-commercial activities access to “ethnic” (i.e. Afro- 
Colombian or Indigenous)’ plants. Finally, the regulation points out that if the 
research moved towards commercialisation, users should immediately notify 
the Ministry of the Environment as to reach newly mutually agreed terms.  
 
Following these policy and legal developments, as well as the mobilisation of 
local researchers to demand changes in the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing, in 
2015, Colombia gave a grace period of 2 years to local researchers who 
previously accessed genetic resources without prior informed consent or 
mutually agreed terms to be in a good standing by submitting a new 
application before the ministry. This amnesty was well received by users who 
were in breach of Colombian legislation. 170 applications were submitted 
during those two years, which added to the 150 sets of mutually agreed terms 
already signed.239  
 
The Colombian legislation and infrastructure designed to implement the 
International Regime on Access to Genetic Resources and Benefit Sharing was 
reconfigured to meet demands of local research, including public ones. This 
approach indicates how open the national authorities were in responding to 
the concerns of local researchers, who were facing significant challenges in 
engaging with strict rules and in navigating a dysfunctional system within the 
state. However, it was not only the concerns from local researchers which led 
to Colombia making significant legal and administrative changes: Colombia’s 
innovation policy has been constructed as seeking to make the country more 
competitive in terms of R&D at the international level. As a result, Colombia 
adapted its innovation policy to comply with international standards. 
 
Yet, those standards do not include practices and knowledge associated with 
 
239 Those mutually agreed terms were mainly reached with universities. For instance, the 
National University of Colombia accounts for 87 of the 245 applications and mutually agreed 
terms granted in Colombia, Andes University 12 and the Antioquia University 7. Dirección de 
Bosques Servicios Ecosistémicos y Biodiversidad-Ministerio de Medio Ambiente (n 220). 
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genetic resources, which are placed into the public domain. As a result, 
Colombian authorities are not enforcing communities’ fundamental rights, 
including public consultation, as mandated by Decision 391 and the 
Colombian constitutional system. The next sections analyse how Colombia’s 
current innovation policy has led local researchers to actively appropriate 
communities’ practices and knowledge without even consulting them. This 
part of the chapter  argues that this is a violation of communities’ fundamental 
rights.  
 
Innovation Policy behind the Exploitation of Genetic Resources 
 
An essential aspect to be considered in this story of Colombia’s 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing is how Colombian economic policies have underlined 
legislative and administrative transformations. When Colombia began the 
process of implementing the regime, the country had just embarked upon a 
process of profound economic reforms. These were part of what was called 
Liberasation of the economy to international trade. In brief, structural 
reforms in the economy and trade sought to make Colombia a more 
competitive country. Among those structural reforms, science and technology 
began to have a more prominent role in the Colombian economic 
environment.  
 
Economic and technological development also came along with political 
reforms that sought to reach populations that were previously alienated. 
Although Colombia has always been a culturally diverse country, its 
recognition as such was only given by the law as late as 1991, when a new 
constitution secured rights for such a diverse population, including local, 
indigenous, and Afro-Colombian communities. However, through its process 
of Liberasation, which continues to the present day, economic development 
become more prominent, compared to other aspects such as social inclusion 
of those communities, particularly in the case of the knowledge associated with 
genetic resources.  
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Colombia’s implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing through the Andean Community in the 1990s 
took place in the context of Colombia finding a place in international trade and 
becoming a more socially inclusive country. As explained above,240 the Andean 
Community’s approach to biodiversity is as a resource of strategic value for 
member countries. In that context, Colombia tried to balance the interest in 
employing its biodiversity for its economic and technological ambitions, and 
at the same time protecting traditional knowledge. However, as explained 
above, at first, the implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing did not meet the government’s 
expectation that overseas companies would share benefits such as transfer of 
technology, and thus would contribute to economic development. Nor did 
overseas companies engage with local, indigenous, and Afro-Colombian 
communities. Instead, it was local researchers who began to engage in access 
activities.  
 
The interests of local researchers in accessing genetic resources and 
understanding communities’ practices and knowledge converged with 
Colombia’s interest in becoming a more prominent actor in international 
trade. Since the country signed up to free trade agreements with the US and 
the EU and revealed its intention to become part of other organizations such 
as the OECD, Colombia’s scientific and technological infrastructure, including 
its legal and administrative infrastructure, was built in terms of becoming a 
key aspect of the economic development of the country as well. As Colombia 
initiated important investment in its scientific and technological capability, it 
decided to adopt a model of innovation which was related to international 
standards, particularly to those set up by the OECD.  
 
Since 1992, the OECD, a club of countries (mainly developed ones) which 
share common policies to evaluate economic development, has published 
guidelines for collecting and interpreting innovation data. Known as the Oslo 
Manual, these guidelines mainly focus on data collected from the government, 
 
240 Prejudicial Interpretation of Articles 5 (c) and 22 of Decision 85 of the Commission of the 
Andean Community of Nations (n 203). 
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sectors, and industries that create new products, processes, and services in a 
variety of areas such as information technology and biotechnology.241 The data 
in the Oslo Manual primarily focuses on how the production of knowledge and 
information is carried out by industries. The Oslo Manual does not consider 
other forms of production of innovation, including traditional knowledge 
associated with genetic resources and local practices.  
 
This problematic issue of what can be innovative in the light of international 
trade and how this approach falls short of including communities’ practices 
and knowledge is another ramification of the complex discussion behind 
bioprospecting. Although a discussion on bioprospecting in general is found 
in Chapter Two, it needs to be contextualised in the light of Colombia’s 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing and its innovation policy.  
 
Colombian Innovation Policy and Bioprospecting 
 
Bioprospecting involves the activities of scanning and scoping of biodiversity 
for the collection of biological material for potential industrial application (see 
Chapter Two). Some actors have defended it as a way to promote sustainable 
use of developing countries’ biodiversity on the verge of the discussions that 
led to the enactment of the Convention on Biological Diversity.242 However, it 
has also been criticised as potentially disregarding the social, cultural, and 
economic value of both biodiversity and traditional knowledge associated with 
genetic resources. While supporters of bioprospecting claim that it brings 
benefits for those who participate in those initiatives (e.g. increasing local 
capability and transfer of technology),243 scholars and social activists point out 
 
241 OECD and Eurostat (n 216)., pp 32-41 
242 For further information on how researchers campaigned for bioprospecting as model of 
transfer of technology between global north and global south on the verge of the discussions 
that led to Convention on Biological Diversity see Eisner and Meinwald (n 78)., and 
Richerzhagen and Holm-Mueller (n 79).  
243 A leading organisation in bioprospecting developing countries’ biodiversity is the 
International Cooperative Biodiversity Groups (ICBG) (a US programme funding), which have 
developed bioprospecting programs in different countries including Mexico and Panama. 
Regarding the latter, ICBG-Panama launched a program with the aim of screening the 
Panamanian ecosystem and supporting the transfer of technology and knowledge. It is 
claimed that the project has encouraged capacity with the intention of providing Panama with 
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its pitfalls.244 In brief, it is claimed that bioprospecting is a neo-colonial 
phenomenon that enables the theft of biodiversity and traditional knowledge 
(biopiracy) (see Chapter Two).  
 
Although the International Regime on Access to Genetic Resources and 
Benefit Sharing aims to address those concerns, there are other aspects, which 
are allegedly not being taken into account. For instance, it is claimed that the 
complexity of research activities leaves almost intact upstream users, who are 
large multinational companies (see Chapter Two).245 For instance, the 
researchers who collect genetic material or interact with communities for leads 
are those who comply with and follow the International Regime on Access to 
Genetic Resources and Benefit Sharing. Once they have collected the material 
or information, they hand it over to laboratories which might even be located 
in developed countries. In turn, laboratories might license upstream users in 
 
high quality training and equipment to exploit its own genetic resources, but this project has 
not delivered a commercially new biochemical compound yet. However, since the ICBG is 
carrying out different projects in Panama in association with universities, museums and 
research centres in the US, scientists have identified within a microorganism, Leptolyngbya, 
a promising anticancer compound named Coibamide A, which is currently in preclinical trials. 
However, this research has not been considered yet to be a commercial research as Panama 
has not reported any change of intent, including on Coibamide A. Further information on the 
benefits of bioprospecting see: Anthony Artuso, ‘Bioprospecting, Benefit Sharing, and 
Biotechnological Capacity Building’ (2002) 30 World Development 1355; Kursar and others 
(n 78); Newman and Cragg (n 85). For the particular case of Colombia see Oscar Duarte Torres 
and Lea Velho, ‘La Bioprospección Como Un Mecanismo de Cooperación Internacional Para 
Fortalecimiento de Capacidades En Ciencia y Tecnología En Colombia’ (2010) 38 Ciência da 
Informação. For further information of the ICBG and Panama program see C Benjamin 
Naman, Christopher A Leber and William H Gerwick, ‘Modern Natural Products Drug 
Discovery and Its Relevance to Biodiversity Conservation’ in Ipeck Kurtböke (ed), Microbial 
Resources: From Functional Existence in Nature to Applications (Academic Press 2017); 
Jeffrey D Serrill and others, ‘Coibamide A, a Natural Lariat Depsipeptide, Inhibits 
VEGFA/VEGFR2 Expression and Suppresses Tumor Growth in Glioblastoma Xenografts’ 
(2016) 34 Investigational New Drugs 24; CBD, ‘Panama: Country Profile’ (Access and Benefit-
Sharing Clearing-House, 2018) <https://absch.cbd.int/countries/PA> accessed February 20 
2018. 
244 Among those scholars and organization, some of the most outspoken are Vandana Shiva 
and the ETC Group, formerly Rural Advancement Foundation International (RAFI), see  Shiva 
(n 108). and ETC Group, ‘From Global Enclosure to Self Enclosure: Ten Years After-A Critique 
of the CBD and the &quot;Bonn Guidelines&quot; on Access and Benefit Sharing (ABS)’ 
(2004) <www.etcgroup.org>. See also Stenton (n 100); Rachel Wynberg, ‘Access and Benefit-
Sharing Agreements in the Commercial Development of Hoodia’ in Rachel Wynberg and Sarah 
Laird (eds), Access and Benefit-Sharing in Practice: Trends in Partnerships Across Sectors 
(Secretariat of the CBD Tecnical Series No 38 2008) 
<http://mddb.apec.org/Documents/2008/IPEG/SEM2/08_ipeg_sem2_015.pdf> accessed 
July 31 2017. For a recent analysis on discussion about biopiracy and bioprospecting see: 
Benjamin D Neimark, ‘Bioprospecting and Biopiracy’ [2017] The International Encyclopedia 
of Geography: People, the Earth, Environment and Technology.  
245 Cloatre (n 21). 
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the research and development pipeline. As those who comply with the access 
and benefit sharing rules are the researchers who appear in the first stages, it 
leaves intact upstream users.246 However, upstream users claim that there is 
still lack of clarity in the implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing in developing countries, 
which has led them to move away from bioprospecting.247  
 
Yet, developing countries such as Colombia are increasingly interested in 
being competitive in terms of innovation in international markets and are 
reconfiguring their policy, legal, and administrative mechanisms behind the 
use of biodiversity. A key aspect of such an approach to innovation in 
developing countries is that the implementation of the International Regime 
on Access to Genetic Resources and Benefit Sharing, as argued in the previous 
section, has been reconfigured to facilitate access to local researchers and 
publicly funded projects. This means that, particularly in Colombia, the 
adoption of international standards of innovation to measure research and 
development is leaving unscathed local researchers in complying with the 
International Regime on Access to Genetic Resources and Benefit Sharing. 
That is why it is important to highlight the impact of Colombia’s innovation 
policy in the bioprospecting debate.  
 
As mentioned above, Colombia has adopted the innovation standards of the 
OECD. The agency in charge of implementing those guidelines is Colciencias, 
which embraced, in its entirety, the Oslo Manual for the approach adopted for 
evaluation and collection of data related to innovation in Colombia. Since 
Colciencias is the national organization that supervises and allocates resources 
to publicly funded universities and research centres, it becomes critical to local 
researchers to meet those OSLO Manual standards. 
 
246 There are even sectorial reports that illustrates this point as they blame that the 
implementation of the Nagoya Protocol, which is part of the International Regime on Access 
to Genetic Resources and Benefit Sharing, has imposed the economic and logistic burden of 
the ABS Regulation in downstream users see Kang, Jung and Ryu (n 139); Bart Van Vooren, 
‘Impact on the Food Industry of New EU Rules Implementing the Nagoya Protocol’ (2016) 3 
European Food and Feed Law Review (EFFL) 220.  
247 It is reported that large pharmaceutical companies have closed their natural products 
research division because of the International Regime on Access to Genetic Resources and 
Benefit Sharing, see for instance: Cragg and others (n 85); Neimark (n 244). 
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As a result, the government addresses resources to universities and research 
centres who carry out R&D activities according to the Oslo Manual. Since 
Colciencias is the leading scientific agency in the government, its primarily 
focus is on increasing innovation in sectors and industries that are considered 
to be innovative, such as biotechnology. This has resulted in an agency that 
supports, for example, PhD and Masters students in science-related fields, as 
well as providing economic resources directly to universities. This 
administrative department also created different programmes and established 
‘lines of action’ in areas related to biotechnology through the National 
Biotechnology Program. At present, the Colciencias’ ScienTI Network has 
identified approximately 108 research groups registered, most of them based 
within universities, which cover different areas including human health. 
Likewise, Colciencias prompted the creation of the Centre for Bioinformatics 
and Computational Biology and the National Centre for Genomic Sequencing 
(CNSG) which serves to increase the country’s scientific and technological 
capability. Similarly, Colciencias promoted the creation of technology parks 
where different actors (such as guilds, universities, and local and national 
authorities) come together to encourage the use of biotechnology in different 
sectors. Examples of these are Ruta N in Medellín, BioPacifico in Valle del 
Cauca and the National Research Centre for Agroindustrialization of Tropical 
Medicinal Aromatic Plant Species in Santander (CENIVAM).248  
 
Turning this discussion to the implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing, the national government 
sought to ease the implementation of the regime in respect of local researchers 
such as publicly funded universities and research centres, so they could 
employ genetic resources in the improvement of Colombian scientific and 
technological capacities according to Colciencias’ policies. In addition, in a 
2011 White Paper, the Colombian government highlighted the importance of 
incentivising bioprospecting among local researchers as part of its strategy to 
 
248Colciencias, ‘History of Colciencias’ (2018) <http://www.colciencias.gov.co/node/94> 
accessed 5 May 2018. Colciencias, ‘Programa Nacional En Biotecnología’ 
<http://www.colciencias.gov.co/node/1133> accessed October 31 2017. BIOS, ‘Centro de 
Bioinformática y Biología Computacional’ <http://www.bios.co/> accessed October 31 2017. 
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increase its national R&D capacity.249 The government also requested the 
National Planning Department (NDP), which is the national agency that 
elaborates the economic plan for the state, to assess the technical viability of 
establishing the first national bioprospecting company (Empresa Nacional de 
Bioprospección).250 Although at this time the NDP has not assessed whether it 
is recommended to create such a publicly funded entity, Colciencias has 
already addressed around USD 165 million to create scientific and 
technological infrastructure in Bogotá for bioprospecting Colombian natural 
products for health research and health industry, known as PhairiLab.251 The 
economic resources are just beginning to be spent in the construction of 
facilities and laboratories in the capital of the country, which means that access 
to genetic resources activities have not begun yet. However, during the whole 
process to date, there has not been a single mention of whether communities 
are to be publicly consulted when access to medicinal plants takes place. This 
aspect of the International Regime on Access to Genetic Resources and Benefit 
Sharing is absent from Colombian governmental policy. 
 
The increasing public expenditure in R&D capacity in the country, the policy 
papers that sought to place biodiversity as a key aspect of increasing 
Colombian research and development capacity, and the different measures 
that facilitate access, all demonstrate the focus of Colombian policies. These 
policies make genetic resources of “strategic value” to health research and 
health industry. This framing has led the implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing towards an 
unbalanced legislation that only considers the contribution of holders of 
technology, either local or overseas users, where that contribution adds value 
to the use of biodiversity innovation.  
 
249 Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 Política Para 
El Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ 
(n 14). p 28 
250 ibid.  
251 Secretaría de Planeación de Bogotá, ‘Implementación de La Plataforma Científica y 
Tecnológica Para La Obtención de Fitomedicamentos Antitumorales Con Estándares 
Internacionales Bogotá D.C. | Regalias Bogota’ (Regalía Bogotá Región e Innovación, 2018) 
<http://regaliasbogota.sdp. 
gov.co:8080/regalias/portfolio/implementación-de-la-plataforma-científica-y-tecnológica-
para-la-obtención-de> accessed November 11 2018. 
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Although this approach could have a noble intention of encouraging local 
researchers to access genetic resources and increase the country’s scientific 
capacity, in practice this innovation policy has placed into the public domain 
the knowledge and practices of those who provide “leads” in the understanding 
of biodiversity for the health industry. As a result, Colombia’s innovation 
policy goes against those constitutional and regional mandates that demand 
inclusion of communities in the decision-making process when their practices 
and knowledge have been or will be employed by users. This situation can be 
exemplified in the cases of the native plants Dividivi (Caesalpinia spinosa) and 
the Anamú (Petiveria alliacea). Both cases are studied in detail in the next 
section.  
 
From Public to Private: The Cases of the Dividivi and Anamú in Colombia  
 
Since Colombia opened its economy, it has built an important scientific and 
technological infrastructure which follows international standards of 
innovation, particularly those established by the OECD’s Oslo Manual. An 
important aspect for Colombia in terms of innovations has been R&D activities 
from local researchers.  
 
The government has recently enacted regulations that have eased the strict 
rules of Decision 391 with the aim of encouraging local researchers to access 
genetic resources. However, as has been discussed throughout this chapter, 
these governmental efforts are in contradiction with the Andean legislation 
and the Constitutional Court mandates on protecting communities’ practices 
and knowledge. This situation can be characterized with two cases involving 
two different plants (Dividivi and Anamú), and an immunobiology research 
group based at the Javeriana University of Colombia, who have worked for 
more than two decades with Colombia’s medicinal plants to treat cancer. This 
section brings the testimony of the members of the research group through a 
series of interviews which evidence how research on two medicinal plants 
involves different legal, scientific, technological and, even, personal 
complexities, which are very challenging to encapsulate in a particular legal, 
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administrative or policy framework. Yet, the evidence collected in the 
interviews also demonstrates how important it is to consider researchers’ own 
experiences with medicinal plants in the construction of any framework that 
implements the International Regime on Access to Genetic Resources and 
Benefit Sharing in Colombia.  
 
That is the case, for instance, of the lead researcher of the Javeriana Group, 
Professor Susana Fiorentino, who has experienced a long professional 
relationship with both medicinal plants. As will be observed, Fiorentino’s work 
has led her to travel around the country experiencing different dynamics 
concerning medicinal plants. Her research has also allowed her to build an 
accomplished scientific career over two decades,252 as well as to navigate the 
changing legal, administrative and policy landscape of the International 
Regime on Access to Genetic Resources and Benefit Sharing Regulation and 
innovation policy in Colombia over the years.  
 
In addition, Fiorentino’s work has had a profound impact in her own personal 
life. In particular, her husband, Javier Barnier, who is in the business of 
producing, promoting, exporting and importing agricultural products, has 
closely accompanied and advised Fiorentino’s personal and professional 
journey in the field of natural products for medicinal applications. The 
professional and personal aspects of Fiorentino’s story are difficult (or perhaps 
impossible) to disentangle. 
 
Furthermore, Professor Fiorentino’s influence and significance extends 
beyond her own career.  In particular, Fiorentino’s approach in Colombia to 
medicinal plants is a constant inspiration for other members of her research 
group, such as Claudia Urueña and Wilmar Olaya.  These are the senior 
researchers of the future in Colombia. All those dynamics and complexities, 
and more, are studied in detail in the following sections.   
 
 
252 Professor Fiorentino has published a large amount of scientific papers, obtained different 
awards and recognition, form a great deal of PhD and Master students. See Florentino’s CV at 
https://scienti.colciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=00002







































Researchers Wilmar Olaya (left) 
and Claudia Urueña (right) at the 
Immunology lab in the Javeriana 
University. Picture taken by the 
author.  
Spouses Javier Barnier (Left) and 
Professor Susana Fiorentino (Right) 
at their home. Picture taken by the 
author.   
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 The Dividivi 
 
The Dividivi (Caesalpinia spinosa) has had a long-standing close relationship 
with the inhabitants of the Ricuarte in the region of Boyacá (see Map 1). The 
plant has not only  been employed by local 
communities of peasants (campesinos) in 
the region to treat tonsillitis, sinusitis, and 
bronchitis, among other conditions, 
because of its qualities as anti-
inflammatory, astringent, and 
disinfectant,253 but it was also a significant 
source of revenue for the region as the seed 
of the plant was employed for 
leatherworking in countries such as the 
United States. Mr. Wilmar Olaya highlights 
that such activity is something that  the local 
community in the region hardly remember 
“as an useful products for leatherworking” (Translation by the author).254 This 
is because the plant was substituted by a laboratory-made component known 
as Chromo VII, which eventually led the leather industry to abandon the crop 
production of the Dividivi.255  
 
However, the plant’s usefulness for inhabitants of Ricaurte did not disappear 
because of the lost interest from the leather industry. The community of 
campesinos continued employing Dividivi as a medicinal plant. Before the 
plant was collected and identified by ethnobotany researchers in 2007, records 
illustrate that the Dividivi had been employed as a medicinal plant by those 
 
253 Vanessa Molina Medina, ‘La Revolución de Los Fitomedicamentos’ (Pequisa Javeriana, 
2010) December <http://www.javeriana.edu.co/pesquisa/la-revolucion-de-los-
fitomedicamentos/> accessed  May 3 2018. 
254 Original transcription in Spanish: “como productos útiles para la peletería”. Interview with 
Wilmar Olaya, Agriculture Engineer and Regulatory expert at the Immunology Javeriana 
Research Group, Javeriana University (Bogotá, Colombia, 19th September 2019) 
255 For further information on the economic and ecologic impact of the Dividivi as plant 
employed by the leather industry see  Joaquín Molano Barrero, ‘Villa de Leiva: Ensayo de 
Interpretación Social de Una Catástrofe Ecológica’ (Fondo FEN Colombia 1990). 
Map 1. Source: http://www.boyacacultural.com/ 
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communities before Spanish colonization.256 Through those ethnobotanical 
studies of the plant, in 2012, the Javeriana research group noticed that the uses 
of the biochemical properties of the plant could have other potential uses in 
medicine.257  
 
In particular, the anti-inflammatory quality of the plant was of great interest 
for the Javeriana research group because of its potential use in the treatment 
of cancer.  Consequently, this research group, which had received public 
funding from Colciencias for carrying out the research, reached mutually 
agreed terms with the Ministry of the Environment for non-commercial 
research, and, consequently, published several scientific papers including one 
that identified that the plant possessed acid gallic, one of the bioactive 
components responsible for its therapeutic activity.258 The research group did 
not focus on the specific uses given by the communities, but on the biochemical 
qualities of the plant itself. Those qualities led the research group to identify 
and extract a natural fraction from the plant, which in combination with 
conventional chemotherapy and other natural products, increases therapeutic 
effectiveness in the treatment of cancer.259 
 
Thus, the information collected from the communities from Ricaurte did not 
include knowledge that the plant had a potential use in the treatment of 
cancer. Rather, the community’s practices and knowledge associated with the 
plant – for treating other illnesses – led the Javeriana research group to 
identify specific qualities of the plant to treat cancer. Dr Claudia Ureaña, a 
researcher in this group, explains how communities’ uses of the plant is a lead 
to find the potential biochemical qualities for the treatment of cancer:  
[C]learly communities do not say 'we have used [the plants] for 
cancer', [...] they have been used [by communities] because they have 
 
256 Diana M Castañeda and others, ‘A Gallotannin-Rich Fraction from Caesalpinia Spinosa 
(Molina) Kuntze Displays Cytotoxic Activity and Raises Sensitivity to Doxorubicin in a 
Leukemia Cell Line.’ (2012) 12 BMC complementary and alternative medicine 38., p 2 
257 ibid., p 2 
258 Tito A Sandoval and others, ‘Standardized Extract from Caesalpinia Spinosa Is Cytotoxic 
Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin’ (2016) 44 The 
American Journal of Chinese Medicine 1693., pp 1702-1708 
259 Dirección de Bosques Servicios Ecosistémicos y Biodiversidad-Ministerio de Medio 
Ambiente (n 220). 
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microbial or anti-inflammatory activity, others because they have 
hypoglycemic activity [...] knowing that cancer is a chronic 
inflammation process, if I have a possible plant that people use as an 
anti-inflammatory, why not think that this plant can have an effect on 
a chronic inflammatory disease like cancer, […], or the fact that [the 
plant]  has a hypoglycemic activity, [we have] the knowledge that 
tumor cells consume a lot of glucose so I have something that decreases 
the uptake of that glucose, that could have an effect on the tumor 
area.260 (Translation by the author) 
 
This view is an aspect of the Javeriana research group’s approach that is shared 
by the other members of the research group. For instance, Mr. Olaya highlights 
that communities “do not refer [the research group] directly to cancer 
treatment […] but that [anti-inflammatory] characteristic powerfully drew the 
attention of the research group and, from there, it was developed everything 
that we have discovered” (Translation by the author).261 In a similar 
perspective, Professor Fiorentino explains that the dissimilarities of 
communities’ practice and knowledge, and research and development in her 
field is not something that she has experienced exclusively with the Dividivi. 
She exemplifies this point by recounting her experience with the Cogui 
community, an indigenous community located in la Sierra Nevada de Santa 
Marta (North of Colombia) (see Map 2), and communities in the region of 
Amazon. First, Florentino mentions visiting the Sierra Nevada, where she had 
the opportunity to inquire of the Cogui community about medicinal plants 
 
260  Original transcription in Spanish: “claramente no dicen las comunidades ‘nosotros lo 
hemos utilizado para cáncer’, […], unas sea han utilizado [por parte de las comunidades] 
porqué tienen actividad microbiana o antinflamatoria, otras porqué tienen actividad 
hipoglucemiante” […]sabiendo que el cáncer es un proceso de inflamación crónica, si tengo 
una posible planta que la gente utiliza como un antinflamatorio porque no pensar que esta 
planta pueda tener efecto en una enfermedad inflamatoria crónica como lo que es el cáncer, 
entonces digamos, o el hecho que [la planta] tiene una actividad hipoglucemiante, [nosotros 
tenemos] el conocimiento que las células tumorales consumen mucha glucosa entonces yo 
tengo algo que disminuya la captación de esa glucosa, podría tener efecto sobre la zona 
tumoral” Interview with Claudia Urueña, Researcher at the Immunology Javeriana Research 
Group, Javeriana University (Bogotá, Colombia, 19th September 2019) 
261 Original transcription in Spanish: “no hacen alusión directa al tratamiento del cáncer” 
“pero esa característica [antiflamatoria] llamó poderosamente la atención del grupo de 
investigación y desde ahí se desarrollo todo lo que hemos venido descubriendo” Interview with 
Claudia Urueña, Researcher at the Immunology Javeriana Research Group, Javeriana 
University (Bogotá, Colombia, 19th September 2019) 
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used for the treatment of cancer. She 
points out that this community 
consider some plants such as the 
Anamu as “a magical plant that cures 
everything. But specifically, cancer, 
[the community] did not have much 
knowledge, because they have no idea 
what cancer is”.262 Second, the 
Professor confirms her empirical 
evidence in the Amazon when visiting 
“a guy who knew a jurgo263 of plants” 
as this person explained to her in 
general terms what the medicinal plants 
were for, including the ‘woman's disease’, which might be a reference to 
cancer. However, according to Florentino, “the guy” never mentioned that the 
plant was used for cancer because he does not “know what cancer is".264   
 
These testimonies are evidence of the difficulties in a legal approach that 
includes protecting practices and knowledge from communities that are used 
in any research and development process. Communities’ practices and 
knowledge are considered to be mere “leads”, and only “useful” (hence, 
valuable in an economic sense, and to be protected) in the context of the 
knowledge (here, about cancer) of the researcher. The researchers’ views 
suggest no sense of improper exploitation or breach of communities’ rights: to 
them, the value-added is the knowledge of the researchers, which is 
incommensurable with the type of knowledge held in local communities. To 
underline this insight, on being questioned whether communities’ uses of 
medicinal could be considered innovative or be understood as involved in, or 
part of, research and development activities, all three researchers (Florentino, 
Olaya and Urueña) and Javier Barnier answered: No. Mr. Olaya, in particular, 
 
262 Original transcript in Spanish: “para ellos [los Cogui] el Anamú es una planta mágica que cura 
todo, pero pues específicamente el cáncer no tenían mucho conocimiento, porque no tienen ni idea 
que es el cáncer” Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology 
Javeriana Research Group, Javeriana University (Bogotá, Colombia, 1st October 2019) 
263 A colloquial term to say a lot. Ibid.  
264 Ibid.  
Map 2: Sierra Nevada de Santa marta. 
Source: Google Maps  
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was emphatic in explaining that, in his view, innovation in health research 
could not dwell in communities’ practices and knowledge, because it was 
“science” which actually transforms those uses into products. As he explains: 
“the innovation lies in the possibility of taking all these resources [Colombia’s 
biodiversity and communities’ practices and knowledge] and making them 
useful for society" (Translation by the author).265 This interpretation of 
knowledge and usefulness shows that the Colombian policy on innovation, 
which recognizes and benefits well-established sectors in the market (e.g. the 
Internet, biotechnology or services), has also an echo in the views and 
understandings of researchers who work with medicinal plants in Colombia. 
This interpretation could potentially involve a clash with Constitutional Court 
rulings, international and regional agreements regarding the rights of 
communities over their practices associated with medicinal plants (see 
Chapters 2 and 3).  
 
However, the interviews with the Javeriana research group’s members also 
indicated that their approach to health research in medicinal plants is lawful 
and compliant with the relevant Constitutional Court rulings and 
regional/international agreements. As Mr. Olaya was questioned about how 
the research group obtained the information related to the medicinal 
characteristics of the Dividivi, he was consistent in stressing that the group 
works on “public knowledge” rather than traditional knowledge or practices. 
According to Mr. Olaya, the group acquired the information on the anti-
inflammatory characteristic of the Dividivi from different sources which are in 
line with Colombia’s legislation:  
[D]igging into a plant, about its presence in the territories and 
knowing not only from the communities; but we also use other sources 
of information for example: patients in hospitals, surveys, in which 
patients are consulted on what plants have been suggested to them, 
how the information has come to them: if by voice-to-voice, consulted 
 
265 Original transcript in Spanish “la innovación esta en poder en tomar todos estos recursos 
[biodiversidad colombiana, y practicas y conocimiento de las comunidades] y convertirlo en 
algo útil para la sociedad” Interview with Wilmar Olaya, Agriculture Engineer and Regulatory 
expert at the Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 19th 
September 2019) 
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a website, or by the experience of a case in the family. (Translation by 
the author) 266 
 
At first glance, this statement could indicate that the research group might be 
in direct conflict with the Decision 391 of the Andean Community, and the 
rulings of the Constitutional Court (see Chapters 2 and 3). The research group, 
according to Mr. Olaya ‘digs into’ information about the plant ‘from the 
communities’. But the information search does not stop there: it includes 
asking patients about their experiences, including interacting with non-
traditional, non-indigenous information sources, such as the internet.  The 
Javeriana group’s approach is more complex than mere exploitation and 
obvious breach of the law suggest. Rather, the interview data indicates that 
local researchers face a more difficult legal landscape, as the Colombian 
authorities are pursuing different agendas that clash with each other. 
 
 As explained above, the economic agenda to meet global markets’ interests 
pulls in direct confrontation with international commitments and local 
constitutional obligations to respect communities’ fundamental rights. In fact, 
although Decision 391 and constitutional precedents regarding local 
communities’ right to be consulted appear to be breached by the Javeriana 
research group, the research group is not in breach of the Resolution 1348 of 
2014 of the Ministry of Environment (see Chapter Three). This is, it will be 
recalled, the Resolution that implements the Andean Decision in Colombia. 
This administrative regulation establishes that prior informed consent is 
required when there is presence of ethnic groups, meaning communities that 
are distinguished by their ethnicity and race such as indigenous or Afro-
Colombian people.  In the particular case of the Dividivi, there is no presence 
of ethnic communities in the Ricaurte, nor relationship between indigenous 
or Afro-Colombian people and the plant; it is rather the local community of 
Campesinos which have interacted with the plant in different ways, from the 
 
266 Original transcript in Spanish: “indagar sobre una planta, sobre su presencia en los 
territorios conocer no solo de mano de las comunidades” sino que echamos mano de otras 
fuentes de información, por ejemplo: pacientes en los hospitales” “encuestas donde se 
consultan a los pacientes que plantas les han sugerido “como ha llegado la información a ellos 
si por el voz a voz, consultado una pagina de internet, o por la experiencia de un caso en la 
familia”.Ibid. 
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use as a material for leatherworking to medicinal uses. As noted above, it was 
the latter that led the Javeriana research group to the anti-inflammatory 
characteristics of the plant. 
 
The issue of different local researchers’ approach to different communities 
depending on their ethnic background was also mentioned in the interview 
with Professor Fiorentino. She was emphatic in declaring that her research 
group worked only in plants, including the Dividivi, “that are not anywhere 
near where there are indigenous communities; a thing that doesn't seem very 
chevere,267 but we did it even on the recommendation of the Ministry [of 
Environment]” (Translation by the Author). As can be observed, it is the very 
administrative authority which oversees the enforceability of the access and 
benefit sharing regulation in Colombia which recommends local researchers 
not to include indigenous and Afro-Colombian communities in innovative 
processes.  This can, of course, be seen as securing compliance with the law: if 
the research group does not include indigenous and Afro-Colombian 
communities, then it does not breach their fundamental rights. 
 
To explore this further, it was appropriate 
to ask Professor Fiorentino in the course of 
the interview why her research group finds 
it difficult to work with indigenous and 
Afro-Colombian communities, but not so 
with local communities. In response, she 
brought two examples from her experience. 
First, her research group “wanted to 
approach for the first time the fair and 
equitable distribution of resources [i.e. benefit sharing] with [ethnic] 
communities" as they found “plants that interested [them] in the Choco, and 
 
267 A local expression that means “cool” or nice. Original transcript in Spanish: “no se 
encuentren en ningún sitio donde haya comunidades indígenas; cosa que no parece muy chévere, pero 
lo hicimos incluso por recomendación del ministerio” Interview with Professor Susana Fiorentino, 
Lead Researcher at the Immunology Javeriana Research Group, Javeriana University (Bogotá, 
Colombia, 1st October 2019) 
Map 3 Department of Choco. Source: Google Maps 
Maps 
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[they] had to make public consultation" (Translation by the author).268 Choco 
is a department in the east part of Colombia (see Map 3) where Afro-
Colombians are the majority, in contrast with the rest of the country.269 The 
department is one of the most biodiverse regions of Colombia, but it is also one 
of the poorest and more violence-affected regions in the country.270 As the 
research group tried to carry out the required prior consultation, it found that 
the process was like “the one who wants to sell a house” (Translation by the 
author),271 meaning that from the point of view of Professor Fiorentino, 
communities tend to bargain for access to their plants in merely economic 
terms without considering technical and scientific complexities. Despite the 
fact that the research group found it difficult to reach out to the community, 
the group still wanted to pursue access to those plants. Consequently, they 
decided to outsource the process of prior consultation to a specialized 
company; but, it turned out that the price asked was 400 million pesos, 
approximately 125,000 USD. As a result, Professor Fiorentino declined the 
offer, or in her own words: “I told them, go to the Cuerno”.272 
 
Second, Professor Fiorentino also pursued the use of medicinal plants from 
indigenous communities, the Kamëntsá, Ingas and Quillacingas,273 in the 
Valle del Sibundoy, located in the department of Putumayo in the region of the 
 
268 Original transcript in Spanish “nos quisimos aproximar por primera vez a la distribución justa y 
equitativa de los recursos [con comunidades]” “Había una de las plantas que nos interesaba en el 
Choco, y nos tocaba hacer consulta previa”. Interview with Professor Susana Fiorentino, Lead 
Researcher at the Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 
1st October 2019) 
269 According to the national department of statistics (DANE, Spanish acronym), the 85.94% 
of the general Colombian population is not ethnic related, while 10.62% is Afro-Colombian. In 
contrast, in Choco, the Afro-Colombian population is 82.12 %. This indicates a clear 
geographical segregation of Afro-decedents in the country. This is more prominent in Bogotá, 
where the main structure of power (central government), wealth (e.g. companies) and 
education such as universities are located, whose general population is 98.27 %, and Afro-
Colombians are only 1.49 %. Dirección de Censos y Demografía (n 229)., p 38 
270 Luis Armando Galvis-Aponte and others, ‘La Persistencia de La Pobreza En El Pacífico 
Colombiano y Sus Factores Asociados’ [2016] Documentos de Trabajo Sobre Economía 
Regional y Urbana; No. 238. 
271 Original transcript in Spanish: “el que quiere vender una casa”. Interview with Professor Susana 
Fiorentino, Lead Researcher at the Immunology Javeriana Research Group, Javeriana University 
(Bogotá, Colombia, 1st October 2019) 
272 It is a Colloquial expression which its English equivalent would be “go to hell”. Ibid.  
273 For further information on indigenous communities in the Valle del Sibundoy and 
medicinal plants see John James Rodríguez-Echeverry, ‘Uso y Manejo Tradicional de Plantas 
Medicinales y Mágicas En El Valle de Sibundoy, Alto Putumayo, y Su Relación Con Procesos 
Locales de Construcción Ambiental’ (2010) 34 Rev. Acad. Colomb. Cienc 309. 
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Amazon (See Map 4). Putumayo, 
like Choco, is a very distant territory 
from the main urban centers of the 
country (e.g. Bogotá, Medellin, Cali 
and Barranquilla). It is also an 
underdeveloped area with a long 
history of violence.274 Professor 
Fiorentino explains how the 
research group found out about 
those communities and their 
relationship with the plants: 
 
 
I had a student from the Valle del Sibundoy, her dad was a Mamo275 
of the Putumayo, and we were going to work with the plants there 
[Valle del Sibondoy]. When we started talking to him [the Mamo], he 
came to college in featherdress one day, and asking me to pay him for 
the information, and I said no, because we're going to build a project 
where you're going to win. (Translation by the author)276 
 
Professor Fiorentino’s expressions and words such as go to the Cuerno and 
featherdress, the latter used by Colombian to singularize indigenous people 
typical dress, denote a clear frustration on her part concerning the difficulties 
in even establishing a dialogue with ethnic and racial communities on the use 
 
274 In the history of violence and poverty of Putumayo converged different actors and 
phenomes of the Colombian armed conflict, including paramilitary groups, guerrilla, drug 
trafficking and border tensions with the Ecuador. Further information see: Salomón Cuesta 
Zapata and Patricio Trujillo Montalvo, ‘La Frontera de Fronteras: Putumayo: Violencia, 
Narcotráfico y Guerrilla’; Laura González, ‘Capítulo III Seguridad Ciudadana y Seguridad 
Nacional En La Frontera Colombo-Ecuatoriana: Estado Del Arte de Investigaciones 
Producidas Entre Los Años 2000-2010’ [2012] Violencia y seguridad ciudadana: algunas 
reflexiones 195. 
275 Mamo is a Chaman who possess the traditional knowledge regarding the use medicinal 
plants 
276 Original transcript in Spanish: “yo tuve una estudiante del Valle del Sibundoy, el papa era un 
Mamo del putumayo, e íbamos a trabajar con las plantas de allá [Valle del Sibundoy]. Cuando 
comenzamos a hablar con él [el mamo], llego un día a la universidad vestido de plumas, y pidiéndome 
que le pagara por la información, y yo le dije no, es que vamos a construir un proyecto donde ustedes 
van a ganar”. Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology 
Javeriana Research Group, Javeriana University (Bogotá, Colombia, 1st October 2019) 
Map 4: Valle del Sibundoy (Putumayo): Source Google Maps 
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of medicinal plants. Her interview data evidences how both parties have widely 
different perspectives and expectations on the use of medicinal plants for 
health research and the health industry. The case of the Mamo, as recounted 
by Fiorentino, illustrates that is difficult to create a dialogue on how benefit 
sharing could take place, as Fiorentino was expecting to construct a long-term 
project based upon medicinal plants and traditional knowledge, while the 
Mamo was expecting to get an upfront payment. Equally, the failed project in 
the Choco also indicates how difficult it may be for a research group to find an 
interlocutor between communities and researchers to carry out the process of 
publicly consulting communities.   
Those experiences, according to my interviewees, led the research group to 
work with wild plants or cultivable plants and local communities instead. 
Fiorentino expresses such a desire to work with local communities of peasants 
(campesinos) as follows: “there are other communities that are peasants, and 
those communities are different” (Translated by the author)277 from ethnic 
communities. The reason it is different working with these communities is not 
only because it is not required to obtain prior informed consent, but it is also 
the fact that campesino’s expertise and experience on working in agriculture 
fit within Professor Fiorentino’s (and, her husband, Javier Barnier’s) vision on 
how share the benefits of the use of medicinal plants.  
In this point, Mr. Barnier’s own experience as a producer, distributer, 
promoter, importer and exporter of agriculture products for food consumption 
becomes a key aspect to understand how Professor Fiorentino aims to create a 
model of benefit sharing with the campesinos of Ricaurte and the use of the 
medicinal plant Dividivi.  
Asking Mr. Barnier about his input in the research on the Dividivi, he points 
out that he supplies the actual biological material, i.e. the plant itself, for the 
laboratory. In particular, he explains that he brought a well-known technology 
in Europe to Colombia to tackle the problem of a very low germination in 
agriculture products such as the tomato, which occurred because “there were 
 
277 Original transcript in Spanish: “hay otras comunidades que son los campesinos, y esas 
comunidades son diferentes”. Ibid. 
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no criteria of seed taking” (Translation by the author) resulting in using non-
mature seeds which resulted in a 30% germination ratio.278  
Mr. Barnier indicated that he was “the first to bring the technology from 
France to produce young seedlings with a material that is the peat, which is a 
material, an aseptic extract, with very good characteristics”279 (Translation by 
the author) employed in different harvests such as tomatoes. The use of the 
peat280 has led them to “obtain 80% germinations". Taking this technology 
into medicinal plants such as Dividivi and Anamú, he adds that “producing 
seedlings in alveolate trays which have as substrate the peat, this is how we 
can reproduce and even manage to sell 20 million seedlings a year of tomato, 
and in the same way we could produce both the Dividivi and Anamú with very 
good quality of seedling” (Translation by the author).281 He also points out that 
they have already created a “seed bank, thinking ahead when they [the 
research group] start working as such and need to make farms dedicated to the 
production of the drug” (Translation by the author).282  
 
This idea of eventually escalating the production of the Dividivi in Ricaurte 
necessarily required campesinos to cultivate the plant. Efforts are underway, 
which, in the words of Professor Fiorentino, involve selling to the campesinos 
the plant “for a representative value” which she estimates could vary between 
800 to 1000 pesos (approximately 0.30 USD) and “teach[ing] them to grow 
[the plant] so as to place it as hedgerow or to put it next to other crops and 
 
278 Original transcript in Spanish: “no había unos criterios de la toma de la semilla”. Interview with 
Javier Barnier, Agronomist Administrator and Entrepreneur,(Bogotá, Colombia, 1st October 2019) 
279 Original transcript in Spanish: “yo fui el primero en traer la tecnología de Francia para producir 
plántulas jóvenes con un material que es la turba, que es un material un extracto aséptico con unas 
características muy buenas”. Ibid.  
280 Mr. Barnier explains that the peat is “is a biological material for the decomposition of 
forests in northern and southern areas, such as Patagonia, Finland, Norway, the Baltic 
countries, Canada". Original transcript: “es un material biológico de descomposición de 
bosques de zonas nordicas y sureñas, como son la Patagonia, Finlandia, Noruega, países 
bálticos, Canada”. Ibid.  
281 Original transcript in Spanish: “producir plántulas en bandejas alveoladas como sustrato la Turba, 
es así como podemos reproducir y inclusive llegar hasta vender 20 millones de plántulas al año de 
tomate, y de la misma manera podríamos producir tanto el dividivi como el Anamú con muy buena 
calidad de plantulación”. Ibid.  
282 Original transcript in Spanish: “tenemos un banco de semillas pensando en el momento en que 
empiecen el medicamento a funcionar como tal y se necesiten hacer unas explotaciones dedicadas a la 
producción del medicamento”. Ibid. 
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everything, and gradually repopulate the Dividivi; and we would buy the 
material for now” (Translation by the author).283 Ideally, Professor Fiorentino 
aims to use blockchain, a technology that will permit that “as soon as a final 
product is sold, at once, the benefits are distributed to each of the members of 
the production chain” (Translation by the author).284 Although Fiorentino 
acknowledges that the use of blockchain is still hypothetical, due to difficulties 
in implementing the technology, she believes that by creating a production 
chain everyone would win, from the campesino to the final product seller.    
However, the interview data shows that the Javeriana research group have not 
defined the mechanism through which the community as such would benefit. 
This is because the research group filed and obtained a non-commercial set of 
mutually agreed terms with the Ministry of the Environment in 2013.285  
Hence they are not required by the national authority to set up benefit sharing 
with the communities, unless they actually commercialise a final product.  
Nonetheless, even they are not legally obliged to do so at this stage, the 
Javeriana group is currently working with the Ministry of Environment to 
secure benefits for the community of Ricaurte such as improving schools, land, 
or training programs on agricultural practices, in the event that a final product 
is commercialized. Again, therefore, a simplistic story of exploitation and 
creative compliance with a sub-optimal national legal regime which leaves 
communities’ rights under-protected is revealed to be more complex than it 
seems. 
 
In the light of this market-based perspective that mainly involves a 
“production chain”, it was important to ask Professor Fiorentino about 
potential risks and challenges to her proposed model of benefit sharing. 
 
283 Original transcript in Spanish: “enseñarles a cultivarlas para que pongan como cerca vivas, para 
que la pongan al lado de otros cultivos y todo, y poco a poco se vaya repoblando el Dividivi, y 
nosotros les compramos el material por ahora”. Interview with Professor Susana Fiorentino, Lead 
Researcher at the Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 
1st October 2019) 
284 Original transcrip in Spanish: “tan pronto se venda un producto final, de una vez se distribuyan los 
beneficios a cada uno de los miembros de la cadena productiva”. Ibid.  
285 See the mutually agreed terms at Ministerio de Medio Ambiente, ‘Contrato de Accesso a 
Recursos Genéticos y/o Productos Derivados Para Investigación Científica Sin Interes 
Comercial No. 60 Ministerio de Ambiente y Susana Fiorentina Gomez’ 8 
<https://drive.google.com/file/d/1I5wjzTjeS8VRGMs16LdEA 
agMIfEe542D/view> accessed June 5 2018.  
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Particularly, two questions were raised: (i) what would occur in the 
hypothetical case that the local community of Ricaurte would not accept the 
offer to participate in Fiorentino’s proposed model of production of the plant; 
and (ii) whether the upcoming of new technologies such as synthetic biology 
or gene editing could eventually lead to production directly from the actual 
genetic resources, leaving campesinos out of the production chain. As analysed 
in Chapter Two, one of the current issues in the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing is 
whether technologies that aim to reproduce in laboratories the functionalities 
of any genetic material would reduce the necessity to access the actual genetic 
resources and traditional knowledge.  
 
Regarding the first question, Professor Fiorentino and Mr. Barnier were rather 
skeptical and reluctant to even consider that campesinos would oppose 
growing the plant or participating in any benefit sharing agreement. Pressing 
on the question, they become rather pragmatic as they said: “don’t sell it, Peru 
sells it, that’s why we’ve already studied it” (Translation by the author).286 In 
fact, Peru, another member of the Andean Community, is the largest producer 
of the Dividivi in the world (Peruvians called Tara) for leatherworking. This 
means that the research group could easily, without breaching Decision 391, 
access the plant in a neighboring country in the event that their proposed 
model of production is not accepted by local Colombian communities.   
  
On the second question, Professor Fiorentino was confident that technologies 
such synthetic biology are rather allies than a threat to natural production. 
This is “because what synthetic biology does is to understand organisms from 
their complexity. With the dream of being able to reproduce” (Translation by 
the author).287 This is a dream that is far from fulfilled according to Fiorentino, 
but it “helps to understand how the disease acts in response to complex plants” 
 
286 Original transcript in Spanish: “no la vendan, Perú la vende, ya por eso nosotros la estudiamos” 
Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology Javeriana Research 
Group, Javeriana University (Bogotá, Colombia, 1st October 2019) 
287 Original transcript in Spanish: “la biología sintética al día de hoy es nuestro mejor aliado, porque 
lo que hace la biología sintética es entender los organismos desde su complejidad. Con el sueño de 
poder reproducir”. Ibid.  
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(Translation by the author).288 The reason why it is so important to understand 
the complexity of medicinal plants through new technologies such as synthetic 
biology is because as the plants is complex, diseases such as cancer are equally 
complex. This is the case of the Dividivi, whose therapeutic activity cannot be 
singularized to one specific molecule, and the cancer, whose symptoms and 
manifestation in the human body are not a single disorder. 
 
The research group has found that the plant has at least 150 molecules, and 
each of those molecules is in “a different concentration from the other” 
(Translation by the author),289 therefore, the research group always aim to get 
the same extract, hence the final medical product is always 150 molecules. This 
product has to be tested against cancer patients.  
 
Continuing with her example, Prof. Fiorentino explains patiently that, as there 
is an inherent complexity in the plant, “the synthetic biology for the sake of 
doing what the pharmaceutical industry is doing, which is mixing [different] 
molecules, [...] allows us to understand how the complexity of a plant can 
improve [and] return the balance to the cancer patient” (Translation by the 
author).290 She continues with her explanation as follows: 
 
From the patient with cancer is taken out plasma, take out his tumor 
cells, do a series of tests, to see together what he has; from there we 
will get a thousand data that we are going to put into a software, and 
we will take a molecular photo of that cancer patient and we will say: 
look at this photo is leaner towards red, green, has this spikes standing 
there, this is the photo of a patient with leukemia. Then we will give 
[the patient] the phytomedicine [from the Dividivi] that already has 
another complex photo and we will see what happens to it next. As [the 
patient] internal photo changes, and we will be able to differentiate 
 
288 Original transcript in Spanish: “ayuda a entender como la enfermedad actúa frente a plantas 
complejas”. Ibid.  
289 Original transcript in Spanish: “cada una esas moléculas esta a una concentración diferente de la 
otra , y siempre que obtenemos el extracto tenemos la misma foto”. Ibid.  
290 Original transcript in Spanish: “la biología sintética en aras de hacer lo que esta haciendo la 
industria farmacéutica que es mezclar [diferentes] moléculas (…) nos permite entender como la 
complejidad de una planta puede mejorar, volver al equilibrio al paciente de cáncer”. Ibid 
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the patients who improve with phytotherapy, from those that do not 
improve, and make groups of patients who respond to the 
phyto[theraphy], of patients who do not respond to phytotherapy, 
that's called personalized phytotherapy, and it’s part of a new 
discipline called network pharmacology.291 (Translation by the author) 
 
She concludes that, as result of this approach, synthetic biology gives great 
potential to everything because it has allowed “all that ancestral knowledge to 
be validated today” in medicinal plants. This means that new breakthrough 
technologies improve the use of those plants without eliminating the need to 
work with the actual biological material.  
 
The answer to those questions evidences that local researchers, who are 
already employing cutting edge technologies and scientific approaches such as 
network pharmacology, are meeting the current access to genetic resources 
and benefit sharing regulation in Colombia. The interview data indicates, as 
result, that the Ministry of Environment regulation (Regulation 1346) and 
Colombian policy in innovation have perhaps led to, or at the very least 
supported and encouraged, a market-based approach to the use of 
communities’ practices and knowledge on medicinal plants, singularizing the 
role of communities as only to grow the plant. In other words, although the 
research group recognised that the community provide insightful information 
on the anti-inflammatory properties of the plant, benefit sharing in Colombia 
follows a policy in innovation that does not consider communities’ uses – and 




291 Original transcript in Spanish: “El paciente con cáncer sacar  el plasma, sacar sus células 
tumorales, hacerle una serie de análisis, para ver en conjunto que tiene, de ahí vamos a obtener mil 
datos que vamos a meter en un software, y vamos a sacarle una foto molecular a ese paciente con 
cáncer y vamos decir: mire esta foto esta más inclinada hacia el rojo, el verde, tiene este picos para 
allá parados, esta es la foto de un paciente con leucemia. Luego le vamos a dar el fitomedicamento 
que ya tiene otra foto compleja y vamos a ver que le pasa después, como cambia su foto interna, y 
vamos a poder diferenciar los pacientes que se mejoran con la fitoterapia, de los que no se mejoran, y 
hacer grupos de pacientes que responden a la fito, de pacientes que no responden a la fitoterapia, eso 
se llama fitoterapia personalizada, y hace parte de una nueva disciplina que se llama farmacología de 
redes” Ibid.  
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Yet, the difficulties in regulating the technological, economic, political and 
ethnobotanic complexities surrounding medicinal plants such as the Dividivi 
concern legal protections beyond Colombia’s access to genetic resources and 
benefit sharing law in Colombia. Patents are also a controversial legal field for 
communities, authorities and local researchers. As analyzed in Chapters 2 and 
3, if a patent application contains information related to genetic resources, 
applicants must disclose such an information according to Decision 486 of the 
Andean Community, the current patent law in Colombia. This legal obligation 
that seems to be clear, in practice falls short in terms of regulating all aspects 
in a complex scientific scenario. The patent granted to the Javeriana group 
over the derivate products of the Divididi illustrates this problematic issue.  
 
As the research group succeeded in demonstrating the effectiveness of the 
combination of gallic acids derived from the Dividivi for the treatment of 
cancer, it filed for a patent in the offices of Colombia, the US, and Canada. The 
first two have already granted to the researchers a patent in the combination 
of acid gallic.292. Yet, the research group did not disclose in any of those patent 
applications that the native plant and local communities played any role in the 
invention. Professor Fiorentino was asked to amplify the reason why they did 
not disclose the origin of the gallic acid in the patent. In her answer, she 
illustrates how different was her invention from the natural product as follows:  
 
Within the compounds of the Dividivi that we have identified are gallic 
acid, and derivatives of the gallic acid, which are in a particular 
concentration each. So it’s not that I take the gallic acid and reproduce 
 
292 The patent was granted in the US in 2018 ( Castañeda and others (n 256); Sandoval and 
others (n 258).) and Colombia in 2015 (Susana Florentino and others, ‘Combination of 
Compounds Derived from Gallic Acid for the Treatment of Cancer’ 
<https://patentimages.storage.googleapis.com/ba/da/81/a5a8e2b6ecc 
fa8/US9931355.pdf> accessed May 3 2018.) and it is pending in Canada (Susana Florentino 
and others, ‘Composición Farmacéutica Que Comprende Derivados Del Ácido Gálico’ 
<http://sipi.sic.gov.co/sipi/Extra/IP/Mutual/Browse.aspx?sid=636609526483865264> 
accessed May 3 2018.) There is also an international patent application via PCT (Susana 
Florentino and others, ‘Combination of Compounds Derived from Gallic Acid for the 
Treatment of Cancer’ <http://brevets-patents.ic.gc.ca/opic-
cipo/cpd/eng/patent/2884784/summary.html> accessed May 3 2018.); see also Carolina 
Gómez Pulido, ‘Patente Javeriana En Lucha Contra El Cáncer’ (Pesquisa Javeriana, 2018) 
<http://www.javeriana.edu.co/pesquisa/patente-javeriana-en-lucha-contra-el-cancer-2/> 
accessed May 3 2018.   
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the activity of the Dividivi, because we have done it. The gallic acid has 
to be in a concentration, attached to the ethyl gallate, to the 
pentagaloil glucosa, and it is that mixture that has the activity [to treat 
cancer]. And that's why the patent has all the possible blends that at 
that time came to mind that could have activity and were based on our 
results, and on the characterization of the extract.(Translation by the 
author)293 
 
In other words, the patent was not over the natural activity of the Dividivi 
itself, but it was rather the research group’s own combination of the Dividivi 
compounds that produces the activity which it is hoped will be able to treat 
cancer. This means that, despite the fact that the research group recognised 
the ethnobotanic origins of the Dividivi and how local knowledge of the plant 
led to the extraction of a bioactive component of a native plant, they did not 
consider that the role of local communities in leading users to discover the 
therapeutic activity of the Dividivi was relevant to include in a patent 
application because the patent was granted over an activity and product made 
in the laboratory. 
 
Against this background, the members of the research group were asked 
whether it was possible to foresee a future in which communities should have 
a more prominent role in research and development in order to pursue a more 
inclusive and sustainable model of innovation in medicinal plants. The 
research group declared themselves open to considering such an agenda. For 
instance, Mr. Olaya considered that further discussion and dialogue was 
necessary, so as to have a better understanding of the role of communities in 
research and development as he says: “we will have to sit down with 
anthropological work with human science professionals and be able to 
 
293 Original transcript in Spanish: “Dentro de los compuestos del dividivi que hemos identificado son 
acido gálico, y derivados del acido gálico, que están en una concentración particular cada uno. 
Entonces no es que yo coja el acido gálico y reproduzca la actividad del dividivi, porque nosotros lo 
hemos hecho. El acido gálico tiene que estar en una concentración, unido al etil galato, al metil galato, 
a la pentagaloil glucosa, y es esa mezcla la que tiene la actividad. Y por eso la patente tiene todas las 
posibles mezclas que en ese momento se nos ocurrieron que podían tener actividad y estaban basadas 
en nuestros resultados, y en la caracterización del extracto.” Interview with Professor Susana 
Fiorentino, Lead Researcher at the Immunology Javeriana Research Group, Javeriana University 
(Bogotá, Colombia, 1st October 2019) 
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establish that it is the best thing that can be done for [the] community that 
established that knowledge” (Translation by the author).294 Meanwhile, 
Professor Fiorentino was more emphatic, in her demand for the Ministry of 
Environment to play a leading role in setting up a credible framework in which 
the Ministry carries out public consultation with indigenous and Afro-
Colombian communities, as well as assuming the responsibility for the whole 
process.295 So, at least if we take these statements at face value, the local 
researchers are aware of the socio-economic dynamics of their work, and the 
broader contexts for local, indigenous and Afro-Colombian communities.  The 
Javeriana research group distinguish local communities from indigenous and 
Afro-Colombian communities, which is consistent with at least some of the 
regulatory environment in which they operate. Their self-understanding is 
that their activities are not only compliant with relevant legal obligations, but 
also consistent with seeking a fair recognition of the contribution of those 
communities with whom they interact in their work. Part of the reason for their 
beliefs and understandings is a notion of innovation that privileges their 
‘scientific’ work as innovative, and treats communities’ knowledge and uses as 
mere prompts or ‘leads’ for the value-added innovation that they – the local 




The Dividivi is not the only plant whose medicinal properties the research 
group from Javeriana University are investigating. As a matter of fact, one of 
the first plants that Professor Fiorentioni analysed to find therapeutic activity 
against cancer was the Anamú (Petiveria alliacea). Based upon previous 
ethnobotanical studies that identify that the plant had been employed in “folk 
medicine” in Tropical and Central America as antispasmodic, antirheumatic, 
 
294 Original transcript in Spanish: “tendremos que sentarnos con un trabajo antropológico con 
profesionales de las ciencias humanas y poder establecer que es lo mejor que se puede hacer por esa 
comunidad que estableció ese conocimiento”. Interview with Wilmar Olaya, Agriculture Engineer 
and Regulatory expert at the Immunology Javeriana Research Group, Javeriana University (Bogotá, 
Colombia, 19th September 2019) 
295 Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology Javeriana 
Research Group, Javeriana University (Bogotá, Colombia, 1st October 2019) 
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anti-inflammatory, antinociceptive, hypoglycaemia, and abortifacient,296 
Professor Fiorentino began her journey in researching medicinal plants.  
 
The Anamú was not only a plant that scientifically interested Fiorentino as a 
professional researcher, but it was also a plant that had had a profound impact 
in her personal life. Fiorentino recounts that, although she wanted to return to 
France, where she obtained her PhD, she was bounded by her scholarship 
which demanded that she work in Colombia when her studies were completed. 
Consequently, she tried to find a way in which she could work 0n a topic that 
was interesting to her (i.e. cancer) in both countries (France and Colombia), 
as well as in combination with her husband’s business activities in France and 
Colombia.297 Those circumstances led her to the study of medicinal plants to 
treat cancer, including the Anamú.  
 
That decision led Professor Fiorentino to face skepticism from colleagues at 
that time and to deal with the ever-changing legal landscape on access to 
genetic resources and benefit sharing in the country. On the first issue, Dr. 
Claudia Urueña points out the difficulties that Professor Fiorentino underwent 
with colleagues at that time: “the criticism was that why an immunologist 
(Fiorentino) was playing with nuances [plants]”.298 In this regard, Olaya 
remembers that colleagues accused Fiorentino of doing something that “was 
not science” and mocked her saying that she was “becoming a yerbatera299”.  
Yerbatera means a seller of plants in urban marketplaces. For scientists, it is 
a derogatory terminology, implying lack of professionalism. However, the 
research group is nowadays very optimistic and proud of what Professor 
Fiorentino and her colleagues have accomplished in Colombia. As an example, 
 
296 Those previous studies are documented by the research group in Claudia Urueña and 
others, ‘Petiveria Alliacea Extracts Uses Multiple Mechanisms to Inhibit Growth of Human 
and Mouse Tumoral Cells’ (2008) 8 BMC complementary and alternative medicine 60. 
297Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology Javeriana 
Research Group, Javeriana University (Bogotá, Colombia, 1st October 2019) 
298 Original transcript in Spanish: la critica era que una inmunóloga que se va a poner a jugar con 
maticas, era la critica de la comunidad científica. Interview with Claudia Urueña, Researcher at the 
Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 19th September 
2019) 
299 Interview with Wilmar Olaya, Agriculture Engineer and Regulatory expert at the 
Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 19th 
September 2019) 
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Urueña points out that they are already very well known and respected in 
Colombia as some of their plant extracts, including the Anamú, have been 
taken forward for clinical trials making them the first Colombia research 
initiative to have reached that stage in the drug development process.300    
Regarding meeting Colombia regulation on access to genetic resources, 
Fiorentino points out that, as she pioneered the study of medicinal plants in 
Colombia, she has witnessed the transformation of the regulation from a very 
strict regulation with low administrative capacity to enforce it, towards a more 
open and pro-research legislation.  Her account suggests that she sought to 
comply with legal requirements at all stages, but that practical matters 
impeded this desire for regulatory compliance. 
 
For instance, when Fiorentino applied for the first time for non-commercial 
mutually agreed terms on the Anamú, she faced the lack of capacity of the 
Ministry in approaching this issue at the time when the implementation of 
Decision 391 in Colombia was very strict. As mentioned above, different 
ethnobotanic research indicates that the Anamú is a plant used in various 
regions in the world by different communities, meaning the plant was not a 
native Colombian plant. However, although Fiorentino tried to explain to the 
Ministry that “the Anamú had a wide distribution” in different geographical 
locations outside Colombia, hence, it would not be necessary to apply for 
mutually agreed terms, the Ministry claimed, according to Fiorentino, that 
“the rule does not clearly say whether the plant was identified here [in 
Colombia] or not, the fact is that it is endemic here” (Translation by the 
author).301 In other words, despite the fact that there are published papers that 
proved that the plant was not native only to Colombia, the Ministry considered 
that it was, solely because it grows in the country  
 
 
300 Interview with Claudia Urueña, Researcher at the Immunology Javeriana Research Group, 
Javeriana University (Bogotá, Colombia, 19th September 2019) 
301 Original transcript in Spanish: “La norma no dice claramente si la planta fue identificada acá [en 
Colombia] o no, el hecho es que se encuentra de manera endémica acá” Interview with Professor Susana 
Fiorentino, Lead Researcher at the Immunology Javeriana Research Group, Javeriana University 
(Bogotá, Colombia, 1st October 2019)  
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As the Javeriana research group was able to obtain non-commercial mutually 
agreed terms,302 it continued its investigation to synthesise the plant’s 
therapeutic compounds. This process mainly involved drying the plant, 
putting it in ethanol, and mixing it with different solvents in order to extract 
its compounds. Proceeding thus, the research group obtained several 
extracts.303 Once the extracts were obtained, the group was able to detect the 
anti-tumoral activity of those extracts. Consequently, the relevant biological 
material was sent to Europe, where the French Institute of Natural Products 
identified the characteristics of the compounds with the aim of purifying them 
and transforming them into pharmaceuticals to treat cancers such as breast 
cancer and leukaemia.304 Finally, the research group filed and obtained 
patents in Colombia, Brazil, Canada, US, and Europe over the extracts, the 
compounds, the pharmaceutical combinations and the method for sequential 
administration of the different pharmaceutical combinations.305  
 
Years later, as Colombia changed its policy towards local researchers and 
innovation in order to facilitate their access to genetic resources, the Javeriana 
research group obtained prior informed consent from the Ministry of the 
Environment and reached mutually agreed terms with this ministry in 2018 to 
establish a “supply chain of the Petiveria alliacea”. A closer look at the official 
documents from the ministry evidences that this set of mutually agreed terms 
replicated the model of production that Professor Fiorentino and Mr. Barnier 
proposed in the case of the Dividivi, in which local communities grow and 
harvest the plant to hand it to laboratories to have the bioactive component 
 
302 Dirección de Bosques Servicios Ecosistémicos y Biodiversidad-Ministerio de Medio 
Ambiente (n 220). File Number: REG 0053 
303 Carolina Navarro, ‘El Anamú, La Inmulogía y El Cáncer’ [2008] Pesquisa Javeriana 
<https://www.javeriana.edu.co/pesquisa/wp-content/uploads/pesquisa08_02.pdf>. , p 6 
304 ibid.  
305 Susana Fiorentino Gomez and others, ‘Fracción Bioactiva de Petiveria Alliacea, 
Composición Farmacéutica Que Contiene La Misma y Combinación Con Inmunoestimulantes 
Para Tratar El Cáncer CO6270030 (A1)’; Susana Fiorentino Gomez and others, ‘Bioactive 
Fraction of Petiveria Alliacea, Pharmaceutical Composition Containing Same, and 
Combination with Immunostimulants for Treating Cancer CA2776446’; Susana Fiorentino 
Gomez and others, ‘Bioactive Fraction of Petiveria Alliacea, Pharmaceutical Composition 
Containing Same, and Combination with Immunostimulants for Treating Cancer EP2522356 
(A2)’; Susana Fiorentino Gomez and others, ‘Bioactive Fraction of Petiveria Alliacea, 
Pharmaceutical Composition Containing Same, and Combination with Immunostimulants for 
Treating Cancer US8734863B2’; Susana Fiorentino Gomez and others, ‘Bioactive Fraction of 
Petiveria Alliacea, Pharmaceutical Composition Containing Same, and Combination with 
Immunostimulants for Treating Cancer BR112012009362 (A2)’.  
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extracted.306 In other words, the contribution of the relevant communities is 
conceptualised and restricted to merely growing the plant. These communities 
are not included in the innovation process or other benefits such as the 
potential commercial benefits of the patents. Again the interview data offers 
an insight into the views of the local research group: in their self-estimation, 
they sought legal compliance at all times, even when the regulatory 
environment seemed illogical and unnecessarily strict to them. 
 
Lessons from the Dividivi and the Anamú 
 
As has been observed in both cases, the Javeriana research group employed a 
similar approach, which can be summarised as follows: The research group 
accessed plants which have been previously documented by ethnobotanical 
research; it synthetised the product; it found that practices and knowledge of 
communities are not relevant for research and development; it filed and 
obtained patents globally without disclosing information regarding mutually 
agreed terms and without carrying out public consultation; and finally, it 
aimed and aims to establish a model of production in which communities are 
restricted to growing, harvesting and handing the plant over to laboratories.  
 
Such an approach clearly goes in line with the Colombian central government 
policy and regulation on encouraging local researchers to easily access genetic 
resources and traditional knowledge; despite the fact that this would 
contradict the mandates of Decision 391 and the Constitutional Court on 
safeguarding communities’ practices and knowledge. Further, this approach 
has been praised by public opinion. For instance, the media is eager to publicly 
reward the group as an example of how Colombia should exploit its 
biodiversity.307  
 
306 Resolución 1471 de 2018 por la cual se otorga el Acceso a Recursos Genéticos y Productos 
Dericados para el Proyecto Denominado: Establecimiento de la Cadena de Abastecimiento de 
Petiveria alliacea dentro de una cadena de aprovechamiento sostenible para la 2018. 
307 For instance, two of the largest media groups in the country, El Espectador and Semana, 
has praised the research group for its milestones, see: El Espectador, ‘Descubren Compuestos 
Activos En Plantas Para Aliviar El Cáncer’ El Espectador (Bogotá, 10 February 2009) 
<www.elespectador.com/noticias/salud/articulo116699-descubren-compuestos-activos-
plantas-aliviar-el-cancer>; Semana, ‘Fitomedicamentos Contra El Cáncer: Superando El 
“Valle de La Muerte”’ Semana Sostenible (Bogotá, 15 September 2015) 
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Furthermore, via its institutional sponsor Javeriana University, this research 
group has been granted more than USD 6m to expand its research focus on 
other native plants and to establish a similar business model to that of the 
Dividivi and Anamú cases.308 Also, this research group is the leading 
institution behind the multimillion dollar investment of PhairiLab in Bogotá, 
which aims to create infrastructure for bioprospecting Colombian natural 
products for health research and health industry in the near future.309 
  
Although both examples could have served as cases of how the understanding 
of biodiversity from local communities actually adds to the industrial 
application of natural products, the legal treatment given to genetic resources 
and to the knowledge of those communities raises important questions about 
whether Colombian policy of innovation is inclusive, so as to recognise without 
discriminating any contribution to research and development from all 
communities, including local, indigenous and Afro-Colombian communities, 
and whether the government is actually eager to enforce communities’ rights 
in the light of the obligations of Decision 391 and constitutional mandates. 
This confirms how different interests clash in the use of medicinal plants: 
while local researchers have created lawful models of carrying out R&D and 
business in the use of medicinal plants to adjust to the Ministry of 
Environment regulation, constitutional and Andean (Decision 391) 
obligations on the protection of communities’ practices and knowledge are not 





308 Pontifica Universidad Javeriana, ‘Proyectos Javerianos En Colombia Científica’ (2018) 
<http://www.javeriana.edu.co/noticias/noticias?aID=9635872&tID=22767#.W0alk9IzqUk
> accessed 12 July 2018. There is also official documents from the Colombian Patent Office 
and Colciencias which celebrates this research group approach, see Colciencias, ‘Susana 
Fiorentino y Las Plantas Contra El Cáncer’ (Hablemos de Ciencia Todo el Tiempo, 2018) 
<http://www.todoesciencia.gov.co/susana-fiorentino> accessed 10 November 2018; Centro 
de Información Tecnológica y Apoyo a la Gestión de la Propiedad Industrial-CIGEPI, ‘Boletín 
Tecnológico: Productos Fitoterapéuticos’ (2015) <www.commons.wikimedia.org> accessed 
November 10 2018. 
309 Secretaría de Planeación de Bogotá, ‘Implementación de La Plataforma Científica y 
Tecnológica Para La Obtención de Fitomedicamentos Antitumorales Con Estándares 
Internacionales Bogotá D.C.| Regalias Bogota’ (Regalía Bogotá Región e Innovación, 2018).  
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Furthermore, there are difficulties in creating a meaningful dialogue and 
establishing interlocutors between ethnic communities and local researchers, 
as the empirical data on Afro-Colombians in Choco and indigenous 
communities in the Valle del Sibundoy illustrates. The interview with the lead 
researcher of the Javeriana Group suggests that those ethnic communities are 
not interested in a dialogue, but rather they are interested in a straightforward 
transaction. If accurate, this means that the way that those communities 
approach benefit sharing is exclusively in monetary terms; as a result, those 
communities are content with the fact that users who are willing to pay the 
price asked would be able to take their knowledge and practices upstream 
without including them in the innovation process. This is a call to observe in a 
different perspective how the International Regime on Access to Genetic 
Resources should be implemented in practice, because it is not only about 
driving resources into communities to secure benefit sharing, but also about 
finding mechanisms to create a dialogue in which users of genetic resources, 
such as local researchers, and holders of practices and knowledge could 
advance together to transform those resources into well-being for their own 
communities.  
Although the case of the Dividivi indicates that a local community of peasants 
has not actively been considered in the construction of the production chain 
of the Javeriana research group, it has been possible to initiate a dialogue in 
which local researchers are approaching the community with technology and 
promises of growing the plant for potential industrial uses so as to create a 
sustainable business with them. However, aspects such as prior informed 
consent and public consultation on how benefit sharing can take place still 
need to be addressed.  
On Colombian innovation policy, the previous sections highlighted that the 
country’s science bureau, Colciencias, has adopted the OECD’s Oslo Manual 
entirely. As a result, the concept of innovation, and the way it is measured and 
evaluated, respond to an international market perspective. In brief, the Oslo 
Manual considers as innovative research and development activities from 
well-placed sectors in markets. Therefore, it does not come as a surprise that 
the government has addressed public resources to bioprospecting initiatives 
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such as the Javeriana University projects (i.e. Dividivi, Anamú, and PhairiLab) 
without requiring Javeriana University to recognise and share the benefits 
with communities beforehand. 
 
Such a fragmentation in the state structure is also reflected in enforcing 
communities’ rights. Chapter Three points out how Decision 391, which is part 
of the Colombian legal system, and the constitution, recognise as pivotal that 
state agents enforce communities’ rights, particularly public consultation, 
when their cultural, social, and economic values are at stake. The fact that 
Colciencias does not enforce, nor acknowledge, communities’ practices and 
knowledge in its innovation policy, or in addressing funding to local research, 
contradicts the Colombian legal system of protection for fundamental rights.  
 
Yet, the cases of the Dividivi and Anamú also illustrate that other 
governmental agencies such as the Ministry of the Environment and the 
Colombian patent office have turned a blind eye on enforcing Decision 391 and 
constitutional mandates. On the former, the Ministry of the Environment 
Resolution 1348 does not request that public consultation is carried out with 
local communities such as the campesinos in the Ricaurte, despite the fact that 
Decision 391 required so. This has created a bias on what communities are, 
leading local researchers to distinguish those groups depending on their ethnic 
background.  Also, the Colombian patent office did not demand that the local 
university disclose all information regarding the use of the countries’ 
biodiversity and communities’ practice and knowledge in the patent 
application as mandated by Decision 391 and Decision 486. But the lack of 
enforceability in the case of the Dividivi has also an international connotation 
as the research group has already filled and obtained patents over the 
combination of gallic acids in Canada and the US, without fulfilling the Andean 
and Colombian requirements. 
 
Ideally, the Colombian authorities should have approached matters differently 
in situations such as the case of the Dividivi. For instance, Colciencias should 
include within its innovation policy the contribution from communities in 
research activities that involves the use of biodiversity. It should also demand 
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that recipients of public funds consult communities if their practice and 
knowledge associated with genetic resources are involved. Also, although this 
would potentially involve an extra burden on local researchers, in both cases, 
Javeriana University was well aware of the relationship between the plants and 
local communities.  Yet the interviews reveal that the research group is open 
to constructing potential dialogue with communities. However, it remains a 
priority for the research group to include campesinos in its market based 
approach in which local communities are invited to grow the plants as a raw 
material to be extracted and synthesised in laboratories.  
 
Regarding the lack of enforceability, there is a paradox. Although the 
government has acted to correct the fragmented structure of the state 
regarding access rules and, even, the granting of patents on inventions derived 
from genetic resources, those administrative changes have mainly addressed 
concerns from local researchers such as universities and research groups. This 
means authorities such as the Ministry of the Environment and the Colombian 
patent office should have enforced communities’ fundamental rights. For 
instance, the Colombian patent office should have at least requested further 
information on the inventions that derive from the use of the plants to define 
how relevant communities’ knowledge and practice was in the discovery of the 
medical properties of the plants. This is especially the case if there are 
published ethnobotanic research papers that attest to the link between the 
plant and communities.310 As the Colombian patent office did not require this 
to happen, it is hard to consider how to demand other patent offices comply 
with rules of another jurisdiction. This is particularly so because the 
Colombian patent office shares information with different patent offices on 
 
310 As it was studied in Chapter Three, any patent applicant should disclose all relevant aspects 
to carry out the invention to obtain a patent. In the case of invention that employ genetic 
resources and traditional knowledge associated with those resources, the Andean patent 
legislation, Decision 486, also requires that the patent applicant disclose all information 
regarding the origin of the genetic resources and also enclose within the patent the mutually 
agreed terms reached with the ministry. In any time during the granting process of the patent, 
the Colombian patent office is obliged to request patent applications such if there are evidence 
that the invention is based upon genetic resources and traditional knowledge (see Articles, 26 
(h), 75 (g) and 275 of the Decision 486).  
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patent requirements, including the US Patent and Trade Mark Office and the 
European Patent Office according to international cooperation treaties.311  
 
It is also fundamental that the Ministry of the Environment works to create a 
dialogue between communities and local researchers not only to avoid that 
research centres such as Fiorentino’s laboratory drops projects like those in 
Putumayo and Choco, but also to build trust and long-term relationships 
between those actors. It is also valuable that the Ministry takes the lead in 
accompanying public consultation processes with communities so as to secure 
those communities’ rights and to encourage research and development in 
medicinal plants in Colombia. 
 
Both cases illustrate how the implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing in Colombia is weighted too 
much in favour of local researchers. This means that Colombia is placing the 
knowledge and practices of communities into the public domain to the point 
that those communities do not have even the possibility of being asked 
whether their practices, uses and knowledge should be employed in research 
and development activities undertaken by local researchers.  
 
On the contrary, the government, the university and the research group have 
not taken into account communities’ practices and knowledge as a key aspect 
in research and development in medicinal plants. This reflects the 
governmental policy that assumes that innovation, including in the use of 
 
311 There is the Patent Cooperation Treaty (PCT) (Patent Cooperation Treaty, 1970, 
Washington, as in force from April 1, 2000) which seeks to provide the basis for a common 
procedure in each Signatory State, including the share of information on patent requirements. 
There is also The Patent Prosecution Highway (PPH) which can be either a bilateral or a 
multilateral treaty which allow patent applicants to accelerate the patentability examination 
in patent offices of other signatures states. Colombia has celebrated 5 bilateral PPH with 
Spain, USPTO, EPO, Japanese Patent Office and Korean Patent office. Colombia is also part 
of different multilateral PPH such as PROSUR ((Brazil, Ecuador, Peru, Chile, Colombia, 
Uruguay, Argentina, Paraguay) and the Pacific Alliance (Mexico, Peru, Colombia and Chile). 
It is important to mention that despite the fact that the PCT and PPH do not establish rules 
on genetic resources and traditional knowledge as it occurs in Decision 486, the Colombian 
patent office through the examination report of the requirements of any invention can inform 
other patent office of the existence of traditional knowledge associated with genetic resources 




biodiversity, only originates from holders of technology such as local 
researchers, and not from Colombia’s communities. Such an unbalanced 
approach towards what can be considered innovative marginalises those 
communities’ traditional knowledge and practices. The lack of enforceability 
by the government on Colombian protection of communities’ rights and the 
access and benefit sharing rules, as well as an unbalanced approach in 




The evolution of the International Regime on Access to Genetic Resources and 
Benefit Sharing and innovation policies in Colombia demonstrates that the 
country has gone from a strict policy that sought to counterbalance 
technological disparity by trading-off genetic resource with technology, 
towards a policy which centres on encouraging local researchers to employ 
Colombia’s growing research and development capability on genetic resources 
to develop products and processes. However, such a transformation has 
always had an underlying assumption that considers that holders of 
technology are only those who are able to access genetic resources and to 
contribute with the understanding of biodiversity in specific sectors, and 
potentially to commercialise products and processes that derive from the 
utilisation of genetic resources. This view also fits within the commercial 
practice of local researchers in obtaining patents over the results of those 
research activities, with the aim of commercialising to upstream users. This is 
a common assumption that stems from the different developments that led to 
the establishment of the International Regime on Access to Genetic Resources 
and Benefit Sharing in Colombia, the assumption being that biodiversity is a 
pool of genetic resources that requires scientific and technical expertise to 
make the availability of such resources valuable.  
 
Therefore, the current policy in Colombia focuses primarily on supporting 
local researchers. The policy has achieved significant milestones, such as 
increasing expenditure in research and development, the use of cutting-edge 
technologies such as synthetic biology to understand the inherent complexity 
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of medicinal plants and knowledge associated with genetic resources, and 
leading local researchers to obtain mutually agreed terms. However, it should 
be considered only a first step in creating a coherent policy on genetic 
resources which requires inclusion of indigenous, local, and Afro-Colombian 
communities as well as demanding authorities to enforce communities’ rights 
and access and benefit sharing rules. As a result, it is important to answer the 
question of how to acknowledge and safeguard the contribution that those 
communities, through their practices and knowledge, provide for biomedical 
health research and related industries.  
 
However, before this thesis suggests legal mechanisms through which 
communities’ contribution could be acknowledged, it is also important to 
discuss another key actor who has also benefited from recent regulation easing 
the access and benefit sharing regulation in the country: The herbal industry. 
Therefore, Chapter Five discusses in detail how this growing industry 
interacts, benefits, and fails to acknowledge indigenous, local, and Afro-
Colombian communities’ role in the industrial application of medicinal plants 
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Chapter Five: Communities’ Traditional Knowledge and 





Chapter Four discussed how local researchers, particularly publicly funded 
researchers in universities, have taken a prominent role in the use of genetic 
resources for health research and the health industry in Colombia. This 
includes not only genetic resources, but also genetic resources associated with 
traditional knowledge. These practices arose as a result of Colombian 
government efforts to employ genetic resources and traditional knowledge as 
key aspects in its innovation policy. As a result, Colombia has encouraged local 
researchers to actively carry out research and development (R&D) into those 
resources for health research and the health industry.  
 
However, indigenous, local, and Afro-Colombian communities’ practices and 
knowledge are not regarded as R&D activities. Certainly, Colombia only 
considers that R&D activities take place in industries such as the internet, 
biotechnology, or pharmaceuticals. Therefore, communities’ understanding of 
Colombia’s biodiversity has been taken into the public domain to facilitate 
local researchers’ R&D activities. The data collected in Chapter Four illustrates 
that there is also a great difficulty to create a meaningful dialogue between 
local researchers and ethnic communities (i.e. Afro-Colombian and 
indigenous communities) as the former usually expects a long-term 
relationship, while the latter aims for a short-term relationship, in which they 
obtained upfront payment for the access to their knowledge. Chapter Four also 
highlights that this situation is even more critical for local (non-ethnic) 
communities such as peasants as the Ministry of Environment and Ministry of 
State’s regulations do not require prior informed consent to users, including 
local researchers, to access to the practices and knowledge of local (non-
ethnic) communities.  
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This has occurred despite the fact that Colombia has adopted compromises to 
safeguard and protect those communities’ contribution to health research and 
health industry at the international, regional and national level, including the 
International Access and Benefit Sharing Regime, and the Andean access and 
benefit sharing regulation (Decision 391 of 1997) and the Colombian 
Constitutional Court rulings (see Chapters Two and Three). Such a situation is 
even more critical as publicly funded researchers are accessing genetic 
resources associated with practices and knowledge without publicly consulting 
the communities who hold that knowledge (i.e. without prior informed 
consent).  
 
This evidences a fragmented state in which the government acts in several 
directions as it pursues different interests which might run against each other. 
In the particular case of local researchers and communities’ rights, on the one 
hand, the Andean Community, in which Colombia is a member, and the 
Constitutional Court, seek to ensure that Colombian authorities enforce the 
rights, including prior informed consent, that local, Afro-Colombian and 
indigenous communities have over their knowledge and practice related to 
genetic resources.  
 
On the other hand, the country aims to advance in terms of capacity building 
and encouraging innovation in the use of biodiversity for health research in 
order to make Colombia more competitive in international markets; yet local 
authorities do not enforce communities’ rights, especially the protection of 
their knowledge over genetic resources. As a result, authorities such as the 
Ministry of the Environment, Colciencias, the science and technological 
bureau, and the Colombian patent office have turned a blind eye in enforcing 
Colombia’s access and benefit sharing regulation and constitutional mandates, 
so as to encourage local researchers to carry out bioprospecting activities. For 
instance, the Andean Community regulation and the Constitutional Court 
decisions do not establish divisions between ethnic (Afro-Colombia and 
Indigenous) and non-ethnic communities (e.g. peasants), while the regulation 
of the Ministry of Environment does; a situation that has led local researches 
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to work with plants that are located in areas where there is no presence of 
indigenous and Afro-Colombian communities.   
 
The state fragmentation in implementing and enforcing the rights of 
communities over their practices and knowledge in their use for health 
research is not the only enduring problem in respect of the protection of 
communities’ rights over their practices and knowledge. There are also 
important aspects to consider in the herbal medicine industry, which involves 
the use of medicinal plants, and communities’ practices and knowledge in 
fabricating and distributing therapeutic medicinal products. Although 
medicinal plants have been employed in different cultures and civilizations 
since ancient times,312 herbal medicine has become a crossroad of a wide range 
of issues that include public health, cultural identity and sustainable 
development. For instance, the poorest populations in developing countries 
employ medicinal plants not only because they are cheaper than conventional 
chemically synthetized medicines, but also because they might be the only 
available medical treatments in remote areas.313 That is why the World Health 
Organization (WHO) has stated that herbal medicine is a key aspect in public 
health, since 80% of the world population relies upon them.314 Also, in 
developed countries, herbal medicine has become popular in treating minor 
ailments and a cost-effective alternative for personal health.315  
 
 
312 For instance, Chinese have employed for centuries Artemisinin (sweet wormwood, annual 
wormwood) to treat fever and malaria, which significance remains nowadays as the World 
Health Organization has recommended to employed in combination with other anti-malaria 
synthetic therapies (i.e. the Artemisinin Combination Therapy (ACT)). ACT combines 
Artemisinin and Lumefantrine, another anti-malaria treatment; Klayman points out that the 
first mentions of Artemisinin medical properties are in the Recipes for 52 Kinds of Diseases 
which was found in a Mawandgdui Han Dinasty´s tomb from 168 B.C., but modern interest in 
this plant began in 1967 when the Chinese government made efforts to carry out a systematic 
review of Chinese medicinal plants; for a summary of Artemisinin medical evolution see DL 
Klayman, ‘Qinghaosu (Artemisinin): An Antimalarial Drug from China.’ (1985) 228 Science 
(New York, N.Y.) 1049., see also WHO, Global Plan for Artemisinin Resistance Containment 
(WHO, 2011)  
313 Nahla S Abdel-Azim and others, ‘Egyptian Herbal Drug Industry: Challenges and Future 
Prospects’ (2011) 5 Res J Med Plant 136. 
314 WHO, ‘WHO Guidelines: Developing Information on Proper Use of Traditional, 
Complementary and Alternative Medicine’ (2004) 
<http://apps.who.int/medicinedocs/pdf/s5525e/s5525e.pdf>. 
315 Abdel-Azim and others (n 313)., pp 136-137 
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As a result, a significant market for the use of medicinal plants, including 
phytomedicines, has emerged worldwide. In brief, phytomedicines are 
bioactive natural products that have pharmacological action and are derived 
from medicinal plants. Further, the production and distribution of herbal 
medicines has raised the interest of developing countries as a model of 
sustainable development.316  
 
However, herbal medicines also raise significant regulatory challenges when it 
comes to communities’ practices and knowledge over medicinal plants. 
Through this chapter, it is shown that there are two aspects of medicinal plants 
in Colombia that should be addressed to secure a more inclusive herbal 
industry. First, as the production and distribution of phytomedicines is 
presented as a model of sustainable development, i.e. the sustainable use of 
biodiversity for industrial application, the Colombian authorities have created 
a regulatory framework that aims to facilitate the granting process of 
marketing authorization for what is called traditional phytomedicines or 
traditional phytotherapeutic product (See Chapter Three). In particular, it has 
been allowed to document the therapeutic effect of those pharmaceutical 
products through traditional knowledge of indigenous, local, and Afro-
Colombian communities or proving that the medicinal plants have been used 
for more than three generations in Colombia. The documentation of those 
practices and knowledge has been carried out in, for instance, urban 
marketplaces. These places are where different stakeholders, including the 
herbal industry, can access genetic resources and the knowledge related to 
therapeutic effect of those resources; knowledge that is transformed, traded 
and transmitted by plant sellers or Yerbateros in urban markets.  That 
therapeutic effect would otherwise have to be demonstrated by expensive and 
time-consuming clinical trials.  
 
Despite the fact that the herbal industry is allowed to employ communities’ 
traditional knowledge to fulfil regulatory requirements in marketing 
 
316 See for instance Philippines’ blueprint on herbal medicines and sustainability: Hilton Y 
Lam and others, ‘Establishing a Blueprint for Nature-Based Products Development and 
Conservation for the Philippines’ (2018) 52 Acta Medica Philippina 296. 
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approvals, this industry is not required to comply with access and benefit 
sharing rules such as obtaining prior informed consent and signing up to 
mutually agreed terms with the government, as well as publicly consulting 
communities to produce and commercialize phytomedicines (see Chapter 
Two). However, the interest in promoting sustainable business is not the only 
reason why the herbal industry is not required to comply with the 
International Regime on Access to Genetic Resources and Benefit Sharing. It 
is also because the implementation of this regime, as discussed in Chapters 
Two and Four, was constructed to secure transfer of technology from 
multinational companies that transform genetic resources into synthetized 
process or products, but not to “less technological” sectors such as the herbal 
medicine industry. Yet, the implementation of this international regime in 
Colombia did not anticipate that it has not been large companies that employ 
those resources for health research and health industry, but local researchers. 
It is local researchers, who hold technologies such as biotechnology, who are 
required to obtain prior informed consent so as to have access to communities’ 
knowledge.   This means that a favourable regulatory approach to market 
approvals and access to genetic resources for the herbal industry appears to be 
not only in contradiction with communities’ rights, but also has favoured the 
herbal industry if compared with regulatory demands on local researchers. 
 
Second, the analysis of the Colombian herbal industry in the light of the 
International Regime on Access to Genetic Resources and Benefit Sharing and 
Constitutional mandates on communities’ rights also reflects the difficulty of 
including different actors that contribute to the production and dissemination 
of practices and knowledge over medicinal plants. As discussed in Chapter 
Two, there has been recent scholarly work on the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
which adopts an inclusive and critical scrutiny that identifies the processes 
lying behind commercialisation of medicinal plants associated with 
communities’ practices and knowledge. For instance, focusing on Mexico, 
Hayden reveals a complex network of actors that goes from indigenous 
communities, road travellers, mine workers, wholesalers of plants, peasants or 
campesinos, to urban markets which create, acquire, develop, sell, and share 
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the knowledge on medicinal plants.317 As a result, it is difficult to identify 
within the access and benefits sharing regulation, for example, who are the 
actual holders of communities’ practices and knowledge, who should be 
consulted or what kind of benefit sharing agreements should take place. In the 
case of Colombia, there have been efforts from academia and the government 
to document practice and knowledge over medicinal plants, which could 
potentially help to answer some of those complex questions. For instance, the 
Ministry of the Environment launched two reports in 2011318 and 2017319 
documenting different communities’ practices and knowledge to describe how 
practices and knowledge have an enormous potential to develop new products 
for different industries. However, those reports are limited to identifying the 
therapeutic effects of medicinal plants, rather than carrying out an in-depth 
ethnobotanical research that could help to solve some of the complex aspects 
behind the use of medicinal plants so as to enforce communities’ rights over 
their practices and knowledge according to Decision 391 and the 
Constitutional Court’s rulings.  
 
Chapter Five explores these issues in two parts. The first part of the chapter 
studies the place of medicinal plants and phytomedicines in the Colombian 
health market. Since the Colombian health system does not provide medicinal 
plants and phytomedicines to patients, Colombians obtain them either 
through urban markets or the herbal industry. While working classes (Clases 
Populares) and inhabitants of small settlements obtain medicinal plants in 
urban markets, well-off classes in large cities get them through the herbal 
industry. Even though urban markets and the herbal industry cover different 
markets, the government’s regulatory efforts to boost the use of medicinal 
plants have focused primarily in the latter rather than the former. This is 
despite the fact the urban markets provide vital therapeutic information on 
 
317 Hayden (n 19). 
318 Henry Yesid Bernal, Hernando García Martínez and German Quevedo Sánchez, ‘Pautas 
Para El Conocimiento, Conservación y Uso Sostenible de Las Plantas Medicinales Nativas En 
Colombia: Estrategia Nacional Para La Conservación de Plantas’ (2011). 
319 Carolina Castellanos Castro, Carolina Safrony Esmeral and Diego Higuera Diaz, ‘Plan de 
Acción de La Estrategia Nacional Para La Conservación de Plantas de Colombia.’ (2017) 
<http://www.minambiente.gov.co/images/BosquesBiodiversidadyServiciosEcosistemicos/p
df/Planes-para-la-conservacion-y-uso-de-la-biodiversidad/PlanAccion-BAJA.pdf> accessed 
October 13 2018. 
 170 
medicinal plants to the herbal industry. This is evidenced by interviews with 
sellers of plants or Yerbateros in the most known urban market specialised in 
medicinal plants in the country: La Plaza Samper Mendoza in Bogotá. Also, 
this section employs the data from interviews with local researchers to show 
how constraining their legal treatment is, compared to the more favourable 
normative landscape for the herbal industry, regarding marketing approvals 
and access to genetic resources.  
 
Such a favourable situation for the herbal industry is even more evident in the 
different governmental and academic efforts to document medicinal plants in 
Colombia. The second part of this chapter highlights different ethnobotanical 
studies which have collected knowledge and practices in urban markets to 
document medicinal uses and therapeutic activity of plants. This information 
ends up in the public domain, where the herbal industry can freely access and 
employ it. Also, this part of the chapter analyses the Colombian governmental 
efforts to document practice and knowledge of communities through a series 
of reports and regulatory measures, which do not aim to contribute to 
identifying the actors behind the use of biodiversity in the herbal industry, but 
have rather encouraged the commercialisation of phytomedicines. This occurs 
despite the fact that the government is obliged by Decision 391 and the 
mandates of the Constitutional Court to protect and safeguard those 
communities’ knowledge and practices.  
 
The Two Paths of the Natural Products Market in Colombia: the 
Growing Herbal Industry and the Urban Markets   
 
As observed in the previous chapter, genetic resources and the traditional 
knowledge and practice associated with those resources have a “strategic” 
value for Colombia’s economic development. As a result, authorities have 
created a series of administrative mechanisms and policies to boost the use of 
biodiversity in health research to make Colombia more competitive worldwide 
in terms of innovation. However, the strategic value of genetic resources and 
traditional knowledge is not only relevant in Colombia’s innovation policy, but 
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also in other sectors, particularly in the production of medicines based upon 
natural products. This means that the use of genetic resources and traditional 
knowledge is not only focused on local researchers. Although Chapter Four 
discusses in depth how Colombia’s innovation policy has centred primary on 
local researchers such as universities, who hold key technologies to transform 
genetic resources and traditional knowledge into products, this chapter 
uncovers two other important actors in the use of Colombia’s biodiversity for 
medical purposes: the growing Colombian herbal industry and urban markets. 
Both the Colombian herbal industry and the urban markets compete to 
interest consumers in alternative medicinal products.   
 
The Colombian health system relies mainly on the use of conventional 
medicine. It is a system in which medical professionals (nurses, doctors, 
pharmacists, therapists, etc.) treat diseases using medical devices, surgery, 
diagnostic and therapeutic methods, and biological and chemical-based 
products (i.e. pharmaceutical products). As a result, the health system secures 
free access only to health care products and services that are included in the 
national mandatory health plan or Plan de Beneficios en Salud (PBS).320 Those 
products and services which are part of the PBS are approved by the Health 
Ministry of Colombia after a technical and scientific assessment is carried out 
to define their efficacy and safety.321 As a result, the Colombian health system 
provides almost exclusively products and services related to conventional 
medicine. The Colombian population benefits directly and without previous 
medical reference by a practitioner from the following health services: Initial 
emergency care, newborn care, and general and dental medical 
consultation.322 In addition, general practitioners can refer patients to other 
specialized medical consultation (e.g. neurology, psychiatric care, etc.) 
laboratory tests, medications, hospitalization, low complexity surgical 
procedures, physical rehabilitation treatments, and various therapies and 
 
320 Articles 162-169 of Act 100 of 1993 
321 Act 1751 of 2015 
322 Ramiro Guerrero and others, ‘Sistema de Salud de Colombia’ (2011) 53 Salud Pública de 
México s144. 
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medical devices.323 The PBS also covers treatment of high-cost diseases, 
including AIDS/HIV and cancer.  
 
However, conventional medicines do not dominate the Colombian health 
market entirely. In fact, 40% of the Colombian population employ alternative 
or complementary treatments, including the traditional use of medicinal 
plants and phytomedicines.324 The Colombian national health system barely 
includes those treatments in the PBS.325 Since alternative and complementary 
medicines are not integrated within the PBS, it is the herbal industry and 
urban markets which aim to supply the demand for medicinal plants and 
phytomedicines in the country.326  
 
Therefore, the alternative medicine market has divided into two main actors. 
On one hand, there is the herbal industry which produces and distributes 
phytomedicines, including traditional phytotherapeutic products. As 
phytomedicines are not part of the PBS, the herbal industry is free to charge 
patients to access them. On the other hand, there are other patients who, 
because of different factors (including affordability, access in remote areas, 
family tradition, etc.), turn to urban markets (Plazas de Mercado) or peasant 
markets (Mercados Campesinos) to obtain similar therapeutic treatment that 
phytomedicines can provide, but which is based on raw medicinal plants and 
sellers or Yerbateros’ knowledge associated with those plants. Nevertheless, 
Colombia authorities are constructing policies and legal rules to prioritise the 
production and distribution of phytomedicines as an important aspect of 
Colombian economic sustainable development. This is because there is a 
 
323 ibid., p s149 
324  Manuel Ignacio Pinto-Barrero and Paola Ruiz-Díaz, ‘The Integration of Alternative 
Medicine into Colombian Health Care Services’ (2012) 12 Aquichan 183. See also WHO, ‘Legal 
Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide 
Review’ (2001) <http://apps.who.int/medicinedocs/pdf/h2943e/h2943e.pdf> accessed May 
25 2018.  
325 Acupuncture and neural therapy are the only complementary therapies covered by the PBS; 
further information see: Ministerio de Salud y Protección Social, ‘Todo Lo Que Usted Debe 
Saber Sobre El Plan de Beneficios’ (2014) <www.minsalud.gov.co> accessed October 25 2018. 
326 Yet, even if it was integrated it would still be the herbal industry that would supply those 
products, hence, they would be distributed through the PBS. 
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growing local industry with an enormous potential in international markets.327 
The next sections study in detail both the herbal industry and urban markets  
 
The Colombian Herbal Industry  
 
The Colombia herbal industry is primary led by local businesses. A recent 
study points out that the Colombian population consumes USD 253m of 
phytomedicines per year, which represents approximately 7% of the total of 
the Colombian pharmaceutical market.328 Such a market share is expected to 
grow as this industry has expanded by 500% in the last two decades.329  
 
An example of such growth is also reflected in the expansion of specialised 
pharmacies for alternative products, which grew from 20 local pharmacies a 
decade ago to 500 nowadays, in Bogotá alone.330 As a result, this industry 
generates an average of 21,000 direct and 100,000 indirect jobs in the country, 
through a comprehensive network of laboratories (35) and specialized 
pharmacies (500) in the production and distribution of phytomedicines.331  
 
It is also expected that the industry will keep growing significantly as Colombia 
has legalised the production and commercialisation of cannabis for medical 
purposes.332 Also, since the national health service does not include traditional 
and complementary medicines, this industry is highly concentrated among 
well-off patients and inhabitants of the largest cities of the country. Indeed, 
72.5% of the market share of traditional and complementary medicine is 
 
327 Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 Política Para 
El Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ 
(n 14)., p 14 
328 Nubia Esperanza Ardila Velandia and Claudia Yohana Ariza Ardila, ‘Modelo Técnico 
Financiero y Analisis de Rentabilidad Para La Farmacia Homeopática’ (Universidad de 
Ciencias Aplicadas y Ambientales 2017) 
<http://repository.udca.edu.co:8080/jspui/bitstream/11158/711/1/TESIS FINAL 29 DE 
AGT 2017.pdf> accessed October 25 2018. 
329 ibid., p34 
330 ibid. 
331ibid. 
332 El Colombiano, ‘Nueva Normativa Para Acceso a Productos a Base de Cannabis’ (El 
Colombiano, 2017) <http://www.elcolombiano.com/negocios/venta-de-productos-
naturistas-a-base-de-cannabis-JN6960478> accessed June 27 2018. 
 174 
located in four of the largest urban centres of the country (Bogotá, Medellin, 
Popayan, and Cali).333  
 
In the light of such a significant market, the government aims to encourage the 
industry to produce and distribute products based upon medicinal plants. To 
that effect, the National Planning Department, the national agency for 
economic planning, has established as an economic priority the sustainable 
use of Colombia’s biodiversity through regulation that promotes the 
commercial release of products that are derived from the use of genetic 
resources such as phytomedicines.334  
 
However, this represents a crossroad with other stakeholders, specifically, 
holders of traditional knowledge such as Yerbateros in urban markets and, 
even, local researchers. Particularly, the government strategy has actually 
facilitated access to the knowledge and practices that exist behind the use of 
medicinal plants in order to benefit the production and distribution of 
phytomedicines. Such a policy has materialised as follows.  
 
First, as explained in Chapter Three, through Resolution 1348, the Colombian 
Ministry of the Environment has exempted the herbal industry in Colombia 
from meeting the regulation on access and benefit sharing as well as consulting 
communities in the use of their practice and knowledge associated with genetic 
resources. Because phytomedicines are not products whose therapeutic 
activity is associated with isolated and purified molecules, or a combination 
thereof, as occurs with chemical synthetized products or biological medicines, 
they are not within the scope of Resolution 1348. In other words, the herbal 
industry’s products do not require prior informed consent or mutually agreed 
terms as required of other users, such as the pharmaceutical industry. Indeed, 
native medicinal plants found in ethnobotanical studies are cross-referenced 
with marketing approvals for phytomedicines, but public records of the 
 
333 Alejandra Rojas Rojas, ‘Servicios de Medicina Alternativa En Colombia’ (2012) 14 Revista 
de Salud Pública 468. 
334 Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 Política Para 
El Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ 
(n 14)., pp 22-23 
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Colombian Ministry of Environment’s mutually agreed terms indicate that the 
herbal industry has not filed a single application for the use of those plants nor 
obtained prior informed consent from holders of knowledge associated with 
medicinal plants. 335 Instead, by 2017, this industry obtained market 
authorisation for 144 products which include extracts and combinations 
derived from native and introduced plants in Colombia without requiring the 
industry to comply with Colombia’s access and benefit sharing regulation.336  
 
Second, the Ministry of Health has facilitated the granting of marketing 
approval for “traditional phytotherapeutic products” by allowing the industry 
to employ practices and knowledge associated with medicinal plants to prove 
efficacy and safety. As a result, according to Decree 2266 of 2004, the herbal 
industry are exempted from proving therapeutic activity through clinical trials 
before the Instituto Nacional de Vigilancia de Medicamentos y Alimentos 
(INVIMA), if two conditions are demonstrated: (i) the medicinal plant, either 
native or introduced, is locally produced; and (ii) there is either documentary 
proof that the plant has been employed for medical uses by three or more 
generations in Colombia, or, in case there is no documentary proof, it can be 
proved by a “competent professional” or the knowledge from “indigenous or 
Afro Colombian groups”.337 This means that even though the herbal health 
industry relies on such information, it has no obligation to carry out public 
consultation when it employs communities’ practices and knowledge in the 
granting process of marketing approvals.  
 
However, as has been discussed in the critical literature on bioprospecting and 
biopiracy (see Chapter Two), it is difficult to define the complex network of 
actors that operates in the production of such a knowledge and practices. This 
 
335 Diaz’s study was cross-referenced with both INVIMA, ‘Listado de Plantas Medicinales 
Aceptadas Con Fines Terapéuticos 2017’ (2017) 
<https://www.invima.gov.co/images/pdf/salas-especializadas/productos-
naturales/LISTADO-DE-PLANTAS-DICIEMBRE-2017.pdf> accessed 3 May 2018. list of 
marketing approval and mutually agreed terms records of the Ministry of Environment, the 
Colombian local authority on access to genetic resources, see JA Diaz, ‘Informe Técnico. 
Caracterización Del Mercado Colombiano de Plantas Medicinales y Aromáticas’ (2003) 
<http://repository.humboldt.org.co/bitstream/handle/20.500.11761/31375/243.pdf?sequen
ce=1&isAllowed=y> accessed May 3 2018.  
336 INVIMA (n 335). 
337 Articles 2, and 31-36 Decree 2266  
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means that in terms of the enforceability of the International Regime on Access 
to Genetic Resources and Benefit Sharing and constitutional mandates it is 
also difficult to define aspects such as who should be entitled to claim any 
rights over those practices and knowledge, who should be publicly consulted 
and what form of benefit sharing should take place. This is even more relevant 
in the development of a local herbal industry in Colombia which would find it 
difficult to bear the burden of untangling the complex network of actors behind 
the use of medicinal plants in order to comply with the access and benefit 
sharing rules.  
 
Nevertheless, as was discussed in Chapter Four, local researchers, who employ 
technologies such as synthetic biology or other biotech-related technologies, 
are obliged to comply with Colombia’s access to genetic resources and benefit 
sharing regulation, if there are ethnic communities associated with medicinal 
plants such as indigenous and Afro-Colombian groups.338 Also, whoever wants 
to introduce a new pharmaceutical product into the market, including those 
based upon natural products, are required to obtain market approval by 
proving safety and efficacy of the product (e.g. preclinical trials and clinical 
trials). Yet, the herbal industry can obtain market approval by employing 
traditional knowledge to prove that their traditional phytotherapeutic 
products are safe and effective.  This indicates that, at least, there is an 
unbalanced approach towards holders of technology such as local researchers 
who bear the legal, administrative and economic burden to, first, obtain prior 
informed consent and negotiate mutually agreed terms if they want to legally 
access genetic resources, including genetic resources associated with 
traditional knowledge, and second, obtain market approvals.  
 
This is an aspect that local researchers such the immunobiology research 
group of the Javeriana University of Colombia, which have worked for more 
than two decades with Colombia’s medicinal plants to treat cancer, considered 
problematic. Wilmer Olaya, the regulatory expert of this group, expressed his 
 
338 Chapter Four criticises that other non-ethnic communities such as peasants are not to be 
consulted if their knowledge and practices are employed in commercial and non-commercial 
activities. This has occurred because it is the same Colombian local authorities that have 
regulated so.  
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discomfort with the herbal industry which does not need to comply with strict 
sanitary controls to obtain marketing authorisation, while his research group 
is making significant efforts to deliver safe and effective medical products, as 
follows:  
 
What annoys me more is that on Saturday or Sunday, I turn on the TV 
and watch an arsenal of commercial products [such as] lycopene, 
brusque coffee, coffee with ganoderma, a lot of products that can 
certainly have some therapeutic activity, but they are being sold 
without a reason, without further argument, are simply becoming a 
fashion choice; and they are using the need of people, […] [as the 
herbal industry is] aware that they have cancer, and unfortunately the 
media [and], some tricks and loopholes in the [sanitary] normative 
[structures/environment] make these products over-the-counter; and 
no one has worried about the side effects […] if it is natural and if it 
comes from a plant does not mean that it is safe; an overexposure to 
an extract can generate a toxicity, they can generate liver and kidney 
damage, […] and such products are sold right and wrong on television 
radio without any control339 (Translation by the Author) 
 
Instead, Mr. Olaya claims that what the Javeriana research group are trying to 
do with their research on the extract of medicinal plants is to “deliver [a 
product] with all the technical and scientific certainty from all the years 
invested in research that is being done here [in the research group]” 
 
339 Original transcription in Spanish “ a mi me molesta que el sábado o el domingo prender el 
televisor y ver un arsenal de comerciales de productos, el licopeno, el café de brusca, el café 
con ganoderma, un montón de productos que sin duda pueden tener alguna actividad 
terapéutica, pero es que se están vendiendo sin mayor razón, […], y están utilizando la 
necesidad de las personas, e incluso la desesperación, porque precisamente trabajamos con 
una enfermedad a la cual mucha gente llega a tomar cualquier cantidad de diversidad de cosas 
es por la desesperación que están consientes que tienen cáncer, y lamentablemente medios de 
comunicación, algunas triquiñuela y cosas laxas en la normatividad hacen que estos productos 
sean de venta libre, y nadie se ha preocupado por efectos colaterales […] que por que se natural 
y porque venga de una planta no quiere decir que sea seguro, una sobreexposición a un 
extracto pueden generar una toxicidad, pueden generar un daño hepático, renal, […], y este 
tipo de productos se venden a diestra y siniestra por radio por televisión sin ningún control” 
Interview with Wilmar Olaya, Agriculture Engineer and Regulatory expert at the Immunology 
Javeriana Research Group, Javeriana University (Bogotá, Colombia, 19th September 2019) 
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(Translation by the Author).340 Similarly, her college, Dr. Urueña points out 
how beneficial is their research on medicinal plants such as the Dividivi if 
compared with the herbal industry:  
 
It is not known in what conditions [the herbal industry], what is being 
produced, what is being sold; we have conditions of good 
manufacturing practices, we have a physicochemical analysis that is 
done to raw material as well as to the product, we have toxicity studies 
that show whether it is effectively toxic or whether is toxic at a certain 
dose; we have a biological activity quite sustained and reported, all 
this gives it a great value [versus] what [the herbal industry] normally 
sell.341 
 
Regarding the regulation on access to genetic resources in Colombia, the lead 
researcher of the Javeriana Group, Professor Susana Florentino, provides a 
frank and direct summary of what she believes regarding the fact that her 
research group has to comply with this regulation, while the herbal industry is 
excepted from it: “make those who do something more sophisticated pay”342 
the price that is involved in dealing with the International Regime in Access to 
Genetic Resources and Benefit Sharing. In other words, while local 
researchers, who carry out research and development activities on genetic 
resources using technologies such as biotechnology, are obliged to bear the 
burden of complying with access to genetic resources regulation, the herbal 
industry is off the hook.  
 
340 Original transcription in Spanish:_“si vamos a entregar un producto se lo vamos a 
entregar con toda una certeza técnica y científica de todos los años invertidos en 
investigación que se están haciendo aca ” Interview with Wilmar Olaya, Agriculture Engineer 
and Regulatory expert at the Immunology Javeriana Research Group, Javeriana University 
(Bogotá, Colombia, 19th September 2019) 
341 Original transcript in Spanish: “no se sabe en que condiciones se produce lo que se esta 
vendiendo, nosotros tenemos unas condiciones de buenas practicas de manofactura , tenemos 
uns análisis fisicoquímicos que se le hace a la materia como al producto , tenemos estudios de 
toxisidad que demuestran que efectivamente es toxico o que es toxico a cierta dosis pero a 
cierta dosis ya no lo es, tenemos una actividad biológica bastante sustentada y reportada , todo 
esto le da un valor grandísimo [frente a] lo que [la industria herbal] venden normalmente” 
Interview with Claudia Urueña, Researcher at the Immunology Javeriana Research Group, 
Javeriana University (Bogotá, Colombia, 19th September 2019) 
342 Original transcript in Spanish: “póngale a pagar a los que hacen algo más sofisticado” 
Interview with Professor Susana Fiorentino, Lead Researcher at the Immunology Javeriana 
Research Group, Javeriana University (Bogotá, Colombia, 1st October 2019)  
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The data collected from the interviews with the different members of the 
Javeriana group provides significant evidence that local Colombian 
researchers believe not only that the herbal industry is in a ‘regulatory blind 
spot’ in relation to Colombia’s implementation of its access to genetic 
resources and benefit sharing obligations. The group also believe that the 
herbal industry is in different regulatory position with regard to the granting 
of market approvals for phytomedicines.  
 
Consequently, it appears, first, that there is an unbalanced approach in the use 
of medicinal plants that does not meet the constitutional and international 
protection granted to holders of traditional knowledge and practices; and, 
second, it appears to be unfair to local researchers, in that they are obliged to 
strictly comply with market approval, and access to genetic resources and 
benefit sharing regulations, while the legal landscape is significantly more 
favorable for the herbal industry.  
 
Therefore, a more effective enforcement of the International Regime on Access 
to Genetic Resources and Benefit Sharing and Constitutional mandates in 
Colombia would require a delicate balance that includes all different 
stakeholders: the local herbal industry, communities as holders of knowledge 
and practices, and local researchers. Although the answer to the question of 
how to find such a delicate balance is provided in the following chapters, a first 
step is to identify who the actors behind medicinal plants are. Chapter Four 
already discussed the role of local researchers in the use of genetic resources, 
and the traditional knowledge related to those resources. Yet, it has not been 
observed so far, the role of plant sellers in urban markets or Yerbateros. The 
next section reports on a series of interviews carried out with the aim of 
untangling the complex, and unique, network of Yerbateros in the use of 
medicinal plants in the main market of medicinal plants in the country:  La 
Plaza Samper Mendoza in Bogotá.  
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Del campo a la plaza y de la plaza a la casa:343 the role of Urban Markets in 
the Use of Medicinal Plants in Colombia 
 
Urban markets are a central piece in Colombia’s strategy in supplying food to 
its population, particularly Clases Populares. In fact, through the first half of 
the 20th century, the Colombian government placed these markets as an 
important intersection point between agricultural production in the 
countryside and supplies of food to urban populations. Such an important 
connotation of urban markets had its peak in the 1950s as almost half of 
Colombia’s GDP originated in agriculture production.344  
 
However, the relevance of the urban market has lately reduced because of 
different socio-economic circumstances, which include: (i) violence and 
internal displacement from agricultural areas to urban centres, which led to a 
reduction in food production, meaning that urban markets are no longer 
adequately supplied; (ii) a growing competitive environment from small shops 
in neighbourhoods (Tiendas de Barrio) and large supermarkets (including 
through the internet); and (iii) a lack of adequate infrastructure to supply and 
sell agricultural products to consumers.345  
 
Yet urban markets remain an important location not only to meet the food 
needs of the Clases Populares,346 but also to supply the Colombian population 
with medicinal plants. In that regard, it is in urban markets where patients rely 
on the knowledge and practices that Yerbateros acquire through a complex 
network of actors that goes from indigenous communities, road travellers, 
 
343 Literal words of Gerardo Vásquez which translates: “From the Countryside to the Urban 
Market and from the Urban Market to the House” 
344 Rafael Ángel Bravo, ‘Galerías y Plazas de Mercado Como Espacio de Conservación Cultural 
y Producción Audiovisual’; for further information on the role of Plazas de Mercado places in 
supplying the nutritional needs of  Clases Populares see: Elmer Castaño Ramírez and Blanca 
Edilia Raigosa Vargas, Mercados Populares Mayoristas de Alimentos En La Zona Andina 
Central Colombiana (Editorial Universidad de Caldas 2001).   
345 Ángel Bravo (n 344). pp 250-251 
346 There have been important efforts from the national and local governments to maintain, 
improve and formalize urban markets across the country. For instance there is a guide from 
the national government on how to construct and improve a Plaza de Mercado; see 
Departamento Nacional de Planeación, ‘Construcción y Dotación de Una Plaza de Mercado’ 
(2018) <https://proyectostipo.dnp.gov.co/images/ 
pdf/plazademercado/PTplazademercado.pdf> accessed October 26 2018.   
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mine workers, wholesalers of plants, peasants or campesinos. Buyers in these 
places access not only the actual plants, but also the cumulative practices and 
knowledge in the use of those plants to treat diseases.  
 
Since urban markets hold such a key role in being a crossroads of different 
networks and actors, it became fundamental to this thesis to visit and 
interview Yerbateros at the most important urban market specialized in 
medicinal plants in the country: La Plaza Samper Mendoza. 
 
The literature and research on the Samper Mendoza are abundant. They 
concern not only the trade in medicinal plants, but consist in a range of 
interdisciplinary studies which goes from anthropological research to 
urbanistic reflections on the transformation of the Samper Mendoza over the 
years, and art-related works.347  
 
Most of those works share a poetic and almost magical realism rhetoric that 
describes the Plaza as part of Colombian heritage. For instance, Barrera and 
Kuklinski observe this place as non-hegemonic market that defies the 
unpersonal and “industrialized” world of supermarkets; a market that always 
attracts and welcomes buyers from different backgrounds who are naively 
interesting in knowing more about such a universe of plants:348   
 
It is a cosmovisional, diverse and intercultural space. Everything that 
circulates in the square looks fresh and healthy, it seems that there is 
a tacit discourse of criticism to what is artificial. In the square 
everything is available to buyers, without persuasions, without 
propaganda, the herbs speak for themselves and being arranged on 
 
347 See for instance: Ana María Güiza Posso, ‘Renovación Urbana En El Barrio Samper 
Mendoza-Simbiosis Entre Las Dinamicas Comercial y Residencial Comunal’ (Bogotá-
Uniandes 2011) 
<https://repositorio.uniandes.edu.co/bitstream/handle/1992/14617/u442607.pdf?sequence
=1>; María Camila Duque Jamaica, ‘Territorios Otros, Intercambios Otros: La Plaza de 
Hierbas Samper Mendoza’ (Universidad Javeriana 2016) 
<https://repository.javeriana.edu.co/bitstream/handle/10554/22182/DuqueJamaicaMaria
Camila2016.pdf?sequence=1&isAllowed=y>. 
348 Gloria Stella Barrera Jurado and Jorge Enrique Kuklinski Sicard, ‘De Los Yerbateros Con 
Sus Hierbas: Creaciones No Hegemónicas En La Plaza Samper Mendoza’ [2018] Tabula Rasa 
277. 
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the floor evokes peasant life in a fantastic encounter between humans 
and non-humans, a place full of medicinal energy healing.349 
(Translation by the author) 
 
This view seeks to evoke a peaceful and colorful life of peasants as creators of 
Samper Mendoza, a point in which buyers from different parts of the city, the 
country and the world can interact with the Yerbateros and their medicinal 
plants.   
 
However, my visit to Samper Mendoza and the data collected evidence a less 
romantic perspective. Since this thesis analyses the International Regime on 
Access to Genetic Resources and Benefit Sharing and its implementation in 
Colombia, the data collected illustrates how little impact, or none at all, has 
this legal framework in the trading of medicinal plants, and communities’ 
practices and knowledge. This means that the objective of that international 
regime to secure that holders of knowledge are adequately compensated for 
the use of their knowledge is an idea that is far from even being acknowledged 
in places such as Plaza Samper Mendoza, where plants and knowledge are 
widely disseminated and placed into the public domain without any 
compensatory or enforceable mechanism taken place. Also, the data collected 
lead to uncovering the role of a stakeholder that has not been properly been 
taken into account in the discussion of benefit sharing, traditional knowledge 
and genetic resources for health industry and health research: the herbal 
industry. The following lines of analysis combine data from a series of 
interviews, photographical records and researcher observations. 
 
My first research visit to Samper Mendoza was during the daytime on a 
Saturday. This day was specifically chosen from my own experience with urban 
markets since it is a regular day and time for buyers to go to these places to 
purchase household goods such as meat, fruit and vegetables.350 The market is 
located in Los Martires, a part of the city which was invigorated by the 
 
349 ibid., p287 
350 Members of my family sell vegetables and fruits in a stall in the Plaza Mercado la 
Concordia in Florencia-Caquetá in a region in the south of the country in the Colombian 
Amazon; as a child, I used to go to la Plaza at weekends.      
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National Rail Service. In fact, the Central Station (Estación de la Sabana) and 
the main building of National Rail Service were located in Los Martires.351 
Nowadays, those buildings are partially abandoned, and services are not 
regular as the train lost relevance in the city and country, being replaced by 
road transport.  
 
The Plaza Samper Mendoza used to be surrounded by ample houses and flats 
for workers, and their families, who were employed by the National Rail 
Service. But, as the train service became obsolete, families abandoned the 
neighborhood. Consequently, houses were replaced by storage facilities 
(Bodegas) and wholesaler buildings.352 Nowadays, buildings and roads are 
occupied by pickup cars, trucks and street sellers, giving a very informal look 






As I entered the facilities, it came as a surprise that there was not a prominent 
trade activity on a Saturday morning. Although there were a few restaurants 
open in the corridors and the food court, there were only some stalls of plants 
 
351 Duque Jamaica (n 347). p 11 
352 Güiza Posso (n 347). pp 11-12 
Picture 1: Surroundings of Plaza Samper Mendoza during the  
daytime  
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open, domesticated animals such as dogs wandering around, and few workers 
were carrying plants through the corridors and main square on their shoulders 
or on wooden loading carts. The appearance of a very informal market was 
prominent (see Pictures 2).  
 
 
I was almost immediately informed by a plant seller or Yerbatera, who refused 
to be interviewed, that the main trade in plants occurs only in the late evenings, 
around 10 pm, on specific days (Monday and Thursdays) until mid-morning 
of the next day. The exchange of words with the Yerbatera was brief and off 
record: she quickly pointed out that despite the fact that interviews with 
Yerbateros were often undertaken by researchers, she always refused to be 
interviewed. Moreover, she did not provide further information why she was 
Pictures 2. Daytime at the Plaza Samper Mendoza 
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reluctant to do so. Yet, the Yerbatera strongly recommended that I visit late at 
night, so as to have a better grasp of how lively and different the Plaza was, 
and so as to be able to interview more candidates.  
 
Although I was a little disappointed not to conclude any interview during 
daytime, she indicated two potential candidates who could be interviewed: 
Gerardo Vásquez, a bureaucrat that works for the institute for social economy 
(IPES Spanish acronym), a local authority that is part of Bogotá’s mayoral 
authority, and manages all urban markets and Mercados Campesinos 
(peasant markets) in the city; and Yaneth Porras, owner of Yerbas la Mona 
(the Blondy’s Herbs) who has experience of 37 years in the trade of medicinal 
plants. 
 
Gerardo Vásquez, at first, refused to go on record, but after a few exchanges of 
words, he was willing to be interviewed, although he did not want any 
photograph of him or his place of work to be taken. He basically argued that as 
a public servant, any declaration which could be misinterpreted had the 
potential to jeopardize his work. That said, it is particular interesting that, as 
he was reading the information sheet and consent form for his interview (see 
appendixes II and III), he was able to decide that giving an opinion on the 
record on issues such as the regulation on traditional knowledge and genetic 
resources did not represent a problem for his role in the IPES.  
 
Consequently, throughout the interview it was striking and palpable that the 
IPES, a city authority organization, and Mr. Vásquez, who works for that 
authority, did not have any idea of what the International Regime on Access to 
Genetic Resources and Benefit Sharing was. For instance, when he was asked 
if there has been any situation in which sellers or Yerbateros were approached 
to obtain their informed consent or to negotiate any mutually agreed terms, or 
whatsoever, he quickly pointed out that the practice of any transaction or 
transfer of information was the “voice to voice”. This was as if his 
understanding that such a communication could not fall within any regulatory 
structures that require informed consent for sharing of such knowledge, or 
mutually agreed terms for its use or exploitation by others. Furthermore, he 
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describes the role of Yerbateros as an important element in providing raw 
material as it occurs with other agriculture products such as flowers:      
 
[The trade of medicinal plants] bears a resemblance to the flower 
market, they start selling the bunch of flowers, then they result in 
selling in boxes, then they result in delivering flower productions.353 
(Translation by the author) 
 
Mr. Vásquez’ words point out not only the fact that the International Regime 
on Access to Genetic Resources does not have any relevance in medicinal 
plants trade for local authorities such as IPES, but also that the aim of those 
institutions is to transform those place of medicinal plants trade into model of 
business where holders of knowledge on genetic resources can be part only of 
a chain value in which they only provide the raw material. The ‘value added’ in 
the chain (the boxes, the flower productions) is added by other economic 
actors, not the Yerbateros. 
 
Furthermore, other parts of Mr. Vasquez’ interview reaffirm the interest of the 
authorities in making sure that the Yerbateros’ trade is focused on providing 
raw material. As he was asked how they deal with visitors to the market, he 
specifically mentioned that, in the case of tourists, especially international 
ones, authorities at the Plaza make sure that the trade of plants is as open as 
possible to them with the aim to promote the trade of raw material: 
 
Normally we approach [the tourists], we ask if they are well taken 
care of, if they have been given an answer, or if they have achieved the 
goal they are looking for, and some ask the seller’s data, possibly to 
have a link to the raw material. (Translated by the author)354 
 
353 Original Transcript in Spanish: “tiene un parecido con el mercado de flores, empiezan a 
vender el manojo de flores, después resultan vendiendo en cajas, después resultan entregando 
producciones de flores”. Interview with Gerardo Vasquez, Employee of the IPES, Plaza Samper 
Mendoza (Bogotá, Colombia, 28th September 2019) 
354 Original Transcript in Spanish: “normalmente nosotros lo abordamos, le preguntamos si 
se encuentran bien atendidos, si se le han dado respuesta, o si han conseguido el objetivo que 
ellos vienen buscando, y algunos preguntan los datos del comerciante, posiblemente para 
tener un enlace para la materia prima” Interview with Gerardo Vasquez, Employee of the IPES, 
Plaza Samper Mendoza (Bogotá, Colombia, 28th September 2019) 
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This indicates that authority’s perspective on the value of medicinal plants in 
Plaza Samper Mendoza does not dwell in Yerbatero’s knowledge, but in the 
raw material as such. Assuming that the evidence from this interview is typical 
of the IPES (and there is no reason not to make this assumption, as Mr Vasquez 
is an ordinary bureaucrat associated with that city authority, this represents 
an astonishing piece of evidence that the central aim and raison d’etra of the 
International Regime on Access to Genetic Resources and Benefit Sharing – 
i.e. that communities are taken into account in the use of plants for industrial 
application and participate in benefit sharing – is not even acknowledged in 
one of the most important places of trade of knowledge related to medicinal 
plants in Colombia. The data collected in the interviews with Yerbateros 
during the daytime and late night provide further evidence on this finding.  
 
Yerbas la Mona and Oscar Sanabria  
 
Yerbas la Mona was one of the few stalls that were open during the daytime. 
It was right in the middle of the main square of the Plaza Samper Mendoza. 
Yaneth Porras, the owner, was both curious and skeptical about the content of 
my research.  At the same time, she was open to answering most of my 
questions. Although the interview was short in duration, lasting less than 30 
minutes, it allows me to observe the ways in which traditional knowledge 
related to medicinal plants is transmitted, traded and transformed in practice 
(See Pictures 3). 
 
 




Mrs. Porras’ trade is a family business, which she has run for 37 years. Her 
mother was only 12 years old when she started this business. Mrs. Porras’ 
mother is 81 and retired, which means Mrs. Porras is now in charge of the daily 
operation of the business. This is a family commitment that will be continued, 
as Mrs. Porras’ daughter also works in the stall (“my daughter already knows 
about plants too”355). Yet, Mrs. Porras does not attribute to herself, nor her 
family, all the understanding of medicinal plants. In fact, she acknowledged 
explicitly that she learned what medicinal plants are for from other colleague 
Yerbateros in La Plaza Samper Mendoza.  
 
As she has obtained the knowledge on medicinal plants from different sources, 
she also transmitted to a variety of customers. As the interview was being 
conducted, it could be observed how different customers approached Mrs. 
Porras’ stall to acquire plants and ask her how to prepare them. For instance, 
a woman in her mid-fifties asked her for Chaparro (Castela tortuosa) and 
whether the plant could help her son-in-law with his sugar levels. Mrs. Porras 
immediately corroborated the information and went into detail about the 
properties of Chaparro for diabetes.   
 
As I watched how she performed her trade and observed her interactions with 
her customers, I asked her to describe how she concludes what plant could be 
more beneficial for each of her customers. Humbly, she explained in detail:  
 
It is not because I believe I am a doctor or anything like that, but I 
know about diseases and I know what plants you can take for that; 
that is why I know when they [patients or clients] come to me and tell 
me ‘I need a herb for the headache or have a lot of migraine or that’, 
so I ask them: ‘did you already go to the doctor? Have you told them 
what it is?’ Then they [the patients] tell me yes, so [for example]  I tell 
them to take the  Comfrey [Symphytum officinale],that the  Comfrey  
 
355 Orginal Transcript in Spanish:_“mi hija ya sabe de plantas también”. Interview with Yaneth 
Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th September 
2019) 
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is for migraine, for triglycerides, cholesterol and rheumatism.” 356 
(Translation by the Author) 
 
Although Mrs. Porras’ answer points out that Yerbateros do not aim to 
attribute to themselves full medical training or replace general practitioners in 
their diagnosis, it also show that Yerbateros genuinely believe that the use of 
medicinal plants brings greater benefits than conventional medicines. In fact, 
Mrs. Porras highlighted that in that regard she considered herself a Naturista, 
a “person who helps with natural plants”,357 who has contributed in the 
wellbeing of their customers. This is a claim that she supported by reference 
to her customer’s feedback and loyalty. She brings an example to illustrate her 
point:  
 
It’s like the gentleman who comes for diabetes and that, I've given him 
Chaparro and it's been very good for him, because he’s come back to 
take more, and he’s giving right now to his daughter, who is now 
having diabetes [...] he was taking insulin that was required to be 
injected, and right now he is no longer injecting that.358 (Translation 
by the Author) 
 
This particular point evidences that Yerbateros feel that they play a key role 
for their customer in their overall well-being, to the point that they even give 
up conventional medicines, substituting medicinal plants. However, this role 
 
356 Original Transcrip in Spanish: “no porque me crea medica ni nada de eso, uno ya sabe las 
enfermedades y uno ya sabe que plantas puede tomar para eso, yo por eso se que cuando ellos 
[pacientes o clientes] vienen y me ‘dicen necesito una yerba para el dolor de cabeza o que 
mucha migraña o esto`, yo les digo: ‘¿ustedes ya fueron al medico? ¿ya les dijeron de qué es?’ 
Entonces ellos [los pacientes] me dicen que sí, entonces [por ejemplo] les digo que tomen el 
Comfrey [Symphytum officinale], que el Comfrey es para la migraña, para el triglicérido, el 
colesterol y para el reumatismo” Interview with Yaneth Porras, Plant Seller or Yerbatera, Plaza 
Samper Mendoza (Bogotá, Colombia, 28th September 2019) 
357 Original transcript in Spanish: “persona que ayuda con las plantas naturales” Interview 
with Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th 
September 2019) 
358 Original transcript in Spanish: “es como el señor que viene para lo de la diabetes y eso, yo 
les he dado  Chaparro y les ha resultado muy bueno, por que él ha venido a llevar más, y le esta 
dando ahoritica a la hija, que ahora esta teniendo diabetes […]él estaba tomando la insulana 
esa que le mandaban aplicar y eso, y ahoritica ya no se esta aplicando eso” Interview with 
Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th 
September 2019)  
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of promoting well being through the use of medicinal plants is in effect being 
taken by another stakeholder: the herbal industry. 
 
As we discussed her different customers, Mrs. Porras also brought up 
examples of people who are in the herbal industry and have interacted with 
her. For instance, she identifies Doña Carmenza, a homeopath doctor and 
regular customer, who “comes and buys herbs to make syrups to give people 
[and] she makes creams and makes vitamins and all that with plants” 
(Translation by the Author).359 Equally, Mrs. Porras points out that other 
regular customers include three herbal laboratories, which “take to make 
remedies for the colon, gastritis” and to “extract in order to pack it in bottles 
and sell it, or in capsules” (Translation by the Author).360 When I asked her for 
further details on these customers, she declined to disclose such information 
(“I don’t give [details] to you”361). This was an example of a non-written 
confidentiality pact that is the result of a long-term relationship of trust and 
loyalty with her customers.  
 
This insight from the interview with Mrs. Porras raised the further question - 
however, do customers from the herbal industry also feel bound to that trust-
based, unwritten, and probably unspoken pact? Apparently, such a 
relationship is one way. It depends on the demand for raw material from Mrs. 
Porras’ stall, in a context where there is no recognition of her own 
understanding of medicinal plants and the whole network of knowledge 
behind it (family, colleagues, etc.). In fact, Mrs. Porras points out: 
 
They [referring to everyone who is going to ask about her knowledge 
on medicinal plants who are not patients]  come to ask and they figure 
 
359 Original spanish Transcript: “ella viene y compra yerbas para hacer jarabes para brindarle 
a la gente [..] ella hace cremas y hace vitaminas y todo eso con las plantas” Interview with 
Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th 
September 2019) 
360 Original transcript in Spanish: “llevan para hacer remedios para el colon, la gastritis” “sacar 
el extracto para empacarlo en frasquitos y venderlo, o en capsulas” Interview with Yaneth 
Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th September 
2019) 
361 Original transcript in Spanish: “eso no se los doy”. Interview with Yaneth Porras, Plant 
Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th September 2019) 
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out the knowledge so that they get back into that knowledge and do it 
more [this means that they carry out industrial process into the plant], 
and change them into their name [then] they put on their papeles 
[labels].362 (Translation by the Author) 
 
Although she refused to give details of what medicinal plants, who exactly are 
those customers, or provide any further details of the transactions, such a 
statement made by Mrs. Porras reflects that the role of Yerbateros and the 
network of actors behind the uses of medicinal plants have been limited to 
merely providing the material for industrial application. Pressed on this issue, 
Mrs. Porras considers that she is not seeking to have any recognition in the 
industrial application of medicinal plants. She is rather afraid of any potential 
paperwork that involves consulting her about her knowledge (“no one likes to 
fill any of that” (Translation by the Author 363)). Furthermore, she is even 
concerned that by linking the plants with her knowledge she would be teased 
or become the subject of mockery. This worry persists, despite the fact that she 
points out that the herbal industry could charge up to 20 times more for a 
phytomedicine or herbal preparation whose main extract are the very same 
plants that she sells at a fraction of the price.   
 
Mrs. Porras’ own perspective on her role and contribution to the 
understanding of medicinal plants by the health industry led to another 
question: is it fair? Again, she is very humble in recognizing that what the 
herbal industry does is “a process in which always money goes out away” 
meaning that the industry requires resources to “maintain machinery [and] 
pay for their employees”364 (Translation by the Author). Yet, she still defends 
her trade: “here we sell the natural, there’s no chemicals, no alcohol [according 
 
362 Original Spanish Transcription:“ellos vienen preguntan [refiriéndose a todos los que van a 
preguntar que no son pacientes] y averiguan los conocimientos para que ellos mismos volverse 
a meter a los conocimientos y hacerlo más, y cambiarlos a nombre de ellos [y depues] ellos 
ponen en sus papeles” Interview with Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper 
Mendoza (Bogotá, Colombia, 28th September 2019) 
363 Original transcript in Spanish: “uno no le gusta llenar nada de eso”. Interview with Yaneth 
Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th September 
2019) 
364 Original Spanish Transcription: “ellos tienen que mantener su maquinaria, pagar sus 
empleados” “un proceso que siempre se va plata”. Interview with Yaneth Porras, Plant Seller 
or Yerbatera, Plaza Samper Mendoza (Bogotá, Colombia, 28th September 2019) 
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to her own understanding those are substances employed in any industrial 
process].”365 (Translation by the Author). Since she was particularly proud of 
the sale of medicinal plants in La Plaza Samper Mendoza and considered it 
better than those plants and products sold by the herbal industry, I probed her 
as to whether she felt that the price difference and the fact that their 
contributions are not recognized by that industry, is fair for Yerbateros. She 
points out that it is customers who prefer to access phytomedicines instead of 
the natural product:   
Because if you have a headache and you don’t want to take the plants, 
you go to a drugstore [referring to natural pharmacy stores] that sells 
you a pill, that pill with all the processes that are necessary to make 
that pill. How many chemicals have they put into it? […] the plant is 
more effective.”366 (Translation by the Author) 
Mrs. Porras’ words highlight a significant aspect of the way that consumers are 
being driven away from urban markets for the supply of medicinal plants to 
natural pharmacy stores. As was pointed out in the previous section, the herbal 
industry is growing significantly in the country, leading consumers to natural 
pharmacy stores in malls and supermarkets, instead of going to urban markets 
(see Pictures 4 and 5). This is despite the fact that the use of medicinal plants 
as sold in urban markets could be cheaper than getting a “pill” with the extract 
of the plant. For instance, while a bunch of Calendula (Calendula Officinalis) 
to treat different diseases (headache, skin disorders, etc.) in Mrs. Porras’ stall 
costs less than 0.50 US, a box of twelve pills of Calendula Officinalis, sold 
under the trademark Dololed, costs 3.50 USD (See Pictures 6).  
As the conversation with Mrs. Porras was coming to an end, it was clear that 
the mere concepts of benefit sharing or informed consent, which are 
fundamental in the International Regime on Access to Genetic Resources and 
 
365 Original transcript in Spanish: “aquí se vende lo natural, no tiene nada de químicos, nada 
de alcohol” Interview with Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza 
(Bogotá, Colombia, 28th September 2019) 
366 Original Spanish Transcription:_“Porque si usted tiene un dolor de cabeza y usted no 
quiere tomarse las yerbas va es a una droguería le vende una pasta, esa pasta todos los procesos 
que le han hecho para hacer esa pasta ¿Cuántos químicos no le han metido?[…]es más efectivo 
la planta” Interview with Yaneth Porras, Plant Seller or Yerbatera, Plaza Samper Mendoza 
(Bogotá, Colombia, 28th September 2019) 
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Benefit Sharing, were not even acknowledged in a place of trade of medicinal 
plants. All these aspects are also reflected in the interview with Oscar Sanabria, 
the most known Yerbatero in La Plaza Samper Mendoza, whose time of trade 






Pictures 4. Top: main entrance of Plaza Samper Mendoza in Bogotá at daytime. Left: 
a corridor leading to the main square and Yerbas la Mona. Right: façade of Yerbas la 






Pictures 5. Top: Centro Internacional area in Bogotá (Torre Colpatria (left of the pic) 
the second tallest building in the city and Tequendama shopping mall on the right of 
the pic. Left: a corridor in Tequendama shopping mall. Right: a Tienda Naturista (a 




Pictures 6. Top: Bunch of 
Calendula (Calendula 
Officinalis) in Mrs. Porras’ 
stall. Bottom: Pills of 
Calendula Officinalis, sold 





During the night, La Plaza Samper Mendoza becomes a more complex 
universe; especially as its informal trade seems to be invigorated. The market 
is absolutely alive: the corridors are full of plants and workers, who sleep in 
improvised beds, while people who carry plants in wooden loading cars invade 
every inch of the Plaza. The look of the main square seems to be amplified by 
the amount of plants on the floor and stalls, and their aroma floods the whole 
environment. For someone who is a new visitor, such aroma is almost 
intoxicating. Outside, the trucks and pickups multiply by the hour as the trade 
intensifies (See Pictures 7) . The reason 
why trade takes place at such time is 
explained by Mr. Vásquez:  
As [the plants] are perishable 
products, they have a time limit, 
that is, if they bring the goods [for 
instance] from Ibagué [see map 
1],367 they [the distributors] come 
with a fair time to get here between 
five in the afternoon and ten at 
night to find themselves here in 
Bogotá […] The goal of these 
traders [and] the  time of departure is 10 pm. […] At 1 a.m. buyers who 
fill the city, who fill the municipalities, and who fill the towns near the 
district, and even the cities of other departments, begin to arrive 
because the trucks at dawn are out [between 5am and 7 am […] to take 
it to a region where that crop does not grow368 (Translation by the 
Author)  
 
367 The capital of the Department of Tolima, which is 3 hours away by car from Bogotá.  
368 Original Transcript in Spanish “como son productos perecederos, tienen un tiempo limite, 
es decir si traen la mercancía de Ibagué, ellos [los distribuidores] se vienen con un tiempo 
justo para llegar aquí tipo entre cinco de la tarde y diez de la noche para encontrarse aquí en 
Bogotá […] La meta de esos comerciantes [y] la hora de partida es las 10 de la noche. […] A la 
una de la mañana comienzan a llegar los compradores que surten la ciudad, que surten los 
municipios, y que surten las poblaciones cercanas al distrito, e inclusive a las ciudades de otros 
Map 1. Red Pin: Ibague. Source Google 
Maps. 
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At night, it can be evidenced that the Plaza Samper Mendoza is right at the 
center of the national trade in medicinal plants. This means that as the plants 
arrive to this point to be traded, the knowledge and practices behind the use 
of those plants also transited through a central point. As a result, Yerbateros 
are the recipients, traders and transmitters of the actual plants and the 
knowledge related to them across a wide network that embraces the entire 
country.   
  
 
departamentos porque los camiones a la madrugada están de salida [entre las 5 am y las 7 
am[…] para llevarlo a una región donde ese cultivo no se da”  Interview with Gerardo Vasquez, 







Pictures 6. Plaza Samper Mendoza at night. 
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As I walked through the corridors and main square of the market, the presence 
of people who were interested in the uses of plants was easy to spot. I 
particularly noticed a group of international people accompanied by a 
Colombian national. I approached the Colombian, who mentioned that he ran 
a sort of informal laboratory that makes preparations from plants and sells 
them to an exclusive market. He also claimed that he normally makes tours 
with international people who are interested in knowing more about plants. 
Unfortunately, he did not want to go on record, be interviewed, or have 
pictures taken of him or his companions, and he gave no reasons for declining. 
But my observations of his activities, and his off-record explanation as 
recounted above gives further evidence of how the knowledge related to 
medicine plants flows freely in the Plaza. 
I was told by several people in the market that the most known Yerbatero was 
Oscar Sanabria. As I approached to Oscar Sanabria, who has been in the 
business for 26 years, I could identify that he occupied not only different stalls 
in La Plaza, but also a large part of floor of the main square (see Pictures 7). 
He was already busy ordering the plants that had just arrived, taking and 
making orders, and ensuring they were dispatched correctly.  
 
 
Since he was occupied, our interview was constantly interrupted by customers, 
collaborators and colleagues who came and went. That activity gave me 
valuable time to form an impression of the Plaza. I observed that, although the 
Pictures 7. Place of Oscar Sanabria’s trade in Plaza Samper Mendoza. 
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trade of plants is a huge operation that includes dozens of Yerbateros, 
customers, truck drivers, workers, security guards, and visitors, the trade was 
rather smooth and well-organized. This is a business that brings together 
people who are familiar with each other, but it is also open to visitors such as 
myself.   
With Mr. Sanabria’s interview, I corroborated most of the data that was 
collected with Yanet Porras. For instance, Yerbateros such as Mr. Sanabria 
and Mrs. Porras have inherited their knowledge through their families. The 
former summarized how he got into medicinal plants as follows: “on my 
mother’s side, it’s a business of my family, from my granny; and because she 
taught my mother, and she taught us.” 369 (Translation by the Author) He also 
mentioned that his sons were getting into the family business too.   
Also, I explicitly asked Mr. Sanabria whether the herbal industry has affected 
the Yerbateros’ trade. He did not hesitate to point out that sales “have fallen 
out of the way”370 because natural pharmacies “have launched so much essence 
[according to his own understanding those are preparations made by the 
herbal industry], so much irrigation [i.e. how Mr. Sanabria describes 
phytomedicines].”371 (Translation by the Author). However, Mr. Sanabria did 
not have any customer from the herbal industry because they pay much less 
than other customers. He even recognized that he used to work with them but 
“it doesn’t give the base [i.e. a word that Mr. Sanabria uses to explain that the 
price does not even cover the actual cost of growing and trading the plant]. It 
doesn’t give the base for the reason that they ask in quantity and they’re going 
to pay a lot cheaper, so it doesn’t work for us”372 (Translation by the Author). 
This is particular alarming because it is not only the fact that stakeholders such 
as the herbal industry directly affect his business, but also this industry does 
 
369 Original transcipt in Spanish: “por parte de mi mamá, es un negocio de mi familia, desde 
mi abuelita; y pues ella le enseño a mi mama, y ella a nosotros” Interview with Oscar Sanabria, 
Plant Seller or Yerbatero, Plaza Samper Mendoza (Bogotá, Colombia, 30th September 2019) 
370 Original transcript in Spanish: “si se han bajado harto las ventas”. Interview with Oscar 
Sanabria, Plant Seller or Yerbatero, Plaza Samper Mendoza (Bogotá, Colombia, 30th 
September 2019)  
371 Original Spanish Transcription: “por lo que han sacada tanta esencia, tanto riego” 
372 Original Spanish Transcription: “hace muchos años trabajamos con ellos, pero es que no 
da la base, no da la base por el motivo que ellos piden en cantidad y van a pagar mucho más 
barato, entonces no nos sirve” Interview with Oscar Sanabria, Plant Seller or Yerbatero, Plaza 
Samper Mendoza (Bogotá, Colombia, 30th September 2019)  
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not even concern itself with making a sustainable trade with Yerbateros for 
their use of medicinal plants. This is despite the fact, as pointed out above, that 
the government aims to make the herbal industry a sustainable business in the 
use of biodiversity.373 
Against this background, I brought the issue if he had any knowledge 
regarding benefit sharing or informed consent. Surprisingly, he actually 
mentioned that he had been told about it: “A person did tell me: ‘don’t start 
giving interviews for that reason’, because it could bring serious consequences 
for me, and that was beneficial to others.” Immediately, I asked him why it 
could bring serious consequences for him, he answered:  
that they did not explain to me but they did tell me not to give 
interviews, and I said to them: ‘I do not know’ if they just ask the 
questions for what such a plant serves, I answer them, I do not see that 
that is a bad thing; and they told me that ‘other people did benefit, but 
what are you benefiting for?’ 374 (Translation by the Author) 
Continuing with his explanation about his perspective on benefit sharing of his 
knowledge, he continued explaining the reasons why he was willing to share 
his understandings of medicinal plants:  “All I do is collaborate with you, and 
I don’t know what you guys are going to do, if you make money or trade this 
interview” (Translation by the Author).375  However, what seems to be a 
collaborative spirit from Yerbateros such as Mr. Sanabria and Mrs. Porras to 
share their knowledge, turns out to be a way to content themselves because of 
promises that other stakeholders have already made to them. Mr. Sanabria 
brought different examples in which researchers from unidentified 
 
373 Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 Política Para 
El Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ 
(n 14). 
374 Original transcript in Spanish“una persona si me dijo, que no me pusiera a dar entrevistas 
por ese motivo, porque podría traer cåircunstancias graves para mi, y eso era beneficio para 
ellos mismos” “ahí sino me explicaron pero si me dijeron que no pusiera a dar entrevistas, y 
les dijo que pues no, que simplemente le hacen las preguntas para que sirve tal planta, pues 
uno les contesta, yo no veo que eso se nada malo, y me dijeron ellos si se beneficia, ¿pero usted 
de que se esta beneficiando?” Interview with Oscar Sanabria, Plant Seller or Yerbatero, Plaza 
Samper Mendoza (Bogotá, Colombia, 30th September 2019) 
375 Original transcript in Spanish: “yo lo único que hago es colaborarle, y ahí si no se que harán 
ustedes, si ganan plata o hacen un comercio con esta entrevista” Interview with Oscar 
Sanabria, Plant Seller or Yerbatero, Plaza Samper Mendoza (Bogotá, Colombia, 30th 
September 2019) 
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universities and people interested in his trade interviewed him, and even went 
to his town in La Mesa to obtain information about his understanding of the 
uses of medicinal plants and the crops.  
Two particular examples from Mr. Sanabria’s interview illustrate how those 
stakeholders have made Yerbateros promises about their knowledge, which 
eventually they were unable to keep. The first example involves a group of 
researchers from an unidentified university:  
About a year and a half ago, four or six came from a university, and 
asked me: ‘how much is my business worth? How much are the plants 
worth?’: I told them: ‘the stall like stands worth four or five million 
[pesos]’376 , [but] she said to me: ‘well, I will buy from you that 
merchandise but that merchandise is useless to me, it is just for a 
study’. That was the answer of the lady.377 (Translation by the Author) 
Clarifying the point, Mr. Sanabria expressed in his own words what the 
researcher said to him:  
I can buy from you all that merchandise, and I return to you the 
merchandise, I give it back to you, back out there at four in the 
morning, I only needed it to study, nothing else.378 
Although further details of this conversation were not provided, it can be 
interpreted to the effect that the failed transaction sought to appropriate Mr. 
Sanabria’s medicinal plants for a period of time, and, potentially, also to use 
his knowledge, without even disclosing what the researcher aimed to achieve. 
Expressions such as “that merchandise is useless to me” and “I only needed it 
to study, nothing else” illustrates the way that Yerbateros such as Mr. Sanabria 
 
376 Between 1200 and 1500 USD 
377 Original transcript in Spanish: “Hace como un año y medio, vinieron cuatro o seis de una 
universidad, y me preguntaron ¿Cuánto vale mi negocio? ¿Cuánto valen las plantas?: Yo les 
dije, así como esta el puesto cuatro o cinco millones, me dijo: bueno yo le compro esa 
mercancía usted pero esa mercancía no me sirve para nada, solo para un estudio. Esa fue la 
respuesta de la señorita”. Interview with Oscar Sanabria, Plant Seller or Yerbatero, Plaza 
Samper Mendoza (Bogotá, Colombia, 30th September 2019)  
378 Original transcript in Spanish: “Yo le puedo comprar toda esa mercancía, y yo su mercancía 
se la regreso, se la regalo otra vez por ahí a las cuatro de la mañana, solo la necesitaban para 
estudiar, nada más” Interview with Oscar Sanabria, Plant Seller or Yerbatero, Plaza Samper 
Mendoza (Bogotá, Colombia, 30th September 2019)  
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perceive how people interested in medicinal plants disregard the role of 
Yerbateros as holders of knowledge. 
The second example is cruder because it involves a visitor from outside the 
country who made Mr. Sanabria promises about how commercially 
successfully Mr. Sanabria’s understanding of medicinal plants would be:        
A gentleman came, a U.S. retired person, he wanted to set up business 
with us to take a plant to another country, to take to another 
department, because we had a gold mine. I told him it may not be a 
gold mine, but at least it provides us with food to eat. [The U.S. 
gentlemen insisted to him] that he [Mr. Sanabria] had a lot of power 
with the plant. [The gentlemen promised to Mr. Sanabria:] ‘if I set up 
a business with you, I would install the business that you want’, as to 
assemble machinery.¡ Mejor dicho que no nos pinto!  [Better said what 
he doesn't paint us!] 379 (Translation by the Author) 
Of course, the U.S. gentlemen has not come back to set up the promised 
business or exploit Mr. Sanabria’s gold mine. Nevertheless, Mr. Sanabria 
immediately raised a remarkable issue about his role and responsibility of the 
Yerbatero; he was genuinely concerned about the side effects of the medicinal 
plants if there was a potential large scale business: “I told [the U.S. gentlemen], 
that it has to be studied […] what the plant is useful for; how many properties 
the plant has” in order to understand the side effects of the plants.380  
The concern of the Yerbatero with the side effects of medicinal plants, and 
their associated responsibility is a point that Mr. Sanabria insistently 
 
379 “Mejor dicho qué no nos pinto” is a colloquial expression that is normally employed to 
describe promises made by someone who exaggerate what he can actually do. Original 
transcript in Spanish: “vino un señor, un pensionado de estados Unidos, el quería montar 
negocio con nosotros para llevar planta a otro país, para llevar a otro departamento, que 
porque nosotros teníamos una mina de plata, le dije puede que no sea una mina de plata, pero 
al menos si le deja para comer” el señor les insistió “que tenia mucho poder con las plantas”     
le prometia “donde yo llegue montar un negocio con ustedes, yo le instalo el negocio que usted 
quiere, que disque para montar maquinas, mejor dicho que no nos pinto”. Interview with 
Oscar Sanabria, Plant Seller or Yerbatero, Plaza Samper Mendoza (Bogotá, Colombia, 30th 
September 2019) 
380 Orginal Transcription in Spanish: “yo le dije, eso toca estudiarlo” por los efectos 
secundarios de un medicamento “para así mismo poder trabajar” “para que sirve, que tantas 
propiedades tiene la planta” Interview with Oscar Sanabria, Plant Seller or Yerbatero, Plaza 
Samper Mendoza (Bogotá, Colombia, 30th September 2019) 
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mentioned throughout the interview. For instance, when he was talking about 
the Anamú he mentioned that it “serves to regulate cancer, but it is very strong, 
it cuts the view a lot, […] it has to be taken, but in a very controlled way”.381 In 
those words, Mr. Sanabria can be observed as a person who not only believes 
in what he does and knows about medicinal plants, but also as a person who 
believes in his responsibility with the well-being of his customers, or perhaps 
better, his patients. Something that in his own words make him “feel well” 
because people assure him that he has levantado382 them.      
 
To summarise this section, the evidence collected in the Plaza Samper 
Mendoza illustrates the complexity of the traditional knowledge and practices 
that lie behind the use of genetic resources by the health industry in Colombia. 
This means that, for instance, forcing the herbal industry to untangle such a 
complex network would result in profound effects on this sector. However, the 
data collected also shows a policy and legal landscape that is particularly 
favorable for the herbal industry, which represents an unbalanced approach 
towards local researchers and holders of knowledge such as the Yerbateros. 
Regarding the former, the interviews with the research group at Javeriana 
University indicate that, while local researchers, who employ “sophisticated 
technologies” need to provide scientifically and technically robust proofs to 
obtain marketing approval, the herbal industry can obtain marketing approval 
by documenting traditional knowledge, which means this industry does not 
need to cover the cost of preclinical or clinical trials.  Also, the interviewees 
consider it is unfair to local researchers, in that they have to comply with the 
regulation on access to genetic resources and benefit sharing regulations, 
while the herbal industry is not subjected to this legislation.  
 
Regarding the holders of knowledge, the International Regime on Access to 
Genetic Resources and Benefit Sharing is not even acknowledged in places of 
trade of medicinal plants such as Plaza Samper Mendoza, meaning that the 
 
381 Original Transcription in Spanish: “sirve para regular el cáncer, sino que es muy fuerte, 
corta mucho la vista” “toca tomarlo, pero muy controlado”. Interview with Oscar Sanabria, 
Plant Seller or Yerbatero, Plaza Samper Mendoza (Bogotá, Colombia, 30th September 2019) 
382 Levantado is a coloquial expression that litaraly translated “raised”, but whose meaning is 
to make people recover from an illness.  
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knowledge and practices behind the uses of those genetic resources are placed 
into the public domain. As a result, local authorities such as IPES and the 
herbal industry transform the role of Yerbateros as providers of the raw 
material into a mere chain value for the herbal industry.  This is despite the 
fact that the government aims to make the herbal industry a sustainable 
business in the use of biodiversity.  
 
However, this is not the only way in which authorities are placing knowledge 
and practices into the public domain, so stakeholders such as the herbal 
industry can freely access them. An ongoing effort to document those uses is 
also placing them into the public domain.   
 
Documenting Information on Medicinal Plants 
 
The analysis above shows that, in practice, it is difficult to determine who 
‘holds’ knowledge that sits behind the use of medicinal plants. Further, even if 
those persons could be identified, it is far from clear how they should be 
publicly consulted and what benefit sharing mechanism should be put in place. 
Since Colombia has not been able to answer those questions, knowledge and 
practices ended up being simply placed into the public domain. As a result, 
anyone can freely access it without publicly consulting those actors or meeting 
any legal requirements. However, in an effort to comply with the UN 
Convention on Biological Diversity’s goals of conservation and sustainable use 
of biodiversity, the government and scholars have been documenting such 
practices and knowledge. 
 
Since 2003, there has been increasing literature and research on the medicinal 
properties and potential commercialisation of plants in Colombia. Díaz carried 
out one of the pioneering ethnobotanical studies in the country which 
identified the plants most employed by specialized pharmacies, laboratories 
and urban markets.383 For instance, this study found that the most popular 
plants in the production of phytomedicines by laboratories were Caléndula 
 
383 Diaz (n 335). 
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(Calendula officinalis), Alcachofa (Cynara scolymus), and Valeriana 
(Valeriana officianalis).  
 
None of those plants are native to Colombia, yet they are all locally cultivated. 
Moreover, the same study also found that both urban markets and laboratories 
also commercialized native species for medical purposes. These include: Sauco 
(Sambucus nigra) employed as expectorants;384 Totumo (Crescentia cujete) 
used in the treatment of respiratory and bronchial affections; 385 Diente de 
León (Taraxacum officinale) to treat liver conditions, and lower cholesterol 
and uric acid levels;386 Anamú (Petiveria alliacea) employed in patients with 
cancer;387 Sangre de Dragon (Croton lechleri) used in the treatment of gastritis 
and ulcers, and a curative of skin disorders;388 and Prontoalivio (Lippia alba) 
employed as an analgesic.389 A key aspect of Diaz’s study is that most of the 
information on the medical properties of all six plants was collected from 
interviews with sellers in urban markets. For instance, it was in the urban 
markets of 7 different cities (Bogotá, Medellin, Cali, Ibagué, Villavicencio, 
Manizales, and Armenia) where the study found that the Sangre de Leon was 
sold to treat gastritis, ulcers, and skin disorders.390  
 
Similarly, Quintero et al. carried out a study in the use of 26 medicinal plants 
in Bogotá’s urban markets.391 Quintero et al. not only researched the alleged 
medical properties of different plants, but also asked sellers for the traditional 
uses and medical practices related to the plants, and how they recommend 
buyers to prepare them.392 Through numerous interviews with sellers, 
Quintero et al. were able to document what are the most popular plants, what 
diseases those plants can treat and how Yerbateros recommend patients to 
prepare them. For instance, this study found that the Albahaca (Ocimum 
 
384 ibid., p 32 
385 ibid., p 37 
386 ibid., p 41 
387 ibid., p 49 
388 ibid., p 57 
389 ibid., p 64 
390 ibid., pp 57-58 
391 Sara Emilia Giraldo Quintero and others, ‘Descripción Del Uso Tradicional de Plantas 
Medicinales En Mercados Populares de Bogotá, DC’ (2015) 13 Nova 73. 
392 ibid., p 75 
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americanum) is employed in the treatment of stomachache, colon 
complications, and kidney stones. Other plants and uses include: Caléndula 
(Calendula officinalis) used in swelling conditions, ulcers, gastritis, etc.; 
Cidrón (Aloysia citriodora) for digestive disorders and blood circulation; Cola 
de caballo (Equisetum bogotense) to treat kidney stones and employed as a 
diuretic; Manzanilla (Matricaria chamomilla) used for headaches, muscle 
relaxation, stress and so on; and Ruda (Ruta graveolens) employed to treat 
women’s womb complications.393 Although most of the plants studied were 
non-native of Colombia, the actual practices and knowledge that reveal the 
medical properties and ways to prepare them were obtained from interviews 
with Yerbaeros in those urban markets.  
 
More recently, Pabón et al. researched medicinal plants for infectious diseases 
(urogenital, respiratory, gastrointestinal, and skin and eye infections) in La 
Plaza de Mercado Samper Mendoza.394 Among the 122 plants researched, the 
study confirmed Díaz’ and Quintero et al.’s findings concerning the medicinal 
properties of plants such as Calendula, Manzanilla and Cola de Caballo.395 
However, this research has a wider scope than those of Díaz and Quintero et 
al. In fact, the interviews with sellers in Samper Mendoza led the research 
team to trace practices and knowledge up to three family generations of sellers. 
The study offers clues that such knowledge and practices were obtained from 
different regions of the country, such as Cundinamarca, Tolima, Valle del 
Cuca, Choco, Amazonia and Caquetá. Unfortunately, this study is limited in its 
scope, and only briefly mentions the geographical origin of those practices and 
knowledge without unravelling the complex network of actors behind those 
practices and knowledge.  
 
All in all, the interest from researchers in documenting practice and knowledge 
on medicinal plants in urban markets reveals how important Yerbateros in 
urban markets are in providing information to help us understand Colombia’s 
 
393 ibid., p 77 
394 Ludy C Pabón, Martha F Rodríguez and Patricia Hernández-Rodríguez, ‘Plantas 
Medicinales Que Se Comercializan En Bogotá (Colombia) Para El Tratamiento de 
Enfermedades Infecciosas’ (2017) 16 Boletín Latinoamericano y del Caribe de Plantas 
Medicinales y Aromáticas 1 529. 
395 ibid., p 532 
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biodiversity. However, ethnobotanical research in Plazas de Mercado has 
fundamental problems in how it is conducted. First, there are no mechanisms 
in which Yerbateros are taken into account, in terms of how the information 
that they provide would be employed. This is because such a contribution, as 
soon as it leaves those urban markets, becomes part of the public domain. 
Second, the ethnobotanic research carried out in Plazas de Mercado only tells 
a part of the story of the practices and knowledge associated with plants, 
because Yerbateros are only a part of the complex network of actors behind 
the contribution that helps us to understand Colombia’s biodiversity.  
 
In addition, the Colombian government has sponsored two reports that collect 
further information on different communities’ (Afro-Colombian, local and 
indigenous) practices and knowledge associated with medicinal plants. Under 
the umbrella of conservation and sustainable use of Colombia’s biodiversity, 
in 2011 and 2017 the Ministry of the Environment commissioned reports that 
aim to create alternative businesses which contribute to the protection of 
environment, according to the UN Convention on Biological Diversity goals of 
conservation and sustainability.  
 
However, a key aspect of both reports is that they call for improving the 
understanding of knowledge and practices of medicinal plants by seeking 
further efforts to collect such information without carrying out public 
consultations. For instance, the 2011 report calls authorities to safeguard and 
restore traditional knowledge associated with medicinal plants by creating in 
situ collections of those plants, and promoting that holders share those 
practices and knowledge with academics and scientists.396 The report makes 
no mention of whether communities should be consulted before those 
activities takes place. Nor does the report establish any mechanism to secure 
benefit sharing. Furthermore, the 2017 report highlights that the importance 
of collecting the knowledge and practices of communities lies in the necessity 
of protecting them since they constitute “an intangible heritage of the country 
and humanity”.397 In other words, this report states that the importance of 
 
396 Bernal, García Martínez and Quevedo Sánchez (n 318)., pp 157-158 
397 Castellanos Castro, Safrony Esmeral and Higuera Diaz (n 265), p 58. 
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conserving practices and knowledge does not rest in securing the fundamental 
rights of communities over such information, but rather in the fact that these 
practices and knowledge belong to the country and humanity in general. This 
approach is far from that required by the UN regime on Access to Genetic 
Resources and Benefit Sharing. 
 
In line with those reports, Colombian authorities have also been promoting 
the documentation of practices and knowledge to facilitate the 
commercialisation of traditional phytomedicines. For instance, there is the 
Vademécum Colombiano de Plantas Medicinales, which is the Colombian 
official pharmacopeia for medicinal plants elaborated by the Specialised 
Working Group of Natural Products of the Ministry of Health.398 This 
document officially collects the species used in Colombia for medicinal 
purposes. It also provides specific information on plant parts, stem, fruits, 
roots, or the plant as a whole. Additionally, the Vademécum mentions the 
phytotoxic properties of the plant, their method of consumption and 
therapeutic form. This document also gives information on the traditional uses 
of the plants. Notwithstanding, holders of traditional knowledge and practices 
are not previously consulted on whether they want to include their knowledge 
and practices in a public document. 
 
But the fact that communities are not consulted in the documenting process of 
medicinal plants is not the only problematic aspect of the regulation. The 
Vademécum is not only a public and official document that collects 
information on the medical properties of plants, but it is also a pharmacopeia 
that assists the producers of herbal medicines in proving the therapeutic value 
of phytomedicines so as to obtain marketing authorisations.399 This means 
that it is the Colombian government itself, through the Ministry of Health, 
which promotes the collecting of information on practices and knowledge 
associated with genetic resources to facilitate the commercialisation of 
phytomedicines without previously consulting right holders.   
 
398 For further information of the Vademécum see Sala Especializada de Productos Naturales 
(n 213).   
399 See Article 3 of Decree 2266 and Resolution 2834 of 2008 of the Ministry of Health  
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This means that those academic and governmental efforts to document 
practices and knowledge on Colombian biodiversity do not aim to unravel the 
complex network of actors so as to enforce Decision 391 and the constitution, 
but they have instead served to place into the public domain those practices 
and knowledge, where sectors such as the herbal industry can easily access and 
use them. As observed in the case of academic research in urban markets, 
those investigations have a limited scope as they only obtain information 
directly from Yerbateros rather than analysing further actors who are 
responsible for revealing practice and knowledge.  
 
Instead, the scope of that research and those official documents can be used 
for different purposes other than simply documenting Colombia’s biodiversity 
and traditional knowledge for conservation and sustainability. In fact, studies 
such as those of Díaz, Quintero et al., and Pabon et al. have served to prove the 
therapeutic effect of medicinal plants. When the plants commercialised in 
urban markets are cross-referenced with marketing approvals for 
phytomedicines, it can be observed how the herbal industry benefits from the 
documented knowledge and practices on the medicinal use of native and 
introduced plants. For instance, public records of traditional phytomedicines’ 
marketing approvals indicate that the Albahaca is registered for stomach ache, 
as was found in urban markets in Quintero et al.’s study. Similar evidence 
exists for other plants such as Caléndula, Cidrón, Cola de caballo, Manzanilla, 
Ruda, Sauco, Totumo, Diente de León, Anamú, Sangre de Dragon, and 
Prontoalivio.400 
 
As a result, the herbal industry greatly benefits from publicly funded research, 
as it employs such information for the production, distribution, and obtaining 
market authorisation for phytomedicines. However, this is not only the result 
of a designed approach by the herbal industry towards such knowledge and 
practice, but it also departs from the interest of Colombian authorities in 
 
400 The study of Quintero and others (n 295) was cross-referenced by the author with the 
National Health Autorothy, Instituto Nacional de Vigilancia y Control de Medicamentos y 
Alimentos (INVIMA), list of phytomedicines approved for commercialisation see INVIMA (n 
335). 
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engaging the industry when it uses them, as was demonstrated in the previous 
section.  
 
Therefore, it is important to question how this process of documentation of 
communities’ practice and knowledge could have a more balanced approach 
that benefits both the herbal industry and communities. Ideally, those 
academic and, especially, governmental efforts should be addressed to create 
an inclusive industry. Consequently, the collection of information relating to 
medicinal plants in Colombia should not be constructed exclusively in terms 
of identifying the therapeutic value of those genetic resources, but also in ways 
that help to identify who are the actors behind the medicinal plants and how 
much they have contributed to unravelling the therapeutic value of medicinal 
plants. In that way, it would be possible to require, through a set of regulatory 
mechanisms applicable to the herbal industry, a responsibility to publicly 
consult communities when the industry employs their practices and 




This chapter analysed the market for medicinal plants, which includes two 
main actors: the herbal industry and urban markets. While the former has 
been favoured by a supportive regulatory framework, and a sustainable policy 
on the use of biodiversity for the production and distribution of 
phytomedicines, the latter has not been included in the country’s strategy of 
sustainable use and conservation of Colombia’s biodiversity. This is despite the 
fact that it is in urban markets where practice and knowledge in the use of 
medicinal plants flows to the public. Although it is difficult to unravel the 
complex network behind the use of medicinal plants so as to identify who 
contributes to the understanding of medicinal plants, and also how, there are 
efforts to document those plants and their indigenously and locally known 
curative properties and uses.  
 
However, as this chapter explains, the documenting of indigenous, local, and 
Afro-Colombian communities’ practices and knowledge associated with 
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medicinal plants has placed such information into the public domain, where 
anyone can access and employ it without publicly consulting those 
communities. Similarly, under the umbrella of conservation and 
sustainability, the Colombian government itself has also documented those 
practices and knowledge in two different reports and the official pharmacopeia 
for phytomedicines.  
 
In one of those reports, it has even been suggested that communities’ 
contribution is something that belongs to the country and even to humankind 
in general. The effect is that communities cannot decide whether their 
knowledge should be documented and, consequently, launched into the public 
domain to be employed. This is the case with the herbal industry which has 
benefited from those documenting efforts and from regulations on medicinal 
safety and efficacy, in order to produce and distribute phytomedicines in 
Colombia.  
 
It is also important to notice that while another stakeholder, local researchers, 
who access genetic resources, including traditional knowledge related to those 
resources, are required to comply not only with access and benefit sharing, and 
market approval regulation, in case they want to commercialise a final 
product, the herbal industry is not subjected of any of those requirements.   
 
Although the herbal industry is a growing sector and contributes to the 
sustainable economic development of the country, it cannot be left outside of 
the scope of Decision 391 rules or the Constitutional Court’s rulings since it 
clearly benefits from practices and knowledge that do not belong to the 
industry. It follows that it is important to create a balance between the 
interests of the growing herbal industry and local researchers, and the 
protection of indigenous, local, and Afro-Colombian communities’ rights over 
their practices and knowledge. The next chapter proposes legal alternatives to 
achieve such a balance.  
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Chapter Six: Sustainable and Inclusive Innovation in 
Health Research and Health Industry 
Introduction  
 
As observed in Chapter Two, the main objective of the International Regime 
on Access to Genetic Resources and Benefit Sharing, which includes the UN 
Convention on Biological Diversity, the Bonn Guidelines, and the Nagoya 
Protocol, is that developing countries rich in biodiversity can obtain, through 
a compensatory mechanism, benefits from the utilisation of genetic resources 
by allowing access-control to them. In other words, what the International 
Regime on Access to Genetic Resources and Benefit Sharing intends to achieve 
is that those who employ genetic resources as a source (i.e. users) to bring 
products and process into the market, share the benefits of their inventions 
such as transfer of technology or joint ownership of intellectual property 
rights. The International Regime on Access to Genetic Resources and Benefit 
Sharing requires Members of the UN Convention on Biological Diversity to 
create legal and administrative mechanisms to secure benefit sharing. Those 
mechanisms include prior informed consent, mutually agreed terms, and 
mechanisms of compliance. Equally, the regime also calls on members to 
include communities in the negotiation of terms and conditions of access and 
the benefits that arise from the utilization of those resources associated with 
their knowledge. 
  
However, the implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing in developing countries rich in 
biodiversity has brought different dynamics which have been overwhelming 
for those countries. This is observed, as analysed in Chapters Three, Four and 
Five, in Colombia. As Colombia has grown in economic terms and has an 
ambitious agenda to make the country more competitive in international 
trade, it has designed its science and technology policies in line with the Oslo 
Manual,401 leaving aside other practices and knowledge from local, 
 
401 OECD and Eurostat (n 216). 
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indigenous, and Afro-Colombian communities associated with genetic 
resources in its innovation policy towards the use of biodiversity.  
 
This has occurred despite the fact that, in the case of Colombia, those 
communities have been entitled – by constitutional mandates and the Andean 
regulation (Decision 391) – to fundamental rights over their economic and 
sociocultural relationship with biodiversity (see Chapter Three). As a result, 
there is a fragmentation within the state regarding the protection of those 
communities’ knowledge and practices. While there is a market-oriented 
policy to benefit local researchers, there are constitutional and regional 
mandates that have been ignored by local authorities in the implementation of 
the International Regime on Access to Genetic Resources and Benefit Sharing 
(see Chapter Four).  
 
Further, the herbal industry has brought a significant regulatory challenge 
regarding the use of medicinal plants for the production and distribution of 
traditional phytomedicines. For instance, the therapeutic effect of those 
pharmaceutical products can be demonstrated by the documentation of 
traditional knowledge of indigenous, local, and Afro-Colombian communities 
or by proving that the medicinal plants have been used for more than three 
generations in Colombia. That therapeutic effect would otherwise have to be 
demonstrated by expensive and time-consuming clinical trials. Yet, the herbal 
industry is not required to comply with access and benefit sharing 
requirements, such as obtaining prior informed consent and signing up to 
mutually agreed terms with the government, as well as publicly consulting 
communities to produce and commercialize phytomedicines (see Chapter 
Five). This also reflected in the fact that the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing was 
designed to secure benefit sharing from holders of important technological 
assets, that transform genetic resources into products and process, but not to 
“less technological” sectors such as the herbal medicine industry. Even more, 
the analysis of the Colombian herbal industry also reflects the difficulty of 
including different actors that add value in the use of Colombian biodiversity. 
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Such a situation is not only a matter of breaching the Colombian constitutional 
mandates and Andean legislation, but also it is a matter of justice towards 
those communities that have long been victimised by landowners, 
paramilitary groups, guerrilla warriors, drug barons, corrupt elites, etc. 
through Colombia’s long history of violence and exclusion (see Chapter One).  
 
To provide a response to these problems, this chapter and the following one 
propose to continue with the analysis of Colombian actors and conditions in 
health research and the health industry. The previous chapters describe the 
different dynamics and problems behind the use of communities’ knowledge 
and practices associated with genetic resources for health research and the 
health industry. This chapter seeks to make a normative claim to justify a more 
inclusive health industry and health research, in which different actors’ 
knowledge over genetic resources is recognised and effectively protected 
through the innovation process.  
 
In order to move towards a more inclusive approach to the implementation of 
the International Regime on Access to Genetic Resources and Benefit Sharing, 
it is necessary to protect and safeguard all activities that add value to the use 
of biodiversity, including the use of technologies such as biotechnology, 
traditional knowledge, local practices and overall to include all actors and 
conditions that are involved in the use of biodiversity for different sectors such 
as health. This claim to inclusion can be accommodated within Sen’s 
Capability Approach. Sen’s framework seeks to secure more inclusive 
economic development by asserting that people’s well-being cannot be 
assessed exclusively in economic terms such as per capita income. The 
Capability Approach rather focuses on people’s conditions, i.e. what people are 
capable of doing and being, so they can live a life according to those doings and 
beings, (or so called functionings), making life worth living. In that way, Sen 
includes within economic analysis different aspects of life, which go beyond 
maximisation of wealth or property, in order to entitle people and 
communities to pursue what they consider a good or worthwhile life.  
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More specifically, the Capability Approach provides a platform for setting out 
to achieve specific goals. It does this by evaluating specific conditions in the 
form of functionings, what people are capable of being or doing. Eventually, a 
bundle or list of functionings are put together to create a capability. A 
capability entitles people to freely choose among a list of functionings as to 
how to achieve that particular capability. For instance, the capability for 
education could encompass a list of functionings such as reading, writing or 
having access to educational material. Without the choice among the 
functionings, people’s freedom to choose a life worth living is compromised 
and they are excluded from full participation in society. Translating this 
approach into the thesis, local, indigenous, and Afro-Colombian communities 
in Colombia should be afforded a full choice of functionings – capabilities of 
doing and being – through the ways that Colombian law and practice enables 
their engagement with its innovation industries, including health research and 
the health industry. Since innovation, and the way that is measured, is biased 
towards holders of technology in industries such as health, the 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing in Colombia should be designed to include the different 
conditions behind the use of biodiversity in the form of functionings, what 
local, indigenous, and Afro-Colombian communities are capable of doing and 
being.  
 
This chapter explores the claim that there should be a capability for 
sustainable innovation in health research and the health industry (or 
capability for sustainable innovation in general) in developing countries rich 
in biodiversity. In particular, the chapter considers that, since communities’ 
practices and knowledge associated with genetic resources have a 
constitutional protection, they should also be included in the innovation policy 
of the country; policy that aims to improve and make the country’s scientific 
capability competitive in international markets, as well as promoting the 
sustainable use of medicinal plants in the herbal industry. This chapter then 
introduces a list of components upon which such a capability could be 
constructed, i.e. functionings, in Sen’s terms. Those functionings provide a 
frame through which Colombian implementation of the International Regime 
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on Access to Genetic Resources and Benefit Sharing can be evaluated, in order 
to move towards a more inclusive approach in Colombia, through suggesting 
practical legal reforms.  
 
Although this thesis has argued that the Colombian market-oriented policy 
and law behind innovation and sustainable development is accountable for 
creating a sub-optimal situation for communities, it does not distance itself 
entirely from Colombia’s aspiration of using its biodiversity to further its 
economic development and increase its scientific and technical capacity. 
 
The data collected in Chapters 4 and 5 points out that there are two 
stakeholders, i.e. local researchers and the herbal industry, that aim to 
consolidate Colombia’s policy of sustainable use of biodiversity, whose main 
aim is to bring products and process to the market without due consideration 
to other actors and conditions: on one hand, local researchers such as the 
Javeriana research group, are emphatic to stress that “innovation lies in the 
possibility of taking all these resources [Colombia’s biodiversity and 
communities’ practices and knowledge] and making them useful for society" 
(Translation by the author);402  a laudable objective that seeks to make genetic 
resources and the practices and knowledge related to them available to society 
in the form of pharmaceutical products to treat disorders such as cancer. It 
also aims to create a chain of value in which local communities of peasants, 
whose knowledge and practices led the research group to the 
autoinflammatory properties of the Dividivi, are place to grow the crop. 
Nevertheless, local communities, and their practices and knowledge, have not 
been acknowledged as innovative.  
 
On the other hand, the government has been successful in promoting a 
growing herbal industry in the use of biodiversity as part of its strategy of 
 
402 Original transcript in Spanish “la innovación esta en poder en tomar todos estos recursos 
[biodiversidad colombiana, y practicas y conocimiento de las comunidades] y convertirlo en 
algo útil para la sociedad” Interview with Wilmar Olaya, Agriculture Engineer and Regulatory 
expert at the Immunology Javeriana Research Group, Javeriana University (Bogotá, Colombia, 19th 
September 2019) 
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sustainability.403 As a result, the herbal industry has benefited from a 
favourable legal and policy landscape, which has allowed the industry to freely 
access genetic resources to distribute and produce phytomedicines, including 
traditional phytotherapeutic products, as well as employing those resources 
and communities’ knowledge to prove safety and effectiveness of their 
products. Yet, communities that have transformed, transmitted and trade 
practices and knowledge in urban markets, such as Yerbateros in the Plaza 
Samper Mendoza, have seen their business affected by this industry and their 
knowledge freely disseminated and placed into the public domain. Also, the 
regulation of phytomedicines, including traditional phytomedicines, has been 
unbalanced towards local researchers, as they are required not only to comply 
with access and benefit sharing regulation, but also with stricter marketing 
approval procedures, while there are no similar obligations applicable to the 
herbal industry. 
 
Therefore, what this thesis suggests, and particularly this chapter, is to secure 
that Colombian law and policy properly acknowledge the different actors 
(communities, local researchers and the herbal industry) and conditions 
behind the use of genetic resources for health industry and health research. 
The reason that this thesis is more focused on the position of various 
Colombian communities, and especially local (peasant) communities, is 
because, as has been observed in the previous chapters, those communities 
have not benefited from the implementation of the International Regime on 
Access to Genetic Resources and Benefit Sharing, whereas local researchers 
and the herbal industry have benefited, to some less or greater extent, from 
different policies and regulations that aim to recognise their role in the use of 
medicinal plants. The objective of this thesis fits within the Capability 
Approach as, through a normative claim (i.e. an inclusive sustainable 
innovation), the thesis aims to add information that brings into view social 
aspects, more explicitly communities’ concerns, that have been ignored in the 
 
403 Consejo Nacional de Política Económica y Social, ‘Documento Conpes 3697 Política Para El 
Desarrollo Comercial de La Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ (n 14)., 
p22 
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development of an economic agenda and a market perspective in the use of 
biodiversity in an specific country.      
 
The first part of the chapter discusses Sen’s Capability Approach and correlates 
his economic analysis of countries’ economic development with the different 
problems that are highlighted in the previous chapters. In particular, this part 
highlights that innovation and its measurement in countries’ productivity 
leaves out other aspects of capability, such as the valuable contribution of the 
network of actors and conditions behind biodiversity. To make a more 
inclusive innovation in health research and the health industry, practices and 
knowledge from communities should also be considered. This would require 
that, in the implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing, what communities are capable of doing and 
being (i.e. functionings) should be included. The second part of the chapter 
puts that claim into material effect, in the form of outlining a capability for 
sustainable innovation. This also allows, in the third part, to establish a list of 
relevant functionings. The overall aim of this chapter is to provide an approach 
that the following chapter can employ, in order to make concrete and practical 
proposals on how to address current deficiencies in Colombian 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing and the role of communities in innovation.  
 
Sen’s Capability Approach and the Capability for Sustainable Innovation 
 
Sen’s work criticises the way in which countries’ economic development is 
evaluated since the assessment is carried out in economic terms such as 
growth in GDP per capita, rather than placing people at the centre. As a result, 
Sen proposes to evaluate whether people have the capability to live a good life 
through an evaluation of what they are cable of doing and being. Therefore, 
poverty, for instance, is not defined in terms of income, but it is studied as the 
deprivation of the capability to live a good life, a life in which people are able 
to be well educated, well nourished, have shelter or have access to public 
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transportation. Since Sen centres on human capabilities, what people can do 
and be, his work is known as the Capability Approach. 404  
 
The Capability Approach provides a platform for achieving specific legal or 
policy goals in the form of a capability, by evaluating the specific people’s 
conditions. This is what people are able of being or doing so as to achieve that 
capability. People’s conditions are framed in the form of a bundle or list of 
functionings, which are put together to create, and therefore, achieve the 
capability. To that end, people are entitled to freely choose among the list of 
functionings, so as to determine how to achieve that particular capability. For 
instance, as already noted above, a capability for education could encompass 
a list of functionings such as reading, writing or having access to educational 
material. Therefore, a state of capability is one in which people can freely 
choose and combine from a list of functionings the kind of education they 
consider worth receiving. Another example is the capability to mobilise, which 
includes functionings such as walking, riding a bicycle, taking public transport, 
and so on. In this example, the entitlement that the capability to mobilise 
provides is the freedom that people possess to choose one of those functionings 
to achieve that particular capability. Without the functionings, people are 
denied a capability, and are as excluded from society as if they were living in 
material poverty. 
 
Sen’s Capability Approach takes as the centre of its analysis people and 
freedom of choice, rather than other measures of quality of life such as 
contentment, e.g. the pleasure that is produced by owning certain 
commodities; or the allocation of resources. In that regard, the Capability 
Approach observes that means such as commodities or wealth cannot be the 
only measure of well-being, but it is also important to observe people’s own 
conditions.405 Take poverty and disability as an example: A way to evaluate 
 
404 Sen elaborates the capability approach throughout different papers, but the first one in 
which he actually mentions a particular capability is Sen, ‘Equality of What?’ (n 22). He 
eventually went on forming its theory in specific task such as poverty and quality of life in 
Amartya Sen, ‘Poor, Relatively Speaking’ (1983) 35 Oxford Economic Papers, New Series 
Oxford Economic Papers 153. or human development in Amartya Sen, Development as 
Freedom (Oxford University Press 1998).   
405 Amartya Sen, ‘Freedom of Choice’ (1988) 32 European Economic Review 269. 
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whether a person is living in poverty is by observing if he or she is above or 
below the per capita income; however, there are conditions that vary the way 
that income can affect people’s functionings such as geographical location, 
gender or disabilities.406 If there is an exclusive focus on income, a disabled 
person would just require more income than a full functional individual to not 
be considered poor; but distribution of income does not consider that there are 
other valuable things that makes life worth living since disability also deprives 
people from carrying out valuable activities such as taking public transport, 
participating in the workplace or political life, or being able secure access to 
proper care.  
 
Consequently, Sen proposes to give further information on how people fare in 
a particular society by analysing functionings. Continuing with the example of 
poverty and disability, for Sen it is important to analyse, apart from income, 
how disabilities would deprive people from transforming income into 
functionings such as being educated, being well nourished, having shelter or 
taking public transport, rather than just meeting an index such as per capita 
income. People are placed at the centre, not material income or wealth. 
Furthermore, Sen’s approach also acknowledges that people’s own conditions 
make them vary the way that they want to transform resources into proper 
functionings, e.g. being well nourished would depend on people’s body size, 
special food requirements (gluten free or vegetarian), gender, etc., rather than 
giving them food or having contentment from eating a good meal.407 
 
The idea of placing people at the centre and acknowledging their conditions is 
thus also in line with Sen’s freedom of choice. Indeed, Sen claims that an 
important element is people’s freedom to select from alternatives that are 
presented to them, so they can decide what kind of life they want to achieve 
accordingly to what they are capable of doing or being.408 As a result of its 
intrinsic value, freedom of choice ought to recognise the existence of a great 
diversity of conditions that have an impact on each individual’s way to achieve 
 
406 Sen, Development as Freedom (n 404). p 88 
407 Sen, ‘Freedom of Choice’ (n 405). p 277-278 
408 ibid. p 278 
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functionings. To that end, Sen structures each capability as a set or “bundles 
of functionings”409 within which people have the freedom to choose. 
Therefore, as people are presented with a list of functionings to achieve a 
capability, they are entitled to select the life that they want to lead. By 
providing people with genuine opportunities to choose the kind of life that they 
wish, Sen’s Capability Approach offers an alternative to an economic analysis 
or approach to structuring society, including its laws and policies.410  
 
Sen’s work, therefore, represents an opportunity to analyse people’s own 
conditions, in the form of capabilities or bundle of functionings, and entitle 
them to the ability to choose, so they can live a life worth living. However, it is 
now important to explain how capabilities and the list of functionings is 
constructed to establish normative claims, and whether Sen’s approach can be 
extended beyond a descriptive analysis. This is important because this thesis 
aims, as discussed above, to establish a normative claim which would then 
provide a framework in which the complexities and “messiness” of the law can 
be addressed, and law and policy changes can be justified on the basis of their 
greater inclusivity.  
 
Although Sen’s Capability Approach focuses on including societal goals within 
economic analysis, his work is not restricted exclusively to that area. Rather, it 
has been deployed to understand a broad range of issues, including the 
implementation of international treaties in developing countries, at issue in 
this thesis. For instance, Chon pointed out the importance of discussing a 
“capability for education”411 in the context of developing countries’ 
implementation of international treaties on copyright such as the World 
Intellectual Property Organization’s (WIPO) Berne Convention for the 
Protection of Literary and Artistic Works, since the exclusivity rights granted 
by copyrights on educational and scientific works limits people’s ability to 
access textbooks. Clague takes a similar task on the global structure of patent 
 
409 ibid. 
410 As mentioned above, such analyses seeks to solve the problem of well-being, by focusing on 
what is good for people in terms of happiness, i.e. how to make prevail pleasure over pain, or 
by allocating resources. 
411 Margaret Chon, ‘Intellectual Property from Below: Copyright and Capability for Education’ 
(2007) 40 UC Davis Law Review. 
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regulation, especially TRIPs, and biotechnological inventions, since this treaty 
has long benefited economic interests over developing countries’ ability to 
respond adequately to, for instance, pandemic diseases such as HIV/AIDS.412 
The reason why the Capability Approach can be deployed in these different 
types of contexts is because it is a framework that is able to encompass many 
modalities that affect people’s capability of being or doing. Since people’s 
capability can be affected by economic decisions, regulations and policies, it is 
possible to employ the Capability Approach in a wide range of interdisciplinary 
work, including socio-legal studies like this thesis. The Capability Approach is 
not a fixed theory, but a flexible analytical tool whose nature permits it to be 
used to set up normative claims in the form of a capability. Once established, 
an evaluation can be carried out to achieve a specific capability in different 
scholarly and other contexts.  
 
Having discussed why the Capability Approach can be employed in areas 
beyond economics, the current analysis should move towards how the bundle 
of functionings and the capability are constructed. It needs to be mentioned in 
the first place that, since the Capability Approach is a dynamic framework that 
helps to solve different aspects in people’s lives, and which prizes autonomy of 
choice, the Capability Approach always requires as much flexibility as possible. 
That is why Sen himself argues that there cannot be a fixed or canonical list of 
capabilities or functionings, but those need to be selected according to the 
purpose(s) that are to be accomplished. For instance, selecting a list of 
functionings to achieve the capability to live a good life, would be completely 
different from the list of functioning to achieve the capability to appear in 
public; hence, Sen considers that selecting a list of functionings should 
respond to variables such as priorities as well as the specific goal to be 
achieved.413 For example, capabilities for people who live in a least developed 
country are very different from those in developed countries, since the former 
aims to solve basic needs such as sanitation or basic human rights, while (at 
least in theory) citizens in a developed country, who can already count on those 
 
412 Julie Clague, ‘“Patent Injustice”: Applying Sen’s Capability Approach to Biotechnologies’ 
(Springer Netherlands 2006). 
413 Amartya Sen, ‘Capabilities, Lists, and Public Reason: Continuing the Conversation’ (2004) 
10 Feminist Economics 77. 
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basic needs, aim to achieve diverse social goals, such as gender equality among 
children.  
 
Nevertheless, Sen does not oppose the creation of a list of capabilities for 
specific purposes such as measuring poverty in specific countries or creating a 
list of basic human rights. On this point, for example, Nussbaum, from a 
philosophical perspective, articulates a list of capabilities based upon human 
dignity, which should be included in every country’s constitution.414 Yet, 
Nussbaum does not preclude the possibility of reviewing her list of capabilities 
to continuously adapt it to new circumstances.415  
 
Since the Capability Approach offers a framework that can be employed in 
interdisciplinary work to set normative claims in the form of capabilities and 
carry out an evaluation of people’s conditions (i.e. functionings), it is possible 
to provide a framework in which the variables identified in the previous 
chapters can be addressed.  
 
Nevertheless, there are aspects in which the Capability Approach is 
continuously challenged. For instance, the impossibility of constructing a full 
account of justice or theory of justice. This is to create a theory in which people 
and institutions can agree a set of principles that regulate all aspects of life.416 
Yet, authors such as Nussbaum have developed partial theories of justice based 
upon the Capability Approach to justify a set of capabilities which should be 
the cornerstone of any institution and law in any country (“the Central Human 
Capabilities”).417 However, Nussbaum’s lists of capabilities have faced 
 
414 Martha Nussbaum, Frontier of Justice: Disability, Nationality and Species Membership 
(Harvard University Press 2007). Nussbaum initially proposed her list of capabilities in 
Martha Nussbaum, Women and Human Development : The Capabilities Approach 
(Cambridge University Press 2000)., see also Martha Nussbaum, ‘Capabilities as 
Fundamental Entitlements: Sen and Social Justice’ (2003) 9 Feminist Economics 33. 
415Nussbaum, Frontier of Justice: Disability, Nationality and Species Membership (n 414)., p 
76 
416 For instance, social contract theories argue that legitimate authority and the content of moral norms 
derive from the implicit or express consent of the governed. This stems from the idea of an initial 
position, renamed the ‘original position’ by Rawls, and parties which are usually considered to be 
rational. Additionally, parties are motivated to come an agreement because there is a mutual advantage 
for those who participate in the construction of the social contract.  Author’s such as Kant, and, more 
recently, Rawls argue that such a mutual benefit can be expressed in terms of an overlapping consensus 
of what can be considered fair or how to achieve justice. 
417 Nussbaum, Frontier of Justice: Disability, Nationality and Species Membership (n 414)., pp 76-78 
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criticisms since she does not provide a full explanation on why those 
capabilities are listed as fundamental for any democracy.418 Similarly, Sen has 
been criticised for not giving further explanation on what is the actual 
reasoning behind creating any functioning and capabilities, rather than 
establishing an objective moral person to define those aspects. Yet, Sen and 
Nussbaum point out that functionings and capabilities can be created by a 
dialogue or consensus in a democratic context. Although that explanation 
might still fall short of giving a full account of justice, the Capability Approach 
has not been constructed, particularly Sen’s approach, to create a theory or 
define a set of moral norms. It rather seeks to create a framework in which 
inequalities in any given scenario (developed and developing countries, 
conservative or liberal societies, etc.) are addressed, to entitle people with a 
freedom of choice.  
 
Another aspect in which the Capability Approach is currently challenged is 
that this approach is too individualistic, being almost impossible to 
accommodate to protect communities.  This is a crucial point for this thesis, 
which is concerned with communities’ entitlements within the International 
Regime on Access to Genetic Resources and Benefit Sharing in Colombia. A 
problematic aspect of the lack of any collectivist consideration in Sen’s 
approach is that it could lead individuals pursuit of their own well-being to 
clash or override another individuals’ well-being. As a result, it is difficult for 
the Capability Approach to create collective capabilities,419 including 
capabilities for groups such as local and indigenous communities. This is 
because Sen’s normative approach centres in individuals rather than groups of 
people. In fact, Sen’s analysis focuses on entitlements that can be granted 
exclusively to individuals (e.g. being well nourished, well educated, etc.). Also, 
the construction of capabilities departs precisely from what individuals are 
capable of being and doing (functionings), aspects that are rather difficult to 
extend to collectives. Additionally, it is argued that if there is a conflict between 
 
418 Robert Sugden, ‘What We Desire, What We Have Reason to Desire, Whatever We Might Desire: 
Mill and Sen on the Value of Opportunity’ (2006) 18 Utilitas 33. 
419 Solava Ibrahim, ‘From Individual to Collective Capabilities: The Capability Approach as a 
Conceptual Framework for Self-Help’ (2011) 7 Journal of Human Development and 
Capabilities; Michael Murphy, ‘Self-Determination as a Collective Capability: The Case of 
Indigenous Peoples’ (2014) 15 Journal of Human Development and Capabilities 320. 
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collective capabilities and individual capabilities, the former could triumph 
over the later, limiting individual freedom to carry out the life that people want 
to pursue.420 Finally, for capability theorists such as Robeyns, it is only 
possible to consider collectives as a mechanism to pursue individual well-
being.421  
 
Yet, recent academic critique claims that matters of justice, inequality and 
well-being cannot be understood as to exclusively to individuals in a 
traditional liberal political view.422 This has been even more prominent in local 
and indigenous communities,423 which experience a collective sense of 
injustice when their ability to function as a community is affected by, for 
instance, exploitation of natural resources (e.g. gold, oil, etc.). This means that 
although the analysis of being and doing might apply strictly to individuals, 
there are actions or functionings that take place at the collective level. For 
instance, in the matter of this thesis, Yerbateros in the Plaza Samper Mendoza 
have acquired, transformed and transfered practices and knowledge 
associated with genetic resources throughout collective channels (family, 
urban markets, roads, communal land, etc.). Equally, local communities of 
peasants in the Ricaurte, whose knowledge and practice led researchers to the 
anti-inflammatory characteristics of the Dividivi, have not been identified and 
acknowledged as the community that contribute to the understanding of that 
medicinal plant.  An individualist perspective would observe communities’ 
practices and knowledge as a mechanism to enlarge individual rights over 
 
420 Francesca Rosignoli, ‘Categorizing Collective Capabilities’ (2019) 11 Partecipazione & 
Conflitto 813. 
421 Ingrid Robeyns, Wellbeing, Freedom and Social Justice: The Capability Approach Re-
Examined (Open Book Publishers 2017) 
<https://www.openbookpublishers.com/product/682> accessed March 8 2019. 
422 Schlosberg D and Carruthers D, ‘Indigenous Struggles, Environmental Justice, and 
Community Capabilities’ (2010) 10 Global Environmental Politics 12 
423 For further information on different approaches of collective capabilities such as ethics and 
economic development see Sikkema SW, ‘The Capability Approach as an Account of Minimal 
Well-Being That Does Justice to Indigenous Peoples’ (Utrecht University 2018) 
<https://dspace.library.uu.nl/handle/1874/368519> accessed 7 March 2019); Bockstael E 
and Watene K, ‘Indigenous Peoples and the Capability Approach: Taking Stock’ (2016) 44 
Oxford Development Studies 265; Merino R, ‘An Alternative to “Alternative Development”?: 





those practices and knowledge, denying the ability of communities as a whole 
to decide over them.  
 
That is why it is so important to extend the analysis of capabilities to 
communities to the implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing in Colombia. This is because, as was 
already pointed out, although the Regime intends to recognise all actors 
involved, the compensatory mechanism of benefit sharing reflects a market-
oriented approach. It only considers individual holders of technologies who 
are the ones capable of adding value to the use of genetic resources for 
industries such as health. This means that the contributions from 
communities’ practices and knowledge are considered as mere “leads” in the 
development of products and process, but communities are not counted as 
actors capable of adding value.  
 
Also, the compensatory mechanism fails short of the realities of research and 
development, and the industrial utilization of medicinal plants in Colombia. 
For instance, the data collected in Chapter Four illustrates the difficulties in 
creating a dialogue between local researchers, and Afro-Colombian and 
indigenous communities on benefit sharing, leading to clashing interests; i.e. 
while local researchers were expecting to create long-term relationships to 
investigate traditional knowledge associated with genetic resources, those 
communities were expecting a straightforward monetary transaction. Equally, 
Chapter Five’s interviews and documentary analysis suggests that the 
compensatory mechanism of the International Regime on Access to Genetic 
Resources and Benefit Sharing is biased towards holders of technology or 
“sophisticated technologies”, leaving outside its scope the herbal industry; a 
sector that has accessed genetic resources and employed Yerbateros’ and other 
communities’ knowledge and practices without sharing the benefits of the 
utilization of genetic resources. 
 
As the compensatory mechanism of benefit sharing is the reflection of a 
market-oriented approach in the use of biodiversity, this thesis aims to analyse 
how to include those complexities in the use of biodiversity for industry. To 
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that end, this thesis proposes to set up a normative claim in the form of the 
capability for sustainable innovation that aims to recognise what different 
actors are capable of doing and being (functionings) so as to recognize the 
contribution they make and entitle them to inclusion in the country’s 
utilisation of genetic resources.  
 
The Capability for Sustainable Innovation in Health Research and the Health 
Industry 
 
What is the capability for sustainable innovation? The first aspect that needs 
to be analysed is why it is necessary to talk about innovation, and particularly 
innovation in the use of biodiversity. Innovation is fundamentally connected 
with the development of output and productivity of countries, meaning that 
the activities from different sectors and industries in the creation of new 
products, services and processes are an important contribution to economic 
development. Thus, these activities are measured to define policies on how 
countries can increase innovation. Since these activities differ depending on 
what economic sector or industry is being evaluated, the mechanism for 
measuring is rather more complex than indices such as per capita income. Yet, 
those measurements represent a market-oriented perspective.424 For instance, 
traditionally, innovation focuses on R&D in high technology sectors such as 
the pharmaceutical industry, but since there has been a new market boom in 
information technology, innovation measurements have been addressed to 
include services which do not necessarily involve R&D in a traditional sense.  
 
But does innovation in a market-oriented perspective involve other aspects 
such as social concern? There are significant scholarly works and policy papers 
from different organisations which demonstrate that is not only possible but 
also desirable to include other aspects beyond markets.425 In the particular 
 
424 The Oslo Manual was originally conceived for industries that addressed important 
resources to R&D for products and process such as the auto industry or pharmaceuticals; 
however, due to new economic and technological realities such as internet, it has been also 
included services; OECD and Eurostat (n 216)., p 8  
425 For instance, there is the Vienna Declaration: The Most Needed Social Innovations and 
Related Research Topics which points out that there is a paradigm shift in the innovation 
system, which was constructed on a technology-oriented paradigm and has transformed into 
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case of the Capability Approach, although there is a lack of scholarly work on 
innovation, there have been authors that pointed out that innovation, 
including social innovation, has an important correlation, albeit unexplored, 
with the analysis of capabilities. 426  
 
Because the analysis of capabilities seeks to address concerns from actors that 
are not normally taken into account in economic analysis, the way that 
innovation is understood for economic development in developing countries 
rich in biodiversity should also consider, for instance, how local and 
indigenous communities contribute to different activities of innovation in the 
use of biodiversity.  
 
As biodiversity can contribute significantly in the development of new 
products and processes, it is worth studying why biodiversity is also an 
opportunity to make innovation more inclusive. There are studies that 
estimate that approximately 700 new medicines from 1981-2010 were based 
on compounds, mainly small molecules, which originate in, or are derived 
from genetic resources.427 Also, Newman and Cragg have indicated that 49% 
of the 175 small molecules approved to treat cancer between the 1940s and 
2014 in the US were based upon genetic resources.428 Additionally, Oldham et 
al.’s paper on patent activity on biodiversity estimates that the research and 
development in genetic resources is very low as it represents only 4% of 
 
a knowledge and services-based society. This critical change demands the inclusion of social 
innovation. Further information see: CSI Challenge Social Innovation, ‘Vienna Declaration: 
The Most Needed Social Innovations and Related Research Topics’, Innovating innovation by 
research-100 years after Schumpeter (2011) 
<https://www.zsi.at/object/news/1891/attach/Vienna Declaration_version 01 for 
discussion.pdf> accessed January 31 2019; Sridhar Venkatapuram, Health Justice : An 
Argument from the Capabilities Approach (Polity 2011); Robert P van der Have and Luis 
Rubalcaba, ‘Social Innovation Research: An Emerging Area of Innovation Studies?’ (2016) 45 
Research Policy 1923; Robert Grimm and others, ‘Social Innovation, an Answer to 
Contemporary Societal Challenges? Locating the Concept in Theory and Practice’ (2013) 26 
Innovation: The European Journal of Social Science Research 436.   
426 There is no scholarly work that discusses what a capability of sustainable innovation is, 
and, even, until recently, there is no much research into innovation at all within the capability 
analysis; see Enrica Chiappero-Martinetti, Christopher Houghton Budd and Rafael Ziegler, 
‘Social Innovation and the Capability Approach—Introduction to the Special Issue’ (2017) 18 
Journal of Human Development and Capabilities 141.  
427 Steven M Ogbourne and Peter G Parsons, ‘The Value of Nature’s Natural Product Library 
for the Discovery of New Chemical Entities: The Discovery of Ingenol Mebutate’ (2014) 98 
Fitoterapia 36. 
428Newman and Cragg (n 85). 
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taxonomically described species on the planet.429 Since innovation in the 
development of medicines based upon natural products illustrates the 
outstanding debt that humans owe to biodiversity, the loss of biodiversity 
would represent without doubt a lost opportunity to find promising 
compounds that could eventually led to life-saving treatments and 
improvement of people’s life conditions.430 That is why the idea of 
sustainability aligns with the use of technology that employs genetic resources 
in a way that it does not destroy biodiversity and its components, including 
genetic resources.  
 
However, in the particular case of Colombia, the other actors should also be 
considered as part of the innovative process in different industries since they 
have been granted constitutional protection regarding their relationship with 
the country’s biodiversity (see Chapter Three). This is even more relevant as 
Colombia aims to employ its biodiversity as a key aspect in economic 
development. It is important to point out that this country has permanently 
considered biodiversity as competitive advantage in international markets, 
making its use a key aspect in its economic development, sustainable use of 
biodiversity and the implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing (see Chapter Four).  
 
Yet, the analysis of Colombia clearly exemplifies that, as the government has 
adopted a market-oriented perspective in the use of its biodiversity, it has not 
enforced the fundamental rights of communities regarding the use of their 
practice and knowledge for health research, despite the fact there are 
constitutional rulings and Andean legislation that requires Colombian 
authorities to protect such rights. The data collected in Chapter Four unmasks 
how the government implementation of the International Regime on Access to 
Genetic Resources has led local researchers to work on plants that have no 
relationship with indigenous and Afro-Colombian communities; yet, if the 
 
429 Oldham, Hall and Forero (n 89).  
430 ‘Human Rights Council Report of the Special Rapporteur on the Issue of Human Rights 
Obligations Relating to the Enjoyment of a Safe, Clean, Healthy and Sustainable Environment’ 
(2017) <http://srenvironment.org/wp-content/uploads/2017/09/A_HRC_34_49-
Final.pdf> accessed June 4 2018., paragraphs 13-14. 
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plant has a relationship with local communities such as peasants, it is not 
mandatory to carry our public consultation with them. Additionally, Chapter 
Four also points out particular challenges to users who aspire to work closely 
with indigenous and Afro-Colombian communities but have found difficulties 
to establish a dialogue in how to share the benefit from the utilisation of 
genetic resources.  This is even more problematic in the herbal medicine 
industry in Colombia, which benefits from indigenous and local knowledge 
and practices, to identify therapeutically benefits of plants and, eventually, 
commercialise them. Since this industry does not employ technologies to 
define the therapeutically effects of medicinal plants, the scope of their 
activities has not been considered to be subject of the International Regime on 
Access to Genetic Resources and Benefit Sharing. Furthermore, the interviews 
with Yerbateros in the Plaza Samper Mendoza bring convincing testimonies 
on how, despite the fact these communities of plant sellers are open to sharing 
their knowledge with patients to treat diseases such as diabetes and cancer, 
and actors who want to exploit their uses commercially, the growing herbal 
industry is taking over the commercialisation of medicinal plants at the 
expense of Yerbateros. Additionally, Colombian authorities and scholarly 
efforts at documentation has been limited to the therapeutic activity of the 
plant, rather than collecting information regarding who are the actors that led 
to the discovery and understanding of these therapeutic effects of the plants 
(see Chapter Five).  
 
All in all, innovation cannot be observed and assessed in a market-oriented 
perspective exclusively, in which only holders of technology, either local or 
overseas users of genetic resources, are seen as those who contribute to the 
added value of biodiversity. That is why it is important to set up as a goal to 
formulate a capability for sustainable innovation in which the herbal industry, 
local, indigenous and Afro-Colombian communities are considered also to be 
holders of technology. Although the analysis of capability would not provide a 
complete answer to all dynamics and complexities that are behind medicinal 
plants, it can provide a procedural approach under which all those aspects can 
be taken into account as Colombia implements the International Regime on 
Access to Genetic Resources and Benefit Sharing. Hence, the proposed 
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capability seeks to explore how developing countries rich in biodiversity, 
particularly Colombia, should include within the concept of innovation in the 
use of biodiversity for the health industry and research the different actors that 
are currently ‘invisible’ and so have been left behind.  
 
This task is possible to achieve through the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing, 
because it leaves policy room for countries to adapt this international treaty to 
local conditions. In fact, although the Nagoya Protocol is cautious in not 
granting express property rights or setting up a sui generis property system 
for traditional knowledge,431 its wording suggests that holders of traditional 
knowledge, especially that associated with genetic resources, are to be 
considered, as countries make their regulatory dispositions to grant access to 
users of genetic resources.  Article 8 (j) of the UN Convention on Biological 
Diversity only requires countries to respect, preserve and protect traditional 
knowledge as well as to involve their holders in benefit sharing, and the UN 
Convention on Biological Diversity does not require countries to regulate any 
particular aspect of prior informed consent from local or indigenous 
communities. However, Article 7 of the Nagoya Protocol takes a step further 
by calling on countries to take measures to ensure that prior informed consent 
of indigenous and local communities is obtained when there is access to 
traditional knowledge associated with genetic resources. 
 
As the Nagoya Protocol goes into detail on what countries should “take into 
consideration” regarding traditional knowledge associated with genetic 
resources, it can be observed that the protocol aims to give further guidance 
 
431 The reason why there has been problematic to establish a Sui Generis system of protection on 
traditional knowledge has been the difficulty to even find a consensus in key aspects such as definitions 
of traditional knowledge. For instance, since 2001 the Intergovernmental Committee on Intellectual 
Property and Genetic Resources, Traditional Knowledge and Folklore (IGC) of the World Intellectual 
Property Organization has been negotiating the creation of an international instrument related to IPRs 
and access to genetic resources and traditional knowledge. The negotiations have produced only drafts 
or ‘consolidated documents’ without any potential chance to achieve a Sui Generis system of protection 
for lack of consensus between developing and developed countries. See an example of the drafts treaties 
of the ICG: Intergovernmental Committee on Intellectual Property and Genetic Resources, 
‘Consolidated Document Relating to Intellectual Property and Genetic Resources’, WIPO/GRTKF/34/4 
(2017) <http://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_34/wipo_grtkf_ic_34_4.pdf> accessed 
31 July 2017. 
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on relevant aspects that Members of the Nagoya Protocol shall observe as they 
implement these measures such as local or indigenous communities’ 
customary laws, community protocols and procedures (Article 12). The 
Nagoya Protocol does not, however, go as far as imposing on countries specific 
obligations of how prior informed consent from those communities should 
take place;432 leaving countries enough legal room to freely implement Article 
7 and 12 of the Nagoya Protocol to suit local conditions and goals or 
aspirations. Furthermore, Article 22.3 of the Nagoya Protocol calls on 
countries to assess capacity to develop their own endogenous research, which 
requires countries to recognise communities’ contribution in the innovative 
process and entitle them to define how to place their practices and ancient 
knowledge in the industry and research.433  
 
As observed, the Capability Approach offers a procedural mechanism to 
include many of the complexities and, particularly, the different actors behind 
the use of biodiversity for health research and health industry in the 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing. In particular, a normative claim in the form of a capability 
for sustainable innovation in health research and the health industry, which 
requires a list of functionings, is proposed here. But before the list of 
functionings associated with a capability for sustained innovation in health 
research and the health industry is explained in detail, it is important to 
explain why the Capability Approach has been adopted in this thesis over other 
approaches or theories.  
 
Why the Capability Approach? 
 
Why does the Capability Approach provide a better perspective for 
implementing the International Regime on Access to Genetic Resources and 
Benefit Sharing in Colombia than other similar approaches? There are two 
reasons. First, the International Regime on Access to Genetic Resources and 
Benefit Sharing has excessively focused on allocating ownership of genetic 
 
432 Morgera, Tsioumani and Buck (n 74)., pp 217-218 
433 Jonas, Bavikatte and Shrumm (n 73). 
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resources to developing countries rich in biodiversity, which left behind the 
complexities that involve biodiversity. Indeed, the third objective of the UN 
Convention on Biological Diversity gave ground to developing countries rich 
in biodiversity to focus on allocating ownership control over specific goods (i.e. 
genetic resources) with the aim that those countries can fairly exchange them 
with other open-ended category of goods (i.e. benefit sharing), e.g. technology 
or royalties, from users of genetic resources.434 This has led to an 
implementation of the UN Convention on Biological Diversity which is limited 
to national, country or, even, community, membership as developing 
countries rich in biodiversity intended to counterbalance inequalities, 
especially the technological gap between them and developed countries, with 
an “exchange of goods and fulfilment of contractual obligations”.435 This 
means that those who benefit from the exchange of those goods are those who 
are part of a country rich in biodiversity or part of a community who holds the 
knowledge or practices over medicinal plants, or at least where the genetic 
resources are located. This can certainly be to the detriment of economic 
development as the exchange of goods and fulfilment of access to genetic 
resources and benefit sharing requirements can place a burden on those who 
add value to biodiversity through technology or growing sectors that represent 
an alternative for sustainable development, as is the case with the herbal 
industry. Also, a purely distributive approach has led to the distancing of 
communities and users of genetic resources and has undermined even the 
possibility of establishing a dialogue between them. The experiences of the 
lead researcher of the Javeriana research group with members of indigenous 
communities at Valle del Sibundoy and Afro-Colombian groups in the Choco 
region indicate that the local Colombian researchers were unable to even begin 
a dialogue on what terms benefit sharing should take place, since members of 
those communities were aiming to obtain monetary benefits, while the 
research group was seeking a long relationship in the development of 
medicines based upon on those communities’ knowledge.  
 
 
434 This model is also known as commutative justice, see Bege Dauda, Yvonne Denier and Kris 
Dierickx, ‘What Do the Various Principles of Justice Mean Within the Concept of Benefit 
Sharing?’ [2016] Biotethical Inquiry. 
435 ibid., p 287  
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Alternatively to such an allocation of resources based exclusively upon 
geographical aspects, authors such as De Jonge, Khortals, Schroeder, and 
Pisupati436 have sought to extend the third objective of the UN Convention on 
Biological Diversity beyond country or community membership established in 
the Convention, to a distributive model of justice, in which goods should be 
distributed due to the moral duty which society has towards those who are in 
need; for instant, global efforts to prevent and treat diseases.  
 
Therefore, this approach claims the benefits that arise from the utilisation of 
genetic resources should not be allocated to specific countries or communities, 
but ought to be distributed to those who are in need or under a condition of 
inequality.437 This can be seen as reflected in some of the provisions of the 
Nagoya Protocol. For instance, Article 10 of the Nagaya Protocol calls on 
parties to create a global multilateral benefit sharing mechanism to support 
conservation and sustainability of biodiversity not in specific countries but 
globally.  
 
However, the distribution of goods based upon people’s needs rather than 
country membership does not recognise the existence of conditions that differ 
from country to country, or community to community. In fact, global 
distribution of goods heavily relies on allocation of resources, rather than 
considering particular aspects that are specific to each country. This means 
that, despite the fact that distribution of goods grants a general normative 
claim, it does not take due account of all the varieties and complexities that the 
use of biodiversity involves. If those particular conditions are not taken into 
account, a purely redistributive approach could in practice mean that some 
communities have to relinquish their practices and knowledge to others who 
claim to be in need or under a condition of inequality.438   
 
436 Korthals and De Jonge (n 109); De Jonge and Korthals (n 109); Schroeder and Pisupati (n 
42); Schroeder and Lucas (n 42). 
437 Dauda, Denier and Dierickx (n 434)., p 291 
438 There is also other mechanism that focuses on allocating goods to increase specific skills: 
capacity building. Yet, this is not an equal term to the capability approach; although they might 
complement each other. Capacity building involves the importance of increasing specific skills 
and abilities.438  However, if capacity building initiatives aim to exclusively allocate resources, 
it could rather add an extra burden since those who carry out those initiatives do not have the 
skills and abilities to make most of the resources provided. That is why is necessary to 
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Also, Sen’s Capability Approach offers an alternative to utilitarian theories. 
The latter analyse the problem of well-being by focusing on what is good for 
people in general in terms of happiness, i.e. how to make prevail pleasure over 
pain, or by allocating resources. In fact, such well-being theorists (e.g. 
utilitarians) do not observe circumstances that surround everyone.439 On the 
one hand, if there is a focus on what can satisfy a person, it can result in 
creating unequal measures. For instance, a woman could accept to be paid 
lower than a man for carrying the exactly type and amount of work as long as 
she is happy about having an income. On the other hand, if the priority is 
allocating resources or goods, the issue of compensating communities for the 
use of their practices and knowledge in medicinal plants by granting them with 
ownership, will not necessarily lead to the creation of further opportunities 
since communities differ culturally and socially in the way to transform those 
resources, such as plants, into well-being.440  
 
That is why the idea of capability for sustainable innovation in health research 
and the health industry offers an alternative analytic frame through which it is 
possible to set up a normative claim and a flexible procedure to achieve the 
proposed capability. Following a Capability Approach, the main objective of 
the International Regime on Access to Genetic Resources and Benefit Sharing 
should thus be interpreted and implemented in a form that not only seeks to 
benefit countries’ economic development, but also to include communities in 
the decision-making processes in health research and the health industry. An 
inclusive and sustainable innovation in the form of capabilities can be achieved 
if communities’ conditions are facilitated by considering lists of functionings 
(i.e. doings and beings). This means that the analysis of the relevant 
 
complement such initiatives with the Capability Approach as to entitle people to enhance local 
resources, initiatives and ownership. Further information see: Deborah Eade, ‘Capacity 
Building: Who Builds Whose Capacity?’ (2007) 17 Development in practice 630.Alexandre 
Apsan Frediani, ‘Sen’s Capability Approach as a Framework to the Practice of Development’ 
(2010) 20 Development in practice 173.   
439 Although well-being theory is not an exclusive matter for utilitarians, they largely emphasis 
in the importance to maximise well-being. See for instance, Bentham’s work on the principle 
of utility, which highlights that the matters that govern mankind are pleasure and pain, 
Jeremy Bentham, An Introduction to the Principles of Morals and Legislation (Oxford, 
Clarendon Press 1823).  
440 Martha Nussbaum, ‘Capabilities and Human Rights’ (1997) 66 Fordham Law Review 273. 
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capabilities does not necessarily contradict the scope of the International 
Regime on Access to Genetic Resources and Benefit Sharing, but on the 
contrary, an interpretation in the light of this approach can fulfil the policy 
making space that the wording of the Regime leaves to Members, particularly 
Colombia, as they implement this international framework. 
 
Second, the reasoning behind Decision 391 and the Colombian Constitutional 
Court rulings on securing a balance between economic development and 
communities’ rights finds echoes in the Capability Approach. Chapter Three 
points out that the 1991 Colombian Constitution and the rulings of the 
Constitutional Court have stressed the importance of reconciling, one the one 
hand, economic development and international trade, and, on the other hand, 
other social and cultural concerns, including the rights of local, indigenous and 
Afro-Colombian communities. Judicial decisions from this high tribunal have 
obliged authorities to include communities in the decision-making process of 
projects that involve the exploitation of non-renewable natural resources and 
trade-related aspects such as the implementation of the International 
Convention for the Protection of New Varieties of Plants 1991 in Colombia, a 
treaty designed to protect plant breeders’ rights (see Chapter Three). Equally, 
Decision 391 highlights that genetic resources, as well as communities’ 
practices and knowledge related to those resources, are not only of “strategic 
value” to the Andean sub region.441 It calls on Andean Community state 
members to recognise that communities have the right to decide on the use of 
their knowledge and practices if someone is interested in accessing traditional 
knowledge associated with genetic resources (Article 7).442  
 
As observed, the constitutional mandates and Decision 391 seek to create a 
balance between economic development and communities’ rights. Equally, 
Sen’s analysis opposes neither economic development nor international trade, 
but rather it calls on stakeholders (e.g. governments, international 
 
441 See Paragraph 4 of the Preface of the Decision 391 on the Common Regime on Access to 
Genetic Resources of 1996.    
442 See the Preamble of the Decision 391, which mentions that it “recognises the historic 
contribution made by the native, Afro-American, and local communities to the biological 
diversity, its conservation and development and the sustained use of its components, as well 
as to the benefits generated by that contribution”  
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organizations, etc.) to place people at the centre of economic analysis and 
policy to bring a flexible and balanced approach to achieve social goals such as 
inclusion. By placing people at centre, it is possible to evaluate people’s 
conditions in terms of what they are cable of doing and being.  
 
Translating Sen’s Capability Approach into the constitutional rules and 
Andean legislation, and the scope of the thesis, a balanced approach would not 
seek to create an unnecessary burden in health research or deprive the herbal 
industry of growing in economic terms, but it would aim to include 
communities as a key factor in Colombia’s health research and health industry. 
Following Sen’s line of reasoning, it would be possible to include communities 
within health research and the health industry if their contribution is analysed 
in terms of what communities are capable of doing and being (functionings). 
As functionings are established, communities would be entitled to select and 
combine from a list of functionings, which forms the capability for sustainable 
innovation, so they can decide how to participate in health research and the 
health industry when their practice and knowledge are employed.  
 
The List of Functionings  
 
In this thesis, the list of functionings has a practical purpose. Previous chapters 
carried out an evaluation of Colombia’s implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing and its impact for 
health research and the health industry, exposing the “messy” realities of law 
in practice on the ground. That thick description shows important exclusions 
from enjoyment of the benefits of Colombian biodiversity, particularly for 
certain communities in Colombia. The list of functionings is the basis for 
solutions on how to achieve the proposed capability for sustainable 
innovation. Those solutions rely on communities having the freedom to 
combine and choose from that list, in order to achieve the capability for 
sustainable innovation. 
 
The list of functionings is based upon securing inclusive innovation in the 
health industry and health research in the regulation of access to genetic 
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resources. Yet, it does not pretend to be a fixed list. Each functioning can be 
subject to a continuing debate as to the very nature of the Capability Approach 
permits constant discussion of each of its key elements.  
 
Possessing Genetic Resources for Benefit Sharing  
 
Since developing countries rich in biodiversity enjoy significant availability of 
genetic resources, they have adopted the International Regime on Access to 
Genetic Resources and Benefit Sharing, which allocates ownership access 
control over genetic resources to those countries with the aim that they could 
demand users to share benefits that arise from the utilisation of those 
resources.  
 
However, the allocation of property control over resources or the granting of 
ownership control over resources to developing countries rich in biodiversity 
has not led to effectively recognised and protection of communities’ practices 
and knowledge. It has rather created almost an exclusive monopoly over the 
utilization of genetic resources without recognising those communities’ 
contribution. As a result, practices and knowledge are driven into the public 
domain for health research and the herbal industry.  
 
Therefore, what should be assessed is not whether genetic resources are key 
sources or commodities to obtain royalties or payments, but rather what actors 
and conditions are behind leading developing countries rich in biodiversity to 
achieve a specific goal, i.e. the capability for sustainable innovation. The 
functioning related to possessing genetic resources for benefit sharing 
evaluates whether developing countries rich in biodiversity systems of 
ownership control of genetic resources acknowledge the existence of 
communities’ practices and communities.  
 
As a result, this functioning renders material and practical the Colombian 
constitutional principles of “recognition and protection and cultural diversity” 
of indigenous and Afro-Colombian communities, as well as the protection of 
local communities’ socio-economic relationship with their environment, since 
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the Constitutional Court calls on authorities to recognise “the practices and 
traditional knowledge of ethnic people and peasants, communities” as 
Colombia implements international treaties such as the International Regime 
on Access to Genetic Resources and Benefit Sharing. 443  In other words, 
Colombian sovereignty over genetic resources cannot rule out the rights that 
communities have over their traditional knowledge and practices associated 
with those genetic resources.    
 
Being Able to Take Part in the Industrial Application of Genetic Resources and the Benefits 
that Arise from it 
 
This functioning requires an assessment of who is participating and how they 
participate in the research into genetic resources. It is important to evaluate 
this aspect, because the different contributions that occur in research activities 
should include not only those who hold technology to carry out investigation 
or those who can place products and service in the market, but also those who 
can contribute to R&D and the commercialisation of goods and services 
through their practices and knowledge. As a result, the capability for 
sustainable innovation in health research and the health industry should 
include communities in the industrial application of genetic resources and 
entitle them to participate in the benefits that arise from the utilization of their 
practices and knowledge associated with genetic resources. In order to put in 
practice this functioning, it is necessary to define a mechanism to establish a 
dialogue, in which stakeholders are identified and contributions in the use of 
genetic resources for health research and health industry are recognised too.  
 
Being Able to Add Value to Health Research and the Health Industry  
 
The functioning of being able to add value to health research and the health 
industry assesses to what extent industries in developing countries rich in 
biodiversity have entitled all actors, e.g. local researchers, and the knowledge 
and practices from local and indigenous communities, particularly in the 
 
443 C-1051 of 2012, Constitutional Court; Recommendation 2017-00057-00 of the Consultant 
Body of the Council of State  
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health industry and health research, to decide whether or not to participate 
and how to participate in the decision-making process. Since this functioning 
aims to recognise the participation of different actors in health research and 
the health industry, it also analyses what legal mechanisms of compliance 
should take place to enforce those actor’s rights. In particular, it assesses the 
current legal mechanism to secure compliance with the International Regime 
on Access to Benefit Sharing such as the Ministry of Environment regulation 
on access to genetic resources, and Ministry of State guidelines on public 
consultation, and evaluates whether it is desirable to establish new 
mechanisms of compliance with norms that impacts the herbal industry, such 




This chapter has introduced a normative element, with the aim of being able 
to make practical proposals to address the problems with the implementation 
of the International Regime on Access to Genetic Resources and Benefit 
Sharing in Colombia, particularly the lack of recognition and protection of 
practices and knowledge from local and indigenous communities in adding 
value to the use of biodiversity for industry and research. The chapter proposes 
employing an analysis of capabilities, an approach which is championed by 
Sen. Sen contributes to the study of economic development by placing at the 
centre of his analysis people’s conditions, preferences and choices. These 
choices take the form of specific conditions that embody functionings (beings 
and doings). This approach has already been adopted in interdisciplinary 
work, similar to this socio-legal inquiry into access to genetic resources and 
benefit sharing in Colombia.  
 
This chapter proposes and justifies the capability for sustainable innovation in 
health research and the health industry, which aims to include what 
indigenous and local communities are capable of doing and being in adding 
value to the use of biodiversity. This chapter also introduces the list of 
functionings that serves to address the complexity of the law with the aim of 
achieving the proposed capability. 
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Chapter Seven: The Capability for Sustainable Innovation 
for the Health Industry and Health Research: Amending 
Colombia’s Implementation of the International Regime 
on Access to Genetic Resources and Benefit Sharing  
Introduction 
 
This chapter brings together all the different aspects discussed above, and the 
findings of previous chapters, to propose a solution to the thesis’ main research 
question: How should Colombia, a developing country rich in biodiversity, 
implement the International Regime on Access to Genetic Resources and 
Benefit Sharing in order to recognise the contribution from local, indigenous, 
and Afro-Colombian communities’ practices and knowledge in adding value to 
the use of genetic resources for the health industry and health research? 
Chapter Seven provides a cohesive analysis of Colombian law and policy in 
practice, building to a proposal for a revised approach to implementation of 
the International Regime on Access to Genetic Resources and Benefit Sharing 
in that country. The chapter begins by summing up the argument so far.  
 
This thesis focused on the International Regime on Access to Genetic 
Resources and Benefit Sharing, its implementation in Colombia, the 
protection of communities’ practices and knowledge associated with genetic 
resources, and the health industry and health research in the country. It 
showed the different ways in which the local, indigenous, and Afro-Colombian 
communities’ practices and knowledge associated with genetic resources in 
Colombia has been ignored in health research and the health industry. This 
has occurred despite the fact that the industry and research rely on those 
practices and knowledge, and the fact that Colombia is bound to protect and 
secure the rights of communities in the use of biodiversity according to 
Decision 391, which implements the International Regime on Access to 
Genetic Resources and Benefit Sharing in the Andean sub-region and the 
country, and according to the rulings of the Constitutional Court.  
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Chapter Two introduced the key aspects of the International Regime on Access 
to Genetic Resources and Benefit Sharing and carried out a review of the 
evolution of this international instrument. Chapter Two revealed a range of 
discussions from questions of geopolitical and economic balancing of power 
between the global north and the global south, intellectual property rights, 
ethics, and justice, as well as sustainability and conservation of the world’s 
biodiversity. There was also discussion of the relationship between 
communities and genetic resources, and whether the International Regime on 
Access to Genetic Resources and Benefit Sharing actually compels members of 
this international treaty to protect communities’ practices and knowledge. 
 
Chapter Two explained that there has been a constant search for recognising 
and protecting communities’ rights over their practices and knowledge, as the 
International Regime on Access to Genetic Resources and Benefit Sharing has 
evolved from the UN Convention on Biological Diversity to the Nagoya 
Protocol. However, that evolution has focused particularly on downstream 
stages of R&D (e.g. botanical gardens, research centres, etc.), leaving upstream 
users unscathed. This means that as communities’ practices and knowledge go 
upstream in R&D, it can potentially fade away as users employ technology to 
isolate and synthetize genetic resources for industrial production and 
research. Further, since the Regime on Access to Genetic Resources and 
Benefit Sharing has focused on industries that employ such technologies, it has 
left in a “blind spot” other industries, particularly the herbal industry, which 
employ practices and knowledge associated with genetic resources. This 
means that, in general terms, with the exception of EU’s recent legislative 
efforts that make this industry fulfil access and benefit sharing requirements, 
the herbal industry is not obliged to comply with it.  
 
Chapter Three centred its discussion on Colombia’s implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing 
through Colombian constitutional rulings, the Andean Decision 391, and the 
administrative decisions taken by different ministers of the central 
government. Chapter Three highlighted that, based upon the fundamental 
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principle of “recognition and protection of ethnic and cultural diversity” of 
indigenous and Afro-Colombian communties, as well as the protection of local 
communities’ socio-economic activities related to the environment, the 
Constitutional Court has sought to reconcile, on the one hand, economic 
development and international trade, and, on the other hand, other social and 
cultural concerns, including the rights of local, indigenous, and Afro-
Colombian communities. As a result, this court has established that all 
branches of government should protect and enforce communities’ rights in any 
circumstance that involves a state action or inaction. 
 
In response to those constitutional requirements, the government has 
promulgated two decrees (Decrees 2164 and 1745 of 1995) that aim to protect 
the cultural and ethnic identity of indigenous and Afro-Colombian 
communities by granting them community land (Resguardos and Tierras de 
las Comunidades Negras, respectively), recognising their own form of 
government and laws, and securing that they are previously consulted if there 
is any project that might affect their communal lands. Although neither decree 
extends rights such as community land to local (or non-ethnic) communities, 
the Constitutional Court in different rulings has extended the right of being 
publicly consulted if action or inaction of the State or other actors affect their 
socio-economic relationship with the environment.  These decrees and 
constitutional rulings were established in the context of exploitation of non-
renewable resources such as gold and oil, and infrastructure projects. 
 
Translating this analysis into genetic resources and traditional knowledge, 
Decision 391 calls on members of the Andean Community, including 
Colombia, to recognise that communities have the right to decide on the use of 
their knowledge and practices if someone is interested in accessing traditional 
knowledge associated with genetic resources (Article 7). The scope of 
protection of communities’ rights in Decision 391 also found echoes in the 
Constitutional Court’s rulings. For instance, the court emphasised that 
Colombia has the exclusive “faculty to use [genetic resources] and take 
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advantage of them economically according to their own interests”, 444 while it 
should recognise and respect the rights of all communities over their practices 
and knowledge.445  
 
However, Chapter Three also pointed out that a series of administrative 
decisions seemed to contradict Decision 391 and the Constitutional Court 
rulings. In fact, through a number of administrative decisions, the Ministry of 
the Environment and Ministry of State has eased the rules on access to genetic 
resources and public consultation to local researchers. For instance, these 
decisions appear to ignore any role that local communities (e.g. peasants) 
might play in leading local researchers to employ medicinal plants for health 
research, as the Ministry of Environment and the Ministry of State only require 
prior informed consent if there is an ethnic community (i.e. indigenous and 
Afro-Colombian communities) involved. This means that the government 
discriminates against some communities in order to facilitate access to genetic 
resources . Also, the Ministry of the Environment has de facto exempted the 
herbal industry, which produces and distributes phytomedicines, from 
obtaining communities’ prior informed consent because phytomedicines are 
not products whose therapeutic activity is accredited to isolated and purified 
molecules, or combination thereof, as occurs with chemical synthetized 
products or biological medicines. Additionally, the herbal industry also 
employ traditional knowledge and practices to prove the therapeutic activity 
of traditional phytomedicines to obtain marketing approval. This means that 
the herbal industry does not need to prove therapeutic activity with expensive 
clinical trials. Nevertheless, the industry is not obliged by law to carry out 
public consultation as it employs communities’ practices and knowledge in the 
granting process of marketing approvals, even if they belong to indigenous and 
Afro-Colombian communities.  
 
Chapter Four exemplifies the contradiction that exists between, on the one 
hand, governmental decisions and policies on health research, and, on the 
 
444 C-519 of 1994, Constitutional Court 
445 C-1051 of 2012, Constitutional Court; Recommendation 2017-00057-00 of the Consultant 
Body of the Council of State 
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other hand, the constitutional mandates and Decision 391 in protecting 
communities’ practices and knowledge. This is evidenced in Colombian 
innovation policy and through a small dataset collected in interviews with a 
representative research group based at Javeriana University related to the use 
of two medicinal plants for health research. On the innovation policy, a 
fragmented implementation of the International Regime on Access to Genetic 
Resources and Benefit Sharing can be observed, as Colombian central 
authorities are pursuing an economic agenda to make Colombia more 
scientifically competitive in international markets according to the OECD’s 
Oslo Manual of innovation. This has occurred despite the fact that such a 
policy has led authorities to ignore the role of communities’ practice and 
knowledge associated with genetic resources in adding value to health 
research. This means that Colombia’s innovation policy contradicts its own 
Constitutional Court rulings and Decision 391.  
 
This fragmentation can also be observed in the cases of two medicinal plants, 
which were investigated by the research group from Javeriana University. 
Throughout the analysis of the development of therapies deriving from two 
medicinal plants (Dividivi and Anamú), it was shown how in practice the 
Dividivi has historically interacted with campesinos of Ricaurte’s socio-
economic activities, and how that interaction led the research group to identify 
the anti-inflammatory properties of the plant. Those properties have been 
transformed into phytotherapeutic cancer treatments. The research group 
materialise the hopes of Colombia in transforming genetic resources and 
practices and knowledge associated with those resources into medicinal 
products that could benefit not only the country’s technical and scientific 
capacity, but also the population as a whole. It is also fundamental to notice 
that the research group has, in its view, complied in full with the Ministry of 
the Environment’s and Ministry of State’s regulations on access to genetic 
resources and prior informed consent, as well as being a beneficiary of public 
funding. However, the research group does not acknowledge the practices and 
knowledge of the local community of peasants as innovative, which means it 
did not recognise any contribution from communities when it reached 
mutually agreed terms with the Ministry of the Environment. Consequently, 
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the research group filed and obtained patents locally and globally without 
disclosing information on communities’ practices and knowledge related to 
the plants and without carrying out public consultation. However, the research 
group has sought to engage with the community by unilaterally establishing a  
production chain  in which the research group facilitated the introduction of 
an improved seed of the Dividivi to communities, and campesinos of these 
communities are consigned to growing, harvesting, and handing the plant over 
to laboratories.  
 
Equally, the data collected in Chapter Four also indicate a lack of dialogue 
between local researchers and ethnic communities. The testimony of Professor 
Fiorentino, the lead researcher of the Javeriana group, regarding her own 
experience with Afro-Colombians in Choco and indigenous in the Valle del 
Sibundoy provides a critical perspective of the compensatory mechanism of 
the International Regime on Access to Genetic Resources, since ethnic 
communities were apparently interested only in a straightforward monetary 
transaction. This means that communities seek to obtain recognition for their 
contribution in pure economic terms without due consideration of how to 
create a dialogue in which users of genetic resources, such as local researchers, 
and holders of practices and knowledge could advance together to transform 
those resources into well-being.  
 
Chapter Five centred its analysis on the use of medicinal plants by the herbal 
industry. It explained how the marketing of herbal medicines works in 
Colombia. Firstly, there is the herbal industry which has benefited from a 
supportive regulatory framework and a sustainable policy on the use of 
biodiversity for the production and distribution of phytomedicines, 
particularly traditional phytomedicines. As part of its strategy of sustainable 
use of Colombia’s biodiversity, the government has allowed this industry to 
prove the therapeutic effect of traditional phytomedicines through 
communities’ knowledge and practices without consulting communities. 
There are also the Yerbateros in urban markets, which have not been included 
into the strategy of sustainable use of Colombia’s biodiversity. Yet, it is in 
urban markets where practice and knowledge in the use of medicinal plants 
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are transferred to those who not only acquire the actual plants, but also access 
the knowledge and practices behind the use of those plants. This is evidenced 
in the small dataset of interviews with the Yerbateros in the Plaza Samper 
Mendoza, whose knowledge is widely disseminated to different stakeholders 
including patients and actors from the herbal industry. The herbal has even 
affected Yerbateros’ business activity, as it has driven away customers from 
urban markets such as Plaza Samper Mendoza to specialist outlets for 
alternative products (i.e. tiendas naturistas). Furthermore, there is also an 
unbalanced legal approach towards local researchers if compared with the 
herbal industry. While the former are required to comply with both access and 
benefit sharing, and market approval, regulations, the herbal industry is not 
subjected of any of those requirements.  Additionally, Chapter Five also 
detailed the difficulty in defining who the actors behind the use of medicinal 
plants actually are, so as to identify how they contribute to the understanding 
of medicinal plants.  
 
Against this background, Chapter Five also identified that there have been 
efforts from academia and the government to document medicinal plants, 
which could potentially help to answer some of those complex questions. 
However, such efforts have a limited scope, since they aim to identify only the 
therapeutic effects of medicinal plants. This means that the documenting of 
traditional knowledge and practices does not seek to solve some of the complex 
aspects behind the use of medicinal plants so as to enforce communities’ rights 
over their practices and knowledge according to Decision 391 and the 
Constitutional Court’s rulings.  
 
As Chapters Three to Five described the difficulties in recognising and 
safeguarding communities’ practices and knowledge for health research and 
the health industry in Colombia, Chapter Six asked whether health research 
and the health industry in a market-oriented perspective could involve other 
aspects, such as social concerns. Chapter Six pointed out that it was possible 
to do so by including social concerns such as communities’ rights in Colombian 
innovation policy. This chapter argued for inclusion of communities in 
Colombian innovation policy by relying on the Capability Approach.  
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Because the Capability Approach seeks to place what people are capable of 
being, or doing, within an economic analysis, the way innovation is analysed 
in Colombia should also consider how local and indigenous communities 
contribute to different activities of innovation in the use of biodiversity for 
health research and the health industry. As a result, Chapter Six argued that 
communities should also be considered as part of the innovative process in 
health research and the health industry since they have been granted 
constitutional protection. In that way, Colombia can address the particular 
circumstances of communities’ practices and knowledge associated with 
genetic resources, as this country employs those resources for economic 
development.  
 
Through the Capability Approach, Chapter Six set up as a goal the formulation 
of a capability for sustainable innovation in which holders of technology, the 
herbal industry, local, indigenous, and Afro-Colombian communities are 
considered. Even though the Capability Approach would not provide a 
complete answer to all dynamics and complexities behind medicinal plants, it 
provides a procedural approach under which all those aspects can be 
considered as Colombia implements the International Regime on Access to 
Genetic Resources and Benefit Sharing. In brief, the capability for sustainable 
innovation, and its functionings, in health research and the health industry 
seeks to include within innovation laws and policies communities that have 
currently been left behind. As a result, communities would be entitled to 
decide whether or not and how to take part in health research and the health 
industry.  
 
This analysis leads to recommendations on how the International Regime on 
Access to Genetic Resources and Benefit Sharing should be implemented in 
Colombia to establish more inclusive forms of innovation in health research 
and the health industry. To that end, Chapter Seven brings together the 
different components of the thesis to address its core research question: How 
should Colombia, a developing country rich in biodiversity, implement the 
International Regime on Access to Genetic Resources and Benefit Sharing, in 
 252 
order to recognise the contribution from local, indigenous, and Afro-
Colombian communities’ practices and knowledge in adding value to the use 
of genetic resources for the health industry and health research? 
 
The thesis has set up a normative claim in the form of the capability for 
sustainable innovation in health research and health industry. This claim, in 
turn, is formed by a list of three functionings. Hence, the legal amendments 
suggested by that claim spring from those functionings. Therefore, this chapter 
is divided into three parts. The first part discusses the functioning of 
possessing genetic resources for benefit sharing, which assesses how to 
address the problem of placing communities’ practice and knowledge into the 
public domain. This is constructed through the analysis of the Constitutional 
Court rulings which aim to balance economic development and state 
sovereignty over natural resources and genetic resources. The second part 
explores the functioning of being able to take part in the industrial application 
of genetic resources and the benefits that arise therefrom, in which is discussed 
how the Colombian innovation policy could help identify who contributes and 
how communities add value to the use of biodiversity for health research and 
the health industry. The final part studies the functioning of being able to add 
value to health research and the health industry, which proposes legal 
mechanisms to enforce communities’ rights, particularly public consultation. 
The conclusion summarises the findings of this chapter in the form of the 
concrete legal amendments Colombia should implement, so as to achieve the 
capability for sustainable innovation in health research and the health 
industry.   
 
Possessing Genetic Resources for Benefit Sharing: Addressing the Problem of 
Placing Practices and Knowledge into the Public Domain 
 
The first aspect to be evaluated in the analysis of the capability is related to 
ownership control over genetic resources. This is analysed first because most 
of the debate in biopiracy and bioprospecting, as well as the ethics behind the 
International Regime on Access to Genetic Resources and Benefit Sharing and 
intellectual property rights, depart from the discussion of property control on 
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genetic resources and traditional knowledge and practices associated with 
those resources. Chapter Two points out that, since developing countries rich 
in biodiversity enjoy large availability of genetic resources, they have adopted 
the International Regime on Access to Genetic Resources and Benefit Sharing, 
which allocates ownership access control over genetic resources to those 
countries with the aim that they could demand users to share benefits that 
arise from the utilisation of those resources. Based upon that ownership 
control, the International Regime on Access to Genetic Resources and Benefit 
Sharing establishes that users of genetic resources require prior informed 
consent and must reach mutually agreed terms according to the law of 
developing countries rich in biodiversity (see Article 1 of the UN Convention 
on Biological Diversity).  
 
However, the granting of ownership control over resources to developing 
countries rich in biodiversity does not necessarily lead to the recognition and 
protection of communities’ practices and knowledge. On the contrary, the 
allocation of ownership control on genetic resources almost exclusively to the 
state through the concept of sovereignty has let those practices and knowledge 
into the public domain for health research and the herbal industry.  
 
For instance, as Colombia enjoys exclusive ownership control over its genetic 
resources, it has implemented the International Regime on Access to Genetic 
Resources and Benefit Sharing in a way that facilitates access to genetic 
resources to local researchers (see Chapter Three), such as publicly funded 
universities and research centres, to encourage them to make use of 
biodiversity for health research. In fact, Decrees 1375 and 1376 of 2013, and 
Resolution 1348 of 2014 ease the access and benefit sharing rules, particularly 
for non-commercial research, which is normally conducted by local 
researchers. As local researchers are those who normally carry out non-
commercial research, requirements such as prior informed consent and 
mutually agreed terms, demand a simple procedure in which it is not necessary 
to provide detail on the use of genetic resources, since non-commercial 




However, as occurred in the case of the Dividivi, a local research group 
employed the knowledge and practices of a local communities of peasants to 
identify the anti-inflammatory properties of the plant with the aim of using 
such properties to treat cancer. Although Constitutional rulings call on 
authorities to recognise and protect practices and knowledge of communities, 
the research group was not obliged to consult with local communities since the 
Ministry of Environment’s regulation only requires them to carry out prior 
informed consent procedures with the Ministry of State if there is involvement 
of ethnic (i.e. indigenous and Afro-Colombian) communities. As a result, 
campesinos in the region of Ricaurte were not even acknowledged in their 
contribution to leading to this group to the medicinal properties of the 
Dividivi. Even more, as the research turned into a commercial investigation, 
i.e. the group filed and obtained patents in Colombia and worldwide, it was 
evidence of how holders of technology appropriate those contributions 
because they are placed into the public domain, as authorities do not demand 
that local communities be involved (see Chapter Four).  
 
Additionally, the national herbal industry benefits from the practices and 
knowledge of ethnic and local communities because it acquires information on 
how to elaborate traditional phytomedicines and demonstrates effectiveness 
and safeness for obtaining marketing authorisation (Decree 2266 of 2000; see 
Chapter Five). For this case, the government has explicitly granted an 
exception from compliance with the access and benefit sharing regulation in 
Resolution 1348, without even considering how such a regulation also places 
into the public domain the knowledge and practices from all communities, 
including indigenous and Afro-Colombian communities, which makes it 
possible for this industry to produce and distribute its products.   
 
Therefore, what should be observed in this functioning is not whether genetic 
resources are key sources or commodities to obtain benefit sharing for 
developing countries rich in biodiversity, but rather what actors and 
conditions are behind those resources, to acknowledge and secure the value of 
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their contribution to the use of biodiversity. This is why the functioning related 
to possessing genetic resources for benefit sharing includes all relevant actors.  
 
For the particular case of Colombia, the Constitutional Court has provided 
some grounds on this functioning as it has already mentioned in the case of 
1991 International Convention for the Protection of New Varieties of Plants. 
The implementation of the 1991 International Convention for the Protection 
of New Varieties of Plants in Colombia was an internationally agreed 
compromise to secure greater protection to plant breeders over new varieties. 
The core of the Colombian Constitutional Court rulings was that the 
government could not establish a system of property rights over new varieties 
for plant breeders if other actors, whose socio-economic and cultural activities 
depended on agricultural plants, were not considered. In particular, the 
Constitutional Court considered fundamental that the government should 
include the participation of communities in the implementation process 
through public consultation. As the government did not consult communities, 
the Constitutional Court pointed out that authorities were ignoring both “the 
practices and traditional knowledge of ethnic people and peasants, 
communities” and “the rights that such communities may have over 
traditional or native varieties, particularly those that do not circulate within 
commercial and technological channels”. 446 Although this public consultation 
was an ongoing effort which has not materialized in any legal or policy 
document, the Constitutional Court ruling illustrates that what is important is 
not to create a parallel plant breeder system, but to include communities in 
any decision making process that might threaten their relationship with 
agricultural plants. 
 
The legal reasoning of the Constitutional Court is an appealing alternative to 
the broader discussion as to what sort of rights can be secured to holders of 
traditional knowledge over genetic resources. Indeed, there is not even an 
international consensus on how to approach this difficult question. For 
example, as the core treaty of the International Regime on Access to Genetic 
 
446 C-1051 of 2012, Constitutional Court  
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Resources and Benefit Sharing, the UN Convention on Biological Diversity 
granted only property rights on genetic resources to states, it calls on countries 
in its Article 8 (j) to respect, preserve, and protect traditional knowledge as 
well as to involve holders of traditional knowledge in benefit sharing. 
However, the UN Convention on Biological Diversity does not require 
countries to regulate any particular aspect of prior informed consent from 
local or indigenous communities (see Chapter Two). The Nagoya Protocol, 
which is also part of the International Regime on Access to Genetic Resources 
and Benefit Sharing, took a step further by calling on countries to take 
measures to ensure prior informed consent of indigenous and local 
communities was obtained when there was access to traditional knowledge 
associated with genetic resources and to consider different aspects such as 
customary laws, community protocols, and procedures (see Chapter Two).447 
Similar dispositions are found in the Decision 391 of the Andean Community. 
  
However, those international provisions provide rather broad considerations, 
and yet not are legally binding commitments for countries, meaning that the 
International Regime on Access to Genetic Resources and Benefit Sharing 
does not grant property rights over traditional knowledge to communities. 
This reflects how difficult it is to secure rights over genetic resources to 
communities when traditional knowledge is involved. As analysed in Chapter 
Two, there is an inconclusive debate on the legal treatment regarding 
traditional knowledge and genetic resources in the Intergovernmental 
Committee on Intellectual Property and Genetic Resources, Traditional 
Knowledge, and Folklore of the WIPO. The intergovernmental committee 
sought to address concerns from developing countries rich in biodiversity on 
the misappropriation of knowledge and practices on genetic resources in 
intellectual property rights, but the intergovernmental committee 
negotiations have reached a stalemate because parties have not agreed 
whether there should be a sui generis property regime or what sort of rights 
should be granted to communities. 
 
 
447 Morgera, Tsioumani and Buck (n 59)., pp 30 
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However, as studied in Chapter Three, the Constitutional Court has set up a 
precedent on the sovereignty of the state to exploit natural resources (e.g. gas 
and oil) and the rights of communities which can also be extended to genetic 
resources. This court has mentioned that – despite the fact that natural 
resources such as oil and gold are exclusively property of the state – their 
economic exploitation should not go against ethnic and peasant communities’ 
cultural, social, and economic rights. That is why before the government 
carries out any economic activity of exploitation on natural resources, 
communities should be consulted. Furthermore, constitutional case law 
relating to the International Convention for the Protection of New Varieties of 
Plants also demonstrates that, although Colombia has acquired international 
trade compromises to grant exclusive rights to plant breeders, the 
Constitutional Court ordered the suspension of the implementation of the 1991 
International Convention for the Protection of New Varieties of Plants until 
the rights of ethnic and peasant communities over those plants were consulted.  
 
A similar analysis could be conducted in the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
Colombia. In fact, through Decrees 1375 and 1376 of 2013, and Resolution 
1348 of 2014, the government has placed into the public domain practices and 
knowledge associated with medicinal plants. As part of its policy of facilitating 
access to genetic resources to local researchers so as to increase the country’s 
scientific capacity, Decrees 1375 and 1376 exempt local researchers from the 
access and benefit sharing requirements when they carry out non-commercial 
activities, specifically the collection and sampling of genetic resources. Also, 
Resolution 1348 points out that access and benefit sharing rules only apply 
when users carry out (i) activities on native species in situ or ex situ, including 
virus and viroids, which involve either the isolation of functional and non-
functional units of DNA and RNA, as found in nature; or (ii) there is isolation 
of one or more molecules, including micro and macromolecules, produced by 
the metabolism of an organism.  
 
None of those administrative decisions state that the use of practices and 
knowledge associated with genetic resources as lead information constitutes 
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an activity that falls within the scope of the access and benefit sharing 
requirements. Since those regulations affect communities’ rights over their 
practices and knowledge, the government should amend those regulations by 
establishing that the use of any communities’ practices and knowledge 
associated with genetic resources constitutes an activity of access as 
established by Decision 391, hence, local researchers or other actors, 
particularly the herbal industry, should consult those communities. 
 
As a result, the functioning of possessing genetic resources for benefit sharing 
would demand that Colombia, based upon its constitution and the rulings 
from the Constitutional Court, secures a position such that neither local 
researchers nor the herbal industry can employ practices and knowledge from 
indigenous, local, and Afro-Colombian communities, without consulting 
them. Therefore, Decrees 1375 and 1376 of 2013, and Resolution 1348 of 2014 
should be amended to include, as an activity of access, the use of indigenous, 
local, and Afro-Colombian communities for health research and the health 
industry. However, to secure those communities’ rights, it is also necessary to 
sort out aspects such as who are the right holders of traditional knowledge and 
practices, and how those holders actually add value to the use of Colombia’s 
biodiversity for health research and the health industry.  
 
Being Able to Take Part in the Industrial Application of Genetic Resources and 
the Benefits that Arise from it 
 
This functioning requires an assessment of who is involved in research into 
genetic resources, and how they participate. It is important to analyse this 
aspect of capability because the different contributions that occur in research 
activities should include not only contributions from those who hold 
technology to carry out investigations, or those who can place products and 
service in the market, but also those who can contribute to R&D and the 
commercialisation of goods and services through their practices and 
knowledge. As a result, the capability for sustainable innovation in health 
research and the health industry should include communities in the industrial 
application of genetic resources and include them in the benefits arising from 
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the utilization of their practices and knowledge associated with genetic 
resources.  
 
First, this functioning requires identifying who contributes and how 
communities contribute in adding value of biodiversity for health research and 
the health industry. As discussed in Chapter Two, this is a critical issue in 
debates on biopiracy and bioprospecting, and a particularly relevant aspect of 
this thesis because it has been pointed out on different occasions how complex 
it is to give a simple legal response to the “messiness” behind the use of 
biodiversity. However, the case analysis of Colombia, and particularly, its 
innovation policy can provide a platform for untangling the complexities 
behind practices and knowledge associated with genetic resources.  
 
As discussed in Chapter Four, Colombian innovation policy does not include 
the practices and knowledge of communities as they do not fit within 
international standards adopted by Colciencias, the country’s science bureau. 
This has led to a fundamental problem with the implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing in 
developing countries rich in biodiversity such as Colombia, which is that such 
an implementation seeks to leave R&D intact to benefit holders of technology, 
including local researchers. This means that it is considered that only those 
who employ technology are considered to be innovative. However, such an 
assumption is not only found in the implementation of the International 
Regime on Access to Genetic Resources and Benefit Sharing in Colombia, but 
is rooted in the way Colombia defines and measures innovation (see Chapter 
Four).  
 
Certainly, Colombia only considers innovative the R&D activities of holders of 
technology, including local researchers. Colciencias, which is in charge of 
addressing resources and measuring what can be innovative, has defined as 
innovative the R&D activities from industries such as the pharmaceutical 
industry (see Chapters Three and Four). This has been the result of Colombian 
interest in employing international standards of innovation to become a more 
competitive economy, not only among developing countries but also within 
 260 
developed countries. In particular, Colciencias adopted in its entirety the 
model of innovation of the Organisation for Economic Co-operation and 
Development (OECD).  
 
The OECD is a club of countries (mainly developed ones) which share common 
policies to evaluate economic development. Since 1992 it has published the 
guidelines for collecting and interpreting innovation data, also known as the 
Oslo Manual, which mainly focuses on data collected from the government, 
sectors, and industries that create new products, processes, and services in a 
variety of areas such as information technology and biotechnology (see 
Chapter Four).448 These data primarily focus on how the production of 
knowledge and information is addressed towards industries. The Oslo Manual 
does not consider other forms of production of innovation, including 
traditional knowledge associated with genetic resources and local practices.  
 
As innovation is only defined and measured by R&D activities from the 
industry as requested by international organizations such as the OECD, 
practices and knowledge from indigenous, local, and Afro-Colombian 
communities are not considered to be innovative in Colombia. Such an 
approach has the potential to bring benefits for Colombia R&D’s capabilities 
and competitiveness in sectors such as health, but it also disavows the role of 
communities in adding value to biodiversity for the health industry. This has 
been reflected in different white papers in Colombia, which seek to engage 
local researchers to access genetic resources by easing access and benefit 
sharing rules and encouraging patenting in inventions deriving from genetic 
resources to allow them to commercialise to the upstream stage.449  
 
448 OECD and Eurostat (n 216). 
449 Chapter Four makes an analysis of different white papers in Colombia and concludes that 
Colombia economic policy and international trade has led them to adopt a model of innovation 
that follows international standards and ignores other forms of innovation; see Consejo 
Nacional de Política Económica y Social, ‘Documento Conpes 3527 Política Nacional de 
Productividad y Competitividad’ (n 217); Consejo Nacional de Política Económica y Social, 
‘Documento Conpes 3866 Politica Nacional de Desarrollo Productivo’ (2016) 
<http://www.colombiacompetitiva.gov.co/prensa/informes/Conpes-3866-de-2016-Politica-
desarrollo-productivo.pdf> accessed 10 October 2017; Consejo Nacional de Política 
Económica y Social, ‘Documento Conpes 3697 Política Para El Desarrollo Comercial de La 
Biotecnología a Partir Del Uso Sostenible de La Biodiversidad’ (n 13); Consejo Nacional de 
Política Económica y Social, ‘Bases de Un Plan de Acción Para La Adecuación Del Sistema de 
Propiedad Intelectual a La Competitividad y Productividad Nacional’ (2008) 
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As a result, Colciencias has supported and even addressed public resources to 
local research to employ genetic resources and practices and knowledge 
associated with those resources for health research. This was clearly 
exemplified in the cases of the two medicinal plants (Dividivi and Anamú) (see 
Chapter Four), employed by a local research group, which have received public 
funds via Colciencias, without due recognition of communities’ practices and 
knowledge.  
 
Also, as communities’ practices and knowledge are not considered to be 
innovative (see Chapters Three and Four), the academic and governmental 
efforts to document have centred exclusively in the therapeutic effects of 
medicinal plants. However, the documenting process does not aim to include 
communities in the industrial application of the medicinal plants. On the 
contrary, the documentation has served the herbal industry to prove the 
safeness and effectiveness of phytomedicines to obtain marketing approvals 
without due recognition of communities’ input in health industry (see Chapter 
Five).  
 
Consequently, it is important to answer the question of how the contribution 
from communities can be considered innovative in Colombia. The answer to 
that question can be found in the International Regime on Access to Genetic 
Resources and Benefit Sharing. The Nagoya Protocol calls on states to assess 
their capacity in carrying out ‘endogenous research to add value to their own 
genetic resources’. Although the Nagoya Protocol does not define what 
endogenous research means, what this treaty aims to include as research in 
genetic resources is not only activities related to the use of technologies such 
as biotechnology, but different activities developed around a community’s 
customary laws, protocols, and procedures.450 A similar reasoning can be 
found in the jurisprudence of the Constitutional Court in the International 
Convention for the Protection of New Varieties of Plants cases when it calls on 
 
<http://www.disanejercito.mil.co//recursos_user///DISAN EJERCITO/LABORATORIO 
DE REFERENCIA E INVESTIGACION/NORMATIVIDAD/conpes_3533_-
_plan_nacional_propiedad_intelectual__-_2008.pdf> accessed June 6 2018. 
450 Jonas, Bavikatte and Shrumm (n 73). 
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the government to safeguard the practices and knowledge of communities 
related to plants as they do not circulate within “commercial and technological 
channels”.  
 
Therefore, Colombia’s innovation policy should be reconstructed to include 
innovation that is not produced within a market-oriented policy. That is why 
this thesis has claimed that is not only desirable to include those practices 
within Colombian innovation policy, but also necessary, so as to harmonise 
constitutional mandates and Decision 391 with the Colombian market 
perspective on innovation. This would require that the Colombian scientific 
authority, Colciencias, include within its innovation assessment of researchers 
and research groups “endogenous research” that adds value to genetic 
resources. Such an approach would demand a change in the policies on 
competitiveness and innovation in Colombia which are drafted in 
governmental white papers such as the National Policy for the use of 
Biodiversity or Colombia Competitive plans.451 If communities’ practices and 
knowledge were included in the construction of innovation policy, it would 
also be possible to harmonise the fragmented implementation of the 
International Regime on Access to Genetic Resources and Benefit Sharing as 
it reconciles the rulings of the Constitutional Court with the administrative 
decisions from central government.  
 
Also, indigenous and Afro-Colombia communities have a legal framework 
(Decrees 2164 and 1745 of 1995, respectively) that defines who can be a 
member of those communities, sets up principles to recognise their own form 
of government, customs and laws, grant them communal land, and the right 
to be publicly consulted if their ethnic and cultural integrity might be affected. 
This means that users of genetic resources, including local researchers, have 
already a framework that help them to identify ethnic communities across the 
country. Although local communities have not the same rights of those ethnic 
communities such as communal land, if the action or inaction of the State or 
other actors could potentially affect their socio-economic relationship with the 
 
451 Ministerio de Ambiente (n 223). 
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environment, the Constitutional Court has granted them on different 
occasions in a case by case approach the right to be publicly consulted to assess 
the impact of the action or inaction and to establish measures to overtake those 
difficulties.  This imposes an extra burden on local researchers, but as in the 
cases of the medicinal plant Dividivi, the research group had already identified 
which local community employed the plants to treat different diseases.  
Further, the efforts to document the therapeutic activity of plants should be 
addressed to identify the different actors behind the use of biodiversity for the 
health industry, rather than serving to prove safeness and effectiveness of 
medicinal plants to obtain market approvals.  Both of these proposals involve 
changes in policy rather than in formal law. 
  
However, a problematic issue is the difficulty in establishing a dialogue 
between users of genetic resources and indigenous and Afro-Colombian 
communities in the use of their knowledge and practices associated with 
genetic resources for health research. For instance, the impossibility to reach 
an agreement on benefit sharing between Afro-Colombian communities in 
Choco and indigenous groups in the Valle del Sibundoy, with the Javeriana 
research group, is according to its lead researcher due to a clashing perspective 
on the compensatory mechanism of the access and benefit sharing regulation. 
To provide solutions, it is necessary to facilitate mechanisms in which those 
communities can create a dialogue with users of genetic resources. To do so, 
the government could intermediate between those stakeholders to advance a 
dialogue that could define how communities can participate in research and 
development, and establish benefit sharing agreements that could lead 
communities to transform those resources into functionalities that enable 
them to function as a community. Since the Ministry of Environment has 
worked closely with local researchers and it is the national authority 
responsible for the implementation of the International Regime on Access to 
Genetic Resources and Benefit Sharing, it could be designated as the authority 
to oversee such a dialogue.  
 
All of the above proposals mean Colombia should amend its innovation policy 
in three respects: (i) by including “endogenous research” that adds value to 
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genetic resources within its innovation assessment of researchers and research 
groups; (ii) by requiring the government to document not only the therapeutic 
value of medicinal plants, but also to identify the different actors behind the 
practices and knowledge of the plants; and (iii) the government through the 
Ministry of Environment should also intermediate between users of genetic 
resources and communities to establish a dialogue in which their practice and 
knowledge are recognised in order to define what form of benefit sharing 
should take place. In particular, it must be observed that driving resources into 
communities is not the only mechanism to secure the adequate protection of 
their rights, but the government should watch that those communities are able 
to transform those resources into functionalities that enable them to function 
as a community.  
 
Being Able to Add Value to Health Research and Health Industry 
 
The functioning of being able to add value to health research and the health 
industry assesses to what extent industries in developing countries rich in 
biodiversity have entitled all actors, e.g. local researchers and the knowledge 
and practices from indigenous, local, and Afro-Colombian communities, 
particularly in the health industry and health research, to effectively decide 
whether or not to participate, and how to participate in the decision-making 
process when their practices and knowledge are involved. This particularly 
involves the creation of mechanisms of compliance. In other words, if 
Colombia seeks to effectively include communities in its innovation policy, it 
become fundamental to establish mechanisms of compliance in order to secure 
that communities can exercise their rights in R&D and industry in practice.  
 
There have been different proposals for establishing a mechanism of effective 
compliance with the International Regime on Access to Genetic Resources and 
Benefit Sharing. At first, developing countries rich in biodiversity, such as the 
Andean Community, established in Decision 391 administrative procedures 
and criminal sanctions to make users of genetic resources comply with Andean 
legislation. Those mechanisms were created with the aim of deterring 
particularly multinational companies from accessing illegally those countries’ 
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genetic resources. In addition, although the UN Convention on Biological 
Diversity did not contemplate it, the Andean Community establishes the 
requirement of disclosure of origin in patents in Decision 486, the Andean 
legislation on patents, as a mechanism that aims to link patent provision with 
the International Regime on Access to Genetic Resources and Benefit Sharing 
to secure enforceability of the latter; if users fail to disclose such information, 
patents are denied or nullified (see Chapter Three). 
  
However, since patents are limited by territory, users are not obliged to 
disclose origin in another jurisdiction which does not establish a similar 
requirement. For instance, the US does not contemplate such a requirement. 
In the case of other developed countries, there is not a consolidated common 
position, even between countries which belong to the same regional 
organisations, leading to different forms of disclosure origin. For instance, 
Belgium, Denmark, Germany, and Sweden (all EU members) have 
implemented disclosure of origin in their national patent legislations, but 
other EU members such as France and Spain have not implemented any 
disclosure of origin provision.452 However, the implementation of disclosure 
of origin does not mean that those measures are necessarily effective. For 
instance, in Norway, despite the fact that disclosure of origin is compulsory, 
there are as yet no cases of disclosure of origin.453 This means that, despite the 
fact that members of the Andean Community have established such a 
requirement, it is difficult to implement globally because of the different 
approaches on disclosure of origin.454  
 
 
452 Danish Act 412 (31/5/2000) amending the Patent Act (consolidated Patent Act 926 22/9 
2000); Section 8c of the Norwich Patents Act (Act No. 9 of 15 December, 1967, as last amended 
by Act No. 20 of May 2004); Article 49a of the Swiss Federal Law on Patents for Inventions of 
June 25 1954 (status as of July 1, 2009) 
453 Morten Walløe Tvedt and Ole Fauchald, ‘Implementing the Nagoya Protocol on ABS: A 
Hypothetical Case Study on Enforcing Benefit Sharing in Norway’ (2011) 14 The Journal of 
World Intellectual Property 383. pp 383-402; see also Morten Walløe Tvedt, ‘Norwegian 
Experiences with ABS’ [2015] Implementing the Nagoya Protocol 175. 
454 Chapter Two analysed how an international patent disclosure of origin has been an issue in 
different forums including the World Trade Organization and the initiatives in the ICG of 
WIPO, in the latter it was proposed to establish a disclosure of origin in the Patent Cooperation 
Treaty (PCT) of WIPO, which assists patent applicants in protecting their inventions 
throughout different jurisdictions.  However, none of those initiatives have been fruitful due 
to opposition from Countries such as the US. 
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There are other initiatives that do not focus on granting property rights, but 
are defensive measures against misappropriation (see Chapter Two). For 
instance, the Traditional Digital Knowledge Library in India seeks to put 
traditional knowledge associated with genetic resources in internet databases 
with the aim of making patent offices and courts dismiss patent protections to 
inventions on the basis that the invention does not fulfil the patent 
requirement of novelty and non-obviousness.455 Also, Peru has established a 
national database for traditional knowledge associated with genetic resources, 
in which local and indigenous communities decide whether to include their 
knowledge in the database, how much they want to share, and with whom they 
want to share it.456 Furthermore, this protection regime also establishes 
“licenses” for those users who want to access those resources, a measure that 
facilitates users’ compliance with prior informed consent and mutually agreed 
terms. In addition, developed countries’ courts and patent offices have 
embraced traditional knowledge and practices as part of the conditions that 
should be assessed to determine patent requirements. For instance, the British 
House of Lords (now Supreme Court) indicated that documented description 
of traditional uses of medicinal plants, although not described in chemical 
terms, serves as a proof of lack of novelty in patents.457 Also, the US Patent 
Office has employed references to the use of a traditional Chinese medicine to 
anticipate patent claims, hence denied them for lack of novelty.458  
 
Because of those initiatives and approaches, the International Regime on 
Access to Genetic Resources and Benefit Sharing has also taken steps towards 
an international database. Article 15 of the Nagoya Protocol calls countries, 
particularly developed ones, to adopt mechanisms of compliance to ensure 
genetic resources employed within their territory have been lawfully accessed 
 
455 See website: http://www.tkdl.res.in/; for further discussion see: Gaudillière (n 116). 
456 The Peruvian Collective Knowledge Protection Regime  or Ley que Establece el Régimen de 
Protección de los Conocimientos Colectivos de los Pueblos Indigenas vinculados a los 
Recursos Biológicos (Ley 27811 de 2012) 
457 Merrell Dow Pharmaceuticals Inc v. HN Norton & Co Ltd [1996] R.P.C. 76 (HL) in 
Dutfield, ‘A Critical Analysis of the Debate on Traditional Knowledge, Drug Discovery and 
Patent-Based Biopiracy’ (n 111)., pp 242-243 
458 ibid., p 243, see also: Board of Patent Appeals and Interferences of US Patent and Trade 
Office , Ex Parte Pfizer, Inc. (2009) at 
<http://ipwatchdogs.com/cases/viagra_bpai_decision.pdf> accessed September 20 2014   
 267 
according to the access and benefit sharing regulation of the country that 
provides the genetic resources and considering traditional knowledge 
associated with those resources. Therefore, Article 17 of the Nagoya Protocol 
defines what those mechanisms are in order to monitor the compliance of 
users of genetic resources. These include checkpoints such as patent offices or 
other administrative agencies, and the Internationally Recognized Certificate 
of Compliance, which aims to secure that the flow of genetic resources and 
traditional knowledge is in accordance with the International Regime on 
Access to Genetic Resources and Benefit Sharing (see Chapter One).  
 
An example of how the Internationally Recognized Certificate of Compliance 
and checkpoints might work is EU Regulation 511/2014, which creates a 
comprehensive mechanism of compliance for the European Union (see 
Chapter Two). This Regulation sets up specific measures to monitor users’ 
compliance. In particular, the EU Regulation requires member states and the 
EU Commission to request publicly funded research to comply with access and 
benefit sharing rules from the country of origin and other users should 
demonstrate that they have complied with access and benefit sharing rules 
when the product needs marketing authorisation, or if there is no need for 
marketing authorisation, when the product is placed on the market in the EU 
for the first time.459 The EU regulation also indicates publicly funded users can 
prove that they lawfully accessed genetic resources and traditional knowledge 
through any information and relevant documents issued by a national 
authority in a developing country rich in biodiversity, including an 
Internationally Recognized Certificate of Compliance, as proof of compliance 
(see Chapter Two).  
 
Since developed countries such as the EU member states are establishing user 
measures of compliance, such measures can only operate as long as there is a 
similar structure that actually oversees access to genetic resources and 
traditional knowledge in developing countries rich in biodiversity. However, 
developing countries rich in biodiversity do not deploy a similar structure to 
 
459 Implementing Regulation 2015/1866 
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those established by the EU. Although India is currently issuing a number of 
important Internationally Recognized Certificates of Compliance,460 other 
developing countries rich in biodiversity do not have the infrastructure to 
implement that approach.461 For instance, the Colombian national authority 
that oversees compliance with the International Regime on Access to Genetic 
Resources and Benefit Sharing, the Ministry of the Environment, has reached 
more than 200 mutually agreed terms (see Chapter Three), yet it has not 
issued the first Internationally Recognized Certificate of Compliance. Even 
more, a close analysis of the different mutually agreed terms in Colombia 
indicates that there are not even the first mutually agreed terms with local, 
indigenous, and Afro-Colombian communities. It is also alarming that users 
such as the research group of Javeriana University in the Dividivi case is 
obtaining patents on inventions derived from practices and knowledge of 
different communities without having publicly consulted them, despite the 
fact that they should have disclosed such information in the patent application 
(see Decision 486). Also, as repeatedly noted above, the fact that the herbal 
industry does not need to comply with access and benefit sharing rules 
indicates a clear lack of effective mechanism to safeguard communities’ 
contribution.  
 
Against this background, how could Colombia improve compliance to secure 
that those communities’ contribution is safeguarded? A first step would be to 
make a practical reality the fundamental right of public consultation in the 
implementation of the International Regime on Access to Genetic Resources 
and Benefit Sharing. According to the Constitutional Court’s precedent on 
public consultation, as observed in Chapter Three, communities have the right 
 
460 India was the first country to issue an IRCC in 2015, ever since this country has issued more 
than 100 IRCC; for further information see Secretariat of the UN Convention on Biological 
Diversity, ‘The First Internationally Recognized Certificate of Compliance Is Issued under the 
Nagoya Protocol on Access and Benefit-Sharing’ <https://www.cbd.int/doc/press/2015/pr-
2015-10-07-abs-en.pdf> accessed 3 July 2018. See also Secretariat of the UN Convention on 
Biological Diversity, ‘Access and Benefit-Sharing Clearing-House: India’ 
<https://absch.cbd.int/countries/in> accessed July 3 2018.  
461 For a comprehensive qualitative analysis of how difficult is to implement the 
Internationally Recognized Certificate of Compliance in developing countries rich in 
biodiversity see Nicolas Pauchard, ‘Access and Benefit Sharing under the Convention on 
Biological Diversity and Its Protocol: What Can Some Numbers Tell Us about the Effectiveness 
of the Regulatory Regime?’ (2017) 6 Resources 11. 
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not only to be consulted, but also to decide over specific activities when their 
rights could be affected before such activity, by either the state or any other 
agent, takes place. Although this precedent has been designed in the light of 
the exploitation of natural resources such as oil and gold, it should be 
implemented in line with the International Regime on Access to Genetic 
Resources and Benefit Sharing, particularly, the Nagoya Protocol which 
requires countries to adopt mechanisms to secure prior informed consent from 
communities (see Chapter Two). 
 
To protect the fundamental right of public consultation and the Nagoya 
Protocol in practice, Colombia could observe the approaches of India and Peru, 
which have not only created databases on traditional knowledge, but have also 
adopted legislation allowing communities to decide whether they want to 
include their practices and knowledge in those databases, how they want to 
include it, and whether they allow users to access to such information. 
Colombia could adopt such legislation. In the event of conflicts between the 
interest of keeping communities’ practices and knowledge secret and the 
interest of getting products based upon those practices and knowledge such as 
medicines into the market, Chapter Two points out that the Nagoya Protocol 
requires countries to pay due regard to situations such as lack of access to 
medicines. In those cases, the Colombian Constitutional Court could interpret 
the relevant legislation in such a way as to strike the adequate balance between 
communities’ rights and the public interest of facilitating access to medicines. 
Finally, a Colombian database of traditional knowledge could also be 
consulted by patent offices, including the Colombian patent office, to decide 
whether users lawfully accessed practices and knowledge, and complied with 
disclosure of origin in patents. 
 
In addition, the protection of public consultation would also require inclusion 
of the herbal industry within Colombia’s access and benefit sharing regulation. 
It has been pointed out throughout this thesis that this industry benefits 
significantly from the knowledge and practices of communities without 
recognising their input. The industry can even employ such an input to obtain 
market authorisation. Therefore, in order to include this industry within the 
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access and benefit sharing regulations, Colombia could adopt a similar 
approach to that of the EU in Regulation 511/2014, in which users should 
disclose information related to their compliance with access and benefit 
sharing rules in market authorisation processes or, if this is not required, 
before the product reaches the market. Such a requirement would also 
represent an equal legal treatment for both the herbal industry and local 
researchers. As noted in Chapter Five, local researchers criticise the fact that 
the herbal industry is excepted de facto from the obligations of the 
implementation of access and benefit sharing rules in Colombia as local 
researchers are required to comply with that regulation and prove through 
expensive clinical tests the safeness and effectiveness of their phytomedicines. 
Therefore, a requirement that this industry must disclose information related 
to the use of practices and knowledge for their own benefit would give an equal 
legal treatment with local researchers too. Also, this requirement will 
necessarily engage the herbal industry with communities such as Yerbateros, 
whose economic activity have been affected by this growing industry, since it 
would require the industry to obtain prior informed consent from them.  
Colombia should include within the Decree 2266, which regulates the 
production and distribution of phytomedicines, including traditional 
phytomedicines, in Colombia, a disclosure of origin as a requirement to obtain 
a marketing authorisation, and in the event in which a product does not 
require marketing authorisation, it would be required to disclose origin before 
the product reaches the Colombian market.  
 
To sum up this point, (i) Colombia should make enforceable public 
consultation within the access and benefit sharing regulations, through the 
creation of a public database related to traditional knowledge and practices, in 
which communities can decide whether they want to include their practices 
and knowledge in those databases, how they want to include it, and whether 
they allow users to access to such information for industrial application; (ii) 
the database can also help to determine whether users of genetic resources are 
disclosing information as they file patent applications. Also, (iii) it would 
require that the herbal industry disclose information in marketing 
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authorisation processes, so as to make this industry comply with Colombia’s 




This thesis has fitted the normative claim of the capability for sustainable 
innovation in the health industry and research within the 1991 Colombian 
Constitution and the rulings of the Constitutional Court on protecting 
community rights, particularly in the exploitation of natural resources such as 
gold and oil. It has been highlighted that since the Constitutional Court has 
aimed to strike a balance between the exploitation of natural resources and 
community rights, it has created an important precedent that can be extended 
in the utilization of genetic resources and traditional knowledge so as to 
balance the interest of the Colombian authorities to employ genetic resources 
and traditional knowledge for health research and the health industry, and 
acknowledging the contribution that local, indigenous, and Afro-Colombian 
communities made in adding value to the use of biodiversity. As the proposed 
capability is justified within Colombia’s constitution and the rulings of the 
Constitutional Court, it is possible to suggest amendments to Colombian law, 
policy and practice, which would address what has been discussed throughout 
the thesis with the analysis of functionings.  
 
On possessing genetic resources for benefit sharing, since Colombia placed 
into the public domain knowledge and practices of communities, it would not 
necessarily be necessary to create a sui generis system but it would rather 
require the country: 
I. To amend Decrees 1375 and 1376 of 2013, and Resolution 1348 
of 2014 as to establish that the use of practices and knowledge of 
indigenous, Afro-Colombian communities constitutes an access 
activity which demands users, including local researchers, and 
the herbal industry, to obtain prior informed consent and reach 
mutually agreed terms with communities.    
Regarding the functioning of being able to take part in the industrial 
application of genetic resources, it demands inclusion of communities’ 
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practices and knowledge into its innovation policy. In particular, it would 
require: 
II. To include “endogenous research” that adds value to genetic 
resources within its innovation assessment of researchers and 
research groups. 
III. To require the government to document not only the therapeutic 
value of medicinal plants, but also to trace and identify the 
different actors behind the practices and knowledge of the 
plants.  
IV. To entitle the Ministry of Environment to create a dialogue 
between users of genetic resources and all communities in order 
to advance in mechanism to reach agreements on benefit sharing    
In the functionings of being able to add value to health research and health 
industry, it would require that Colombia effectively make concrete public 
consultation in the regulation of access and benefit sharing. This would require 
Colombia: 
V. To create a public database related to traditional knowledge and 
practices, in which communities can decide whether they want 
to include their practices and knowledge in those databases, how 
they want to include them, and whether they allow users to 
access to such information for industrial application. 
VI. The database should also help determine when users of genetic 
resources are not disclosing information as they require patents.  
VII. To amend Decree 2266 to require that the herbal industry 
disclose information in marketing authorisations when the 
industry employ practices and knowledge to obtain marketing 
approvals for traditional phytomedicines in order to make this 
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Appendix III Information Sheet for Candidates 
Participant Information Sheet September 2019 (Plant Sellers) 
 
Access to Genetic Resources and Sustainable Innovation in the Health Industry and Health 
Research: A Colombian Legal Perspective  
 You are invited to take part in a research project investigating to explore Colombian law on 
health research and the biomedical industry regarding the use of the knowledge and 
practices of local, indigenous and Afro-Colombian communities. Before you decide to take 
part, please read the following information, and do not hesitate to request further 
information or explanation of anything that is not clear.  
Project Purpose 
The project seeks to explore the contribution of local, indigenous and Afro-Colombian 
communities in the use of medicinal plants and whether the law includes the ways in which 
health research and the health industry in Colombia use the knowledge and practices of 
those communities.  
Why have I been chosen? 
You have been chosen to participate due to your knowledge as a provider of medicinal plants 
in a market place.  In the course of this research, another providers of medicinal plants in 
different market places will also be interviewed. 
Do I have to take part? 
No. It is up to you to decide whether or not to participate. If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. Once your 
data has been captured, it will be available to the PhD team, and once published it will be 
available generally. You can still withdraw from any on-going or future data collection in the 
project at any time, by emailing the PhD candidate Carlos Augusto Conde Gutierrez 
(c.conde@sheffield.ac.uk), and Supervisors Professor Tamara Hervey 
(t.hervey@sheffield.ac.uk) and Professor Emilie Cloatre (e.cloatre@kent.ac.uk) and do not 
have to give a reason. If you withdraw, the information you have given will be destroyed and 
will not be used in the project. 
What will happen to me if I take part? 
If you choose to take part in this research, you will be interviewed about your understandings 
of one or more aspects of the use of local, indigenous and Afro-Colombian communities’ 
knowledge and practices related to medicinal plants in market places, and the ways that the 
law regulates the use of medicinal plants. The interview will seek to draw out aspects about 
which you, or those you represent, are concerned.  Those aspects will be used to support an 
analysis of Colombian policies and law behind the use of communities’ practices and 
knowledge related to medicinal plants for health research and the health industry.  We will 




knowledge on the use of medicinal plant in urban markets, and whether the law regulates it. 
The interview will last approximately one hour, or longer if you wish, and will be recorded in 
note form and electronically. We may request one or two follow-up interviews.  
 
What are the risks and benefits of taking part? 
You are being included in the research in your legal capacity, so personal discomforts, 
disadvantages and risks are highly unlikely to arise. 
Participating in this project as a member of plant traders’ network in urban markets is 
intended to secure benefits for you and your organisation.  You will feed into in-depth 
analysis of the context of the Colombian policies and law behind the use of local, indigenous 
and Afro-Colombian communities’ practices and knowledge of medicinal plants’, through 
helping to articulate specific legal questions which your organisation, or those it represents, 
would like to have answered.  You will help illuminate the meanings of how your role as a 
plant trader contributes with the dissemination to the public of communities’ practices and 
knowledge of communities related to medicinal plants, and their legal implications.  You will 
assist in understandings of accountability for the health industry and health research in the 
use of Colombia’s biodiversity and ethnic diversity, and its legitimacy, among local, 
indigenous and Afro-Colombian communities, as well as the public in general. 
Will my taking part in this project be kept confidential? 
No. You have been asked to participate because of your unique knowledge in the use of 
medicinal plants. Due to the small number of plant traders involved in this project, it will not 
be possible to keep your participation in the project confidential.  Nor will it be necessary or 
desirable: your interview is designed to uncover those aspects of the use of medicinal plants, 
as well as the law that regulates it, that concern you as a stakeholder, in your official capacity. 
We will offer a bespoke analysis of a legal issue that is of concern to you, and we will publish 
that analysis as part of a PhD thesis.  Thus, it is part of the project’s design that who you are, 
as well as the information you provide, will be used in the dissemination or publication of 
this research. While it is being analysed and before dissemination, all data will be stored and 
analysed in a secure location to ensure proper security. During that time, you will have a 
chance to review the recording of your interview, to ensure you are happy with its contents. 
Will I be recorded, and how will the recorded media be used? 
Yes. To ensure accuracy, as well as handwritten notes being taken during and after the 
interview, this interview will be audio recorded and later transcribed. During and following 
transcription, the sound recording will be stored in a secure location for verification 
purposes. Since the recorded interviews will take place in an urban market, some background 
noise is expected, therefore, we will also take some photos of the surroundings to 
complement the interview. As noted above, and explained further below, parts of the data 
will be published.   




According to the EU and UK data protection legislation, we are required to inform you that 
the legal basis we are applying in order to process your personal data is that ‘processing is 
necessary for the performance of a task carried out in the public interest’ (Article 6(1)(e)) of 
General Data Protection Regulation 2016/679. Further information can be found in the 
University’s Privacy Notice https://www.sheffield.ac.uk/govern/data-
protection/privacy/general.   
The University of Sheffield will act as the Data Controller for this study.  
What will happen to the results of the research project? 
The results of this research project will be disseminated in the following way. You and other 
stakeholders’ interviews, including other researchers and plant traders, will provide the 
basis for analysis of whether the law includes the ways that researchers and the health 
industry use practices and knowledge of local, indigenous and Afro-Colombian 
communities related to medicinal plants. These will be published as part of a PhD Law 
thesis. In addition, the project will produce publications aimed at international academic 
conference papers, publications in peer-reviewed academic journals and reflective blogs.   
Who has ethically reviewed the project? 
This project has been ethically reviewed and formally approved through the University of 
Sheffield’s Ethics Review Procedure, as administered by the Department of Politics, 
University of Sheffield. 
What if something goes wrong and I wish to complain about the research? 
Should you wish to raise a complaint about the research, please raise it with Professor 
Tamara Hervey, the main Supervisor of the PhD candidate in the first instance. If you feel 
your complaint has not been handled to your satisfaction, please contact the Head of the 
School of Law, Professor Graham Gee, who will then escalate the complaint through the 
appropriate channels. Information about how to raise a complaint about handling of 
personal data can be found in the University’s Privacy Notice: 
https://www.sheffield.ac.uk/govern/data-protection/privacy/general. 
 
Contact for further information. 
LEAD RESEARCHER: 
Carlos Augusto Conde Gutiérrez,  
Mobile: 0057350149817, 
Email: c.conde@sheffield.ac.uk,  
Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  
SUPERVISOR 





Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  
HEAD OF THE SCHOOL OF LAW,  
Professor Graham Gee,  
Email: g.gee@sheffield.ac.uk  
Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  
Thank you for taking part in this project and agreeing to become a co-producer of its 
results. 
 
Participant Information Sheet September 2019 (Researchers) 
 
Access to Genetic Resources and Sustainable Innovation in the Health Industry and Health 
Research: A Colombian Legal Perspective  
 You are invited to take part in a research project investigating to explore Colombian law on 
health research and the biomedical industry regarding the use of the knowledge and 
practices of local, indigenous and Afro-Colombian communities. Before you decide to take 
part, please read the following information, and do not hesitate to request further 
information or explanation of anything that is not clear.  
Project Purpose 
The project seeks to explore the contribution of local, indigenous and Afro-Colombian 
communities in the use of medicinal plants and whether the law includes the ways in which 
health research and the health industry in Colombia use the knowledge and practices of 
those communities.  
Why have I been chosen? 
You have been chosen to participate as an expert and leading researcher in Colombia in the 
field of the use of medicinal plants for health research.  In the course of this research, another 
experts might also be consulted, as well as providers of medicinal plants whose place of trade 
are urban market places. 
Do I have to take part? 
No. It is up to you to decide whether or not to participate. If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. Once your 
data has been captured, it will be available to the PhD team, and once published it will be 
available generally. You can still withdraw from any on-going or future data collection in the 
project at any time, by emailing the PhD candidate Carlos Augusto Conde Gutierrez 
(c.conde@sheffield.ac.uk), and Supervisors Professor Tamara Hervey 




have to give a reason. If you withdraw, the information you have given will be destroyed and 
will not be used in the project. 
What will happen to me if I take part? 
If you choose to take part in this research, you will be interviewed about your understandings 
of one or more aspects of the use of local, indigenous and Afro-Colombian communities’ 
knowledge and practices related to medicinal plants for health research, and the ways that 
the law regulates the use of medicinal plants. The interview will seek to draw out a specific 
scenario or scenarios about which you, or those you represent, are concerned.  This scenario 
will be used to support an analysis of Colombian policies and law behind the use of 
communities’ practices and knowledge related to medicinal plants for health research and 
the health industry.  We will also use the interview data to understand how researchers 
approach towards the use of medicinal plants and communities’ practices and knowledge, 
as it applies to health research regulation. The interview will last approximately one hour, or 
longer if you wish, and will be recorded in note form and electronically. We may request one 
or two follow-up interviews. 
 
What are the risks and benefits of taking part? 
You are being included in the research in your professional capacity, so personal discomforts, 
disadvantages and risks are highly unlikely to arise. 
Participating in this project as one of a small number of experts in the use of medicinal plants 
for health is intended to secure benefits for you and your organisation.  You will feed into in-
depth analysis of the context of the Colombian policies and law behind the use of local, 
indigenous and Afro-Colombian communities’ practices and knowledge medicinal plants’, 
through helping to articulate specific legal questions which your organisation, or those it 
represents, would like to have answered.  You will help illuminate the meanings of the use 
of medicinal plants and communities’ practices and knowledge legal and policy texts, and 
their implications for health research.  You will assist in understandings of accountability for 
researchers in the use of Colombia’s biodiversity and ethnic diversity for health research, and 
its legitimacy, among local, indigenous and Afro-Colombian communities, as well as the 
public in general. 
Will my taking part in this project be kept confidential? 
No. You have been asked to participate because of your unique expertise in the use of 
medicinal plants for health research.  Due to the small number of experts involved in this 
project, it will not be possible to keep your participation in the project confidential.  Nor will 
it be necessary or desirable: your interview is designed to uncover those aspects of the use 
of medicinal plants and communities’ practices and knowledge, as well as the law that 
regulates that concern you as a stakeholder, in your official capacity. We will offer a bespoke 
analysis of a legal issue that is of concern to you, and we will publish that analysis as part of 
an PhD thesis.  Thus, it is part of the project’s design that who you are, as well as the 




While it is being analysed and before dissemination, all data will be stored and analysed in a 
secure location to ensure proper security. During that time, you will have a chance to review 
the recording of your interview, to ensure you are happy with its contents. 
Will I be recorded, and how will the recorded media be used? 
Yes. To ensure accuracy, as well as handwritten notes being taken during and after the 
interview, this interview will be audio recorded and later transcribed. During and following 
transcription, the sound recording will be stored in a secure location for verification 
purposes.  As noted above, and explained further below, parts of the data will be published.   
What is the legal basis for processing my personal data? Who is the Data Controller? 
According to the EU and UK data protection legislation, we are required to inform you that 
the legal basis we are applying in order to process your personal data is that ‘processing is 
necessary for the performance of a task carried out in the public interest’ (Article 6(1)(e)) of 
General Data Protection Regulation 2016/679. Further information can be found in the 
University’s Privacy Notice https://www.sheffield.ac.uk/govern/data-
protection/privacy/general.   
The University of Sheffield will act as the Data Controller for this study.  
What will happen to the results of the research project? 
The results of this research project will be disseminated in the following way. You and other 
stakeholders, including other researchers and plant traders, to be interviewed will provide 
the basis for analysis of whether the law includes the ways that researchers uses practices 
and knowledge of local, indigenous and Afro-Colombian communities related to medicinal 
plants. These will be published as part of a PhD Law thesis. In addition, the project will 
produce publications aimed at international academic conference papers, publications in 
peer-reviewed academic journals, reflective blogs.   
Who has ethically reviewed the project? 
This project has been ethically reviewed and formally approved through the University of 
Sheffield’s Ethics Review Procedure, as administered by the Department of Politics, 
University of Sheffield. 
What if something goes wrong and I wish to complain about the research? 
Should you wish to raise a complaint about the research, please raise it with Professor 
Tamara Hervey, the main Supervisor of the PhD candidate in the first instance. If you feel 
your complaint has not been handled to your satisfaction, please contact the Head of the 
School of Law, Professor Graham Gee, who will then escalate the complaint through the 
appropriate channels. Information about how to raise a complaint about handling of 






Contact for further information. 
LEAD RESEARCHER: 
Carlos Augusto Conde Gutiérrez,  
Mobile: 0057350149817, 
Email: c.conde@sheffield.ac.uk,  
Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  
SUPERVISOR 
Professor Tamara Hervey 
email: t.hervey@sheffield.ac.uk 
Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  
HEAD OF THE SCHOOL OF LAW,  
Professor Graham Gee,  
Email: g.gee@sheffield.ac.uk  
Address: School of Law, University of Sheffield 
Bartolomé House, Winter Street 
Sheffield S3 7ND, UK  












Appendix V: Decision 391 of 1996 




ON THE DEFINITIONS 
Article 1.- The following definitions shall apply for purposes of this Decision: 
ACCESS: the obtaining and use of genetic resources conserved in situ and ex 
situ, of their by-products and, if applicable, of their intangible components, for 
purposes of research, biological prospecting, conservation, industrial 
application and commercial use, among other things. 
ACCESS CONTRACT: agreement between the Competent National Authority 
in representation of the State, and a person that establishes the terms and 
conditions for access to genetic resources, their by-products and, if applicable, 
the associated intangible component. 
ACCESS RESOLUTION: an administrative order issued by the Competent 
National Authority that executes the access to genetic resources or their by-
products, after having fulfilled all requirements or conditions stipulated in the 
access procedure. 
BIOLOGICAL DIVERSITY: the variability of living organisms of any source 
whatsoever, including, among others, land and ocean ecosystems and other 
aquatic ecosystems, as well as the ecological complexes of which they are a 
part. Covers the diversity that exists within each species and between species 
and within ecosystems as a result of natural and cultural processes. 
BIOLOGICAL RESOURCES: individuals, organisms or parts of them, 
populations or any biotic component of value or of real or potential use that 
contains a genetic resource or its by-products. 
BIOTECHNOLOGY: any technological application that utilizes biological 
systems or live organisms, parts of them or their by-products, to create or 
modify products or processes for specific uses. 
BY-PRODUCT: a molecule, a combination or mixture of natural molecules, 
including crude extracts of live or dead organisms of biological origin that 
come from the metabolism of living beings. 
COMPETENT NATIONAL AUTHORITY: State entity or public institution 
appointed by each Member Country, authorized to supply the genetic resource 
or its by-products and therefore to sign or supervise the access contracts, to 
take the actions provided for in this common regime and to ensure their 
performance. 
COUNTRY OF ORIGIN OF THE GENETIC RESOURCE: country that 
possesses genetic resources in in situ conditions, including those which, 
having been in in situ conditions, are now in ex situ conditions. 
ECOSYSTEM: a dynamic complex of communities of human beings, plants, 
animals and micro-organisms and their non-living medium that interact as a 
functional unit. 
EX SITU CONDITIONS: those in which the genetic resources are not found in 




EX SITU CONSERVATION CENTER: a person or institution recognized by 
the Competent National Authority that conserves and collects genetic 
resources or their by-products outside their in situ conditions. 
GENETIC DIVERSITY: variation of genes and genotypes between and within 
species. Sum total of the genetic information contained in biological 
organisms. 
GENETIC EROSION: the loss of or decrease in genetic diversity. 
GENETIC RESOURCES: all biological material that contains genetic 
information of value or of real or potential use. 
IN SITU CONDITIONS: those in which the genetic resources are found in their 
ecosystems and natural environments; in the case of domesticated or 
cultivated species or those having escaped domestication, in the environments 
where they developed their specific properties. 
INTANGIBLE COMPONENT: all know-how, innovation or individual or 
collective practice, with a real or potential value, that is associated with the 
genetic resource, its by-products or the biological resource that contains them, 
whether or not protected by intellectual property regimes. 
NATIONAL SUPPORT INSTITUTION: national institution devoted to 
biological research of a scientific or technical nature, that accompanies the 
applicant and participates jointly with it in the access activities. 
NATIVE, AFRO-AMERICAN OR LOCAL COMMUNITY: a human group 
whose social, cultural and economic conditions distinguish it from other 
sectors of the national community, that is governed totally or partially by its 
own customs or traditions or by special legislation and that, irrespective of its 
legal status, conserves its own social, economic, cultural and political 
institutions or a part of them. 
PROGRAM FOR THE LIBERALIZATION OF GOODS AND SERVICES: a 
program whose purpose is to eliminate levies and restrictions of all kinds on 
the importation of goods originating in the territory of any Member Country, 
pursuant to the provisions of the pertinent chapter of the Cartagena 
Agreement and all other applicable rules and regulations of its body of law. 
SUPPLIER OF THE BIOLOGICAL RESOURCE: a person empowered by this 
Decision and complementary national legislation to supply the biological 
resource that contains the genetic resource or its by-products. 
SUPPLIER OF THE INTANGIBLE COMPONENT: a person that, through an 
access contract and pursuant to this Decision and to complementary national 
legislation, is empowered to supply the intangible component associated with 
the genetic resource or its by-products. 
SUSTAINABLE USE: use of the components of biological diversity in a way 
and at a rate that does not cause their reduction in the long term and that 
enables them to maintain their possibilities for satisfying the needs and the 
aspirations of existing and future generations. 
SYNTHESIZED PRODUCT: a substance obtained through the artificial 
processing of genetic information or of information from other biological 
molecules. Includes semi-processed extracts and substances obtained by 
converting a by-product through an artificial process (hemisynthesis). 
TITLE II 
ON THE PURPOSE AND AIMS 
Article 2.- The purpose of this Decision is to regulate access to the genetic 




a) Establish the conditions for just and equitable participation in 
the benefits of the access; 
b) Lay the foundations for the recognition and valuation of the 
genetic resources and their by-products and of their associated 
intangible components, especially when native, Afro-American 
or local communities are involved; 
c) Promote conservation of the biological diversity and the 
sustainable use of the biological resources that contain genetic 
resources; 
d) Promote the consolidation and development of scientific, 
technological and technical capacities at the local, national and 
subregional levels; and 
e) Strengthen the negotiating capacity of the Member Countries. 
TITLE III 
ON THE SCOPE 
Article 3.- This Decision is applicable to genetic resources for which is the 
Member Countries are the countries of origin, to their by-products, to their 
intangible components and to the genetic resources of the migratory species 
that for natural reasons are found in the territories of the Member Countries. 
Article 4.- The following are excluded from the scope of this Decision: 
a) Human genetic resources and their by-products; and 
b) The exchange of genetic resources, their by-products, the 
biological resources containing them, or their associated 
intangible components among native, Afro-American and local 
communities of the Member Countries for their own 
consumption, based on their customary practices. 
TITLE IV 
ON THE PRINCIPLES 
CHAPTER I 
ON THE SOVEREIGNY OVER GENETIC RESOURCES AND 
THEIR BY-PRODUCTS 
  
Article 5.- The Member Countries exercise sovereignty over their genetic 
resources and their by-products and consequently determine the conditions 
for access to them, pursuant to the provisions of this Decision. 
The conservation and sustainable use of the genetic resources and their by-
products are regulated by each Member Country in keeping with the principles 
and provisions of the Biological Diversity Agreement and of this Decision. 
Article 6.- The genetic resources and their by-products which originated in the 
Member Countries are goods belonging to or the heritage of the Nation or of 
the State in each Member Country, as stipulated in their respective national 
legislation. 
Those resources are inalienable, not subject to prescription and not subject to 
seizure or similar measures, without detriment to the property regimes 
applicable to the biological resources that contain those genetic resources, the 









ON THE GENERAL ASPECTS 
Article 16.- All access procedures shall require the presentation, admittance, 
publication and approval of an application, the signing of a contract, the 
issuing and publication of the corresponding Resolution and the declarative 
registration of the acts connected with that access. 
Article 17.- The applications for access and access contracts and, if 
appropriate, accessory contracts shall include conditions like the following: 
a) The participation of Subregional nationals in the research on 
genetic resources and their by-products and on the associated 
intangible component; 
b) Support for research within the jurisdiction of the Member 
Country of origin of the genetic resource or in any other 
Subregional Member Country that contributes to the 
conservation and sustainable use of the biological diversity; 
c) The strengthening of mechanisms for the transfer of know-
how and technology, including biotechnology, that is culturally, 
socially and environmentally healthy and safe; 
d) The supply of information about the background and status of 
the science and about other matters that would contribute to a 
better knowledge of the situation regarding the genetic resource 
that originated in the Member Country, its by-product or 
synthesized product and its associated intangible component; 
e) The strengthening and development of the institutional 
capacity of the country or the Subregion in regard to genetic 
resources and their by-products; 
f) The strengthening and development of the capacities of the 
native, Afro-American and local communities with relation to 
the associated intangible components, the genetic resources and 
their by-products; 
g) The compulsory deposit of duplicates of all material collected, 
at institutions designated by the Competent National Authority; 
h) The obligation to inform the Competent National Authority 
about the results of the research carried out; and 
i) The terms for the transfer of the material to which third parties 
are given access. 
Article 18.- The documents connected with the access procedure shall appear 
in a public file that the Competent National Authority shall keep. 
That file shall consist of the following, at least: the application; the 
identification of the applicant, the resource supplier, and the national support 
person or institution; the site or area to which the access applies; the access 
methodology; the project proposal; the parts of the access contract that are not 
subject to confidentiality; the opinion about and registry of visits; and, if 
applicable, the evaluation studies of the economic, social and environmental 
impact or of the environmental permits. 
Also included in the file are the Resolution executing the access, the reports 
supplied by the national support person or institution, and the follow-up and 
supervisory reports provided by the Competent National Authority or the 
entity delegated to perform that task. That file is open to consultation by any 
person. 
Article 19.- The Competent National Authority may give confidential 




procedure or the contract performance, and not previously disclosed, which 
could be put to unfair commercial use by third parties, unless the knowledge 
of this data and information by the public is necessary to protect the social 
interest or the environment. 
Accordingly, the applicant should state the grounds for its petition, 
accompanied by a non-confidential summary that will become a part of the 
public file. 
The information or documents referred to in the second paragraph of Article 
18 of this Decision cannot be made confidential. 
The confidential aspects shall be covered in a separate file, in the custody of 
the Competent National Authority, and may not be disclosed to third parties, 
unless that is judicially ordered. 
Article 20.- If the petition for confidential treatment fails to comply with the 
requirements established in the previous article, the Competent National 
Authority shall deny it as a matter of right. 
Article 21.- The Competent National Authority shall keep a public registry 
where the following information shall be entered, among other data: the 
Resolution that may possibly deny the petition, the access contract signing, 
amendment, suspension and termination dates, the date and number of the 
Resolution executing or canceling it, the date and number of the Resolution, 
award or sentence determining the nullity or imposing penalties, with an 
indication of their kind and the parties, and accessory contract signing, 
amendment, suspension, termination and nullification dates. 
That registry shall be of a declaratory nature. 
Article 22.- As stipulated in Article 15, the execution of the access is dependent 
upon the provision of full and reliable information by the applicant, as called 
for by law. 
In this connection, the applicant should present the Competent National 
Authority with all of the information about the genetic resource and its by-
products that it knows or is in a position to know at the moment the application 
is presented. That information shall include the present and potential uses of 
the resource, by-product or intangible component, their sustainability and the 
risks that could result from the access. 
The statements made by the applicant in the application and in the contract, 
including their respective annexes, shall be in the nature of a sworn statement. 
Article 23.- The permits, authorizations and other documents that support the 
investigation, obtaining, provision, transfer, etc., of biological resources, shall 
not determine, qualify or presume the authorization of the access. 
Article 24.- It is forbidden to use genetic resources and their by-products in 
biological weapons or for practices that are harmful to the environment or to 
human health. 
Article 25.- The transfer of technology shall be carried out in accordance with 
the provisions contained in the body of law of the Cartagena Agreement, 
complementary national provisions and such rules and regulations on 
biosecurity and the environment as the Member Countries may approve. 
Article 26.- The access to and transfer of technology subject to patents or other 
intellectual property rights, shall be accomplished in keeping with the 
Subregional and complementary national provisions regulating that area. 
CHAPTER II 




Article 26.- The procedure starts with the presentation to the Competent 
National Authority of an application for access which should contain: 
a) Identification of the applicant and, if pertinent, documents 
that accredit its legal capacity to make a contract; 
  
b) Identification of the supplier of the genetic and biological 
resources and their by-products or of the associated intangible 
component; 
c) Identification of the national support person or institution; 
d) Identification and curriculum vitae of the person responsible 
for the project and of his working group; 
e) The access activity applied for; and 
f) The location or area where the access is to be carried out, with 
an indication of its geographical coordinates. 
The application shall be accompanied by the project proposal, considering the 
referential model the Board approves through a Resolution. 
Article 27.- If the application with its accompanying project proposal is 
complete, the Competent National Authority shall accept it, assign it a 
presentation or filing date, record it in the report and enter it with a declarative 
intent in the public registry it shall keep for that purpose and open the 
corresponding file. 
Were the application to be incomplete, the Competent National Authority 
would return it without delay, indicating the information that is missing, so 
that it might be completed. 
Article 28.- Within five working days following the date of entry of the 
application in the public registry referred to in the previous article, an extract 
of that application shall be published in a newspaper with broad national 
circulation and in another medium of the place where the access is to be 
effected, so that those that wish to might supply information to the Competent 
National Authority. 
Article 29.- Within thirty working days after its registration, the Competent 
National Authority shall evaluate the application, make the visits it deems 
necessary and issue a technical and legal opinion about its propriety or 
invalidity. That period may be extended to up to sixty working days if the 
Competent National Authority considers it desirable. 
Article 30.- When the time limit stipulated in the previous article expires, or 
before that, if appropriate, the Competent National Authority shall accept or 
deny the application, based on the results of the opinion, the records of visits, 
the information supplied by third parties, and the fulfillment of the conditions 
established in this Decision. 
The applicant shall be advised about the acceptance of the application and 
project proposal within five working days after this occurs. The access contract 
shall then be immediately drawn up and negotiated. 
In the event that the application and project proposal are denied, this shall be 
communicated through a justified Resolution and the matter shall be 
considered finished. This does not, however, preclude the filing of such 
objections as are in order, according to the procedures established in the 
national legislation of Member Countries. 
Article 31.- If required by the national law of the Member Country or if the 
Competent National Authority deems it necessary, the applicant shall comply 




The procedures that should be followed in that event shall be independent 
from those stipulated in this Decision and may be started beforehand. 
Nonetheless, they must be concluded before the expiration of the time limit 
stipulated in Article 29 and must be considered by the Competent National 
Authority in making its evaluation. 
Were the Competent National Authority to require such studies, it could grant 
the applicant a supplementary period set exclusively in accordance with the 
time needed to complete and submit them for its consideration. 
CHAPTER III 
ON THE ACCESS CONTRACT 
Article 32.- The parties to the access contract are: 
a) The State, represented by the Competent National Authority; 
and 
b) The applicant requesting the access. 
The applicant must be legally empowered to make a contract in the Member 
Country in which it requests the access. 
Article 33.- The terms of the access contract must be in keeping with the 
provisions of this Decision and Member Country national legislation. 
Article 34.- The access contract shall bear in mind the rights and interests of 
the suppliers of genetic resources and their by-products, the biological 
resources that contain them and the intangible component as applicable, in 
accordance with the corresponding contracts. 
Article 35.- When access is requested to genetic resources or their by-products 
with an intangible component, the access contract shall incorporate, as an 
integral part of that contract, an annex stipulating the fair and equitable 
distribution of the profits from use of that component. 
The annex shall be signed by the supplier of the intangible component and the 
applicant for the access. It may also be signed by the Competent National 
Authority, in accordance with the provisions of national law of the Member 
Country. If that annex is not signed by the Competent National Authority, it 
shall be subject to the suspensive condition referred to in Article 42 of this 
Decision. 
Failure to comply with the stipulations of the annex shall constitute grounds 
for the rescission and nullification of the access contract. 
Article 36.- The Competent National Authority may enter into access contracts 
with universities, research centers or well-known researchers to support the 
execution of several projects, as provided for in this Decision and in keeping 
with the national legislation of each Member Country. 
Article 37.- The ex-situ conservation centers or other institutions that perform 
activities involving access to genetic resources or their by-products and, if 
appropriate, the associated intangible component, should enter into access 
contracts with the Competent National Authority, pursuant to this Decision. 
That Authority may likewise sign access contracts with third parties in regard 
to genetic resources of which the Member Country is the country of origin and 
which have been deposited at those centers, bearing in mind the rights and 
interests referred to in Article 34. 
CHAPTER IV 
ON THE EXECUTION OF THE ACCESS 
Article 38.- Once the contract has been adopted and signed, the corresponding 
Resolution shall be issued in a joint act. This resolution shall then be published 




newspaper with wide national circulation. As of that moment, the access shall 
be considered to have been granted. 
Article 39.- Such contracts as are signed in violation of the provisions of this 
regime shall be null and void. The nullification procedure shall be subject to 
the national provisions of the Member Country in which it is invoked. 
Article 40.- The rescission or resolution of the contract shall be motive for the 
official cancellation of the registration by the Competent National Authority. 
TITLE VI 
ON THE ANCILLARY CONTRACTS TO THE ACCESS CONTRACT 
Article 41.- Ancillary contracts are those that are signed in order to carry out 
activities connected with the genetic resource or its by-products, between the 
applicant and: 
a) The owner, possessor or manager of the land where the 
biological resource containing the genetic resource is located; 
b) The ex situ conservation center; 
c) The owner, possessor or manager of the biological resource 
containing the genetic resource; or 
d) The national support institution, with regard to activities that 
it should perform and that are not a part of the access contract. 
Making an ancillary contract does not authorize access to the genetic resource 
or its by-product, and its contents are subject to the stipulations of the access 
contract as provided for in this Decision. 
The national support institution must be accepted by the Competent National 
Authority. 
Article 42.- Such ancillary contracts as are signed shall include a condition that 
subjects their execution to that of the access contract. 
As of that moment, they shall become effective and binding and shall be 
governed by the mutually agreed terms, the provisions of this Decision and 
applicable Subregional and national legislation. The responsibility for their 
execution and compliance lies only with the parties to the contract. 
Article 43.- Without detriment to what has been agreed upon in the accessory 
contract and independently of it, the national support institution shall be 
obliged to collaborate with the Competent National Authority in the follow-up 
and supervision of the genetic resources, by-products or synthesized products 
and associated intangible components, and to submit reports about the 
activities for which it is responsible, in the way or with the frequency that the 
Authority stipulates, according to the access activity. 
Article 44.- The nullity of the access contract produces the nullity of the 
ancillary contract. 
The Competent National Authority may also terminate the access contract 
when the nullity of the ancillary contract is declared, if the latter is essential 
for the access. 
Its amendment, suspension, rescission or resolution may likewise produce the 
amendment, suspension, rescission or resolution of the access contract by the 
Competent National Authority if it substantially affects the conditions of the 
latter contract. 
TITLE VII 
ON THE LIMITATIONS TO ACCESS 
Article 45.- Member Countries may establish, through an express legal rule, 
partial or total limitations on access to genetic resources or their by-products 




a) Endemism, rarity or danger of extinction of species, 
subspecies, varieties or races or breeds; 
b) Vulnerability or fragility of the structure or functioning of the 
ecosystems that could worsen as a result of access activities; 
c) Adverse effects of access activities on human health or on 
elements essential to the cultural identity of nations; 
d) Undesirable or not easily controlled environmental effects of 
access activities on the ecosystems; 
e) Danger of genetic erosion caused by access activities; 
f) Regulations on biosecurity; or 
g) Genetic resources or geographic areas rated as strategic. 
TITLE VIII 
ON VIOLATIONS AND SANCTIONS 
Article 46.- Any person performing access activities without the respective 
authorization shall be liable for punishment. 
Also to be sanctioned is any person carrying out transactions with regard to 
by-products or synthesized products of such genetic resources or the 
associated intangible component, that is not protected by the corresponding 
contracts, signed in keeping with the provisions of this Decision. 
Article 47.- The Competent National Authority, pursuant to the procedure 
provided for in its own national legislation, may apply administrative 
sanctions, such as fines, preventive or definitive confiscation, temporary or 
definitive closing-down of establishments and disqualification of the violator 
from applying for new accesses in cases of violation of this regime. 
Those sanctions shall be applied without detriment to the suspension, 
cancellation of nullification of the access, the payment of compensation for 
such damages and losses as are incurred, including those caused to the 
biological diversity, and the civil and criminal sanctions that may possibly be 
in order. 
TITLE IX 
ON THE NOTIFICATIONS BETWEEN MEMBER COUNTRIES 
Article 48.- The Member Countries shall notify each other immediately 
through the Board, of all applications for access and access resolutions and 
authorizations, as well as of the suspension and termination of such contracts 
as are signed. 
They shall also advise each other about the signing of any bilateral or 
multilateral agreement on the subject, which must be in keeping with the 
provisions of this Decision. 
Article 49.- Without prejudice to the stipulations of the previous article, the 
Member Countries shall immediately inform each other through the Board of 
all provisions, decisions, regulations, judgments, resolutions and other rules 
and acts adopted nationally that have to do with the provisions of this 
Decision. 
TITLE X 
ON THE COMPETENT NATIONAL AUTHORITY 
Article 50.- The Competent National Authority shall perform all of the 
functions conferred on it in this Decision and in Member Country national 
legislation. In this connection, it shall be empowered to: 
a) Issue the necessary internal administrative provisions to 




rules and regulations are enacted, stipulate how the genetic 
resources and their by-products shall be identified and packed; 
b) Receive, evaluate, accept or deny applications for access; 
c) Negotiate, sign and authorize access contracts and issue the 
corresponding access resolutions; 
d) Ensure the rights of suppliers of biological resources that 
contain genetic resources and of the intangible component; 
e) Keep the technical files and the Public Registry of Access to 
Genetic Resources and their by-products; 
f) Keep a directory of persons or institutions pre-qualified to 
perform scientific or cultural support tasks; 
g) Amend, suspend, nullify or terminate access contracts and 
arrange their cancellation, as the case may be, in keeping with 
the terms of those contracts, this Decision and Member Country 
legislation; 
h) Oppose the suitability of the national support institution 
proposed by the applicant and demand its replacement by 
another, suitable one; 
i) Supervise and control compliance with the contractual 
conditions and the provisions of this Decision and accordingly 
establish such monitoring and evaluation mechanisms as it 
deems advisable; 
j) Review, in keeping with this Decision, contracts involving 
access already signed with other institutions or persons and 
carry out the corresponding actions for repossession; 
k) Delegate supervisory activities to other institutions, while 
keeping the responsibility and direction over that supervision, in 
conformity with national legislation; 
l) Supervise the state of conservation of the biological resources 
containing the genetic resources; 
m) Coordinate continuously with its respective liaison 
institutions all matters having to do with fulfillment of the 
provisions of this Decision; 
n) Keep the national inventory of genetic resources and their by-
products; 
o) Keep in continuous contact with the competent national 
offices for industrial property and set up appropriate 
information systems with them; and 
p) All such other functions as the domestic legislation of the 




FIRST.- The Member Countries shall, in keeping with their national 
legislation, set up or reinforce funds or other types of financial mechanisms 
financed by the profits from the access and resources from other sources to 
promote compliance with the aims of this Decision, under the direction of the 
Competent National Authority. 
Through the Andean Committee on Genetic Resources, the Member Countries 




resources and shall study the viability and desirability of creating an Andean 
Fund for their conservation. 
SECOND.- The Member Countries shall not acknowledge rights, including 
intellectual property rights, over genetic resources, by-products or synthesized 
products and associated intangible components, that were obtained or 
developed through an access activity that does not comply with the provisions 
of this Decision. 
Furthermore, the Member Country affected may request nullification and 
bring such actions as are appropriate in countries that have conferred rights 
or granted protective title documents. 
THIRD.- The Competent National Offices on Intellectual Property shall 
require the applicant to give the registration number of the access contract and 
supply a copy of it as a prerequisite for granting the respective right, when they 
are certain or there are reasonable indications that the products or processes 
whose protection is being requested have been obtained or developed on the 
basis of genetic resources or their by-products which originated in one of the 
Member Countries. 
The Competent National Authority and the Competent National Offices on 
Intellectual Property shall set up systems for exchanging information about 
the authorized access contracts and intellectual property rights granted. 
FOURTH.- Such health certificates supporting the export of biological 
resources as are issued in accordance with Commission Decision 328, its 
amendments or addenda, shall incorporate the following statement at the end 
of the format: "Use of this product as a genetic resource is not authorized." 
FIFTH.- The Competent National Authority may enter into, with the 
institutions referred to in Article 36, contracts for the deposit of genetic 
resources or their by-products or of the biological resources containing them, 
exclusively for purposes of their care, keeping those resources under its 
jurisdiction and control. 
Likewise, it may make contracts that do not involve access, such as 
intermediation or administration contracts, in relation to genetic resources or 
their by-products or synthesized products, in keeping with the provisions of 
this Regime. 
SIXTH.- When requesting access to genetic resources from protected areas or 
their by-products, the applicant must fulfill, in addition to the stipulations of 





















On Patentability Requirements 
Article 14.- The Member Countries shall grant patents for inventions, whether 
goods or processes, in all areas of technology, that are new, involve an 
inventive step, and are industrially applicable. 
 
Article 15.- The following shall not be considered inventions: 
a) discoveries, scientific theories, and mathematical methods; 
b) Any living thing, either complete or partial, as found in nature, natural 
biological processes, and biological material, as existing in nature, or able to 
be separated, including the genome or germ plasm of any living thing; 
c) literary and artistic works or any other aesthetic creation protected by 
copyright; 
d) plans, rules, and methods for the pursuit of intellectual activities, playing of 
games, or economic and business activities; 
e) computer programs and software, as such; and, 
f) methods for presenting information. 
 
Article 16.- An invention may be deemed new when not included in the state 
of the art. 
The state of the art comprises everything that has been made available to the 
public by written or oral description, use, marketing, or any other means prior 
to the filing date of the patent or, where appropriate, of the priority claimed. 
Solely for the purpose of determining novelty, the contents of a patent 
application pending before the competent national office and having a filing 
date or priority application date earlier than the date of the patent or patent 
priority application under examination, shall likewise be considered part of 
the state of the art, provided that the said contents are included in the earlier 
application when published or that the period stipulated in Article 40 has 
concluded. 
 
Article 17.- For the purposes of determining patentability, no account shall be 
taken of any disclosure of the contents of the patent during the year prior to 
the filing date of the application in the Member Country or during the year 
before the date of priority, if claimed, providing that the disclosure was 
attributable to: 
a) the inventor or the inventor’s assignee; 
b) a competent national office that publishes the contents of a patent 
application filed by the inventor or the inventor’s assignee in contravention of 




c) a third party who obtained the information directly or indirectly from the 
inventor or the inventor’s assignee. 
 
Article 18.- An invention shall be regarded as involving an inventive step if, for 
a person in the trade with average skills in the technical field concerned, the 
said invention is neither obvious nor obviously derived from the state of the 
art. 
 
Article 19.- An invention shall be regarded as industrially applicable when its 
subject matter may be produced or used in any type of industry; industry being 
understood as that involving any productive activity, including services. 
 
Article 20.- The following shall not be patentable: 
a) inventions, the prevention of the commercial exploitation within the 
territory of the respective Member Country of the commercial exploitation is 
necessary to protect public order or morality, provided that such exclusion is 
not merely because the exploitation is prohibited or regulated by a legal or 
administrative provision; 
b) inventions, when the prevention of the commercial exploitation within the 
respective Member Country of the commercial exploitation is necessary to 
protect human or animal life or health or to avoid serious prejudice to plant 
life and the environment, provided that such exclusion is not made merely 
because the exploitation is prohibited or regulated by a legal or administrative 
provision; 
c) plants, animals, and essentially biological processes for the production of 
plants or animals other than non-biological or microbiological processes; 
d) diagnostic, therapeutic, and surgical methods for the treatment of humans 
or animals. 
 
Article 21.- Products or processes already patented and included in the state of 
the art within the meaning of Article 16 of this Decision may not be the subject 
of new patents on the sole ground of having been put to a use different from 
that originally contemplated by the initial patent. 
 
CHAPTER II 
On the Patent Owners 
Article 22.- The right to a patent belongs to the inventor and may be assigned 
or transferred by succession. 
Patent owners may be natural or judicial persons. 
If several persons make an invention jointly, they shall share the right to patent 
it. 
If several persons make the same invention, each independently of the others, 
the patent shall be granted to the person or assignee with the first filing date 
or, where priority is claimed, date of application. 
 
Article 23.- Without prejudice to the provisions of national law in each 
Member Country, in the case of inventions made in the course of an 
employment relationship, the employer, whatever its form and nature, may 
transfer part of the economic benefits deriving from the innovations to the 




Entities receiving state funding for their research shall reinvest part of the 
royalties received from the marketing of those inventions to generate a 
continuing supply of research funds and encourage researchers by giving them 
a share of the proceeds from the innovations, in accordance with the legislation 
in each Member Country. 
 
Article 24.- The inventor shall have the right to be cited as such in the patent 
or to oppose being so mentioned. 
(..) 
CHAPTER VIII 
On Acts Subsequent to the Grant 
 
Article 70.- A patent owner may request the competent national office to 
modify the patent in order to enter any change in the name, address, residence 
or other information about the rights holder or the inventor or to amend or 
limit the scope of one or more of the claims. The owner of the patent may, 
likewise, request that any material error in the patent be rectified. 
The provisions in respect of the modification or correction of an application 
shall be applicable as pertinent. 
 
Article 71.- The owner of a patent may, through a declaration addressed to the 
competent national office, withdraw one or more patent claims or a claim to 
the patent as a whole. That withdrawal shall become effective as of the date the 
respective declaration is received. 
 
Article 72.- The owner of a patent may divide it into two or more fractional 
patents. The provisions regarding the division of an application shall be 
applicable to that of patents, in all pertinent matters. 
 
Article 73.- A patent owner may also combine two or more patents. The 
provisions regarding the combination of applications shall be applicable to 
these patents, in all pertinent matters. 
 
Article 74.- The competent national office may establish the fees on acts 
carried out after the patent grant. 
 
CHAPTER IX 
On the Invalidation of the Patent 
 
Article 75.- The competent national authority may, either ex officio or at the 
request of a party, and at any time, declare a patent null and void, where: 
a) the subject matter of the patent is not an invention according to the 
requirements stipulated in article 15; 
b) the invention fails to comply with the requirements for patentability set out 
in article 14; 
c) the patent was granted for an invention covered by article 20; 
d) the patent fails to disclose the invention, as required by article 28 and, if 
pertinent, article 29; 





f) use of the patent granted has been broader than was indicated in the original 
application and requires having to extend its scope of protection; 
g) when pertinent, the products or processes in respect of which the patent is 
being filed have been obtained and developed on the basis of genetic resources 
or their byproducts originating in one of the Member Countries, if the 
applicant failed to submit a copy of the contract for access to that genetic 
material; 
h) when pertinent, the products or processes whose protection is being 
requested have been obtained or developed on the basis of traditional 
knowledge belonging to indigenous, African American, or local communities 
in the Member Countries, if the applicant has failed to submit a copy of the 
document certifying the existence of a license or authorization for use of that 
knowledge originating in any one of the Member Countries; or, 
i) there are grounds for absolute invalidation according to domestic legislation 
covering administrative acts. 
Where the grounds specified above are applicable only to some of the claims 
or some parts of a claim, invalidation shall be pronounced only in respect of 
those claims or those parts of the said claim, as the case may be. 
The patent, claim, or part of a claim that has been invalidated shall be deemed 
null and void as from the filing date of the patent application. 
 
Article 76.- Where defects in administrative acts fail to produce absolute 
invalidation as specified in the preceding article, those acts shall be relatively 
invalidated. In such cases, the competent national authority shall, in 
conformity with domestic legislation, declare them null and void within a 
period of five years counted from the patent grant date. 
 
Article 77.- The competent national authority may, where a patent has been 
granted to a person who has no right to it, annul that patent. Invalidation 
proceedings may be initiated only by the person who has a right to obtain that 
patent. That right of action shall lapse five years after the patent grant date or 
two years following the date on which the person to whom that right belongs 
learned about the use of the invention, whichever period expires first. 
 
Article 78.- In invalidation proceedings, the competent national authority shall 
request the patent owners to present arguments and submit the proof they 
deem advisable. 
Where that authority under the domestic law of a Member Country is the 
competent national office, the patent owner shall present the arguments and 
submit the proof referred to in the previous article within a period of two 
months after being notified thereof. 
Before the expiry of the period stipulated in the previous article, the interested 
party may request an extension of two additional months. 
Once the periods stipulated in this article have expired, the competent national 
office shall rule on the patent’s invalidation and inform the parties of its 
decision. 
 
Article 79.- The competent national authority may, where necessary to rule on 
the invalidation of a patent, request the patent owner to submit one or more 
of the documents referred to in article 46 with regard to the patent that is the 
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